Positron O +
emission O +
tomography O +
in O +
a O +
case O +
of O +
intracranial O +
hemangiopericytoma O -
. O +

Due O +
to O +
the O +
low O +
prevalence O +
of O +
hemangiopericytomas O +
( O -
HPCs O -
) O -
, O +
data O +
on O +
the O +
biophysiological O +
characteristics O +
of O +
this O +
tumor O +
are O +
rare O -
. O +

Positron O +
emission O +
tomography O +
( O -
PET O -
) O +
demonstrated O +
a O +
sixfold O +
increased O +
uptake O +
of O +
[ B-Chemical -
11C I-Chemical -
] I-Chemical -
methionine I-Chemical +
and O +
hyperperfusion O +
in O +
the O +
HPC O -
, O +
whereas O +
glucose B-Chemical +
utilization O +
was O +
decreased O +
in O +
this O +
area O -
. O +

This O +
low O +
glucose B-Chemical +
utilization O +
is O +
in O +
contrast O +
to O +
the O +
high O +
[ B-Chemical -
11C I-Chemical -
] I-Chemical -
methionine I-Chemical +
uptake O +
and O +
the O +
malignancy O +
of O +
these O +
tumors O -
. O +

The O +
characteristics O +
of O +
HPCs O +
in O +
PET O +
described O +
herein O +
for O +
the O +
first O +
time O +
offer O +
additional O +
diagnostic O +
criteria O +
and O +
may O +
help O +
especially O +
to O +
differentiate O +
these O +
tumors O +
from O +
meningiomas O -
. O +

Bradycardia O -
- O -
induced O +
coronary O +
angiogenesis O +
is O +
dependent O +
on O +
vascular O +
endothelial O +
growth O +
factor O -
. O +

A O +
marked O +
coronary O +
angiogenesis O +
is O +
known O +
to O +
occur O +
with O +
chronic O +
bradycardia O -
. O +

We O +
tested O +
the O +
hypothesis O +
that O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
, O +
an O +
endothelial O +
cell O +
mitogen O +
and O +
a O +
major O +
regulator O +
of O +
angiogenesis O -
, O +
is O +
upregulated O +
in O +
response O +
to O +
low O +
heart O +
rate O +
and O +
consequential O +
increased O +
stroke O +
volume O -
. O +

Bradycardia O +
was O +
induced O +
in O +
rats O +
by O +
administering O +
the O +
bradycardic O +
drug O +
alinidine B-Chemical +
( O -
3 O +
mg O -
/ O -
kg O +
body O +
weight O -
) O +
twice O +
daily O -
. O +

Heart O +
rate O +
decreased O +
by O +
32 O -
% O +
for O +
20 O +
to O +
40 O +
minutes O +
after O +
injection O +
and O +
was O +
chronically O +
reduced O +
by O +
10 O -
% O -
, O +
14 O -
% O -
, O +
and O +
18.5 O -
% O +
after O +
1 O -
, O +
2 O -
, O +
and O +
3 O +
weeks O +
of O +
treatment O -
, O +
respectively O -
. O +

Arterial O +
pressure O +
and O +
cardiac O +
output O +
were O +
unchanged O -
. O +

Left O +
ventricular O +
capillary O +
length O +
density O +
( O -
mm O -
/ O -
mm O -
( O -
3 O -
) O -
) O +
increased O +
gradually O +
with O +
alinidine B-Chemical +
administration O -
; O +
a O +
15 O -
% O +
increase O +
after O +
2 O +
weeks O +
and O +
a O +
40 O -
% O +
increase O +
after O +
3 O +
weeks O +
of O +
alinidine B-Chemical +
treatment O +
were O +
documented O -
. O +

Left O +
ventricular O +
weight O -
, O +
body O +
weight O -
, O +
and O +
their O +
ratio O +
were O +
not O +
significantly O +
altered O +
by O +
alinidine B-Chemical +
treatment O -
. O +

After O +
1 O +
week O +
of O +
treatment O -
, O +
before O +
an O +
increase O +
in O +
capillary O +
length O +
density O -
, O +
VEGF O +
mRNA O +
increased O +
greater O +
than O +
2-fold O +
and O +
then O +
declined O +
to O +
control O +
levels O +
after O +
3 O +
weeks O +
of O +
treatment O -
. O +

VEGF O +
protein O +
was O +
higher O +
in O +
alinidine B-Chemical -
- O -
treated O +
rats O +
than O +
in O +
controls O +
after O +
2 O +
weeks O +
and O +
increased O +
further O +
after O +
3 O +
weeks O +
of O +
treatment O -
. O +

Injection O +
of O +
VEGF O -
- O -
neutralizing O +
antibodies O +
over O +
a O +
2-week O +
period O +
completely O +
blocked O +
alinidine B-Chemical -
- O -
stimulated O +
angiogenesis O -
. O +

In O +
contrast O -
, O +
bFGF O +
mRNA O +
was O +
not O +
altered O +
by O +
alinidine B-Chemical +
treatment O -
. O +

These O +
data O +
suggest O +
that O +
VEGF O +
plays O +
a O +
key O +
role O +
in O +
the O +
angiogenic O +
response O +
that O +
occurs O +
with O +
chronic O +
bradycardia O -
. O +

The O +
mechanism O +
underlying O +
this O +
VEGF O -
- O -
associated O +
angiogenesis O +
may O +
be O +
an O +
increase O +
in O +
stretch O +
due O +
to O +
enhanced O +
diastolic O +
filling O -
. O +

Increased O +
serum O +
levels O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
in O +
patients O +
with O +
renal O +
cell O +
carcinoma O -
. O +

Neovascularization O -
, O +
an O +
essential O +
event O +
for O +
the O +
growth O +
of O +
solid O +
tumors O -
, O +
is O +
regulated O +
by O +
a O +
number O +
of O +
angiogenic O +
factors O -
. O +

One O +
such O +
factor O -
, O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
, O +
is O +
considered O +
to O +
exert O +
a O +
potent O +
angiogenic O +
activity O -
, O +
as O +
indicated O +
by O +
immunohistochemical O +
and O +
molecular O +
evidence O -
. O +

In O +
this O +
study O +
we O +
investigated O +
the O +
serum O +
VEGF O +
level O +
( O -
s O -
- O -
VEGF O -
) O +
in O +
patients O +
with O +
renal O +
cell O +
carcinoma O +
( O -
RCC O -
) O -
. O +

s O -
- O -
VEGF O +
in O +
peripheral O +
blood O +
samples O +
was O +
analyzed O +
in O +
40 O +
RCC O +
patients O +
and O +
40 O +
patients O +
without O +
cancer O +
( O -
controls O -
) O +
using O +
a O +
sandwich O +
enzyme O -
- O -
linked O +
immunoassay O -
. O +

In O +
20 O +
RCC O +
patients O -
, O +
serum O +
samples O +
were O +
obtained O +
separately O +
from O +
the O +
bilateral O +
renal O +
veins O -
. O +

s O -
- O -
VEGF O +
was O +
also O +
measured O +
before O -
, O +
4 O +
and O +
8 O +
weeks O +
after O +
nephrectomy O +
in O +
11 O +
patients O -
. O +

There O +
were O +
significant O +
differences O +
in O +
s O -
- O -
VEGF O +
between O +
the O +
RCC O +
patients O +
and O +
the O +
controls O +
( O -
207.3+ O -
/ O -
-32.9 O +
vs. O +
71.5+ O -
/ O -
-9.1 O +
pg O -
/ O -
ml O -
, O +
mean+ O -
/ O -
-SE O -
) O +
( O -
P O +
less O +
than O +
0.005 O -
) O -
, O +
between O +
the O +
tumor O -
- O -
bearing O +
renal O +
veins O +
and O +
the O +
contralateral O +
ones O +
( O -
P O +
less O +
than O +
0.01 O -
) O -
, O +
between O +
the O +
pre- O +
and O +
post O -
- O -
nephrectomy O +
situations O +
( O -
P O +
less O +
than O +
0.01 O -
) O +
and O +
among O +
the O +
various O +
parameters O +
of O +
tumor O +
status O +
such O +
as O +
tumor O +
extent O +
( O -
P O +
less O +
than O +
0.001 O -
) O +
and O +
existence O +
of O +
metastasis O +
( O -
P O +
less O +
than O +
0.001 O -
) O -
. O +

s O -
- O -
VEGF O +
significantly O +
correlated O +
with O +
the O +
tumor O +
volume O +
obtained O +
by O +
a O +
three O -
- O -
dimensional O +
measurement O +
( O -
r=0.802 O -
, O +
P O +
less O +
than O +
0.0001 O -
) O -
. O +

The O +
sensitivity O +
and O +
specificity O +
of O +
s O -
- O -
VEGF O +
at O +
the O +
cut O -
- O -
off O +
level O +
of O +
100 O +
pg O -
/ O -
ml O -
, O +
as O +
determined O +
by O +
the O +
receiver O -
- O -
operating O -
- O -
characteristics O +
curve O -
, O +
were O +
80.0 O -
% O +
and O +
72.5 O -
% O -
, O +
respectively O -
. O +

The O +
results O +
indicate O +
that O +
tumor O +
tissue O +
of O +
RCC O +
liberates O +
VEGF O +
into O +
the O +
systemic O +
blood O +
flow O +
and O +
that O +
s O -
- O -
VEGF O +
is O +
a O +
possible O +
marker O +
for O +
RCC O -
. O +

Insulin O -
- O -
induced O +
vascular O +
endothelial O +
growth O +
factor O +
expression O +
in O +
retina O -
. O +

PURPOSE O -
: O +
Clinical O +
studies O +
have O +
demonstrated O +
that O +
intensive O +
insulin O +
therapy O +
causes O +
a O +
transient O +
worsening O +
of O +
retinopathy O -
. O +

The O +
mechanisms O +
underlying O +
the O +
initial O +
insulin O -
- O -
induced O +
deterioration O +
of O +
retinal O +
status O +
in O +
patients O +
with O +
diabetes O +
remain O +
unknown O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
is O +
known O +
to O +
be O +
operative O +
in O +
the O +
pathogenesis O +
of O +
diabetic O +
retinopathy O -
. O +

The O +
current O +
study O +
was O +
conducted O +
to O +
characterize O +
the O +
effect O +
of O +
insulin O +
on O +
retinal O +
VEGF O +
gene O +
expression O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

METHODS O -
: O +
The O +
effect O +
of O +
insulin O +
on O +
VEGF O +
expression O +
in O +
vivo O +
was O +
examined O +
by O +
in O +
situ O +
hybridization O +
studies O +
of O +
rat O +
retinal O +
VEGF O +
transcripts O -
. O +

To O +
examine O +
the O +
mechanisms O +
by O +
which O +
insulin O +
regulates O +
VEGF O +
expression O -
, O +
human O +
retinal O +
pigment O +
epithelial O +
( O -
RPE O -
) O +
cells O +
were O +
exposed O +
to O +
insulin O -
, O +
and O +
VEGF O +
mRNA O +
levels O +
were O +
quantified O +
with O +
RNase O +
protection O +
assays O +
( O -
RPAs O -
) O -
. O +

Conditioned O +
media O +
from O +
insulin O -
- O -
treated O +
RPE O +
cells O +
were O +
assayed O +
for O +
VEGF O +
protein O +
and O +
capillary O +
endothelial O +
cell O +
proliferation O -
. O +

The O +
capacity O +
of O +
insulin O +
to O +
stimulate O +
the O +
VEGF O +
promoter O +
linked O +
to O +
a O +
luciferase O +
reporter O +
gene O +
was O +
characterized O +
in O +
transient O +
transfection O +
assays O -
. O +

RESULTS O -
: O +
Insulin O +
increased O +
VEGF O +
mRNA O +
levels O +
in O +
the O +
ganglion O -
, O +
inner O +
nuclear O -
, O +
and O +
RPE O +
cell O +
layers O -
. O +

In O +
vitro O -
, O +
insulin O +
increased O +
VEGF O +
mRNA O +
levels O +
in O +
human O +
RPE O +
cells O +
and O +
enhanced O +
VEGF O +
promoter O +
activity O +
without O +
affecting O +
transcript O +
stability O -
. O +

Insulin O +
treatment O +
also O +
increased O +
VEGF O +
protein O +
levels O +
in O +
conditioned O +
RPE O +
cell O +
media O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
with O +
a O +
median O +
effective O +
concentration O +
of O +
5 O +
nM. O +
The O +
insulin O -
- O -
conditioned O +
RPE O +
cell O +
media O +
stimulated O +
capillary O +
endothelial O +
cell O +
proliferation O -
, O +
an O +
effect O +
that O +
was O +
completely O +
blocked O +
by O +
anti O -
- O -
VEGF O +
neutralizing O +
antibody O -
. O +

CONCLUSIONS O -
: O +
Insulin O +
increases O +
VEGF O +
mRNA O +
and O +
secreted O +
protein O +
levels O +
in O +
RPE O +
cells O +
through O +
enhanced O +
transcription O +
of O +
the O +
VEGF O +
gene O -
. O +

Intensive O +
insulin O +
therapy O +
may O +
cause O +
a O +
transient O +
worsening O +
of O +
retinopathy O +
in O +
patients O +
with O +
diabetes O +
through O +
increased O +
retinal O +
VEGF O +
gene O +
expression O -
. O +

The O +
antiangiogenic O +
agent O +
linomide B-Chemical +
inhibits O +
the O +
growth O +
rate O +
of O +
von O +
Hippel O -
- O -
Lindau O +
paraganglioma O +
xenografts O +
to O +
mice O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
ascertain O +
the O +
potential O +
usefulness O +
of O +
the O +
antiangiogenic O +
compound O +
linomide B-Chemical +
for O +
treatment O +
of O +
von O +
Hippel O -
- O -
Lindau O +
( O -
VHL O -
) O -
-related O +
tumors O -
. O +

Paraganglioma O +
tissue O +
fragments O +
obtained O +
at O +
surgery O +
from O +
a O +
VHL O +
type O +
2a O +
patient O +
were O +
transplanted O +
s.c O -
. O +

to O +
male O +
BALB O -
/ O -
c O +
nu O -
/ O -
nu O +
( O -
nude O -
) O +
mice O -
: O +
( O -
a O -
) O +
2 O -
- O -
3-mm O +
fragments O +
for O +
" O -
prevention O -
" O +
experiments O -
; O +
and O +
( O -
b O -
) O +
2 O -
- O -
3-mm O +
fragments O +
allowed O +
to O +
grow O +
to O +
1 O +
cm O +
for O +
" O -
intervention O -
" O +
studies O -
. O +

Both O +
groups O +
received O +
either O +
0.5 O +
mg O -
/ O -
ml O +
linomide B-Chemical +
in O +
drinking O +
water O +
or O +
acidified O +
water O +
and O +
were O +
followed O +
until O +
tumor O +
diameter O +
reached O +
3 O +
cm O +
or O +
for O +
4 O +
weeks O -
. O +

In O +
both O +
the O +
prevention O +
and O +
intervention O +
experiments O -
, O +
a O +
significant O +
diminution O +
of O +
tumor O +
size O +
and O +
weight O +
was O +
observed O +
in O +
the O +
drug O -
- O -
treated O +
animals O -
. O +

In O +
vivo O +
nuclear O +
magnetic O +
resonance O +
analysis O +
of O +
tumor O +
blood O +
flow O +
in O +
linomide B-Chemical -
- O -
treated O +
animals O +
showed O +
localization O +
of O +
blood O +
vessels O +
almost O +
exclusively O +
to O +
the O +
periphery O +
of O +
the O +
poorly O +
vascularized O +
tumors O +
with O +
a O +
significant O +
reduction O +
of O +
both O +
vascular O +
functionality O +
and O +
vasodilation O -
. O +

Histological O +
examination O +
of O +
tumors O +
from O +
linomide B-Chemical -
- O -
treated O +
animals O +
revealed O +
marked O +
avascularity O -
. O +

Treated O +
animals O +
also O +
displayed O +
a O +
2.4-fold O +
reduction O +
of O +
tumor O +
vascular O +
endothelial O +
growth O +
factor O +
mRNA O +
levels O -
. O +

Taken O +
together O -
, O +
our O +
data O +
indicate O +
that O +
in O +
VHL O +
disease O -
, O +
therapy O +
directed O +
at O +
inhibition O +
of O +
constitutively O +
expressed O +
VEGF O +
induction O +
of O +
angiogenesis O +
by O +
VHL O +
tumors O +
may O +
constitute O +
an O +
effective O +
medical O +
treatment O -
. O +

Active O +
hair O +
growth O +
( O -
anagen O -
) O +
is O +
associated O +
with O +
angiogenesis O -
. O +

After O +
the O +
completion O +
of O +
skin O +
development O -
, O +
angiogenesis O -
, O +
i.e. O -
, O +
the O +
growth O +
of O +
new O +
capillaries O +
from O +
pre O -
- O -
existing O +
blood O +
vessels O -
, O +
is O +
held O +
to O +
occur O +
in O +
the O +
skin O +
only O +
under O +
pathologic O +
conditions O -
. O +

It O +
has O +
long O +
been O +
noted O -
, O +
however O -
, O +
that O +
hair O +
follicle O +
cycling O +
is O +
associated O +
with O +
prominent O +
changes O +
in O +
skin O +
perfusion O -
, O +
that O +
the O +
epithelial O +
hair O +
bulbs O +
of O +
anagen O +
follicles O +
display O +
angiogenic O +
properties O -
, O +
and O +
that O +
the O +
follicular O +
dermal O +
papilla O +
can O +
produce O +
angiogenic O +
factors O -
. O +

Despite O +
these O +
suggestive O +
observations O -
, O +
no O +
formal O +
proof O +
is O +
as O +
yet O +
available O +
for O +
the O +
concept O +
that O +
angiogenesis O +
is O +
a O +
physiologic O +
event O +
that O +
occurs O +
all O +
over O +
the O +
mature O +
mammalian O +
integument O +
whenever O +
hair O +
follicles O +
switch O +
from O +
resting O +
( O -
telogen O -
) O +
to O +
active O +
growth O +
( O -
anagen O -
) O -
. O +

This O +
study O +
uses O +
quantitative O +
histomorphometry O +
and O +
double O -
- O -
immunohistologic O +
detection O +
techniques O +
for O +
the O +
demarcation O +
of O +
proliferating O +
endothelial O +
cells O -
, O +
to O +
show O +
that O +
synchronized O +
hair O +
follicle O +
cycling O +
in O +
adolescent O +
C57BL O -
/ O -
6 O +
mice O +
is O +
associated O +
with O +
substantial O +
angiogenesis O -
, O +
and O +
that O +
inhibiting O +
angiogenesis O +
in O +
vivo O +
by O +
the O +
intraperitoneal O +
application O +
of O +
a O +
fumagillin B-Chemical +
derivative I-Chemical +
retards O +
experimentally O +
induced O +
anagen O +
development O +
in O +
these O +
mice O -
. O +

Thus O -
, O +
angiogenesis O +
is O +
a O +
physiologic O +
event O +
in O +
normal O +
postnatal O +
murine O +
skin O -
, O +
apparently O +
is O +
dictated O +
by O +
the O +
hair O +
follicle O -
, O +
and O +
appears O +
to O +
be O +
required O +
for O +
normal O +
anagen O +
development O -
. O +

Anagen O -
- O -
associated O +
angiogenesis O +
offers O +
an O +
attractive O +
model O +
for O +
identifying O +
the O +
physiologic O +
controls O +
of O +
cutaneous O +
angiogenesis O -
, O +
and O +
an O +
interesting O +
system O +
for O +
screening O +
the O +
effects O +
of O +
potential O +
antiangiogenic O +
drugs O +
in O +
vivo O -
. O +

CD40 O +
expression O +
on O +
human O +
lung O +
cancer O +
correlates O +
with O +
metastatic O +
spread O -
. O +

PURPOSE O -
: O +
The O +
poor O +
prognosis O +
associated O +
with O +
lung O +
cancer O +
is O +
related O +
to O +
the O +
high O +
incidence O +
of O +
regional O +
and O +
distant O +
metastasis O -
. O +

There O +
is O +
a O +
crucial O +
need O +
to O +
identify O +
parameters O +
that O +
can O +
predict O +
a O +
tendancy O +
to O +
metastatic O +
spread O +
to O +
allow O +
better O +
prognostic O +
evaluation O +
and O +
therapeutic O +
approach O -
. O +

METHODS O -
: O +
Using O +
flow O +
cytometry O +
we O +
evaluated O +
18 O +
human O +
lung O +
cancer O +
cell O +
lines O +
for O +
the O +
expression O +
of O +
different O +
surface O +
markers O +
on O +
lung O +
cancers O +
suggested O +
to O +
be O +
possible O +
prognostic O +
parameters O -
, O +
including O +
epidermal O +
growth O +
factor O +
receptor O +
( O -
EGFR O -
) O -
, O +
intercellular O +
adhesion O +
molecule O +
1 O +
( O -
ICAM-1 O -
) O -
, O +
Fas O +
and O +
CD40 O -
. O +

RESULTS O -
: O +
No O +
correlation O +
was O +
found O +
between O +
tumor O +
prognosis O +
and O +
EGFR O -
, O +
ICAM-1 O +
or O +
Fas O -
. O +

However O -
, O +
a O +
statistically O +
significant O +
correlation O +
was O +
found O +
between O +
the O +
surface O +
expression O +
of O +
CD40 O +
and O +
the O +
metastatic O +
spread O +
of O +
the O +
tumor O -
. O +

In O +
this O +
study O -
, O +
14 O +
of O +
18 O +
lung O +
cancer O +
cell O +
lines O +
( O -
78 O -
% O -
) O +
expressed O +
CD40 O +
on O +
their O +
surface O -
. O +

All O +
of O +
the O +
4 O +
tumors O +
that O +
were O +
CD40-negative O -
, O +
were O +
stage O +
I O +
tumors O -
, O +
without O +
any O +
evidence O +
of O +
regional O +
or O +
distant O +
metastasis O -
. O +

Of O +
the O +
14 O +
tumors O +
that O +
expressed O +
CD40 O -
, O +
all O +
but O +
1 O +
( O -
93 O -
% O -
) O +
had O +
either O +
nodal O +
or O +
systemic O +
metastasis O +
at O +
the O +
time O +
of O +
diagnosis O -
. O +

Patients O +
whose O +
tumors O +
were O +
CD40-negative O +
showed O +
a O +
significantly O +
better O +
N O +
stage O -
, O +
overall O +
stage O +
at O +
presentation O +
and O +
survival O +
than O +
those O +
patients O +
with O +
CD40-positive O +
patients O -
. O +

No O +
significant O +
differences O +
between O +
the O +
two O +
groups O +
were O +
observed O +
in O +
tumor O +
size O -
, O +
gender O -
, O +
age O -
, O +
histology O -
, O +
differentiation O +
or O +
preoperative O +
therapy O -
. O +

CONCLUSIONS O -
: O +
These O +
results O +
suggest O +
that O +
CD40 O +
expression O +
on O +
lung O +
cancer O +
may O +
play O +
a O +
role O +
in O +
metastatic O +
spread O -
, O +
and O +
also O +
may O +
serve O +
as O +
a O +
prognostic O +
marker O +
and O +
an O +
indicator O +
of O +
advanced O +
disease O -
. O +

The O +
value O +
of O +
serum O +
S-100beta O +
and O +
interleukins O +
as O +
tumour O +
markers O +
in O +
advanced O +
melanoma O -
. O +

Recently O +
serum O +
S-100beta O +
has O +
shown O +
promise O +
as O +
a O +
tumour O +
marker O +
in O +
melanoma O -
; O +
however O -
, O +
its O +
use O +
as O +
a O +
prognostic O +
marker O +
in O +
the O +
advanced O +
stage O +
needs O +
to O +
be O +
confirmed O -
. O +

Interleukins O +
( O -
ILs O -
) O +
may O +
mediate O +
regression O +
or O +
progression O +
of O +
cancer O -
. O +

In O +
order O +
to O +
study O +
their O +
relation O +
to O +
the O +
metastatic O +
profile O +
and O +
survival O -
, O +
we O +
evaluated O +
the O +
association O +
between O +
pretreatment O +
serum O +
levels O +
of O +
S-100beta O -
, O +
IL-6 O -
, O +
IL-10 O +
and O +
IL-12 O +
and O +
metastatic O +
site O +
and O +
survival O +
in O +
50 O +
patients O +
with O +
advanced O +
melanoma O +
who O +
were O +
to O +
receive O +
chemoimmunotherapy O -
. O +

Patients O +
with O +
liver O +
and/or O +
bone O +
metastases O +
had O +
significantly O +
higher O +
median O +
concentrations O +
of O +
S-100beta O -
, O +
IL-6 O +
and O +
IL-10 O +
than O +
those O +
with O +
only O +
skin O -
, O +
nodal O +
and/or O +
lung O +
involvement O -
. O +

The O +
differences O +
in O +
IL-12 O +
levels O +
were O +
unremarkable O -
. O +

Using O +
univariate O +
analysis O -
, O +
the O +
S-100beta O +
level O +
and O +
metastatic O +
profile O +
were O +
found O +
to O +
be O +
statistically O +
significant O +
prognostic O +
factors O +
for O +
survival O -
. O +

Using O +
multivariate O +
analysis O +
the O +
S-100beta O +
level O +
was O +
the O +
most O +
powerful O +
prognostic O +
indicator O -
, O +
while O +
the O +
metastatic O +
profile O +
was O +
found O +
to O +
be O +
significant O +
after O +
exclusion O +
of O +
S-100beta O -
. O +

The O +
findings O +
suggest O +
that O +
elevated O +
serum O +
levels O +
of O +
S-100beta O -
, O +
IL-6 O +
and O +
IL-10 O +
reflect O +
concurrent O +
liver O +
or O +
bone O +
metastases O +
in O +
melanoma O -
. O +

S-100beta O +
is O +
also O +
an O +
independent O +
prognostic O +
marker O -
. O +

Pretreatment O +
IL O +
levels O +
were O +
not O +
associated O +
with O +
outcome O -
. O +

Urokinase O +
receptor O -
: O +
a O +
molecular O +
organizer O +
in O +
cellular O +
communication O -
. O +

In O +
a O +
variety O +
of O +
cell O +
types O -
, O +
the O +
glycolipid O -
- O -
anchored O +
urokinase O +
receptor O +
( O -
uPAR O -
) O +
is O +
colocalized O +
pericellularly O +
with O +
components O +
of O +
the O +
plasminogen O +
activation O +
system O +
and O +
endocytosis O +
receptors O -
. O +

uPAR O +
is O +
also O +
coexpressed O +
with O +
caveolin O +
and O +
members O +
of O +
the O +
integrin O +
adhesion O +
receptor O +
superfamily O -
. O +

The O +
formation O +
of O +
functional O +
units O +
with O +
these O +
various O +
proteins O +
allows O +
the O +
uPAR O +
to O +
mediate O +
the O +
focused O +
proteolysis O +
required O +
for O +
cell O +
migration O +
and O +
invasion O +
and O +
to O +
contribute O +
both O +
directly O +
and O +
indirectly O +
to O +
cell O +
adhesive O +
processes O +
in O +
a O +
non O -
- O -
proteolytic O +
fashion O -
. O +

This O +
dual O +
activity O -
, O +
together O +
with O +
the O +
initiation O +
of O +
signal O +
transduction O +
pathways O +
by O +
uPAR O -
, O +
is O +
believed O +
to O +
influence O +
cellular O +
behaviour O +
in O +
angiogenesis O -
, O +
inflammation O -
, O +
wound O +
repair O +
and O +
tumor O +
progression O -
/ O -
metastasis O +
and O +
open O +
up O +
the O +
way O +
for O +
uPAR O -
- O -
based O +
therapeutic O +
approaches O -
. O +

p75 O +
mediated O +
apoptosis O +
in O +
neuroblastoma O +
cells O +
is O +
inhibited O +
by O +
expression O +
of O +
TrkA. O +
BACKGROUND O -
: O +
Neurotrophins O +
mediate O +
their O +
effects O +
by O +
binding O +
to O +
members O +
of O +
the O +
Trk O +
family O +
of O +
receptor O +
tyrosine O +
kinases O +
and O +
to O +
the O +
low O -
- O -
affinity O +
nerve O +
growth O +
factor O +
receptor O +
p75 O -
. O +

Nerve O +
growth O +
factor O +
( O -
NGF O -
) O +
has O +
been O +
demonstrated O +
to O +
support O +
survival O +
and O +
differentiation O +
of O +
neuroblastoma O +
( O -
NB O -
) O +
cells O +
by O +
activation O +
of O +
the O +
TrkA O +
receptor O -
. O +

The O +
p75 O +
receptor O +
belongs O +
to O +
the O +
tumor O +
necrosis O +
factor O +
( O -
TNF O -
) O +
family O +
of O +
death O +
receptors O +
and O +
has O +
been O +
suggested O +
as O +
a O +
receptor O +
that O +
mediates O +
apoptosis O +
in O +
neuronal O +
and O +
NB O +
cells O -
. O +

PROCEDURE O -
: O +
To O +
investigate O +
the O +
effect O +
of O +
p75 O +
expression O +
in O +
NB O -
, O +
we O +
transfected O +
the O +
p75 O +
cDNA O +
into O +
SH O -
- O -
SY5Y O +
cells O -
, O +
an O +
NB O +
cell O +
line O +
lacking O +
expression O +
of O +
both O +
p75 O +
and O +
TrkA. O +
RESULTS O -
: O +
Cell O +
clones O +
expressing O +
elevated O +
levels O +
of O +
p75 O +
showed O +
a O +
high O +
degree O +
of O +
apoptosis O +
even O +
in O +
10 O -
% O +
serum O -
- O -
supplemented O +
medium O -
. O +

Apoptotic O +
signaling O +
by O +
p75 O +
was O +
ligand O -
- O -
independent O +
and O +
only O +
partly O +
caspase O -
- O -
dependent O -
. O +

The O +
level O +
of O +
apoptosis O +
correlated O +
directly O +
with O +
the O +
expression O +
level O +
of O +
the O +
receptor O -
, O +
indicating O +
that O +
p75 O +
may O +
activate O +
the O +
cell O +
death O +
program O +
directly O -
. O +

However O -
, O +
additional O +
transfection O +
of O +
TrkA O +
into O +
SY5Y O -
- O -
p75 O +
cells O +
resulted O +
in O +
a O +
significantly O +
reduced O +
rate O +
of O +
apoptosis O +
even O +
in O +
the O +
absence O +
of O +
NGF O -
. O +

CONCLUSIONS O -
: O +
Thus O -
, O +
expression O +
of O +
the O +
TrkA O +
receptor O +
itself O +
inhibits O +
p75 O +
mediated O +
apoptosis O +
in O +
NB O +
cells O -
. O +

RNA O +
damage O +
and O +
inhibition O +
of O +
neoplastic O +
endothelial O +
cell O +
growth O -
: O +
effects O +
of O +
human O +
and O +
amphibian O +
ribonucleases O -
. O +

Angiogenesis O +
defines O +
the O +
many O +
steps O +
involved O +
in O +
the O +
growth O +
and O +
migration O +
of O +
endothelial O +
cell O -
- O -
derived O +
blood O +
vessels O -
. O +

This O +
process O +
is O +
necessary O +
for O +
the O +
growth O +
and O +
metastasis O +
of O +
tumors O -
, O +
and O +
considerable O +
effort O +
is O +
being O +
expended O +
to O +
find O +
inhibitors O +
of O +
tumor O +
angiogenesis O -
. O +

This O +
usually O +
involves O +
screening O +
of O +
potential O +
anti O -
- O -
angiogenic O +
compounds O +
on O +
endothelial O +
cells O -
. O +

To O +
this O +
end O -
, O +
two O +
candidate O +
anti O -
- O -
angiogenic O +
RNA O -
- O -
damaging O +
agents O -
, O +
onconase B-Chemical +
and O +
( B-Chemical -
-4 I-Chemical -
) I-Chemical -
rhEDN I-Chemical -
, O +
were O +
screened O +
for O +
their O +
effects O +
on O +
endothelial O +
cell O +
proliferation O +
using O +
three O +
distinct O +
types O +
of O +
endothelial O +
cells O +
in O +
culture O -
: O +
HPV-16 O +
E6 O -
/ O -
E7-immortalized O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
( O -
HUVECs O -
) O -
, O +
a O +
Kras O -
- O -
transformed O +
HPV-16 O +
E6 O -
/ O -
E7 O +
HUVEC O +
( O -
Rhim O +
et O +
al. O -
, O +
Carcinogenesis O +
4 O -
, O +
673 O -
- O -
681 O -
, O +
1998 O -
) O -
, O +
and O +
primary O +
HUVECs O -
. O +

Onconase B-Chemical +
similarly O +
inhibited O +
proliferation O +
in O +
all O +
three O +
cell O +
lines O +
( O -
IC O -
( O -
50 O -
) O +
= O +
0.3 O -
- O -
1.0 O +
microM O -
) O +
while O +
( B-Chemical -
-4 I-Chemical -
) I-Chemical -
rhEDN I-Chemical +
was O +
more O +
effective O +
on O +
immortalized O +
HUVEC O +
cell O +
lines O +
( O -
IC O -
( O -
50 O -
) O +
= O +
0.02 O -
- O -
0.06 O +
microM O -
) O +
than O +
on O +
primary O +
HUVECs O +
( O -
IC O -
( O -
50 O -
) O +
> O +
0.1 O +
microM O -
) O -
. O +

Differential O +
sensitivity O +
to O +
these O +
agents O +
implies O +
that O +
more O +
than O +
one O +
endothelial O +
cell O +
type O +
must O +
be O +
used O +
in O +
proliferation O +
assays O +
to O +
screen O +
for O +
novel O +
anti O -
- O -
angiogenic O +
compounds O -
. O +

A O +
small O +
peptide O +
derived O +
from O +
Flt-1 O +
( O -
VEGFR-1 O -
) O +
functions O +
as O +
an O +
angiogenic O +
inhibitor O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
is O +
an O +
angiogenic O +
stimulator O +
which O +
functions O +
through O +
two O +
endothelial O +
specific O +
tyrosine O +
kinase O +
receptors O -
, O +
Flt-1 O +
and O +
Flk-1 O -
. O +

In O +
this O +
work O -
, O +
we O +
show O +
that O +
an O +
11-amino O +
acid O +
peptide O +
derived O +
from O +
the O +
second O +
immunoglobulin O -
- O -
like O +
domain O +
of O +
Flt-1 O +
functions O +
as O +
an O +
angiogenic O +
inhibitor O +
in O +
chick O +
chorioallantoic O +
membrane O +
and O +
inhibited O +
VEGF O -
- O -
induced O +
vascular O +
permeability O +
in O +
Miles O -
' O +
assay O +
without O +
binding O +
to O +
VEGF O +
directly O -
. O +

Circular O +
dichroism O +
and O +
nuclear O +
magnetic O +
resonance O +
analyses O +
indicate O +
that O +
this O +
peptide O +
forms O +
a O +
stable O +
extended O +
structure O +
in O +
solution O -
, O +
presumably O +
beta O -
- O -
sheet O +
structure O +
and O +
is O +
most O +
likely O +
existing O +
as O +
a O +
dimer O -
. O +

Our O +
results O +
suggest O +
that O +
this O +
small O +
peptide O +
functions O +
as O +
an O +
angiogenic O +
inhibitor O +
by O +
inhibiting O +
VEGF O +
function O +
through O +
a O +
non O -
- O -
VEGF O +
binding O +
mechanism O -
. O +

[ O -
mRNA O +
expression O +
of O +
metastasis O -
- O -
suppressor O +
gene O +
nm23 O +
in O +
carcinoma O +
of O +
buccal O +
mucosa O -
. O +

II O -
. O +

Quantitative O +
reverse O +
transcription O +
PCR O +
amplification O -
] O -
. O +

The O +
nm23 O +
gene O +
is O +
a O +
conspicuous O +
metastasis O -
- O -
suppressor O +
gene O -
. O +

The O +
authors O +
detected O +
both O +
nm23-H1 O +
and O +
nm23-H2 O +
mRNA O +
levels O +
in O +
47 O +
tissues O +
samples O +
of O +
patients O +
with O +
carcinoma O +
of O +
buccal O +
mucosa O +
( O -
CBM O -
) O +
by O +
quantitative O +
reverse O +
transcription O +
PCR O +
amplification O -
. O +

The O +
results O +
showed O +
that O +
expression O +
levels O +
of O +
both O +
nm23-H1 O +
and O +
nm23-H2 O +
mRNA O +
varied O +
in O +
normal O +
buccal O +
mucosa O -
, O +
leukoplakia O -
, O +
adjacent O +
nontumorous O +
mucosa O -
, O +
submandibular O +
gland O -
, O +
CBM O +
and O +
lymph O +
nodes O +
with O +
or O +
without O +
metastasis O -
. O +

The O +
nm23-H1 O +
mRNA O +
expression O +
levels O +
in O +
CBM O +
with O +
lymph O +
nodes O +
metastases O +
were O +
lower O +
than O +
those O +
in O +
CBM O +
without O +
metastases O +
( O -
P O +
< O +
0.05 O -
) O -
, O +
while O +
no O +
significance O +
of O +
nm23-H2 O +
mRNA O +
expression O +
levels O +
was O +
found O +
between O +
CBM O +
with O +
and O +
CBM O +
without O +
metastasis O +
( O -
P O +
> O +
0.05 O -
) O -
. O +

The O +
results O +
were O +
comparative O +
to O +
those O +
of O +
Northern O +
blotting O +
of O +
the O +
same O +
cases O -
. O +

The O +
authors O +
concluded O +
that O -
, O +
as O +
also O +
in O +
the O +
study O +
of O +
Northern O +
blotting O -
, O +
the O +
expression O +
of O +
nm23-H1 O +
mRNA O +
significantly O +
correlated O +
inversely O +
with O +
lymph O +
node O +
metastasis O +
in O +
CBM O -
, O +
while O +
the O +
expression O +
of O +
nm23-H2 O +
mRNA O +
not O -
. O +

Q O -
- O -
RT O -
- O -
PCR O +
was O +
a O +
useful O +
method O +
to O +
detect O +
the O +
mRNA O +
levels O +
of O +
nm23 O +
gene O +
in O +
buccal O +
carcinoma O -
. O +

Clinical O +
significance O +
of O +
plasma O +
endostatin O +
in O +
acute O +
myeloid O +
leukemia O -
/ O -
myelodysplastic O +
syndrome O -
. O +

BACKGROUND O -
: O +
Endostatin O -
, O +
a O +
C O -
- O -
terminal O +
fragment O +
of O +
collagen O +
XVIII O -
, O +
is O +
an O +
endogenous O +
angiogenesis O +
inhibitor O -
. O +

While O +
endostatin O +
is O +
being O +
investigated O +
for O +
its O +
usefulness O +
in O +
treating O +
solid O +
tumors O -
, O +
its O +
significance O +
in O +
hematologic O +
malignancies O +
is O +
unknown O -
. O +

METHODS O -
: O +
The O +
authors O +
evaluated O +
plasma O +
endostatin O +
( O -
PE O -
) O +
levels O +
using O +
an O +
enzyme O +
linked O +
immunoassay O +
in O +
71 O +
patients O +
with O +
acute O +
myeloid O +
leukemia O +
( O -
AML O -
) O +
and O +
43 O +
patients O +
with O +
myelodysplastic O +
syndrome O +
( O -
MDS O -
) O -
, O +
and O +
correlated O +
PE O +
with O +
various O +
clinical O +
parameters O -
. O +

RESULTS O -
: O +
There O +
was O +
no O +
significant O +
difference O +
in O +
the O +
median O +
PE O +
level O +
between O +
AML O -
/ O -
MDS O +
patients O +
and O +
the O +
normal O +
controls O -
. O +

Nevertheless O -
, O +
patients O +
who O +
achieved O +
complete O +
remission O +
( O -
CR O -
) O +
had O +
a O +
significantly O +
lower O +
median O +
PE O +
level O +
compared O +
to O +
those O +
who O +
did O +
not O -
. O +

In O +
multivariate O +
analysis O -
, O +
PE O +
was O +
found O +
to O +
be O +
a O +
significant O +
( O -
P O +
= O +
0.03 O -
) O +
predictor O +
of O +
overall O +
survival O +
( O -
OS O -
) O +
with O +
adjustment O +
of O +
the O +
other O +
baseline O +
covariates O -
, O +
including O +
patient O +
age O -
, O +
history O +
of O +
antecedent O +
hematologic O +
disorders O -
, O +
and O +
the O +
use O +
of O +
protective O +
environments O -
. O +

The O +
prognostic O +
value O +
of O +
PE O +
was O +
also O +
evaluated O +
by O +
dividing O +
MDS O -
/ O -
AML O +
patients O +
into O +
high O +
and O +
low O +
PE O +
groups O +
using O +
the O +
median O +
PE O +
level O +
of O +
normal O +
controls O +
as O +
the O +
cut O -
- O -
off O -
. O +

The O +
authors O +
found O +
that O +
patients O +
in O +
the O +
high O +
PE O +
group O +
survived O +
for O +
a O +
significantly O +
shorter O +
time O +
than O +
those O +
patients O +
in O +
the O +
low O +
PE O +
group O -
. O +

CONCLUSIONS O -
: O +
PE O +
is O +
a O +
useful O +
prognostic O +
predictor O +
of O +
CR O +
and O +
OS O +
for O +
AML O -
/ O -
MDS O +
patients O -
. O +

The O +
mechanism O +
underlying O +
the O +
association O +
between O +
high O +
PE O +
and O +
poor O +
clinical O +
outcome O +
is O +
unclear O -
, O +
although O +
it O +
may O +
be O +
related O +
to O +
the O +
possible O +
PE O +
reflection O +
of O +
tumor O +
burden O -
. O +

VEGF165 O +
mediates O +
formation O +
of O +
complexes O +
containing O +
VEGFR-2 O +
and O +
neuropilin-1 O +
that O +
enhance O +
VEGF165-receptor O +
binding O -
. O +

Co O -
- O -
expression O +
of O +
NRP1 O +
and O +
( O -
VEGFR-2 O -
) O +
KDR O +
on O +
the O +
surface O +
of O +
endothelial O +
cells O +
( O -
EC O -
) O +
enhances O +
VEGF165 O +
binding O +
to O +
KDR O +
and O +
EC O +
chemotaxis O +
in O +
response O +
to O +
VEGF165 O -
. O +

Overexpression O +
of O +
NRP1 O +
by O +
prostate O +
tumor O +
cells O +
in O +
vivo O +
results O +
in O +
increased O +
tumor O +
angiogenesis O +
and O +
growth O -
. O +

We O +
investigated O +
the O +
molecular O +
mechanisms O +
underlying O +
NRP1-mediated O +
angiogenesis O +
by O +
analyzing O +
the O +
association O +
of O +
NRP1 O +
and O +
KDR O -
. O +

An O +
intracellular O +
complex O +
containing O +
NRP1 O +
and O +
KDR O +
was O +
immunoprecipitated O +
from O +
EC O +
by O +
anti O -
- O -
NRP1 O +
antibodies O +
only O +
in O +
the O +
presence O +
of O +
VEGF165 O -
. O +

In O +
contrast O -
, O +
VEGF121 O -
, O +
which O +
does O +
not O +
bind O +
to O +
NRP1 O -
, O +
did O +
not O +
support O +
complex O +
formation O -
. O +

Complexes O +
containing O +
VEGF165 O -
, O +
NRP1 O -
, O +
and O +
KDR O +
were O +
also O +
formed O +
in O +
an O +
intercellular O +
fashion O +
by O +
co O -
- O -
culture O +
of O +
EC O +
expressing O +
KDR O +
only O -
, O +
with O +
cells O +
expressing O +
NRP1 O +
only O -
, O +
for O +
example O -
, O +
breast O +
carcinoma O +
cells O -
. O +

VEGF165 O +
also O +
mediated O +
the O +
binding O +
of O +
a O +
soluble O +
NRP1 O +
dimer O +
to O +
cells O +
expressing O +
KDR O +
only O -
, O +
confirming O +
the O +
formation O +
of O +
such O +
complexes O -
. O +

Furthermore O -
, O +
the O +
formation O +
of O +
complexes O +
containing O +
KDR O +
and O +
NRP1 O +
markedly O +
increased O +
125I O -
- O -
VEGF165 O +
binding O +
to O +
KDR O -
. O +

Our O +
results O +
suggest O +
that O +
formation O +
of O +
a O +
ternary O +
complex O +
of O +
VEGF165 O -
, O +
KDR O -
, O +
and O +
NRP1 O +
potentiates O +
VEGF165 O +
binding O +
to O +
KDR O -
. O +

These O +
complexes O +
are O +
formed O +
on O +
the O +
surface O +
of O +
EC O +
and O +
in O +
a O +
juxtacrine O +
manner O +
via O +
association O +
of O +
tumor O +
cell O +
NRP1 O +
and O +
EC O +
KDR O -
. O +

Pten O +
signaling O +
in O +
gliomas O -
. O +

In O +
1997 O -
, O +
the O +
PTEN O +
gene O +
( O -
phosphatase O +
and O +
tensin O +
homolog O +
deleted O +
on O +
chromosome O +
10 O -
) O +
was O +
identified O +
as O +
a O +
tumor O +
suppressor O +
gene O +
on O +
the O +
long O +
arm O +
of O +
chromosome O +
10 O -
. O +

Since O +
then O -
, O +
important O +
progress O +
has O +
been O +
made O +
with O +
respect O +
to O +
the O +
understanding O +
of O +
the O +
role O +
of O +
the O +
Pten O +
protein O +
in O +
the O +
normal O +
development O +
of O +
the O +
brain O +
as O +
well O +
as O +
in O +
the O +
molecular O +
pathogenesis O +
of O +
human O +
gliomas O -
. O +

This O +
review O +
summarizes O +
the O +
current O +
state O +
of O +
the O +
art O +
concerning O +
the O +
involvement O +
of O +
aberrant O +
Pten O +
function O +
in O +
the O +
development O +
of O +
different O +
biologic O +
features O +
of O +
malignant O +
gliomas O -
, O +
such O +
as O +
loss O +
of O +
cell O -
- O -
cycle O +
control O +
and O +
uncontrolled O +
cell O +
proliferation O -
, O +
escape O +
from O +
apoptosis O -
, O +
brain O +
invasion O -
, O +
and O +
aberrant O +
neoangiogenesis O -
. O +

Most O +
of O +
the O +
tumor O -
- O -
suppressive O +
properties O +
of O +
Pten O +
are O +
dependent O +
on O +
its O +
lipid B-Chemical +
phosphatase O +
activity O -
, O +
which O +
inhibits O +
the O +
phosphatidylinositol-3'-kinase O +
( O -
PI3K O -
) O -
/ O -
Akt O +
signaling O +
pathway O +
through O +
dephosphorylation O +
of O +
phosphatidylinositol- B-Chemical -
( I-Chemical -
3,4,5 I-Chemical -
) I-Chemical -
-triphosphate I-Chemical -
. O +

The O +
additional O +
function O +
of O +
Pten O +
as O +
a O +
dual O -
- O -
specificity O +
protein O +
phosphatase O +
may O +
also O +
play O +
a O +
role O +
in O +
glioma O +
pathogenesis O -
. O +

Besides O +
the O +
wealth O +
of O +
data O +
elucidating O +
the O +
functional O +
roles O +
of O +
Pten O -
, O +
recent O +
studies O +
suggest O +
a O +
diagnostic O +
significance O +
of O +
PTEN O +
gene O +
alterations O +
as O +
a O +
molecular O +
marker O +
for O +
poor O +
prognosis O +
in O +
anaplastic O +
astrocytomas O +
and O +
anaplastic O +
oligodendrogliomas O -
. O +

Furthermore O -
, O +
the O +
possibility O +
of O +
selective O +
targeting O +
of O +
PTEN O +
mutant O +
tumor O +
cells O +
by O +
specific O +
pharmacologic O +
inhibitors O +
of O +
members O +
of O +
the O +
Pten O -
/ O -
PI3K O -
/ O -
Akt O +
pathway O +
opens O +
up O +
new O +
perspectives O +
for O +
a O +
targeted O +
molecular O +
therapy O +
of O +
malignant O +
gliomas O -
. O +

[ O -
A O +
case O +
report O +
of O +
advanced O +
gastric O +
cancer O +
responding O +
to O +
TS-1 B-Chemical -
, O +
a O +
novel O +
oral O +
fluorouracil B-Chemical +
derivative O -
] O -
. O +

TS-1 B-Chemical +
is O +
a O +
new O -
, O +
oral O +
anticancer O +
agent O +
composed O +
of O +
two O +
modulators O -
, O +
gimeracil B-Chemical +
( O -
CDHP B-Chemical -
) O +
and O +
oteracil B-Chemical +
potassium I-Chemical +
( O -
Oxo B-Chemical -
) O +
are O +
mixed O +
with O +
tegafur B-Chemical +
in O +
a O +
ratio O +
of O +
1:0.4:1 O -
. O +

We O +
report O +
one O +
case O +
of O +
advanced O +
gastric O +
cancer O +
with O +
lung O +
and O +
lymph O +
node O +
metastases O +
that O +
completely O +
responded O +
to O +
TS-1 B-Chemical -
. O +

A O +
71-year O -
- O -
old O +
woman O +
was O +
admitted O +
to O +
our O +
hospital O +
because O +
of O +
breathlessness O -
. O +

A O +
diagnosis O +
of O +
advanced O +
gastric O +
cancer O +
with O +
extensive O +
lymph O +
node O +
metastases O +
and O +
multiple O +
pulmonary O +
metastases O +
was O +
made O -
. O +

One O +
hundred O +
mg O -
/ O -
body O -
/ O -
day O +
of O +
TS-1 B-Chemical +
was O +
orally O +
administrated O +
for O +
4 O +
weeks O -
. O +

A O +
partial O +
response O +
( O -
PR O -
) O +
was O +
obtained O +
after O +
the O +
first O +
course O +
with O +
regression O +
of O +
multiple O +
pulmonary O +
metastases O -
. O +

After O +
1 O +
drug O -
- O -
free O +
week O -
, O +
the O +
second O +
course O +
was O +
administered O +
with O +
120 O +
mg O -
/ O -
body O -
/ O -
day O +
of O +
TS-1 B-Chemical +
for O +
4 O +
weeks O -
. O +

After O +
two O +
courses O -
, O +
the O +
primary O +
tumor O +
was O +
reduced O +
to O +
an O +
ulcer O +
scar O +
with O +
pathological O +
confirmation O +
of O +
a O +
complete O +
disappearance O +
of O +
the O +
cancer O +
tissue O -
. O +

Moreover O -
, O +
computed O +
tomography O +
( O -
CT O -
) O +
showed O +
a O +
complete O +
regression O +
of O +
the O +
extensive O +
lymph O +
node O +
and O +
diffuse O +
lung O +
metastases O -
, O +
for O +
a O +
complete O +
response O +
( O -
CR O -
) O -
. O +

The O +
serum O +
level O +
of O +
CEA O +
was O +
reduced O +
from O +
172.7 O +
ng O -
/ O -
ml O +
to O +
8.1 O +
ng O -
/ O -
ml O +
after O +
TS-1 B-Chemical +
treatment O -
. O +

As O +
for O +
adverse O +
events O -
, O +
only O +
pigmentation O +
of O +
the O +
skin O +
and O +
Grade O +
2 O +
oral O +
aphta O +
were O +
observed O -
. O +

Simian O +
virus O +
40 O +
large O +
T O +
antigen O +
and O +
two O +
independent O +
T O -
- O -
antigen O +
segments O +
sensitize O +
cells O +
to O +
apoptosis O +
following O +
genotoxic O +
damage O -
. O +

The O +
simian O +
virus O +
40 O +
( O -
SV40 O -
) O +
large O +
tumor O +
( O -
T O -
) O +
antigen O +
is O +
sufficient O +
to O +
transform O +
cells O +
in O +
cultures O +
and O +
induce O +
tumors O +
in O +
experimental O +
animals O -
. O +

Transformation O +
of O +
primary O +
cells O +
in O +
cultures O +
requires O +
both O +
overcoming O +
growth O +
arrest O +
by O +
stimulating O +
the O +
cell O +
cycle O +
and O +
blocking O +
cell O +
death O +
activities O +
presumably O +
activated O +
by O +
oncogene O -
- O -
mediated O +
hyperproliferation O +
signals O -
. O +

The O +
study O +
presented O +
here O +
examined O +
the O +
ability O +
of O +
specific O +
regions O +
and O +
activities O +
of O +
T O +
antigen O +
to O +
modulate O +
apoptosis O +
in O +
cells O +
treated O +
with O +
the O +
genotoxic O +
agent O +
5-fluorouracil B-Chemical +
( O -
5-FU B-Chemical -
) O -
. O +

The O +
results O +
showed O +
that O +
the O +
expression O +
of O +
full O -
- O -
length O +
T O +
antigen O +
rendered O +
rat O +
embryo O +
fibroblasts O +
( O -
REF O -
) O +
sensitive O +
to O +
5-FU B-Chemical -
- O -
induced O +
apoptosis O -
. O +

Thus O -
, O +
neither O +
the O +
p53-binding O +
region O +
nor O +
the O +
Bcl-2 O +
homology O +
region O +
of O +
T O +
antigen O +
was O +
sufficient O +
to O +
prevent O +
cell O +
death O +
induced O +
by O +
the O +
DNA O -
- O -
damaging O +
agent O -
. O +

T O -
- O -
antigen O -
- O -
mediated O +
sensitization O +
occurred O +
independently O +
of O +
retinoblastoma O +
protein O +
or O +
p53 O +
and O +
p300 O +
binding O -
. O +

An O +
N O -
- O -
terminal O +
segment O +
containing O +
the O +
first O +
127 O +
T O -
- O -
antigen O +
amino O +
acids O +
( O -
T1 O -
- O -
127 O -
) O +
was O +
sufficient O +
to O +
sensitize O +
cells O -
. O +

A O +
C O -
- O -
terminal O +
segment O +
consisting O +
of O +
T O -
- O -
antigen O +
amino O +
acids O +
251 O +
to O +
708 O +
( O -
T251 O -
- O -
708 O -
) O +
also O +
sensitized O +
cells O +
to O +
5-FU B-Chemical -
- O -
induced O +
apoptosis O -
. O +

This O +
sensitization O +
did O +
not O +
occur O +
when O +
T251 O -
- O -
708 O +
was O +
targeted O +
to O +
the O +
nucleus O +
by O +
inclusion O +
of O +
the O +
SV40 O +
nuclear O +
localization O +
signal O -
. O +

The O +
introduction O +
of O +
mutations O +
into O +
the O +
T O -
- O -
antigen O +
J O +
domain O +
resulted O +
in O +
mutation O -
- O -
specific O +
and O +
variable O +
inhibition O +
of O +
apoptosis O -
. O +

This O +
result O +
suggested O +
that O +
either O +
the O +
structural O +
or O +
the O +
functional O +
integrity O +
of O +
the O +
J O +
domain O +
is O +
required O +
to O +
sensitize O +
cells O +
to O +
apoptosis O -
. O +

Treatment O +
of O +
REF O +
or O +
REF O +
expressing O +
full O -
- O -
length O +
T O +
antigen O -
, O +
an O +
N O -
- O -
terminal O +
segment O -
, O +
or O +
T251 O -
- O -
708 O +
resulted O +
in O +
increased O +
expression O +
of O +
the O +
p53-responsive O +
MDM2 O +
gene O -
; O +
apoptosis O +
occurred O +
through O +
a O +
p53-dependent O +
pathway O -
, O +
as O +
p53-null O +
cells O +
expressing O +
these O +
T O +
antigens O +
were O +
resistant O +
to O +
5-FU B-Chemical -
- O -
induced O +
apoptosis O -
. O +

Possible O +
mechanisms O +
involved O +
in O +
sensitizing O +
cells O +
to O +
a O +
p53-dependent O +
apoptosis O +
pathway O +
in O +
spite O +
of O +
the O +
ability O +
of O +
T O +
antigen O +
to O +
bind O +
and O +
inactivate O +
the O +
transcriptional O +
transactivating O +
activity O +
of O +
p53 O +
are O +
discussed O -
. O +

Optimizing O +
treatment O +
of O +
choroidal O +
neovascularization O +
feeder O +
vessels O +
associated O +
with O +
age O -
- O -
related O +
macular O +
degeneration O -
. O +

PURPOSE O -
: O +
To O +
optimize O +
the O +
method O +
of O +
treating O +
choroidal O +
neovascularization O +
( O -
CNV O -
) O +
associated O +
with O +
age O -
- O -
related O +
macular O +
degeneration O +
( O -
AMD O -
) O -
. O +

DESIGN O -
: O +
Experimental O +
study O +
and O +
interventional O +
case O +
series O -
. O +

METHODS O -
: O +
The O +
parameters O +
associated O +
with O +
locating O +
and O +
then O +
photocoagulating O +
CNV O +
feeder O +
vessels O +
were O +
identified O +
and O +
optimized O +
using O +
published O +
data O +
and O +
data O +
derived O +
from O +
modeling O +
the O +
choroidal O +
vasculature O -
. O +

Based O +
on O +
these O +
optimized O +
parameters O -
, O +
a O +
prototype O +
diagnostic O -
/ O -
treatment O +
system O +
was O +
designed O +
that O +
captures O +
high O -
- O -
speed O +
indocyanine B-Chemical +
green I-Chemical +
( O -
ICG B-Chemical -
) O +
angiogram O +
images O +
and O +
facilitates O +
analysis O +
of O +
the O +
images O +
by O +
enhancing O +
visualization O +
of O +
dye O +
movement O +
through O +
CNV O +
feeder O +
vessels O +
( O -
FVs O -
) O -
. O +

The O +
system O +
also O +
permits O +
precise O +
aiming O +
and O +
delivery O +
of O +
810- O +
nm O +
wavelength O +
photocoagulation O +
laser O +
energy O +
to O +
target O +
FVs O +
on O +
a O +
real O -
- O -
time O +
ICG B-Chemical +
angiogram O +
image O +
of O +
the O +
choroidal O +
vasculature O -
. O +

Target O +
FVs O +
are O +
tracked O +
by O +
a O +
joy O -
- O -
stick O +
controlled O +
laser O +
aiming O +
beam O +
until O +
an O +
intravenously O -
- O -
injected O +
high O -
- O -
concentration O +
ICG B-Chemical +
dye I-Chemical +
bolus O +
is O +
observed O +
to O +
enter O +
the O +
target O +
vessel O -
, O +
at O +
which O +
time O +
the O +
laser O +
is O +
fired O -
. O +

Proof O +
of O +
principle O +
of O +
the O +
combined O +
diagnosis O -
/ O -
treatment O +
system O +
design O +
for O +
performing O +
dye O -
- O -
enhanced O +
photocoagulation O +
( O -
DEP O -
) O +
in O +
the O +
clinical O +
setting O +
and O +
determination O +
of O +
the O +
minimum O +
DEP O +
laser O +
energy O +
needed O +
to O +
close O +
CNV O +
FVs O +
was O +
made O +
in O +
11 O +
AMD O +
patients O +
requiring O +
treatment O +
of O +
CNV O -
, O +
but O +
for O +
whom O +
other O +
treatment O +
was O +
not O +
appropriate O -
. O +

RESULTS O -
: O +
Using O +
ICG B-Chemical -
- O -
DEP O -
, O +
CNV O +
feeder O +
vessels O +
were O +
closed O +
with O +
single O +
pulse O +
laser O +
energy O -
, O +
delivering O +
as O +
little O +
as O +
0.6 O +
to O +
1.8 O +
J O +
of O +
energy O +
to O +
the O +
fundus O -
, O +
producing O +
no O +
visible O +
change O +
in O +
the O +
fundus O -
. O +

Successful O +
FV O +
closure O +
was O +
usually O +
indicated O +
immediately O +
by O +
presence O +
of O +
incarcerated O +
ICG B-Chemical +
dye I-Chemical +
in O +
the O +
vessel O +
adjacent O +
to O +
the O +
burn O +
site O -
. O +

The O +
prototype O +
system O +
proved O +
relatively O +
easy O +
to O +
operate O -
. O +

After O +
acquiring O +
and O +
interpreting O +
diagnostic O +
angiograms O +
and O +
repositioning O +
a O +
patient O +
in O +
front O +
of O +
the O +
device O -
, O +
feeder O +
vessel O +
DEP O +
and O +
treatment O +
evaluation O +
required O +
15 O +
to O +
20 O +
minutes O -
. O +

CONCLUSIONS O -
: O +
Indocyanine B-Chemical +
green I-Chemical +
dye I-Chemical -
- O -
enhanced O +
photocoagulation O +
of O +
CNV O +
feeder O +
vessels O -
, O +
facilitated O +
by O +
use O +
of O +
a O +
device O +
that O +
permits O +
real O -
- O -
time O +
visualization O +
of O +
the O +
choroidal O +
circulation O +
while O +
aiming O +
the O +
treatment O +
laser O +
beam O -
, O +
appears O +
to O +
minimize O +
the O +
amount O +
of O +
energy O +
applied O +
to O +
the O +
fundus O +
and O +
the O +
volume O +
of O +
fundus O +
tissue O +
affected O +
by O +
treatment O -
, O +
compared O +
with O +
other O +
treatment O +
modalities O -
. O +

The O +
combination O +
diagnosis O -
/ O -
treatment O +
device O +
should O +
be O +
useful O +
in O +
optimizing O +
FV O +
treatment O +
and O +
in O +
refining O +
and O +
evaluating O +
the O +
efficacy O +
of O +
DEP O +
in O +
future O +
clinical O +
trials O -
. O +

Inhibition O +
of O +
angiogenesis O +
by O +
the O +
cancer O +
chemopreventive O +
agent O +
conjugated B-Chemical +
linoleic I-Chemical +
acid I-Chemical -
. O +

Dietary O +
conjugated B-Chemical +
linoleic I-Chemical +
acid I-Chemical +
( O -
CLA B-Chemical -
) O +
has O +
been O +
shown O +
previously O +
to O +
inhibit O +
rat O +
mammary O +
carcinogenesis O -
. O +

In O +
addition O +
to O +
direct O +
effects O +
on O +
mammary O +
epithelial O +
cells O -
, O -
including O +
decreased O +
proliferation O +
and O +
induction O +
of O +
apoptosis O -
, O +
CLA B-Chemical +
may O +
exert O +
its O +
effects O +
indirectly O +
by O +
inhibiting O +
the O +
differentiation O +
of O +
mammary O +
stromal O +
cells O +
to O +
an O +
endothelial O +
cell O +
type O -
. O +

Specifically O -
, O +
CLA B-Chemical +
was O +
found O +
to O +
decrease O +
the O +
ability O +
of O +
mammary O +
stromal O +
cells O +
to O +
form O +
complex O +
anastomosing O +
microcapillary O +
networks O +
in O +
vitro O +
on O +
Engelbreth O -
- O -
Holm O -
- O -
Swarm O -
- O -
derived O +
reconstituted O +
basement O +
membrane O -
. O +

This O +
suggested O +
that O +
CLA B-Chemical +
might O +
inhibit O +
angiogenesis O +
in O +
vivo O -
. O +

To O +
test O +
this O +
possibility O -
, O +
CD2 O -
/ O -
F O -
( O -
1 O -
) O +
mice O +
were O +
placed O +
on O +
synthetic O +
diets O +
containing O +
0 O -
, O +
1 O -
, O +
or O +
2 O -
% O +
CLA B-Chemical +
for O +
6 O +
weeks O -
, O +
before O +
angiogenic O +
challenge O +
by O +
s.c O -
. O +

injection O +
with O +
an O +
angiogenic O +
gel O +
substrate O +
( O -
Matrigel O +
pellet O +
assay O -
) O -
. O +

After O +
7 O +
days O -
, O +
the O +
pellets O +
from O +
animals O +
fed O +
the O +
control O +
diet O +
were O +
infiltrated O +
by O +
abundant O +
branching O +
networks O +
of O +
blood O +
vessels O +
with O +
patent O +
lumen O -
- O -
containing O +
RBCs O -
. O +

In O +
contrast O -
, O +
pellets O +
from O +
the O +
CLA B-Chemical -
- O -
fed O +
animals O +
contained O +
fewer O +
infiltrating O +
cells O -
, O +
which O +
formed O +
limited O +
branching O +
cellular O +
networks O -
, O +
the O +
majority O +
of O +
which O +
had O +
collapsed O +
lumen O +
and O +
no O +
RBCs O -
. O +

Both O +
levels O +
of O +
dietary O +
CLA B-Chemical +
showed O +
similar O +
effects O -
, O +
with O +
the O +
number O +
of O +
RBC O -
- O -
containing O +
vessels O +
per O +
20x O +
field O +
decreased O +
to O +
a O +
third O +
of O +
that O +
seen O +
in O +
control O -
. O +

Dietary O +
CLA B-Chemical +
decreased O +
serum O +
levels O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
and O +
whole O +
mammary O +
gland O +
levels O +
of O +
VEGF O +
and O +
its O +
receptor O +
Flk-1 O -
. O +

Both O +
cis-9 B-Chemical -
, O +
trans-11 B-Chemical +
and O +
trans-10 B-Chemical -
, O +
cis-12 B-Chemical +
CLA I-Chemical +
isomers I-Chemical +
were O +
effective O +
in O +
inhibiting O +
angiogenesis O +
in O +
vitro O +
in O +
a O +
dose O -
- O -
dependent O +
fashion O -
. O +

The O +
ability O +
of O +
CLA B-Chemical +
to O +
inhibit O +
angiogenesis O +
may O +
contribute O +
to O +
its O +
efficacy O +
as O +
a O +
chemopreventive O +
agent O -
. O +

Retinal O +
microangiopathies O +
overlying O +
pigment O +
epithelial O +
detachment O +
in O +
age O -
- O -
related O +
macular O +
degeneration O -
. O +

PURPOSE O -
: O +
To O +
evaluate O +
alterations O +
in O +
the O +
retinal O +
vasculature O +
overlying O +
pigment O +
epithelial O +
detachments O +
( O -
PED O -
) O +
in O +
exudative O +
age O -
- O -
related O +
macular O +
degeneration O +
( O -
ARMD O -
) O +
using O +
indocyanine B-Chemical +
green I-Chemical +
and O +
fluorescein B-Chemical +
angiography O -
. O +

METHODS O -
: O +
Forty O -
- O -
one O +
patients O +
( O -
41 O +
eyes O -
) O +
with O +
a O +
clinical O +
diagnosis O +
of O +
exudative O +
ARMD O +
with O +
PED O +
underwent O +
simultaneous O +
fluorescein B-Chemical +
and O +
indocyanine B-Chemical +
green I-Chemical +
angiography O -
, O +
also O +
under O +
high O +
( O -
10 O +
degrees O +
) O +
magnification O -
. O +

Vascular O +
abnormalities O +
in O +
the O +
retina O +
were O +
compared O +
between O +
patients O +
with O +
vascularized O +
( O -
n O +
= O +
34 O -
, O +
group O +
1 O -
) O +
and O +
nonvascularized O +
( O -
n O +
= O +
7 O -
, O +
group O +
2 O -
) O +
PED O +
on O +
indocyanine B-Chemical +
green I-Chemical +
angiography O +
and O +
correlated O +
with O +
the O +
size O +
of O +
the O +
PED O +
and O +
the O +
presence O +
of O +
serous O +
retinal O +
detachment O -
. O +

RESULTS O -
: O +
In O +
all O -
, O +
67 O +
vascular O +
abnormalities O +
were O +
found O +
by O +
indocyanine B-Chemical +
green I-Chemical +
angiography O +
and O +
only O +
22 O +
by O +
fluorescein B-Chemical +
angiography O -
; O +
this O +
finding O +
was O +
statistically O +
significant O +
( O -
P O +
less O +
than O +
0.0001 O -
) O -
. O +

The O +
finding O +
of O +
retinal O +
vasculopathy O +
( O -
32 O +
patients O +
in O +
group O +
1 O +
and O +
two O +
patients O +
in O +
group O +
2 O -
) O +
was O +
directly O +
correlated O +
with O +
the O +
presence O +
of O +
choroidal O +
neovascularizations O +
( O -
P O +
= O +
0.002 O -
) O -
. O +

There O +
was O +
also O +
a O +
direct O +
correlation O +
between O +
the O +
presence O +
of O +
choroidal O +
neovascularization O +
and O +
size O +
of O +
the O +
PED O +
( O -
P O +
= O +
0.03 O -
) O -
. O +

The O +
number O +
of O +
retinal O +
vascular O +
findings O +
was O +
not O +
significantly O +
correlated O +
with O +
serous O +
elevation O +
of O +
the O +
retina O -
. O +

CONCLUSIONS O -
: O +
Retinal O +
vasculopathies O +
may O +
be O +
observed O +
in O +
eyes O +
with O +
PED O +
and O +
are O +
detectable O +
by O +
indocyanine B-Chemical +
green I-Chemical +
and O +
fluorescein B-Chemical +
angiography O -
. O +

Effects O +
of O +
4-alkylmorpholine B-Chemical +
N I-Chemical -
- I-Chemical -
oxides I-Chemical +
on O +
ATP B-Chemical -
- O -
producing O +
processes O +
in O +
Ehrlich O +
ascites O +
and O +
L1210 O +
leukaemia O +
cells O -
. O +

The O +
main O +
purpose O +
of O +
the O +
present O +
investigation O +
was O +
to O +
study O +
the O +
effect O +
of O +
the O +
homologous O +
series O +
of O +
4-alkylmorpholine B-Chemical +
N I-Chemical -
- I-Chemical -
oxides I-Chemical +
on O +
ATP B-Chemical -
- O -
producing O +
processes O +
in O +
Ehrlich O +
ascites O +
and O +
L1210 O +
murine O +
leukaemia O +
cells O -
. O +

The O +
effects O +
on O +
aerobic O +
glucose B-Chemical +
consumption O -
, O +
lactic B-Chemical +
acid I-Chemical +
formation O -
, O +
content O +
of O +
total O +
( O -
T O -
- O -
SH O -
) O +
and O +
non O -
- O -
protein O +
thiol O +
groups O +
( O -
NP O -
- O -
SH O -
) O -
, O +
endogenous O +
and O +
exogenous O +
respiration O +
and O +
the O +
level O +
of O +
ATP B-Chemical +
in O +
tumour O +
cells O +
incubated O +
in O +
vitro O +
were O +
investigated O -
. O +

4-Dodecylmorpholine B-Chemical +
N I-Chemical -
- I-Chemical -
oxide I-Chemical +
( O -
DMNO B-Chemical -
) O -
, O +
one O +
of O +
the O +
most O +
active O +
compounds O -
, O +
decreased O +
the O +
level O +
of O +
ATP B-Chemical +
immediately O +
after O +
addition O +
to O +
the O +
suspension O +
of O +
Ehrlich O +
cells O +
in O +
an O +
ice O +
bath O -
. O +

After O +
2 O +
h O +
incubation O +
at O +
37 O +
degrees O +
C O +
the O +
drop O +
in O +
the O +
ATP B-Chemical +
level O +
was O +
much O +
lower O -
. O +

A O +
possible O +
explanation O +
for O +
the O +
decrease O +
in O +
the O +
ATP B-Chemical +
level O +
might O +
be O +
interaction O +
of O +
the O +
amine B-Chemical +
oxide I-Chemical +
with O +
the O +
cell O +
membrane O -
. O +

Enforced O +
expression O +
of O +
tissue O +
inhibitor O +
of O +
matrix O +
metalloproteinase-3 O +
affects O +
functional O +
capillary O +
morphogenesis O +
and O +
inhibits O +
tumor O +
growth O +
in O +
a O +
murine O +
tumor O +
model O -
. O +

Homeostasis O +
of O +
the O +
extracellular O +
matrix O +
is O +
a O +
delicate O +
balance O +
between O +
degradation O +
and O +
remodeling O -
, O +
the O +
balance O +
being O +
maintained O +
by O +
the O +
interaction O +
of O +
activated O +
matrix O +
metalloproteinases O +
( O -
MMPs O -
) O +
and O +
specific O +
tissue O +
inhibitors O +
of O +
matrix O +
metalloproteinases O +
( O -
TIMPs O -
) O -
. O +

Up O -
- O -
regulation O +
of O +
MMP O +
activity O -
, O +
favoring O +
proteolytic O +
degradation O +
of O +
the O +
basement O +
membrane O +
and O +
extracellular O +
matrix O -
, O +
has O +
been O +
linked O +
to O +
tumor O +
growth O +
and O +
metastasis O -
, O +
as O +
well O +
as O +
tumor O -
- O -
associated O +
angiogenesis O -
, O +
whereas O +
inhibition O +
of O +
MMP O +
activity O +
appears O +
to O +
restrict O +
these O +
processes O -
. O +

We O +
have O +
used O +
retroviral O -
- O -
mediated O +
gene O +
delivery O +
to O +
effect O +
sustained O +
autocrine O +
expression O +
of O +
TIMP-3 O +
in O +
murine O +
neuroblastoma O +
and O +
melanoma O +
tumor O +
cells O +
in O +
order O +
to O +
further O +
examine O +
the O +
ability O +
of O +
TIMPs O +
to O +
inhibit O +
angiogenesis O +
in O +
vivo O -
. O +

Growth O +
of O +
both O +
histologic O +
types O +
of O +
gene O -
- O -
modified O +
tumor O +
cells O +
in O +
severe O +
combined O +
immunodeficiency O +
( O -
SCID O -
) O +
mice O +
was O +
significantly O +
restricted O +
when O +
compared O +
with O +
controls O -
. O +

Grossly O -
, O +
these O +
tumors O +
were O +
small O +
and O +
had O +
few O +
feeding O +
vessels O -
. O +

Histologic O +
evaluation O +
revealed O +
that O +
although O +
tumors O +
overexpressing O +
TIMP-3 O +
had O +
an O +
increased O +
number O +
of O +
CD31 O -
( O -
+ O -
) O +
endothelial O +
cells O -
, O +
these O +
endothelial O +
cells O +
had O +
not O +
formed O +
functional O +
tubules O -
, O +
as O +
evidenced O +
by O +
decreased O +
vessel O +
continuity O +
and O +
minimal O +
pericyte O +
recruitment O -
. O +

This O +
effect O +
appears O +
to O +
be O +
mediated O -
, O +
in O +
part O -
, O +
by O +
decreased O +
expression O +
of O +
vascular O +
endothelial O +
( O -
VE O -
) O -
-cadherin O +
by O +
endothelial O +
cells O +
in O +
the O +
presence O +
of O +
TIMP-3 O +
as O +
seen O +
both O +
in O +
an O +
in O +
vitro O +
assay O +
and O +
in O +
TIMP-3-overexpressing O +
tumors O -
. O +

Taken O +
together O -
, O +
these O +
results O +
demonstrate O +
that O +
overexpression O +
of O +
TIMP-3 O +
can O +
inhibit O +
angiogenesis O +
and O +
associated O +
tumor O +
growth O -
, O +
and O +
that O +
the O +
antiangiogenic O +
effects O +
of O +
TIMP-3 O +
appear O +
to O +
be O +
mediated O +
through O +
the O +
inhibition O +
of O +
functional O +
capillary O +
morphogenesis O -
. O +

Fibroblast O +
growth O +
factor O +
2 O +
promotes O +
microvessel O +
formation O +
from O +
mouse O +
embryonic O +
aorta O -
. O +

To O +
delineate O +
the O +
roles O +
that O +
oxygen B-Chemical +
and O +
fibroblast O +
growth O +
factors O +
( O -
FGFs O -
) O +
play O +
in O +
the O +
process O +
of O +
angiogenesis O +
from O +
the O +
embryonic O +
aorta O -
, O +
we O +
cultured O +
mouse O +
embryonic O +
aorta O +
explants O +
( O -
thoracic O +
level O +
to O +
lateral O +
vessels O +
supplying O +
the O +
mesonephros O +
and O +
metanephros O -
) O +
in O +
a O +
three O -
- O -
dimensional O +
type O +
I O +
collagen O +
gel O +
matrix O -
. O +

During O +
8 O +
days O +
of O +
culture O +
under O +
5 O -
% O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
, O +
but O +
not O +
room O +
air O -
, O +
the O +
addition O +
of O +
FGF2 O +
to O +
explants O +
stimulated O +
the O +
formation O +
of O +
Gs O -
- O -
IB O -
( O -
4- O -
) O -
positive O -
, O +
CD31-positive O -
, O +
and O +
Flk-1-positive O +
microvessels O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O -
. O +

FGF2-stimulated O +
microvessel O +
formation O +
was O +
inhibited O +
by O +
sequestration O +
of O +
FGF2 O +
via O +
addition O +
of O +
soluble O +
FGF O +
receptor O +
( O -
FGFR O -
) O +
chimera O +
protein O +
or O +
anti O -
- O -
FGF2 O +
antibodies O -
. O +

FGFR1 O +
and O +
FGFR2 O +
were O +
present O +
on O +
explants O -
. O +

Levels O +
of O +
FGFR1 O -
, O +
but O +
not O +
FGFR2 O -
, O +
were O +
increased O +
in O +
embryonic O +
aorta O +
cultured O +
under O +
5 O -
% O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
relative O +
to O +
room O +
air O -
. O +

Our O +
data O +
suggest O +
that O +
low O +
oxygen B-Chemical +
upregulates O +
FGFR1 O +
expression O +
in O +
embryonic O +
aorta O +
in O +
vitro O +
and O +
renders O +
it O +
more O +
responsive O +
to O +
FGF2 O -
. O +

Downregulation O +
of O +
c O -
- O -
FLIP O +
sensitizes O +
DU145 O +
prostate O +
cancer O +
cells O +
to O +
Fas O -
- O -
mediated O +
apoptosis O -
. O +

Although O +
DU145 O +
prostate O +
cancer O +
cells O +
are O +
resistant O +
to O +
exogenously O +
applied O +
Fas O +
agonist O +
CH-11 O +
( O -
anti O -
- O -
Fas O +
monoclonal O +
antibody O -
) O -
, O +
Fas O -
- O -
resistance O +
can O +
be O +
overcome O +
using O +
a O +
FasL O +
expressing O +
adenovirus O +
( O -
AdGFPFasL O -
( O -
TET O -
) O -
) O +

[ O -
Hyer O +
et O +
al. O -
, O +
Molecular O +
Therapy O -
, O +
2000 O -
; O +
2:348 O -
- O -
58 O +
( O -
ref.12 O -
) O -
] O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
try O +
to O +
understand O +
why O +
DU145 O +
cells O +
are O +
resistant O +
to O +
CH-11 O +
and O +
determine O +
the O +
signaling O +
pathway O +
utilized O +
by O +
AdGFPFasL O -
( O -
TET O -
) O +
to O +
induce O +
apoptosis O +
in O +
these O +
Fas O -
- O -
resistant O +
cells O -
. O +

Using O +
immunoblot O +
analysis O -
, O +
we O +
show O +
that O +
AdGFPFasL O -
( O -
TET O -
) O +
is O +
capable O +
of O +
initiating O +
the O +
classic O +
Fas O -
- O -
mediated O +
apoptotic O +
pathway O +
in O +
DU145 O +
cells O -
, O +
which O +
includes O +
activation O +
of O +
caspases-8 O -
, O +
-3 O -
, O +
-7 O -
, O +
and O +
-9 O -
, O +
BID O +
cleavage O -
, O +
cytochrome O +
c O +
release O +
from O +
mitochondria O -
, O +
and O +
PARP O +
cleavage O -
. O +

In O +
contrast O -
, O +
CH-11 O +
binds O +
to O +
Fas O -
, O +
but O +
is O +
unable O +
to O +
transmit O +
the O +
death O +
signal O +
beyond O +
the O +
plasma O +
membrane O +
suggesting O +
a O +
block O +
at O +
the O +
DISC O +
( O -
death O +
inducing O +
signaling O +
complex O -
) O -
. O +

The O +
anti O -
- O -
apoptotic O +
protein O +
c O -
- O -
FLIP O +
( O -
cellular O +
Flice O -
- O -
like O +
inhibitory O +
protein O -
) O -
, O +
which O +
has O +
been O +
shown O +
to O +
inhibit O +
Fas O -
- O -
mediated O +
apoptosis O +
at O +
the O +
DISC O -
, O +
was O +
down O -
- O -
regulated O +
following O +
AdGFPFasL O -
( O -
TET O -
) O +
treatment O +
prompting O +
us O +
to O +
investigate O +
its O +
role O +
in O +
inhibiting O +
CH-11-induced O +
cell O +
death O -
. O +

Using O +
c O -
- O -
FLIP O +
anti O -
- O -
sense O +
oligonucleotides O +
to O +
down O -
- O -
regulate O +
c O -
- O -
FLIP O +
we O +
sensitized O +
DU145 O +
cells O +
to O +
CH-11-induced O +
apoptosis O -
. O +

These O +
data O +
suggest O +
that O +
c O -
- O -
FLIP O +
may O +
play O +
a O +
critical O +
role O +
in O +
regulating O +
Fas O -
- O -
mediated O +
apoptosis O +
in O +
prostate O +
cancer O +
cells O +
and O +
that O +
modulation O +
of O +
c O -
- O -
FLIP O +
may O +
enhance O +
Fas O +
signaling O +
based O +
therapies O -
. O +

Insulin O -
- O -
like O +
growth O +
factor O -
- O -
I O +
receptor O -
- O -
mediated O +
vasculogenesis O -
/ O -
angiogenesis O +
in O +
human O +
lung O +
development O -
. O +

The O +
structural O +
and O +
functional O +
development O +
of O +
the O +
pulmonary O +
system O +
is O +
dependent O +
upon O +
appropriate O +
early O +
vascularization O +
of O +
the O +
embryonic O +
lung O -
. O +

Our O +
previous O +
in O +
vitro O +
studies O +
in O +
a O +
rat O +
model O +
indicated O +
that O +
insulin O -
- O -
like O +
growth O +
factor O -
- O -
I O +
( O -
IGF O -
- O -
I O -
) O +
is O +
a O +
potent O +
angiogenic O +
agent O +
for O +
fetal O +
lung O +
endothelial O +
cells O -
. O +

To O +
assess O +
its O +
role O +
on O +
human O +
vascular O +
lung O +
development O -
, O +
we O +
first O +
examined O +
the O +
expression O +
of O +
IGF O -
- O -
I O -
/ O -
II O +
and O +
IGF O +
receptor O +
type O +
I O +
( O -
IGF O -
- O -
IR O -
) O +
in O +
human O +
embryonic O +
and O +
fetal O +
lung O +
tissues O +
at O +
4 O -
- O -
12 O +
wk O +
of O +
gestation O -
. O +

Immunohistochemical O +
and O +
in O +
situ O +
hybridization O +
studies O +
revealed O +
the O +
presence O +
of O +
IGF O -
- O -
I O -
/ O -
II O -
- O -
IGF O -
- O -
IR O +
ligands O +
and O +
mRNA O +
transcripts O +
in O +
embryonic O +
lungs O +
as O +
early O +
as O +
4 O +
wk O +
gestation O -
. O +

Immunotargeting O +
using O +
an O +
anti O -
- O -
IGF O -
- O -
IR O +
neutralizing O +
antibody O +
on O +
human O +
fetal O +
lung O +
explants O +
demonstrated O +
a O +
significant O +
blockade O +
of O +
IGF O -
- O -
IR O +
signaling O -
. O +

Inactivation O +
of O +
IGF O -
- O -
IR O +
resulted O +
in O +
a O +
loss O +
of O +
endothelial O +
cells O -
, O +
accompanied O +
by O +
dramatic O +
changes O +
in O +
fetal O +
lung O +
explant O +
morphology O -
. O +

Terminal O +
transferase O +
dUTP O +
end O -
- O -
labeling O +
assay O +
and O +
TEM O +
studies O +
of O +
anti O -
- O -
IGF O -
- O -
IR O -
- O -
treated O +
lungs O +
demonstrated O +
numerous O +
apoptotic O +
mesenchymal O +
cells O -
. O +

Rat O +
embryonic O +
lung O +
explant O +
studies O +
further O +
validated O +
the O +
importance O +
of O +
the O +
IGF O -
- O -
IGF O -
- O -
IR O +
system O +
for O +
lung O +
vascular O +
development O -
. O +

These O +
data O +
provide O +
the O +
first O +
demonstration O +
of O +
IGF O -
- O -
I O -
/ O -
II O +
expression O +
in O +
the O +
human O +
lung O +
in O +
early O +
gestation O +
and O +
indicate O +
that O +
the O +
IGF O +
family O +
of O +
growth O +
factors O -
, O +
acting O +
through O +
the O +
IGF O -
- O -
IR O -
, O +
is O +
required O +
as O +
a O +
survival O +
factor O +
during O +
normal O +
human O +
lung O +
vascularization O -
. O +

Inhibition O +
of O +
glucose B-Chemical +
metabolism O +
sensitizes O +
tumor O +
cells O +
to O +
death O +
receptor O -
- O -
triggered O +
apoptosis O +
through O +
enhancement O +
of O +
death O -
- O -
inducing O +
signaling O +
complex O +
formation O +
and O +
apical O +
procaspase-8 O +
processing O -
. O +

Tumors O +
display O +
a O +
high O +
rate O +
of O +
glucose B-Chemical +
uptake O +
and O +
glycolysis O -
. O +

We O +
investigated O +
how O +
inhibition O +
of O +
glucose B-Chemical +
metabolism O +
could O +
affect O +
death O +
receptor O -
- O -
mediated O +
apoptosis O +
in O +
human O +
tumor O +
cells O +
of O +
diverse O +
origin O -
. O +

We O +
show O +
that O +
both O +
substitution O +
of O +
glucose B-Chemical +
for O +
pyruvate B-Chemical +
and O +
treatment O +
with O +
2-deoxyglucose B-Chemical +
enhanced O +
apoptosis O +
induced O +
by O +
tumor O +
necrosis O +
factor O +
( O -
TNF O -
) O -
-alpha O -
, O +
CD95 O +
agonistic O +
antibody O -
, O +
and O +
TNF O -
- O -
related O +
apoptosis O -
- O -
inducing O +
ligand O +
( O -
TRAIL O -
) O -
. O +

Inhibition O +
of O +
glucose B-Chemical +
metabolism O +
enhanced O +
killing O +
of O +
myeloid O +
leukemia O +
U937 O -
, O +
cervical O +
carcinoma O +
HeLa O -
, O +
and O +
breast O +
carcinoma O +
MCF-7 O +
cells O +
upon O +
death O +
receptor O +
ligation O -
. O +

Caspase O +
activation O -
, O +
mitochondrial O +
depolarization O -
, O +
and O +
cytochrome O +
c O +
release O +
were O +
increased O +
under O +
these O +
conditions O -
. O +

Glucose B-Chemical +
deprivation O -
- O -
mediated O +
sensitization O +
to O +
apoptosis O +
was O +
prevented O +
in O +
MCF-7 O +
cells O +
overexpressing O +
BCL-2 O -
. O +

Interestingly O -
, O +
the O +
human O +
B O -
- O -
lymphoblastoid O +
cell O +
line O +
SKW6.4 O -
, O +
a O +
prototype O +
for O +
mitochondria O -
- O -
independent O +
death O +
receptor O -
- O -
induced O +
apoptosis O -
, O +
was O +
also O +
sensitized O +
to O +
anti O -
- O -
CD95 O +
and O +
TRAIL O -
- O -
induced O +
apoptosis O +
under O +
glucose B-Chemical -
- O -
free O +
conditions O -
. O +

Changes O +
in O +
c O -
- O -
FLIP O -
( O -
L O -
) O +
and O +
cFLIPs O +
levels O +
were O +
observed O +
in O +
some O +
but O +
not O +
all O +
the O +
cell O +
lines O +
studied O +
following O +
glucose B-Chemical +
deprivation O -
. O +

Glucose B-Chemical +
deprivation O +
enhanced O +
death O +
receptor O -
- O -
triggered O +
formation O +
of O +
death O -
- O -
inducing O +
signaling O +
complex O +
and O +
early O +
processing O +
of O +
procaspase-8 O -
. O +

Altogether O -
, O +
these O +
results O +
suggest O +
that O +
the O +
glycolytic O +
pathway O +
may O +
be O +
an O +
important O +
target O +
for O +
therapeutic O +
intervention O +
to O +
sensitize O +
tumor O +
cells O +
to O +
selectively O +
toxic O +
soluble O +
death O +
ligands O +
or O +
death O +
ligand O -
- O -
expressing O +
cells O +
of O +
the O +
immune O +
system O +
by O +
facilitating O +
the O +
activation O +
of O +
initiator O +
caspase-8 O -
. O +

NF O -
- O -
kappaB O -
/ O -
Rel O +
transcriptional O +
pathway O -
: O +
implications O +
in O +
pancreatic O +
cancer O -
. O +

Despite O +
considerable O +
efforts O +
in O +
understanding O +
the O +
cellular O +
mechanisms O +
contributing O +
to O +
pancreatic O +
cancer O -
, O +
the O +
prognosis O +
of O +
this O +
malignant O +
disease O +
is O +
still O +
extremely O +
poor O -
. O +

Although O +
pancreatic O +
cancer O +
is O +
the O +
fifth O +
common O +
cause O +
of O +
cancer O +
death O +
in O +
Western O +
countries O -
, O +
current O +
options O +
in O +
treatment O +
enable O +
a O +
5-yr O +
survival O +
rate O +
for O +
all O +
stages O +
of O +
less O +
than O +
5 O -
% O -
. O +

In O +
the O +
face O +
fo O +
the O +
fatal O +
outcome O -
, O +
new O +
approaches O +
to O +
the O +
therapy O +
have O +
been O +
established O -
. O +

Based O +
on O +
its O +
role O +
in O +
malignant O +
transformation O -
, O +
apoptosis O -
, O +
and O +
cell O +
proliferation O -
, O +
the O +
transcription O +
factor O +
NF O -
- O -
kappaB O -
/ O -
Rel O +
has O +
gained O +
the O +
attention O +
of O +
many O +
laboratories O -
. O +

This O +
review O +
provides O +
basic O +
information O +
for O +
the O +
understanding O +
of O +
the O +
biology O +
of O +
NF O -
- O -
kappaB O +
and O +
aims O +
at O +
presenting O +
experimental O +
data O +
illustrating O +
the O +
involvement O +
of O +
NF O -
- O -
kappaB O -
/ O -
Rel O +
in O +
pancreatic O +
cancer O -
. O +

Bee O +
venom O +
induces O +
apoptosis O +
and O +
inhibits O +
expression O +
of O +
cyclooxygenase-2 O +
mRNA O +
in O +
human O +
lung O +
cancer O +
cell O +
line O +
NCI O -
- O -
H1299 O -
. O +

To O +
investigate O +
whether O +
bee O +
venom O +
( O -
BV O -
) O +
induces O +
apoptosis O -
, O +
the O +
3- B-Chemical -
( I-Chemical -
4,5-dimethylthiazol-2-yl I-Chemical -
) I-Chemical -
-2,5-diphenyltetrazolium I-Chemical +
bromide I-Chemical +
assay O -
, O +
terminal O +
deoxynucleotidyl O +
transferase- O +
mediated O +
dUTP B-Chemical +
nick O +
end O -
- O -
labeling O +
assay O -
, O +
4,6-diamidino-2-phenylindole B-Chemical +
staining O -
, O +
flow O +
cytometric O +
analysis O -
, O +
and O +
DNA O +
fragmentation O +
assay O +
were O +
performed O +
on O +
NCI O -
- O -
H1299 O +
lung O +
cancer O +
cells O +
treated O +
with O +
BV O -
. O +

Through O +
morphological O +
and O +
biochemical O +
analyses O -
, O +
it O +
was O +
demonstrated O +
that O +
NCI O -
- O -
H1299 O +
cells O +
treated O +
with O +
BV O +
exhibit O +
several O +
features O +
of O +
apoptosis O -
. O +

In O +
addition O -
, O +
reverse O +
transcription O -
- O -
polymerase O +
chain O +
reaction O +
and O +
prostaglandin B-Chemical +
E I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
( O -
PGE B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
) O +
immunoassay O +
were O +
performed O +
to O +
verify O +
whether O +
BV O +
possesses O +
an O +
inhibitory O +
effect O +
on O +
the O +
expression O +
of O +
cyclooxygenase O +
( O -
COX O -
) O +
and O +
PGE B-Chemical -
( I-Chemical -
2 I-Chemical +
) I-Chemical -
synthesis O -
. O +

Expression O +
of O +
COX-2 O +
mRNA O +
and O +
synthesis O +
of O +
PGE B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
were O +
inhibited O +
by O +
BV O -
. O +

These O +
results O +
suggest O +
the O +
possibility O +
that O +
BV O +
may O +
exert O +
an O +
anti O -
- O -
tumor O +
effect O +
on O +
human O +
lung O +
cancer O -
. O +

Tumor O +
angiogenesis O +
modulates O +
leukocyte O -
- O -
vessel O +
wall O +
interactions O +
in O +
vivo O +
by O +
reducing O +
endothelial O +
adhesion O +
molecule O +
expression O -
. O +

The O +
expression O +
of O +
endothelial O +
cell O +
( O -
EC O -
) O +
adhesion O +
molecules O +
involved O +
in O +
leukocyte O -
- O -
vessel O +
wall O +
interactions O +
is O +
suppressed O +
in O +
malignancies O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
investigated O +
in O +
vivo O +
the O +
regulation O +
of O +
leukocyte O -
- O -
vessel O +
wall O +
interactions O +
by O +
the O +
presence O +
of O +
a O +
tumor O -
. O +

By O +
means O +
of O +
intravital O +
microscopy O -
, O +
tumor O +
necrosis O +
factor O +
alpha O -
- O -
stimulated O +
leukocyte O -
- O -
vessel O +
wall O +
interactions O +
were O +
studied O +
in O +
ear O +
skin O +
microvessels O +
of O +
nude O +
mice O +
bearing O +
small O +
human O +
LS174 O -
T O +
colon O +
carcinomas O +
and O +
in O +
C57Bl O -
/ O -
6 O +
mice O +
bearing O +
murine O +
B16F10 O +
melanomas O -
. O +

Leukocyte O -
- O -
vessel O +
wall O +
interactions O +
were O +
studied O +
both O +
within O +
and O +
outside O +
small O +
tumors O +
growing O +
in O +
the O +
ear O -
, O +
and O +
in O +
ear O +
microvessels O +
of O +
mice O +
with O +
a O +
large O +
tumor O +
growing O +
on O +
their O +
flank O -
. O +

Tumor O -
- O -
free O +
mice O +
were O +
used O +
as O +
controls O -
. O +

Compared O +
with O +
values O +
measured O +
at O +
the O +
edge O +
of O +
the O +
ear O +
and O +
in O +
the O +
contralateral O +
ear O -
, O +
leukocyte O +
adhesion O +
was O +
found O +
to O +
be O +
diminished O +
significantly O +
in O +
vessels O +
inside O +
the O +
ear O +
tumor O +
in O +
both O +
mouse O +
models O -
. O +

This O +
reduction O +
disappeared O +
with O +
increasing O +
distance O +
from O +
the O +
tumor O -
. O +

Surprisingly O -
, O +
the O +
level O +
of O +
leukocyte O +
adhesion O +
in O +
ear O +
venules O +
of O +
mice O +
with O +
a O +
large O +
flank O +
tumor O +
was O +
also O +
reduced O +
significantly O -
. O +

Leukocyte O +
rolling O -
, O +
i.e. O -
, O +
the O +
step O +
preceding O +
adhesion O -
, O +
was O +
not O +
influenced O +
by O +
the O +
presence O +
of O +
a O +
tumor O +
in O +
nude O +
mice O -
, O +
but O +
was O +
down O -
- O -
regulated O +
in O +
immune O -
- O -
competent O +
C57Bl O -
/ O -
6 O +
mice O -
. O +

Treatment O +
of O +
mice O +
bearing O +
a O +
small O +
ear O +
tumor O +
with O +
a O +
humanized O +
antivascular O +
endothelial O +
growth O +
factor O +
antibody O +
prevented O +
the O +
down O -
- O -
regulation O +
of O +
leukocyte O -
- O -
vessel O +
wall O +
interactions O +
inside O +
the O +
tumor O +
vessels O +
compared O +
with O +
the O +
nontreated O +
group O -
. O +

Fluorescence O -
- O -
activated O +
cell O +
sorter O +
analysis O +
showed O +
that O +
isolated O +
tumor O +
ECs O +
have O +
suppressed O +
levels O +
of O +
intercellular O +
adhesion O +
molecule O +
1 O +
as O +
compared O +
with O +
ECs O +
from O +
normal O +
mouse O +
tissues O -
. O +

In O +
cultured O +
b. O +

END5 O +
cells O +
the O +
tumor O +
necrosis O +
factor O +
alpha O -
- O -
induced O +
up O -
- O -
regulation O +
of O +
intercellular O +
adhesion O +
molecule O +
1 O +
and O +
vascular O +
cell O +
adhesion O +
molecule O +
1 O +
was O +
reduced O +
in O +
ECs O +
that O +
were O +
preincubated O +
with O +
basic O +
fibroblast O +
growth O +
factor O +
or O +
vascular O +
endothelial O +
growth O +
factor O -
. O +

The O +
current O +
results O +
may O +
have O +
an O +
impact O +
on O +
the O +
effectiveness O +
of O +
clinical O +
immunotherapeutic O +
treatment O +
protocols O -
, O +
because O +
immune O +
effector O +
cells O +
may O +
not O +
be O +
able O +
to O +
enter O +
tumor O +
tissue O -
. O +

The O +
role O +
of O +
organ O +
vascularization O +
and O +
lipoplex B-Chemical -
- O -
serum O +
initial O +
contact O +
in O +
intravenous O +
murine O +
lipofection O -
. O +

Following O +
intravenous O +
administration O +
of O +
cationic O +
lipid O -
- O -
DNA O +
complexes O +
( O -
lipoplexes B-Chemical -
) O +
into O +
mice O -
, O +
transfection O +
( O -
lipofection O -
) O +
occurs O +
predominantly O +
in O +
the O +
lungs O -
. O +

This O +
was O +
attributed O +
to O +
high O +
entrapment O +
of O +
lipoplexes B-Chemical +
in O +
the O +
extended O +
lung O +
vascular O +
tree O -
. O +

To O +
determine O +
whether O +
lipofection O +
in O +
other O +
organs O +
could O +
be O +
enhanced O +
by O +
increasing O +
the O +
degree O +
of O +
vascularization O -
, O +
we O +
used O +
a O +
transgenic O +
mouse O +
model O +
with O +
tissue O -
- O -
specific O +
angiogenesis O +
in O +
liver O -
. O +

Tail O +
vein O +
injection O +
of O +
N- B-Chemical -
( I-Chemical -
1- I-Chemical -
( I-Chemical -
2,3-dioleoyloxy I-Chemical -
) I-Chemical -
propyl I-Chemical -
) I-Chemical -
-N I-Chemical -
, I-Chemical -
N I-Chemical -
, I-Chemical -
N I-Chemical -
- I-Chemical -
trimethylammonium I-Chemical +
chloride I-Chemical +
( I-Chemical -
DOTAP I-Chemical -
) I-Chemical -
/ I-Chemical -
cholesterol I-Chemical +
lipoplexes I-Chemical +
resulted O +
in O +
increased O +
lipoplex B-Chemical +
entrapment O +
in O +
hypervascularized O +
liver O +
but O +
did O +
not O +
boost O +
luciferase O +
expression O -
, O +
suggesting O +
that O +
lipoplex B-Chemical +
delivery O +
is O +
not O +
a O +
sufficient O +
condition O +
for O +
efficient O +
organ O +
lipofection O -
. O +

Because O +
the O +
intravenously O +
injected O +
lipoplexes B-Chemical +
migrated O +
within O +
seconds O +
to O +
lungs O -
, O +
we O +
checked O +
whether O +
the O +
effects O +
of O +
immediate O +
contact O +
with O +
serum O +
correlate O +
with O +
lung O +
lipofection O +
efficiency O +
of O +
different O +
DOTAP B-Chemical -
- O -
based O +
formulations O -
. O +

Under O +
conditions O +
mimicking O +
the O +
injection O +
environment O -
, O +
the O +
lipoplex B-Chemical -
- O -
serum O +
interaction O +
was O +
strongly O +
dependent O +
on O +
helper O +
lipid B-Chemical +
and O +
ionic O +
strength O -
: O +
lipoplexes B-Chemical +
prepared O +
in O +
150 O +
mM O +
NaCl O +
or O +
lipoplexes B-Chemical +
with O +
high O +
( O +
greater O +
than O +
33 O +
mol% O -
) O +
cholesterol B-Chemical +
were O +
found O +
to O +
aggregate O +
immediately O -
. O +

This O +
aggregation O +
process O +
was O +
irreversible O +
and O +
was O +
inversely O +
correlated O +
with O +
the O +
percentage O +
of O +
lung O +
cells O +
that O +
took O +
up O +
lipoplexes B-Chemical +
and O +
with O +
the O +
efficiency O +
of O +
lipofection O -
. O +

No O +
other O +
structural O +
changes O +
in O +
serum O +
were O +
observed O +
for O +
cholesterol B-Chemical -
- I-Chemical -
based I-Chemical +
lipoplexes I-Chemical -
. O +

Dioleoyl B-Chemical +
phosphatidylethanolamine I-Chemical -
- I-Chemical -
based I-Chemical +
lipoplexes I-Chemical +
were O +
found O +
to O +
give O +
low O +
expression O -
, O +
apparently O +
because O +
of O +
an O +
immediate O +
loss O +
of O +
integrity O +
in O +
serum O -
, O +
without O +
lipid O -
- O -
DNA O +
dissociation O -
. O +

Our O +
study O +
suggests O +
that O +
efficient O +
in O +
vivo O +
lipofection O +
is O +
the O +
result O +
of O +
cross O -
- O -
talk O +
between O +
lipoplex B-Chemical +
composition O -
, O +
interaction O +
with O +
serum O -
, O +
hemodynamics O -
, O +
and O +
target O +
tissue O +
" O -
susceptibility O -
" O +
to O +
transfection O -
. O +

Cloning O +
and O +
characterization O +
of O +
the O +
latent O +
membrane O +
protein O +
( O -
LMP O -
) O +
of O +
a O +
specific O +
Epstein O -
- O -
Barr O +
virus O +
variant O +
derived O +
from O +
the O +
nasopharyngeal O +
carcinoma O +
in O +
the O +
Taiwanese O +
population O -
. O +

A O +
DNA O +
fragment O +
containing O +
Epstein O -
- O -
Barr O +
virus O +
( O -
EBV O -
) O +
terminal O +
fragment O +
sequence O +
was O +
obtained O +
from O +
a O +
genomic O +
library O +
of O +
nasopharyngeal O +
carcinoma O +
( O -
NPC O -
) O -
. O +

One O +
of O +
the O +
clones O +
( O -
clone O +
1510 O -
) O +
contained O +
the O +
gene O +
encoding O +
latent O +
membrane O +
protein O +
( O -
LMP O -
) O -
. O +

Sequence O +
analysis O +
revealed O +
that O +
this O +
gene O +
had O +
95 O -
% O +
homology O +
with O +
the O +
LMP O +
sequence O +
of O +
the O +
B95 O -
- O -
8 O +
strain O -
. O +

Among O +
the O +
sequence O +
variations O -
, O +
there O +
was O +
a O +
change O +
from O +
G O +
to O +
T O +
at O +
nucleotide O +
position O +
169,426 O -
, O +
resulting O +
in O +
the O +
loss O +
of O +
an O +
XhoI O +
site O +
in O +
exon O +
1 O +
of O +
the O +
LMP O +
gene O -
. O +

A O +
pair O +
of O +
primers O +
bracketing O +
the O +
XhoI O +
site O +
were O +
designed O +
to O +
synthesize O +
the O +
EBV O +
DNA O +
fragment O +
from O +
nucleotides O +
169,081 O -
- O -
169,577 O +
by O +
using O +
the O +
polymerase O +
chain O +
reaction O +
( O -
PCR O -
) O +
method O -
. O +

The O +
PCR O +
products O +
were O +
then O +
subject O +
to O +
XhoI O +
digestion O +
and O +
to O +
DNA O +
sequencing O +
analysis O -
. O +

This O +
restriction O +
enzyme O +
site O +
polymorphism O +
along O +
with O +
the O +
sequence O +
variations O +
were O +
also O +
observed O +
in O +
50 O +
biopsy O +
tissues O +
as O +
well O +
as O +
in O +
the O +
throat O +
washings O +
of O +
6 O +
out O +
of O +
20 O +
healthy O +
individuals O +
that O +
we O +
examined O -
, O +
indicating O +
that O +
the O +
EBV O +
strain O +
predominantly O +
existing O +
in O +
these O +
biopsy O +
tissues O +
was O +
different O +
from O +
strains O +
of O +
B95 O -
- O -
8 O -
, O +
Jijoye O +
or O +
nude O +
mouse O +
passaged O +
cells O +
( O -
C15 O -
) O +
with O +
an O +
African O +
origin O -
, O +
but O +
closely O +
resembled O +
other O +
nude O +
mouse O +
passaged O +
CAO O +
cells O +
which O +
were O +
originally O +
derived O +
from O +
China O -
. O +

Balb O -
/ O -
c O +
3T3 O +
cells O +
carrying O +
this O +
NPC O -
- O -
LMP O +
gene O +
showed O +
a O +
transformed O +
cell O +
morphology O +
and O +
were O +
tumorigenic O +
in O +
nude O +
mice O -
. O +

The O +
relationship O +
between O +
this O +
unique O +
type O +
of O +
EBV O +
and O +
NPC O +
has O +
yet O +
to O +
be O +
established O -
. O +

Transcriptional O +
and O +
post O -
- O -
translation O +
regulation O +
of O +
the O +
Tie1 O +
receptor O +
by O +
fluid O +
shear O +
stress O +
changes O +
in O +
vascular O +
endothelial O +
cells O -
. O +

The O +
interaction O +
between O +
the O +
vascular O +
endothelium O +
and O +
hemodynamic O +
forces O +
( O -
and O +
more O +
specifically O -
, O +
fluid O +
shear O +
stress O -
) O -
, O +
induced O +
by O +
the O +
flow O +
of O +
blood O -
, O +
plays O +
a O +
major O +
role O +
in O +
vascular O +
remodeling O +
and O +
in O +
new O +
blood O +
vessels O +
formation O +
via O +
a O +
process O +
termed O +
arteriogenesis O -
. O +

Tie1 O +
is O +
an O +
orphan O +
tyrosine O +
kinase O +
receptor O +
expressed O +
almost O +
exclusively O +
in O +
endothelial O +
cells O +
and O +
is O +
required O +
for O +
normal O +
vascular O +
development O +
and O +
maintenance O -
. O +

The O +
present O +
study O +
demonstrates O +
that O +
Tie1 O +
expression O +
is O +
rapidly O +
down O -
- O -
regulated O +
in O +
endothelial O +
cells O +
exposed O +
to O +
shear O +
stress O -
, O +
and O +
more O +
so O +
to O +
shear O +
stress O +
changes O -
. O +

This O +
down O -
- O -
regulation O +
is O +
accompanied O +
by O +
a O +
rapid O +
cleavage O +
of O +
Tie1 O +
and O +
binding O +
of O +
the O +
cleaved O +
Tie1 O +
45 O +
kDa O +
endodomain O +
to O +
Tie2 O -
. O +

The O +
rapid O +
cleavage O +
of O +
Tie1 O +
is O +
followed O +
by O +
a O +
transcriptional O +
down O -
- O -
regulation O +
in O +
response O +
to O +
shear O +
stress O -
. O +

The O +
activity O +
of O +
the O +
Tie1 O +
promoter O +
is O +
suppressed O +
by O +
shear O +
stress O +
and O +
by O +
tumor O +
necrosis O +
factor O +
alpha O -
. O +

Shear O +
stress O -
- O -
induced O +
transcriptional O +
suppression O +
of O +
Tie1 O +
is O +
mediated O +
by O +
a O +
negative O +
shear O +
stress O +
response O +
element O -
, O +
localized O +
in O +
a O +
region O +
of O +
250 O +
bp O +
within O +
the O +
promoter O -
. O +

The O +
rapid O +
down O -
- O -
regulation O +
of O +
Tie1 O +
by O +
shear O +
stress O +
changes O +
and O +
its O +
rapid O +
binding O +
to O +
Tie2 O +
may O +
be O +
required O +
for O +
destabilization O +
of O +
endothelial O +
cells O +
in O +
order O +
to O +
initiate O +
the O +
process O +
of O +
vascular O +
restructuring O -
. O +

Effects O +
of O +
dietary O +
folate B-Chemical +
on O +
ulcerative O +
colitis O -
- O -
associated O +
colorectal O +
carcinogenesis O +
in O +
the O +
interleukin O +
2- O +
and O +
beta O -
( O -
2 O -
) O -
-microglobulin O -
- O -
deficient O +
mice O -
. O +

Folate B-Chemical +
supplementation O +
may O +
reduce O +
the O +
risk O +
of O +
colorectal O +
dysplasia O +
and O +
cancer O +
in O +
subjects O +
with O +
chronic O +
ulcerative O +
colitis O +
( O -
UC O -
) O -
. O +

The O +
interleukin O +
( O -
IL O -
) O +
2- O +
and O +
beta O -
( O -
2 O -
) O -
-microglobulin O +
( O -
beta O -
( O -
2 O -
) O -
m O -
) O -
-deficient O +
( O -
IL-2 O -
( O -
null O -
) O +
x O +
beta O -
( O -
2 O -
) O -
m O -
( O -
null O -
) O -
) O +
mice O +
spontaneously O +
develop O +
colon O +
cancer O +
in O +
the O +
setting O +
of O +
chronic O +
UC O -
. O +

This O +
study O +
investigated O +
the O +
effects O +
of O +
dietary O +
folate B-Chemical +
on O +
the O +
development O +
of O +
UC O -
- O -
associated O +
colon O +
cancer O +
in O +
the O +
IL-2 O -
( O -
null O -
) O +
x O +
beta O -
( O -
2 O -
) O -
m O -
( O -
null O -
) O +
mice O -
. O +

Weaning O +
IL-2 O -
( O -
null O -
) O +
x O +
beta O -
( O -
2 O -
) O -
m O -
( O -
null O -
) O +
mice O +
were O +
randomized O +
to O +
receive O +
0 O +
( O -
deficient O -
; O +
n O +
= O +
40 O -
) O -
, O +
2 O +
( O -
basal O +
requirement O -
; O +
control O -
; O +
n O +
= O +
46 O -
) O -
, O +
or O +
8 O +
( O -
supplemented O -
; O +
n O +
= O +
36 O -
) O +
mg O +
folate B-Chemical -
/ O -
kg O +
diet O +
for O +
32 O +
weeks O -
. O +

At O +
necropsy O -
, O +
all O +
macroscopic O +
colonic O +
tumors O +
were O +
identified O +
and O +
histologically O +
classified O +
as O +
dysplasia O +
or O +
adenocarcinoma O -
. O +

The O +
incidence O +
of O +
high O -
- O -
grade O +
lesions O +
( O -
high O -
- O -
grade O +
dysplasia O -
/ O -
carcinoma O +
in O +
situ O +
and O +
invasive O +
adenocarcinoma O -
) O +
in O +
the O +
folate B-Chemical -
- O -
supplemented O +
group O +
was O +
46 O -
% O +
lower O +
than O +
that O +
in O +
the O +
control O +
group O +
( O -
35.3 O -
% O +
versus O +
65.1 O -
% O -
, O +
P O +
= O +
0.009 O -
) O -
. O +

The O +
incidence O +
of O +
high O -
- O -
grade O +
lesions O +
in O +
the O +
folate B-Chemical -
- O -
deficient O +
group O +
was O +
also O +
49 O -
% O +
lower O +
than O +
that O +
in O +
the O +
control O +
group O +
( O -
33.3 O -
% O +
versus O +
65.1 O -
% O -
, O +
P O +
= O +
0.007 O -
) O -
. O +

The O +
higher O +
mortality O +
rate O +
in O +
the O +
folate B-Chemical -
- O -
deficient O +
group O +
compared O +
with O +
the O +
other O +
two O +
groups O +
( O -
25 O -
% O +
versus O +
6.5 O -
% O +
and O +
5.6 O -
% O -
, O +
P O +
< O +
0.02 O -
) O +
partially O +
accounted O +
for O +
the O +
low O +
incidence O +
of O +
high O -
- O -
grade O +
lesions O +
in O +
this O +
group O -
. O +

These O +
data O +
indicate O +
that O +
dietary O +
folate B-Chemical +
supplementation O +
at O +
4x O +
the O +
basal O +
dietary O +
requirement O +
significantly O +
suppresses O +
UC O -
- O -
associated O +
colorectal O +
carcinogenesis O +
in O +
the O +
IL-2 O -
( O -
null O -
) O +
x O +
beta O -
( O -
2 O -
) O -
m O -
( O -
null O -
) O +
mice O -
. O +

These O +
data O +
also O +
suggest O +
that O +
folate B-Chemical +
deficiency O +
may O +
inhibit O +
colorectal O +
carcinogenesis O +
in O +
chronic O +
UC O -
. O +

However O -
, O +
the O +
high O +
mortality O +
observed O +
in O +
the O +
folate B-Chemical -
- O -
deficient O +
group O +
precludes O +
a O +
definitive O +
conclusion O +
concerning O +
the O +
effect O +
of O +
folate B-Chemical +
deficiency O +
on O +
UC O -
- O -
associated O +
colorectal O +
carcinogenesis O +
in O +
this O +
model O -
. O +

Expression O +
of O +
EphA2 O +
and O +
E O -
- O -
cadherin O +
in O +
colorectal O +
cancer O -
: O +
correlation O +
with O +
cancer O +
metastasis O -
. O +

Recently O -
, O +
overexpression O +
of O +
EphA2 O -
, O +
a O +
member O +
of O +
the O +
Eph O +
family O +
of O +
receptor O +
tyrosine O +
kinases O -
, O +
has O +
been O +
reported O +
in O +
several O +
cancers O -
. O +

Reduced O +
expression O +
of O +
E O -
- O -
cadherin O -
, O +
an O +
intercellular O +
adhesion O +
molecule O +
of O +
epithelial O +
cells O -
, O +
has O +
been O +
reported O +
to O +
be O +
associated O +
with O +
aggressive O +
clinicopathological O +
phenotypes O +
in O +
various O +
cancers O -
. O +

In O +
epithelial O +
cells O -
, O +
EphA2 O +
and O +
E O -
- O -
cadherin O +
co O -
- O -
localize O +
to O +
sites O +
of O +
cell O -
- O -
cell O +
contact O -
, O +
and O +
it O +
has O +
been O +
shown O +
that O +
E O -
- O -
cadherin O +
regulates O +
EphA2 O -
. O +

This O +
study O +
aimed O +
to O +
clarify O +
the O +
relationship O +
between O +
the O +
expression O +
of O +
the O +
EphA2 O +
and O +
E O -
- O -
cadherin O +
proteins O +
and O +
clinicopathological O +
characteristics O -
, O +
with O +
reference O +
to O +
the O +
expression O +
levels O +
of O +
both O +
EphA2 O +
and O +
E O -
- O -
cadherin O -
, O +
in O +
patients O +
with O +
colorectal O +
cancer O -
. O +

We O +
performed O +
immunohistochemical O +
staining O +
of O +
EphA2 O +
and O +
E O -
- O -
cadherin O +
with O +
EphA2 O +
and O +
E O -
- O -
cadherin O +
monoclonal O +
antibodies O +
in O +
samples O +
from O +
194 O +
primary O +
lesions O +
of O +
colorectal O +
cancer O -
. O +

The O +
expression O +
level O +
of O +
EphA2 O +
had O +
a O +
statistically O +
significant O +
relationship O +
with O +
liver O +
metastasis O -
, O +
lymphatic O +
vessel O +
invasion O +
and O +
clinical O +
stage O +
( O -
p=0.0477 O -
, O +
0.0316 O +
and O +
0.0467 O -
, O +
respectively O -
) O -
. O +

In O +
addition O -
, O +
the O +
positivity O +
rate O +
of O +
EphA2 O +
was O +
significantly O +
higher O +
in O +
primary O +
lesions O +
with O +
lymph O +
node O +
metastasis O +
than O +
in O +
those O +
without O +
metastasis O +
( O -
p=0.0014 O -
) O -
. O +

However O -
, O +
the O +
expression O +
level O +
of O +
E O -
- O -
cadherin O +
had O +
an O +
inverse O +
relationship O +
with O +
both O +
differentiation O +
level O +
of O +
the O +
tumor O +
and O +
lymphatic O +
vessel O +
invasion O +
( O -
p=0.0430 O +
and O +
0.0320 O -
, O +
respectively O -
) O -
. O +

Furthermore O -
, O +
a O +
significant O +
relationship O +
between O +
the O +
expression O +
of O +
EphA2 O +
and O +
E O -
- O -
cadherin O +
was O +
observed O -
. O +

In O +
conclusion O -
, O +
our O +
study O +
revealed O +
that O +
the O +
overexpression O +
of O +
EphA2 O +
protein O +
in O +
colorectal O +
carcinoma O +
tissue O +
correlates O +
closely O +
with O +
cancer O +
progression O +
and O +
hematogenous O +
and O +
lymphogenous O +
metastasis O -
, O +
suggesting O +
that O +
both O +
EphA2 O +
and O +
E O -
- O -
cadherin O +
may O +
play O +
an O +
important O +
role O +
in O +
tumor O +
metastasis O +
in O +
colorectal O +
cancer O -
. O +

[ O -
Correlation O +
between O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factor O -
- O -
C O +
in O +
tumor O -
- O -
associated O +
macrophages O +
and O +
lymphatic O +
metastasis O +
in O +
oral O +
cancer O -
] O -
. O +

BACKGROUND O +
& O +
OBJECTIVE O -
: O +
Previous O +
study O +
shows O +
that O +
both O +
vascular O +
endothelial O +
growth O -
- O -
C O +
( O -
VEGF O -
- O -
C O -
) O +
and O +
tumor O -
- O -
associated O +
macrophages O +
( O -
TAMs O -
) O +
are O +
related O +
to O +
lymphatic O +
metastasis O -
. O +

This O +
study O +
aimed O +
to O +
explore O +
the O +
correlation O +
between O +
the O +
expression O +
of O +
VEGF O -
- O -
C O +
in O +
TAMs O +
and O +
lymphatic O +
metastasis O +
in O +
human O +
oral O +
squamous O -
- O -
cell O +
carcinoma O +
( O -
OSCC O -
) O -
. O +

METHODS O -
: O +
After O +
immunohistochemical O +
staining O -
, O +
light O +
microscope O +
was O +
used O +
for O +
counting O +
macrophages O +
and O +
automated O +
image O +
analysis O +
quantification O +
was O +
used O +
to O +
determine O +
VEGF O -
- O -
C O +
expression O -
, O -
which O +
was O +
reflected O +
by O +
positive O +
index O +
( O -
PI O -
) O -
. O +

In O +
addition O -
, O -
the O +
double O +
staining O +
was O +
also O +
used O +
to O +
determine O +
VEGF O -
- O -
C O +
expression O +
in O +
TAMs O -
. O +

RESULTS O -
: O +
VEGF O -
- O -
C O +
expression O +
was O +
higher O +
in O +
lymphatic O +
metastasis O +
group O +
( O -
PI=12.169+ O -
/ O -
-2.778 O -
) O +
than O +
in O +
no O -
- O -
metastasis O +
group O +
( O -
PI=8.498+ O -
/ O -
-2.674 O -
, O +
P O -
< O +
0.05 O -
) O -
. O +

TAMs O +
counts O +
was O +
related O +
to O +
VEGF O -
- O -
C O +
expression O +
in O +
OSCC O +
( O -
r=0.370 O -
, O +
P O -
< O +
0.05 O -
) O -
. O +

The O +
result O +
of O +
double O +
staining O +
indicated O +
that O +
macrophage O +
with O +
positive O +
VEGF O -
- O -
C O +
expression O +
accounted O +
for O +
about O +
22.8 O -
% O +
of O +
the O +
total O -
. O +

CONCLUSION O -
: O +
Not O +
only O +
tumor O +
cells O +
but O +
also O +
TAMs O +
secrete O +
the O +
VEGF O -
- O -
C O +
in O +
OSCC O -
, O +
and O +
TAMs O +
may O +
play O +
a O +
major O +
role O +
in O +
peritumoral O +
lymphatic O +
neoangiogenesis O +
and O +
lymphatic O +
metastasis O -
. O +

Nuclear O +
translocation O +
of O +
a O +
clusterin O +
isoform O +
is O +
associated O +
with O +
induction O +
of O +
anoikis O +
in O +
SV40-immortalized O +
human O +
prostate O +
epithelial O +
cells O -
. O +

Clusterin O +
gene O +
expression O +
is O +
potently O +
induced O +
in O +
experimental O +
models O +
in O +
which O +
apoptosis O +
is O +
activated O -
, O +
such O +
as O +
rat O +
prostate O +
involution O +
following O +
castration O -
. O +

Nevertheless O -
, O +
its O +
precise O +
physiological O +
role O +
has O +
not O +
yet O +
been O +
established O -
, O +
and O +
both O +
anti O -
- O -
apoptotic O +
and O +
pro O -
- O -
apoptotic O +
functions O +
have O +
been O +
suggested O +
for O +
this O +
gene O -
. O +

Clusterin O +
expression O +
level O +
depends O +
on O +
cell O +
proliferation O +
state O -
, O +
and O +
we O +
recently O +
showed O +
that O +
its O +
over O -
- O -
expression O +
inhibited O +
cell O +
cycle O +
progression O +
of O +
SV40-immortalized O +
human O +
prostate O +
epithelial O +
cells O +
PNT2 O +
and O +
PNT1a O -
. O +

Here O +
we O +
studied O +
clusterin O +
expression O +
in O +
PNT1a O +
cells O +
subjected O +
to O +
serum O -
- O -
starvation O +
with O +
the O +
aim O +
of O +
defining O +
clusterin O +
early O +
molecular O +
changes O +
following O +
apoptosis O +
induction O -
. O +

Under O +
serum O -
- O -
starvation O +
conditions O -
, O +
decreased O +
growth O +
rate O -
, O +
slow O +
rounding O -
- O -
up O +
of O +
cells O -
, O +
cell O +
detachment O -
, O +
and O +
formation O +
of O +
apoptotic O +
bodies O +
indicative O +
of O +
anoikis O +
( O -
detachment O -
- O -
induced O +
apoptosis O -
) O +
were O +
preceded O +
by O +
significant O +
downregulation O +
of O +
70 O +
kDa O +
clusterin O +
precursor O +
and O +
upregulation O +
of O +
45 O -
- O -
40 O +
kDa O +
isoforms O -
. O +

On O +
the O +
8th O +
day O +
of O +
serum O -
- O -
free O +
culturing O -
, O +
only O +
the O +
higher O +
molecular O +
weight O +
protein O -
- O -
band O +
of O +
about O +
45 O +
kDa O +
was O +
clearly O +
induced O +
and O +
accumulated O +
in O +
detached O +
cells O +
and O +
apoptotic O +
bodies O +
in O +
which O +
PARP O +
was O +
activated O -
. O +

Anoikis O +
was O +
preceded O +
by O +
induction O +
and O +
transloction O +
of O +
a O +
45-kDa O +
clusterin O +
isoform O +
to O +
the O +
nucleus O -
. O +

Thus O -
, O +
nuclear O +
targeting O +
of O +
a O +
specific O +
45-kDa O +
isoform O +
of O +
clusterin O +
appeared O +
to O +
be O +
an O +
early O +
and O +
specific O +
molecular O +
signal O +
triggering O +
anoikis O -
- O -
death O -
. O +

Considering O +
also O +
that O +
clusterin O +
is O +
downregulated O +
during O +
prostate O +
cancer O +
onset O +
and O +
progression O -
, O +
and O +
that O +
its O +
upregulation O +
has O +
inhibited O +
DNA O +
synthesis O +
and O +
cell O +
cycle O +
progression O +
of O +
immortalized O +
human O +
prostate O +
epithelial O +
cells O -
, O +
we O +
suggest O +
that O +
clusterin O +
might O +
be O +
a O +
new O +
anti O -
- O -
oncogene O +
in O +
the O +
prostate O -
. O +

TGFbeta1 O -
, O +
back O +
to O +
the O +
future O -
: O +
revisiting O +
its O +
role O +
as O +
a O +
transforming O +
growth O +
factor O -
. O +

TGFbeta1 O +
was O +
initially O +
identified O +
in O +
culture O +
media O +
from O +
transformed O +
cells O +
as O +
part O +
of O +
a O +
factor O +
that O +
could O +
produce O +
a O +
transformed O +
phenotype O +
in O +
a O +
nontransformed O +
cell O +
line O -
. O +

Subsequently O +
this O +
activity O +
was O +
separated O +
into O +
TGFbeta O +
and O +
TGFalpha O +
an O +
EGF O +
receptor O +
ligand O -
. O +

With O +
the O +
discovery O +
that O +
TGFbeta1 O +
was O +
a O +
potent O +
growth O +
inhibitor O +
of O +
epithelial O +
cells O -
, O +
and O +
the O +
identification O +
of O +
inactivating O +
mutations O +
within O +
the O +
TGFbeta1 O +
signaling O +
pathway O +
in O +
cancers O +
it O +
became O +
clear O +
that O +
TGFbeta1 O +
signaling O +
is O +
a O +
tumor O +
suppressor O +
pathway O +
for O +
early O +
stages O +
of O +
cancer O -
. O +

However O +
many O +
human O +
carcinomas O +
overexpress O +
TGFbeta1 O +
and O +
this O +
is O +
associated O +
with O +
poor O +
patient O +
prognosis O +
and O +
increased O +
frequency O +
of O +
metastasis O -
. O +

Similar O +
results O +
have O +
been O +
obtained O +
with O +
tumor O +
cell O +
lines O +
and O +
experimental O +
animal O +
models O -
. O +

Thus O +
stage O +
specific O +
duality O +
of O +
function O +
is O +
the O +
emerging O +
paradigm O +
for O +
the O +
role O +
of O +
TGFbeta1 O +
in O +
cancer O -
. O +

This O +
review O +
will O +
focus O +
on O +
the O +
evidence O +
for O +
TGFbeta1 O +
as O +
a O +
tumor O +
promoting O +
and O +
metastasis O +
factor O +
and O +
examine O +
the O +
biological O +
and O +
molecular O +
basis O +
for O +
these O +
effects O -
. O +

It O +
is O +
proposed O +
that O +
the O +
switch O +
from O +
tumor O +
suppressor O +
to O +
oncogene O +
reflects O +
genetic O +
or O +
epigenetic O +
alterations O +
in O +
signaling O +
pathways O +
in O +
tumor O +
cells O +
that O +
alter O +
the O +
readout O +
from O +
the O +
TGFbeta1 O +
pathway O -
. O +

Levels O +
of O +
expression O +
of O +
CYR61 O +
and O +
CTGF O +
are O +
prognostic O +
for O +
tumor O +
progression O +
and O +
survival O +
of O +
individuals O +
with O +
gliomas O -
. O +

The O +
biological O +
properties O +
of O +
CCN O +
proteins O +
include O +
stimulation O +
of O +
cell O +
proliferation O -
, O +
migration O -
, O +
and O +
adhesion O -
, O +
as O +
well O +
as O +
angiogenesis O +
and O +
tumorigenesis O -
. O +

We O +
quantified O +
CYR61 O -
, O +
CTGF O -
, O +
WISP-1 O -
, O +
and O +
NOV O +
mRNA O +
expression O +
levels O +
in O +
samples O +
from O +
sixty O -
- O -
six O +
primary O +
gliomas O +
and O +
five O +
normal O +
brain O +
samples O +
using O +
quantitative O +
real O -
- O -
time O +
PCR O +
assay O -
. O +

Statistical O +
analysis O +
was O +
performed O +
to O +
explore O +
the O +
links O +
between O +
expression O +
of O +
the O +
CCN O +
genes O +
and O +
clinical O +
and O +
pathological O +
parameters O -
. O +

Overexpression O +
of O +
CYR61 O -
, O +
CTGF O -
, O +
WISP-1 O -
, O +
and O +
NOV O +
occurred O +
in O +
48 O -
% O +
( O -
32 O +
of O +
66 O -
) O -
, O +
58 O -
% O +
( O -
38 O +
of O +
66 O -
) O -
, O +
36 O -
% O +
( O -
24 O +
of O +
66 O -
) O -
, O +
and O +
15 O -
% O +
( O -
10 O +
of O +
66 O -
) O +
of O +
primary O +
gliomas O -
, O +
respectively O -
. O +

Interestingly O -
, O +
significant O +
associations O +
were O +
found O +
between O +
CYR61 O +
expression O +
versus O +
tumor O +
grade O -
, O +
pathology O -
, O +
gender O -
, O +
and O +
age O +
at O +
diagnosis O -
. O +

Also O -
, O +
a O +
significant O +
correlation O +
existed O +
between O +
CTGF O +
mRNA O +
levels O +
versus O +
tumor O +
grade O -
, O +
gender O -
, O +
and O +
pathology O -
. O +

In O +
contrast O +
to O +
CYR61 O +
and O +
CTGF O -
, O +
no O +
significant O +
association O +
was O +
found O +
between O +
expression O +
of O +
either O +
WISP-1 O +
or O +
NOV O +
versus O +
any O +
of O +
the O +
pathological O +
features O -
. O +

Furthermore O -
, O +
Cox O +
regression O +
analysis O +
showed O +
that O +
CYR61 O +
and O +
CTGF O +
expression O +
had O +
a O +
significant O +
correlation O +
with O +
patient O +
survival O -
. O +

These O +
results O +
suggest O +
that O +
CYR61 O +
and O +
CTGF O +
may O +
play O +
a O +
role O +
in O +
the O +
progression O +
of O +
gliomas O -
; O +
their O +
levels O +
at O +
diagnosis O +
may O +
have O +
prognostic O +
significance O -
; O +
and O +
these O +
proteins O +
might O +
serve O +
as O +
valuable O +
targets O +
for O +
therapeutic O +
intervention O -
. O +

NIH3T3 O +
transfectant O +
containing O +
human O +
K O -
- O -
ras O +
oncogene O +
shows O +
enhanced O +
metastatic O +
activity O +
after O +
in O +
vivo O +
tumor O +
growth O +
or O +
co O -
- O -
culture O +
with O +
fibroblasts O -
. O +

A O +
clone O +
of O +
NIH3T3 O +
transformant O +
( O -
H-3 O -
) O -
, O +
obtained O +
by O +
transfecting O +
genomic O +
DNA O +
of O +
a O +
human O +
colon O +
carcinoma O +
cell O +
line O -
, O +
contains O +
human O +
K O -
- O -
ras O +
oncogene O +
and O +
yields O +
metastatic O +
pulmonary O +
nodules O +
after O +
intravenous O +
injection O +
of O +
the O +
cells O +
into O +
nude O +
mice O -
. O +

This O +
metastatic O +
ability O +
was O +
enhanced O +
remarkably O +
after O +
in O +
vivo O +
tumor O +
growth O +
( O -
subcutaneous O +
tumor O +
formation O +
in O +
nude O +
mice O -
) O +
accompanied O +
by O +
increased O +
mRNA O +
expression O +
and O +
gene O +
amplification O +
of O +
the O +
human O -
- O -
derived O +
K O -
- O -
ras O +
oncogene O -
, O +
while O +
it O +
declined O +
gradually O +
as O +
the O +
passage O +
number O +
increased O +
in O +
vitro O -
, O +
with O +
corresponding O +
decreases O +
of O +
gene O +
amplification O +
and O +
mRNA O +
expression O -
. O +

Six O +
subclones O +
were O +
randomly O +
selected O +
from O +
H-3 O +
cells O +
which O +
had O +
been O +
subcultured O +
to O +
passage O +
22 O -
. O +

All O +
of O +
the O +
clones O +
in O +
culture O +
showed O +
almost O +
the O +
same O +
low O +
level O +
of O +
metastatic O +
ability O +
and O +
exhibited O +
little O +
K O -
- O -
ras O +
oncogene O +
amplification O +
with O +
correspondingly O +
low O +
mRNA O +
expression O -
. O +

However O -
, O +
after O +
they O +
formed O +
tumors O +
in O +
nude O +
mice O -
, O +
every O +
clone O +
acquired O +
high O +
metastatic O +
ability O +
and O +
the O +
gene O +
amplification O +
increased O -
, O +
with O +
elevated O +
mRNA O +
expression O -
. O +

These O +
experimental O +
facts O +
indicated O +
that O +
acquisition O +
of O +
metastatic O +
ability O +
coupled O +
with O +
the O +
function O +
of O +
K O -
- O -
ras O +
oncogene O +
was O +
conditional O +
in O +
nature O -
, O +
being O +
strongly O +
affected O +
by O +
in O +
vivo O +
tumor O +
circumstances O -
. O +

The O +
low O +
metastatic O +
and O +
G-418-resistant B-Chemical +
H-3 O +
cells O +
were O +
co O -
- O -
cultured O +
with O +
BALB O -
/ O -
c3T3 O +
fibroblasts O +
for O +
2 O -
- O -
4 O +
weeks O -
. O +

After O +
removal O +
of O +
fibroblasts O +
by O +
exposure O +
to O +
G-418 B-Chemical -
, O +
the O +
tumor O +
cells O +
exhibited O +
increased O +
metastatic O +
ability O +
and O +
human O +
K O -
- O -
ras O +
oncogene O +
mRNA O -
, O +
suggesting O +
an O +
intimate O +
interaction O +
between O +
H-3 O +
cells O +
and O +
fibroblasts O +
influencing O +
the O +
function O +
of O +
transfected O +
human O +
K O -
- O -
ras O +
oncogene O -
. O +

Fibroblasts O +
of O +
the O +
host O +
animal O +
may O +
thus O +
have O +
an O +
important O +
role O +
in O +
generating O +
enhanced O +
metastatic O +
activity O +
of O +
H-3 O +
cells O -
. O +

Safety O +
of O +
verteporfin B-Chemical +
for O +
treatment O +
of O +
subfoveal O +
choroidal O +
neovascular O +
membranes O +
associated O +
with O +
age O -
- O -
related O +
macular O +
degeneration O -
. O +

Photodynamic O +
therapy O +
( O -
PDT O -
) O +
is O +
a O +
novel O +
treatment O +
entity O +
that O +
exploits O +
the O +
photophysical O +
properties O +
of O +
various O +
photosensitive O +
chemical O +
entities O +
which O -
, O +
upon O +
light O +
activation O -
, O +
results O +
in O +
targeted O +
photooxidation O +
and O +
subsequent O +
tissue O +
destruction O -
. O +

The O +
antiangiogenic O +
properties O +
of O +
PDT O +
have O +
been O +
adapted O +
for O +
treatment O +
of O +
subfoveal O +
choroidal O +
neovascular O +
membranes O +
due O +
to O +
disease O +
states O +
such O +
as O +
age O -
- O -
related O +
macular O +
degeneration O +
( O -
AMD O -
) O -
. O +

Historically O -
, O +
PDT O +
has O +
been O +
limited O +
by O +
a O +
lack O +
of O +
suitable O +
photosensitive O +
dyes O -
. O +

However O -
, O +
agents O +
such O +
as O +
verteporfin B-Chemical -
, O +
a O +
second O -
- O -
generation O +
benzoporphyrin B-Chemical +
derivative O -
, O +
appear O +
to O +
be O +
free O +
from O +
the O +
extensive O +
phototoxicity O +
that O +
limited O +
the O +
success O +
of O +
previous O +
agents O -
. O +

Verteporfin B-Chemical +
has O +
a O +
high O +
affinity O +
for O +
choroidal O +
neovascular O +
membranes O -
, O +
typically O +
found O +
with O +
exudative O +
AMD O -
, O +
and O +
upon O +
photoactivation O +
results O +
in O +
targeted O +
microvascular O +
damage O +
and O +
thrombus O +
formation O +
with O +
resultant O +
vessel O +
occlusion O -
. O +

Scrutiny O +
of O +
diagnostic O +
indicators O +
for O +
verteporfin B-Chemical +
administration O -
, O +
including O +
critical O +
angiographic O +
evaluation O +
of O +
lesion O +
size O +
and O +
visual O +
acuity O -
, O +
is O +
essential O +
to O +
treatment O +
success O -
. O +

Large O +
lesions O +
with O +
relatively O +
good O +
visual O +
acuity O +
( O -
20 O -
/ O -
50 O +
or O +
better O -
) O +
may O +
be O +
at O +
particular O +
risk O +
for O +
marked O +
vision O +
loss O +
following O +
verteporfin B-Chemical +
administration O -
. O +

Lesion O +
composition O +
also O +
appears O +
to O +
influence O +
visual O +
outcome O +
with O +
verteporfin B-Chemical +
use O -
. O +

The O +
safety O +
of O +
verteporfin B-Chemical +
is O +
directly O +
dependent O +
upon O +
the O +
appropriate O +
integration O +
of O +
dosage O -
, O +
infusion O +
and O +
light O +
activation O +
required O +
for O +
a O +
suitable O +
pharmacotherapeutic O +
outcome O -
. O +

When O +
used O +
appropriately O -
, O +
and O +
with O +
adequate O +
patient O +
education O +
regarding O +
photosensitivity O -
, O +
the O +
risk O -
- O -
benefit O +
of O +
verteporfin B-Chemical +
for O +
the O +
medical O +
treatment O +
of O +
neovascular O +
AMD O +
is O +
favourable O -
. O +

Expression O +
of O +
DCC O +
and O +
netrin-1 O +
in O +
normal O +
human O +
endometrium O +
and O +
its O +
implication O +
in O +
endometrial O +
carcinogenesis O -
. O +

OBJECTIVE O -
: O +
Although O +
DCC O +
has O +
been O +
considered O +
as O +
a O +
candidate O +
tumor O +
suppressor O -
, O +
the O +
roles O +
it O +
plays O +
in O +
the O +
uterine O +
endometrium O +
and O +
in O +
the O +
carcinogenic O +
process O +
remains O +
unclear O -
. O +

To O +
define O +
these O +
roles O +
more O +
clearly O -
, O +
we O +
examined O +
the O +
expression O +
of O +
DCC O +
and O +
its O +
ligand O -
, O +
netrin-1 O -
, O +
in O +
the O +
normal O +
endometrium O +
and O +
in O +
endometrial O +
cancer O -
. O +

METHODS O -
: O +
The O +
expression O +
of O +
DCC O +
and O +
netrin-1 O +
in O +
normal O +
endometrial O +
glands O +
and O +
in O +
cancer O +
cell O +
lines O +
was O +
examined O +
by O +
RT O -
- O -
PCR O +
and O +
immunohistochemistry O -
. O +

The O +
effects O +
of O +
exogenous O +
DCC O +
and O +
netrin-1 O +
expression O +
were O +
observed O +
together O +
with O +
the O +
respective O +
expression O +
vector O +
transfection O -
. O +

RESULTS O -
: O +
Endometrial O +
glands O +
in O +
the O +
proliferative O +
and O +
early O +
secretory O +
phase O +
expressed O +
both O +
DCC O +
and O +
netrin-1 O -
, O +
but O +
glands O +
in O +
the O +
late O -
- O -
secretory O +
phase O +
tended O +
to O +
silence O +
DCC O +
expression O -
. O +

In O +
addition O -
, O +
all O +
of O +
the O +
endometrial O +
cancer O +
cell O +
lines O +
lost O +
normal O +
DCC O +
expression O -
. O +

Restored O +
DCC O +
expression O +
in O +
the O +
cancer O +
cell O +
lines O +
in O +
the O +
absence O +
of O +
netrin-1 O +
induced O +
apoptosis O -
. O +

However O -
, O +
no O +
changes O +
were O +
observed O +
in O +
the O +
presence O +
of O +
netrin-1 O -
. O +

CONCLUSION O -
: O +
Our O +
observations O +
suggest O +
that O +
DCC O -
/ O -
netrin-1 O +
signaling O +
may O +
commit O +
cells O +
to O +
the O +
transition O +
of O +
endometrial O +
gland O +
architecture O +
or O +
function O +
from O +
a O +
proliferating O +
to O +
a O +
secretory O +
phase O -
. O +

In O +
addition O -
, O +
the O +
silencing O +
of O +
DCC O +
expression O +
may O +
contribute O +
to O +
the O +
escape O +
of O +
endometrial O +
cancer O +
cells O +
from O +
a O +
DCC O -
- O -
regulated O +
apoptotic O +
program O -
, O +
thereby O +
promoting O +
malignant O +
phenotypes O -
. O +

Hypoxia O -
- O -
responsive O +
element O -
- O -
mediated O +
soluble O +
Tie2 O +
vector O +
exhibits O +
an O +
anti O -
- O -
angiogenic O +
activity O +
in O +
vitro O +
under O +
hypoxic O +
condition O -
. O +

Hypoxia O -
- O -
inducible O +
factor-1 O +
( O -
HIF-1 O -
) O +
is O +
one O +
of O +
the O +
key O +
mammalian O +
transcription O +
factors O +
and O +
shows O +
increased O +
levels O +
in O +
both O +
protein O +
stability O +
and O +
intrinsic O +
transcriptional O +
activity O +
during O +
low O +
oxygen B-Chemical +
tension O -
. O +

Hypoxia O -
- O -
activated O +
functional O +
HIF-1 O +
protein O +
binds O +
to O +
hypoxia O -
- O -
responsive O +
elements O +
( O -
HRE O -
) O +
in O +
the O +
enhancers O +
of O +
several O +
genes O +
including O +
VEGF O -
, O +
the O +
major O +
player O +
in O +
angiogenesis O -
, O +
and O +
initiates O +
their O +
mRNA O +
expression O -
. O +

The O +
molecular O +
mechanisms O +
regulating O +
the O +
gene O +
expression O +
under O +
hypoxic O +
conditions O +
could O +
increase O +
the O +
therapeutic O +
window O +
of O +
tumor O -
- O -
specific O +
delivery O +
systems O -
. O +

In O +
this O +
study O -
, O +
to O +
examine O +
hypoxia O -
- O -
specific O +
production O +
of O +
anti O -
- O -
angiogenic O +
therapeutic O +
gene O -
, O +
we O +
constructed O +
5 O +
copies O +
of O +
HRE O +
( O -
5xHRE O -
) O +
of O +
human O +
VEGF O +
linked O +
to O +
soluble O +
Tie2 O +
( O -
sTie2 O -
) O +
driven O +
by O +
minimal O +
SV40 O +
promoter O +
( O -
5xHRE O -
/ O -
SV40 O -
/ O -
sTie2 O -
) O -
. O +

Our O +
data O +
showed O +
that O +
under O +
hypoxia O +
the O +
secreted O +
sTie2 O +
selectively O +
inhibited O +
tube O +
formation O +
and O +
migration O +
capacities O +
of O +
endothelial O +
cells O +
in O +
vitro O -
. O +

Hence O -
, O +
we O +
propose O +
that O +
the O +
vector O +
system O -
, O +
5xHRE O -
/ O -
SV40 O -
/ O -
sTie2 O -
, O +
might O +
be O +
a O +
useful O +
tool O +
for O +
down O -
- O -
regulating O +
tumor O +
angiogenesis O +
under O +
hypoxic O +
condition O -
. O +

Matrix O +
metalloproteinase O -
/ O -
tissue O +
inhibitors O +
of O +
matrix O +
metalloproteinase O +
phenotype O +
identifies O +
poor O +
prognosis O +
colorectal O +
cancers O -
. O +

PURPOSE O -
: O +
The O +
matrix O +
metalloproteinases O +
( O -
MMPs O -
) O +
are O +
a O +
family O +
of O +
proteolytic O +
enzymes O +
involved O +
in O +
tumor O +
invasion O -
; O +
several O +
individual O +
members O +
of O +
which O +
have O +
been O +
implicated O +
in O +
tumor O +
prognosis O -
. O +

These O +
enzymes O +
and O +
their O +
physiologic O +
inhibitors O -
, O +
the O +
tissue O +
inhibitors O +
of O +
matrix O +
metalloproteinases O +
( O -
TIMPs O -
) O -
, O +
act O +
in O +
a O +
coordinated O +
manner O +
to O +
form O +
an O +
integrated O +
system O -
. O +

Therefore O -
, O +
to O +
understand O +
their O +
role O +
in O +
tumor O +
invasion O -
, O +
it O +
is O +
necessary O +
to O +
evaluate O +
them O +
collectively O -
. O +

EXPERIMENTAL O +
DESIGN O -
: O +
In O +
this O +
study O +
all O +
of O +
the O +
major O +
members O +
of O +
the O +
matrix O +
metalloproteinase O +
( O -
MMP-1 O -
, O +
MMP-2 O -
, O +
MMP-3 O -
, O +
MMP-7 O -
, O +
MMP-9 O -
, O +
MMP-13 O -
, O +
MT1-MMP O +
and O +
MT2-MMP O -
) O -
/ O -
tissue O +
inhibitor O +
of O +
matrix O +
metalloproteinase O +
( O -
TIMP-1 O -
, O +
TIMP-2 O -
, O +
and O +
TIMP-3 O -
) O +
system O +
have O +
been O +
investigated O +
by O +
immunohistochemistry O +
in O +
a O +
series O +
( O -
n O +
= O +
90 O -
) O +
of O +
stage O +
III O +
( O -
Dukes O -
' O +
C O -
) O +
colorectal O +
cancers O -
. O +

An O +
immunohistochemical O +
score O +
based O +
on O +
the O +
intensity O +
of O +
immunoreactivity O +
and O +
proportion O +
of O +
immunoreactive O +
cells O +
was O +
established O +
for O +
each O +
MMP O +
and O +
TIMP O -
. O +

RESULTS O -
: O +
The O +
MMP O -
/ O -
TIMP O +
profile O +
defined O +
by O +
hierarchical O +
cluster O +
analysis O +
of O +
the O +
immunohistochemical O +
score O +
identifies O +
a O +
distinct O +
group O +
of O +
colorectal O +
cancers O +
with O +
poor O +
prognosis O +
( O -
log O -
- O -
rank O +
test O -
, O +
12.22 O -
, O +
P O +
= O +
0.0005 O -
) O -
. O +

The O +
median O +
survival O +
time O +
of O +
patients O +
in O +
this O +
survival O +
group O +
was O +
18 O +
months O +
compared O +
with O +
a O +
median O +
survival O +
of O +
49 O +
months O +
in O +
the O +
" O -
good O -
" O +
survival O +
group O -
. O +

Multivariate O +
analysis O +
showed O +
that O +
this O +
profile O +
was O +
independently O +
the O +
most O +
significant O +
prognostic O +
factor O +
( O -
P O +
= O +
0.001 O -
) O -
. O +

CONCLUSIONS O -
: O +
This O +
study O +
has O +
identified O +
that O +
the O +
MMP O -
/ O -
TIMP O +
profile O +
is O +
an O +
independent O +
indicator O +
of O +
poor O +
prognosis O +
in O +
colorectal O +
cancer O -
. O +

2-methoxyestradiol B-Chemical +
inhibits O +
hypoxia O -
- O -
inducible O +
factor O +
1alpha O -
, O +
tumor O +
growth O -
, O +
and O +
angiogenesis O +
and O +
augments O +
paclitaxel B-Chemical +
efficacy O +
in O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O -
. O +

PURPOSE O -
: O +
Head O +
and O +
neck O +
squamous O +
cell O +
carcinomas O +
have O +
been O +
reported O +
to O +
overexpress O +
hypoxia O -
- O -
inducible O +
factor O +
( O -
HIF O -
) O -
-1alpha O -
, O +
a O +
transcription O +
factor O +
that O +
promotes O +
expression O +
of O +
angiogenesis O +
factors O +
and O +
resistance O +
to O +
programmed O +
and O +
therapy O -
- O -
induced O +
cell O +
death O -
. O +

2-Methoxyestradiol B-Chemical +
( O -
2ME2 B-Chemical -
) O +
is O +
a O +
natural O +
compound O +
with O +
HIF-1alpha O +
inhibitory O +
activity O +
that O +
is O +
currently O +
being O +
evaluated O +
in O +
phase O +
1 O +
and O +
2 O +
clinical O +
trials O +
for O +
advanced O +
solid O +
tumors O +
and O +
multiple O +
myeloma O -
. O +

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
study O +
to O +
evaluate O +
the O +
effects O +
of O +
2ME2 B-Chemical +
in O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O -
. O +

EXPERIMENTAL O +
DESIGN O -
: O +
In O +
the O +
present O +
study O -
, O +
we O +
investigated O +
the O +
effects O +
of O +
2ME2 B-Chemical +
alone O +
and O +
in O +
combination O +
with O +
paclitaxel B-Chemical -
, O +
an O +
active O +
agent O +
in O +
recurrent O +
or O +
advanced O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O -
. O +

RESULTS O -
: O +
2ME2 B-Chemical +
exhibited O +
antiproliferative O +
and O +
cytotoxic O +
effects O +
in O +
a O +
panel O +
of O +
five O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O +
cell O +
lines O +
in O +
the O +
0.5 O +
to O +
10 O +
micromol O -
/ O -
L O +
range O -
, O +
including O +
induction O +
of O +
G2-M O +
blockade O -
, O +
caspase-3 O -
/ O -
7 O +
activation O -
, O +
and O +
apoptosis O +
at O +
48 O +
hours O -
. O +

2ME2 B-Chemical +
resulted O +
in O +
decreased O +
nuclear O +
HIF-1alpha O -
- O -
binding O +
activity O +
and O +
affected O +
the O +
expression O +
of O +
downstream O +
genes O -
, O +
such O +
as O +
bid O -
, O +
a O +
proapoptotic O +
bcl-2 O +
family O +
member O -
, O +
and O +
vascular O +
endothelial O +
growth O +
factor O -
, O +
a O +
proangiogenic O +
cytokine O -
. O +

The O +
up O -
- O -
regulation O +
of O +
Bid O +
( O -
57.5 O -
% O +
at O +
12 O +
hours O -
, O +
P O +
less O +
than O +
0.0006 O -
) O +
and O +
inhibition O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
secretion O +
( O -
57.7 O -
% O +
at O +
24 O +
hours O -
, O +
P O +
less O +
than O +
0.015 O -
; O +
and O +
50.3 O -
% O +
at O +
48 O +
hours O -
, O +
P O +
less O +
than O +
0.0006 O -
) O +
could O +
be O +
partially O +
attributed O +
to O +
the O +
effects O +
on O +
HIF-1alpha O -
, O +
because O +
HIF-1alpha O +
small O +
interfering O +
RNAs O +
produced O +
similar O +
effects O -
. O +

Finally O -
, O +
in O +
vivo O -
, O +
in O +
a O +
xenograft O +
model O +
of O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O +
using O +
UM O -
- O -
SCC-11A O +
cells O -
, O +
2ME2 B-Chemical +
exhibited O +
antitumor O +
and O +
antiangiogenic O +
activity O -
, O +
as O +
measured O +
by O +
CD31 O +
immunostaining O -
. O +

CONCLUSIONS O -
: O +
These O +
results O +
provide O +
support O +
for O +
the O +
use O +
of O +
2ME2 B-Chemical +
in O +
combination O +
with O +
paclitaxel B-Chemical +
for O +
the O +
treatment O +
of O +
recurrent O +
or O +
advanced O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O -
. O +

HIF-2alpha O +
expression O +
in O +
human O +
fetal O +
paraganglia O +
and O +
neuroblastoma O -
: O +
relation O +
to O +
sympathetic O +
differentiation O -
, O +
glucose B-Chemical +
deficiency O -
, O +
and O +
hypoxia O -
. O +

Solid O +
tumors O +
are O +
frequently O +
necrotic O +
and O +
hypoxic O +
due O +
to O +
poor O +
vascularization O -
. O +

Tumor O +
cells O +
adapt O +
to O +
hypoxia O +
by O +
modulating O +
their O +
phenotype O -
. O +

Key O +
players O +
in O +
this O +
process O +
are O +
the O +
hypoxia O -
- O -
inducible O +
factors O +
( O -
HIF-1alpha O +
to O +
3alpha O -
) O -
. O +

HIFs O +
are O +
also O +
expressed O +
during O +
normal O +
development O -
; O +
for O +
example O -
, O +
HIF-2alpha O +
is O +
specifically O +
expressed O +
and O +
appears O +
to O +
be O +
involved O +
in O +
the O +
development O +
of O +
the O +
murine O +
sympathetic O +
nervous O +
system O +
( O -
SNS O -
) O -
. O +

Here O -
, O +
we O +
demonstrate O +
that O +
HIF-2alpha O +
protein O +
is O +
selectively O +
present O +
in O +
human O +
fetal O +
week O +
8.5 O +
SNS O +
paraganglia O -
. O +

Neuroblastoma O +
is O +
derived O +
from O +
SNS O +
precursors O -
. O +

In O +
a O +
subset O +
of O +
neuroblastomas O -
, O +
a O +
spontaneous O +
neuronal O +
to O +
neuroendocrine O +
differentiation O +
occurs O +
in O +
areas O +
adjacent O +
to O +
necrotic O +
zones O -
. O +

As O +
HIF-2alpha O +
activity O +
has O +
been O +
associated O +
not O +
only O +
with O +
hypoxic O +
but O +
also O +
with O +
hypoglycemic O +
conditions O -
, O +
we O +
have O +
investigated O +
putative O +
effects O +
of O +
hypoxia O -
, O +
glucose B-Chemical +
depletion O -
, O +
and O +
HIF-2alpha O +
on O +
the O +
neuroblastoma O +
phenotype O -
. O +

HIF-2alpha O +
was O +
detected O +
in O +
hypoxic O +
and O +
in O +
well O -
- O -
oxygenized O +
neuroblastoma O +
cells O +
and O +
tissue O -
, O +
presumably O +
reflecting O +
their O +
embryonic O +
features O -
. O +

With O +
regard O +
to O +
differentiation O -
, O +
hypoxic O +
cells O +
lost O +
their O +
neuronal O -
/ O -
neuroendocrine O +
features O +
and O +
gained O +
marker O +
gene O +
expression O +
associated O +
with O +
an O +
immature O -
, O +
neural O +
crest O -
- O -
like O +
phenotype O -
. O +

Low O +
glucose B-Chemical +
potentiated O +
the O +
effect O +
of O +
hypoxia O -
. O +

These O +
findings O +
suggest O +
that O +
poorly O +
vascularized O +
neuroblastomas O +
become O +
immature O +
and O +
maintain O +
a O +
more O +
aggressive O +
phenotype O -
, O +
which O +
possibly O +
could O +
involve O +
a O +
sustained O +
stabilization O +
and O +
activation O +
of O +
HIF-2alpha O -
. O +

Role O +
of O +
thrombogenic O +
factors O +
in O +
the O +
development O +
of O +
atherosclerosis O -
. O +

Hemostatic O +
factors O +
play O +
a O +
crucial O +
role O +
in O +
generating O +
thrombotic O +
plugs O +
at O +
sites O +
of O +
vascular O +
damage O +
( O -
atherothrombosis O -
) O -
. O +

However O -
, O +
whether O +
hemostatic O +
factors O +
contribute O +
directly O +
or O +
indirectly O +
to O +
the O +
pathogenesis O +
of O +
atherosclerosis O +
remains O +
uncertain O -
. O +

Autopsy O +
studies O +
have O +
revealed O +
that O +
intimal O +
thickening O +
represents O +
the O +
first O +
stage O +
of O +
atherosclerosis O +
and O +
that O +
lipid O -
- O -
rich O +
plaque O +
arises O +
from O +
such O +
lesions O -
. O +

Several O +
factors O +
contribute O +
to O +
the O +
start O +
of O +
intimal O +
thickening O -
. O +

Platelets O +
release O +
several O +
growth O +
factors O +
and O +
bioactive O +
agents O +
that O +
play O +
a O +
central O +
role O +
in O +
development O +
of O +
not O +
only O +
thrombus O +
but O +
also O +
of O +
intimal O +
thickening O -
. O +

We O +
have O +
been O +
investigating O +
which O +
coagulation O +
factors O +
simultaneously O -
, O +
or O +
subsequently O +
with O +
platelet O +
aggregation O -
, O +
participate O +
in O +
thrombus O +
formation O -
. O +

Tissue O +
factor O +
( O -
TF O -
) O +
is O +
an O +
essential O +
initiator O +
of O +
blood O +
coagulation O +
that O +
is O +
expressed O +
in O +
various O +
stages O +
of O +
atherosclerotic O +
lesions O +
in O +
humans O +
and O +
other O +
animals O -
. O +

Factors O +
including O +
thrombin O +
and O +
fibrin O -
, O +
which O +
are O +
downstream O +
of O +
the O +
coagulation O +
cascade O +
activated O +
by O +
TF O -
, O +
also O +
contribute O +
to O +
atherosclerosis O -
. O +

TF O +
is O +
involved O +
in O +
cell O +
migration O -
, O +
embryogenesis O +
and O +
angiogenesis O -
. O +

Thus O +
TF O -
, O +
in O +
addition O +
to O +
factors O +
downstream O +
of O +
the O +
coagulation O +
cascade O +
and O +
the O +
protease O -
- O -
activated O +
receptor O +
2 O +
activation O +
system O -
, O +
would O +
be O +
a O +
multifactorial O +
regulator O +
of O +
atherogenesis O -
. O +

Angiogenin O +
is O +
up O -
- O -
regulated O +
in O +
the O +
nucleus O +
and O +
cytoplasm O +
in O +
human O +
primary O +
breast O +
carcinoma O +
and O +
is O +
associated O +
with O +
markers O +
of O +
hypoxia O +
but O +
not O +
survival O -
. O +

Angiogenin O -
, O +
a O +
14.2 O +
kD O +
polypeptide O +
that O +
was O +
originally O +
noted O +
for O +
its O +
angiogenic O +
activity O -
, O +
is O +
now O +
increasingly O +
recognized O +
to O +
have O +
a O +
multiplicity O +
of O +
biological O +
roles O +
in O +
both O +
physiological O +
and O +
pathological O +
conditions O -
. O +

In O +
breast O +
cancer O -
, O +
there O +
are O +
conflicting O +
studies O +
questioning O +
the O +
role O +
of O +
angiogenin O -
. O +

Here O -
, O +
the O +
pattern O +
of O +
expression O +
of O +
angiogenin O +
during O +
the O +
transition O +
from O +
normal O +
breast O +
tissue O +
to O +
ductal O +
carcinoma O +
in O +
situ O +
and O +
invasive O +
carcinoma O +
is O +
reported O +
together O +
with O +
the O +
correlates O +
between O +
the O +
level O +
of O +
angiogenin O +
in O +
239 O +
invasive O +
carcinomas O +
and O +
standard O +
clinicopathological O +
parameters O -
, O +
hypoxia O -
- O -
inducible O +
factor O +
( O -
HIF O -
) O -
-1 O +
alpha O +
and O +
the O +
HIF-1 O +
alpha O +
target O +
gene O +
DEC-1 O -
. O +

This O +
study O +
shows O +
that O +
angiogenin O +
expression O +
is O +
up O -
- O -
regulated O +
in O +
the O +
cytoplasmic O +
and O +
nuclear O +
compartments O +
in O +
in O +
situ O +
carcinoma O +
and O +
invasive O +
carcinoma O +
compared O +
with O +
normal O +
breast O +
tissue O +
and O +
that O +
angiogenin O +
expression O +
in O +
invasive O +
carcinomas O +
is O +
significantly O +
positively O +
associated O +
with O +
high O +
tumour O +
grade O +
( O -
p O +
= O +
0.03 O -
) O -
, O +
positive O +
oestrogen O +
receptor O +
( O -
ER O -
) O +
status O +
( O -
p O +
= O +
0.01 O -
) O -
, O +
HIF-1 O +
alpha O +
( O -
p O +
= O +
0.001 O -
) O +
and O +
DEC O +
1 O +
( O -
p O +
= O +
0.001 O -
) O -
, O +
but O +
not O +
with O +
patient O +
age O +
( O -
p O +
= O +
0.8 O -
) O -
, O +
tumour O +
size O +
( O -
p O +
= O +
0.25 O -
) O -
, O +
lymph O +
node O +
status O +
( O -
p O +
= O +
0.69 O -
) O -
, O +
epidermal O +
growth O +
factor O +
receptor O +
( O -
p O +
= O +
0.56 O -
) O +
or O +
microvessel O +
density O +
( O -
p O +
= O +
0.32 O -
) O -
. O +

No O +
difference O +
in O +
relapse O -
- O -
free O +
( O -
p O +
= O +
0.26 O -
) O +
or O +
overall O +
( O -
p O +
= O +
0.63 O -
) O +
survival O +
was O +
observed O +
in O +
patients O +
stratified O +
by O +
angiogenin O +
expression O -
. O +

This O +
study O +
suggests O +
that O +
angiogenin O +
may O +
be O +
important O +
in O +
breast O +
cancer O +
progression O +
and O +
that O -
, O +
through O +
its O +
relationship O +
with O +
ER O -
, O +
it O +
may O +
be O +
a O +
target O +
for O +
tamoxifen B-Chemical -
. O +

Mouse O +
p10 O -
, O +
an O +
alternative O +
spliced O +
form O +
of O +
p15INK4b O -
, O +
inhibits O +
cell O +
cycle O +
progression O +
and O +
malignant O +
transformation O -
. O +

The O +
INK4 O +
family O +
of O +
proteins O +
negatively O +
regulates O +
cell O +
cycle O +
progression O +
at O +
the O +
G O -
( O -
1 O -
) O -
-S O +
transition O +
by O +
inhibiting O +
cyclin O -
- O -
dependent O +
kinases O -
. O +

Two O +
of O +
these O +
cell O +
cycle O +
inhibitors O -
, O +
p16 O -
( O -
INK4A O -
) O +
and O +
p15 O -
( O -
INK4B O -
) O -
, O +
have O +
tumor O +
suppressor O +
activities O +
and O +
are O +
inactivated O +
in O +
human O +
cancer O -
. O +

Interestingly O -
, O +
both O +
INK4 O +
genes O +
express O +
alternative O +
splicing O +
variants O -
. O +

In O +
addition O +
to O +
p16 O -
( O -
INK4A O -
) O -
, O +
the O +
INK4A O +
locus O +
encodes O +
a O +
splice O +
variant O -
, O +
termed O +
p12 O -
- O -
-specifically O +
expressed O +
in O +
human O +
pancreas O -
-- O -
and O +
ARF O -
, O +
a O +
protein O +
encoded O +
by O +
an O +
alternative O +
reading O +
frame O +
that O +
acts O +
as O +
a O +
tumor O +
suppressor O +
through O +
the O +
p53 O +
pathway O -
. O +

Similarly O -
, O +
the O +
human O +
INK4B O +
locus O +
encodes O +
the O +
p15 O -
( O -
INK4B O -
) O +
tumor O +
suppressor O +
and O +
one O +
alternatively O +
spliced O +
form O -
, O +
termed O +
as O +
p10 O -
. O +

We O +
show O +
here O +
that O +
p10 O -
, O +
which O +
arises O +
from O +
the O +
use O +
of O +
an O +
alternative O +
splice O +
donor O +
site O +
within O +
intron O +
1 O -
, O +
is O +
conserved O +
in O +
the O +
mouse O +
genome O +
and O +
is O +
widely O +
expressed O +
in O +
mouse O +
tissues O -
. O +

Similarly O +
to O +
mouse O +
p15 O -
( O -
INK4B O -
) O -
, O +
p10 O +
expression O +
is O +
also O +
induced O +
by O +
oncogenic O +
insults O +
and O +
transforming O +
growth O +
factor O -
- O -
beta O +
treatment O +
and O +
acts O +
as O +
a O +
cell O +
cycle O +
inhibitor O -
. O +

Importantly O -
, O +
we O +
show O +
that O +
mouse O +
p10 O +
is O +
able O +
to O +
induce O +
cell O +
cycle O +
arrest O +
in O +
a O +
p53-dependent O +
manner O -
. O +

We O +
also O +
show O +
that O +
mouse O +
p10 O +
is O +
able O +
to O +
inhibit O +
foci O +
formation O +
and O +
anchorage O -
- O -
independent O +
growth O +
in O +
wild O -
- O -
type O +
mouse O +
embryonic O +
fibroblasts O -
, O +
and O +
that O +
these O +
antitransforming O +
properties O +
of O +
mouse O +
p10 O +
are O +
also O +
p53-dependent O -
. O +

These O +
results O +
indicate O +
that O +
the O +
INK4B O +
locus O -
, O +
similarly O +
to O +
INK4A O -
- O -
ARF O -
, O +
harbors O +
two O +
different O +
splicing O +
variants O +
that O +
can O +
be O +
involved O +
in O +
the O +
regulation O +
of O +
both O +
the O +
p53 O +
and O +
retinoblastoma O +
pathways O -
, O +
the O +
two O +
major O +
molecular O +
pathways O +
in O +
tumor O +
suppression O -
. O +

Therapeutic O +
Electromagnetic O +
Field O +
( O -
TEMF O -
) O +
and O +
gamma O +
irradiation O +
on O +
human O +
breast O +
cancer O +
xenograft O +
growth O -
, O +
angiogenesis O +
and O +
metastasis O -
. O +

BACKGROUND O -
: O +
The O +
effects O +
of O +
a O +
rectified O +
semi O -
- O -
sinewave O +
signal O +
( O -
15 O +
mT O +
amplitude O -
, O +
120 O +
pulses O +
per O +
second O -
, O +
EMF O +
Therapeutics O -
, O +
Inc. O -
) O +
( O -
TEMF O -
) O +
alone O +
and O +
in O +
combination O +
with O +
gamma O +
irradiation O +
( O -
IR O -
) O +
therapy O +
in O +
nude O +
mice O +
bearing O +
a O +
human O +
MDA O +
MB231 O +
breast O +
cancer O +
xenograft O +
were O +
tested O -
. O +

Green O +
fluorescence O +
protein O +
transfected O +
cancer O +
cells O +
were O +
injected O +
into O +
the O +
mammary O +
fat O +
pad O +
of O +
young O +
female O +
mice O -
. O +

Six O +
weeks O +
later O -
, O +
mice O +
were O +
randomly O +
divided O +
into O +
four O +
treatment O +
groups O -
: O +
untreated O +
controls O -
; O +
10 O +
minute O +
daily O +
TEMF O -
; O +
200 O +
cGy O +
of O +
IR O +
every O +
other O +
day O +
( O -
total O +
800 O +
cGy O -
) O -
; O +
IR O +
plus O +
daily O +
TEMF O -
. O +

Some O +
mice O +
in O +
each O +
group O +
were O +
euthanized O +
24 O +
hours O +
after O +
the O +
end O +
of O +
IR O -
. O +

TEMF O +
treatment O +
continued O +
for O +
3 O +
additional O +
weeks O -
. O +

Tumor O +
sections O +
were O +
stained O +
for O -
: O +
endothelial O +
cells O +
with O +
CD31 O +
and O +
PAS B-Chemical +
or O +
hypoxia O +
inducible O +
factor O +
1alpha O +
( O -
HIF O -
) O -
. O +

RESULTS O -
: O +
Most O +
tumors O +
less O +
than O +
35 O +
mm3 O +
were O +
white O +
but O +
tumors O +
greater O +
than O +
35 O +
mm3 O +
were O +
pink O +
and O +
had O +
a O +
vascularized O +
capsule O -
. O +

The O +
cortex O +
within O +
100 O +
microns O +
of O +
the O +
capsule O +
had O +
little O +
vascularization O -
. O +

Blood O +
vessels O -
, O +
capillaries O -
, O +
and O +
endothelial O +
pseudopods O +
were O +
found O +
at O +
greater O +
than O +
100 O +
microns O +
from O +
the O +
capsule O +
( O -
subcortex O -
) O -
. O +

Tumors O +
greater O +
than O +
35 O +
mm3 O +
treated O +
with O +
IR O +
24 O +
hours O +
previously O +
or O +
with O +
TEMF O +
had O +
decreased O +
blood O +
vessels O +
in O +
the O +
subcortex O +
and O +
more O +
endothelial O +
pseudopods O +
projecting O +
into O +
hypoxic O -
, O +
HIF O +
positive O +
areas O +
than O +
tumors O +
from O +
the O +
control O +
group O -
. O +

Mice O +
that O +
received O +
either O +
IR O +
or O +
TEMF O +
had O +
significantly O +
fewer O +
lung O +
metastatic O +
sites O +
and O +
slower O +
tumor O +
growth O +
than O +
did O +
untreated O +
mice O -
. O +

No O +
harmful O +
side O +
effects O +
were O +
attributed O +
to O +
TEMF O -
. O +

CONCLUSION O -
: O +
TEMF O +
therapy O +
provided O +
a O +
safe O +
means O +
for O +
retarding O +
tumor O +
vascularization O -
, O +
growth O +
and O +
metastasis O -
. O +

Thrombospondins O -
, O +
metallo O +
proteases O +
and O +
thrombospondin O +
receptors O +
messenger O +
RNA O +
and O +
protein O +
expression O +
in O +
different O +
tumour O +
sublines O +
of O +
the O +
Dunning O +
prostate O +
cancer O +
model O -
. O +

Thrombospondin O +
is O +
a O +
potent O +
inhibitor O +
of O +
angiogenesis O +
and O +
might O +
therefore O +
be O +
important O +
in O +
controlling O +
tumour O +
growth O -
. O +

TSP O +
interacts O +
with O +
a O +
number O +
of O +
proteases O +
and O +
receptors O +
and O +
in O +
this O +
way O +
inhibits O +
stimulation O +
of O +
angiogenesis O -
. O +

An O +
earlier O +
study O +
showed O +
that O +
thrombospondin O +
is O +
expressed O +
in O +
benign O +
prostatic O +
hyperplasia O +
( O -
BPH O -
) O +
and O +
high O -
- O -
grade O +
prostatic O +
intraepithelial O +
neoplasia O +
( O -
PIN O -
) O +
but O +
is O +
absent O +
in O +
prostate O +
cancer O -
. O +

The O +
present O +
study O +
was O +
therefore O +
designed O +
to O +
evaluate O +
the O +
expression O +
of O +
thrombospondin O +
1 O +
and O +
2 O +
( O -
TSP-1 O -
, O +
TSP-2 O -
) O -
, O +
TSP O +
receptors O +
CD36 O +
and O +
CD47 O -
, O +
and O +
matrix O -
- O -
metalloproteases O +
2 O +
and O +
9 O +
( O -
MMP- O -
, O +
MMP-9 O -
) O +
in O +
a O +
rat O +
prostate O +
cancer O +
model O -
. O +

By O +
using O +
immunohistochemistry O -
, O +
Western O +
blot O -
, O +
and O +
real O -
- O -
time O +
PCR O +
the O +
expression O +
patterns O +
of O +
TSP-1 O -
, O +
TSP-2 O -
, O +
CD36 O -
, O +
CD47 O -
, O +
MMP-2 O -
, O +
and O +
MMP-9 O +
were O +
investigated O +
in O +
normal O +
rat O +
prostate O +
tissue O +
and O +
five O +
malignant O +
Dunning O +
sublines O +
tissue O -
. O +

TSP-1 O +
mRNA O +
levels O +
were O +
decreased O +
in O +
all O +
tumours O +
compared O +
with O +
normal O +
prostate O -
. O +

However O -
, O +
there O +
was O +
no O +
difference O +
in O +
expression O +
of O +
TSP-2 O +
and O +
CD36 O +
mRNA O +
in O +
these O +
samples O -
. O +

MMP-2 O +
was O +
increased O +
with O +
malignancy O -
, O +
but O +
no O +
expression O +
of O +
MMP-9 O +
was O +
seen O -
. O +

The O +
CD47 O +
receptor O +
did O +
slightly O +
increase O +
with O +
malignancy O +
except O +
for O +
H3327 O -
. O +

The O +
results O +
showed O +
that O +
thrombospondin O +
is O +
expressed O +
in O +
normal O +
prostate O +
but O +
not O +
in O +
prostate O +
tumours O +
in O +
a O +
rat O +
model O -
. O +

Simultaneously O -
, O +
MMP-2 O +
expression O +
increases O +
with O +
malignancy O -
. O +

Molecular O +
requirements O +
for O +
epithelial O -
- O -
mesenchymal O +
transition O +
during O +
tumor O +
progression O -
. O +

Epithelial O -
- O -
mesenchymal O +
transitions O +
( O -
EMTs O -
) O +
occur O +
as O +
key O +
steps O +
during O +
embryonic O +
morphogenesis O -
, O +
and O +
are O +
now O +
implicated O +
in O +
the O +
progression O +
of O +
primary O +
tumors O +
towards O +
metastases O -
. O +

Recent O +
advances O +
have O +
fostered O +
a O +
more O +
detailed O +
understanding O +
of O +
molecular O +
mechanisms O +
and O +
networks O +
governing O +
EMT O +
in O +
tumor O +
progression O -
. O +

Besides O +
TGFbeta O +
and O +
RTK O -
/ O -
Ras O +
signaling O -
, O +
autocrine O +
factors O +
and O +
Wnt- O -
, O +
Notch- O -
, O +
Hedgehog- O +
and O +
NF O -
- O -
kappaB O -
- O -
dependent O +
pathways O +
were O +
found O +
to O +
contribute O +
to O +
EMT O -
. O +

Repression O +
of O +
E O -
- O -
cadherin O +
by O +
transcriptional O +
regulators O +
such O +
as O +
Snail O +
or O +
Twist O +
emerges O +
as O +
one O +
critical O +
step O +
driving O +
EMT O -
, O +
and O +
this O +
stage O +
is O +
currently O +
being O +
molecularly O +
linked O +
with O +
many O +
of O +
the O +
new O +
players O -
. O +

Increasing O +
evidence O +
suggests O +
that O +
EMT O +
plays O +
a O +
specific O +
role O +
in O +
the O +
migration O +
of O +
cells O +
from O +
a O +
primary O +
tumor O +
into O +
the O +
circulation O +
and O +
may O +
provide O +
a O +
rationale O +
for O +
developing O +
more O +
effective O +
cancer O +
therapies O -
. O +

Impaired O +
coronary O +
collateral O +
vessel O +
development O +
in O +
patients O +
with O +
proliferative O +
diabetic O +
retinopathy O -
. O +

BACKGROUND O -
: O +
Diabetic O +
patients O +
have O +
been O +
reported O +
to O +
have O +
impaired O +
coronary O +
collateral O +
vessel O +
growth O -
, O +
although O +
they O +
have O +
excessive O +
neovascularization O +
in O +
the O +
retina O -
. O +

HYPOTHESIS O -
: O +
This O +
study O +
was O +
designed O +
to O +
compare O +
coronary O +
collateral O +
circulation O +
( O -
CCC O -
) O +
in O +
patients O +
with O +
proliferative O +
diabetic O +
retinopathy O +
( O -
PDR O -
) O +
with O +
that O +
in O +
patients O +
without O +
DR O -
. O +

METHODS O -
: O +
Ninety O +
diabetic O +
patients O +
with O +
chronic O +
total O +
occlusion O +
in O +
at O +
least O +
one O +
major O +
epicardial O +
coronary O +
artery O +
were O +
enrolled O +
in O +
the O +
study O -
. O +

Groups O +
1 O +
and O +
2 O +
consisted O +
of O +
48 O +
patients O +
without O +
DR O +
and O +
42 O +
patients O +
with O +
PDR O -
, O +
respectively O -
. O +

Coronary O +
collateral O +
circulation O +
( O -
CCC O -
) O +
was O +
analyzed O +
according O +
to O +
the O +
Rentrop O +
system O -
. O +

Each O +
group O +
was O +
also O +
divided O +
into O +
two O +
subgroups O +
according O +
to O +
poor O +
and O +
good O +
CCC O -
. O +

Serum O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
levels O +
were O +
measured O +
using O +
the O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O +
( O -
ELISA O -
) O +
kit O -
. O +

RESULTS O -
: O +
The O +
mean O +
Rentrop O +
collateral O +
score O +
was O +
higher O +
in O +
Group O +
1 O +
than O +
in O +
Group O +
2 O +
( O -
2.39 O +
+ O -
/- O +

1.07 O +
vs. O +
1.76 O +
+ O -
/- O +

0.76 O -
, O +
respectively O -
, O +
p O +
less O +
than O +
0.001 O -
) O -
. O +

When O +
the O +
two O +
groups O +
were O +
compared O +
with O +
respect O +
to O +
poor O +
and O +
good O +
CCC O -
, O +
poor O +
CCC O +
was O +
higher O +
in O +
patients O +
with O +
PDR O +
( O -
64 O +
vs. O +
36 O -
% O -
, O +
respectively O -
, O +
p O +
= O +
0.01 O -
) O -
. O +

Serum O +
VEGF O +
levels O +
were O +
higher O +
in O +
patients O +
with O +
PDR O +
than O +
in O +
those O +
without O +
DR O +
( O -
219 O +
+ O -
/- O +
99 O +
vs. O +
139 O +
+ O -
/- O +

98 O +
pg O -
/ O -
ml O -
, O +
p O +
less O +
than O +
0.001 O -
) O -
; O +
however O -
, O +
patients O +
with O +
poor O +
and O +
good O +
CCC O +
had O +
similar O +
VEGF O +
levels O -
. O +

CONCLUSIONS O -
: O +
We O +
have O +
shown O +
that O +
patients O +
with O +
PDR O +
have O +
a O +
lower O +
coronary O +
collateral O +
score O +
than O +
patients O +
without O +
DR O -
. O +

Also O -
, O +
serum O +
VEGF O +
was O +
significantly O +
higher O +
in O +
patients O +
with O +
PDR O +
than O +
in O +
those O +
without O +
DR O -
. O +

These O +
findings O +
have O +
suggested O +
that O +
diabetes O +
mellitus O +
may O +
have O +
a O +
different O +
action O +
on O +
retinal O +
and O +
coronary O +
circulation O -
. O +

The O +
differential O +
regulation O +
of O +
human O +
telomerase O +
reverse O +
transcriptase O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
may O +
contribute O +
to O +
the O +
clinically O +
more O +
aggressive O +
behavior O +
of O +
p63-positive O +
breast O +
carcinomas O -
. O +

p63 O -
, O +
a O +
p53 O +
homologue O -
, O +
is O +
a O +
myoepithelial O +
cell O +
marker O +
in O +
the O +
normal O +
mammary O +
gland O +
but O +
p63-positive O +
neoplastic O +
cells O +
may O +
be O +
found O +
in O +
up O +
to O +
11 O -
% O +
of O +
invasive O +
breast O +
carcinomas O -
. O +

This O +
study O +
aims O +
to O +
verify O +
the O +
relationship O +
between O +
p63 O +
expression O +
and O +
several O +
clinicopathological O +
features O +
and O +
tumor O +
markers O +
of O +
clinical O +
significance O +
in O +
breast O +
pathology O +
including O +
key O +
regulators O +
of O +
the O +
cell O +
cycle O -
, O +
oncogenes O -
, O +
apoptosis O -
- O -
related O +
proteins O -
, O +
metalloproteinases O +
and O +
their O +
inhibitors O -
. O +

Immunohistochemistry O +
with O +
27 O +
primary O +
antibodies O +
was O +
performed O +
in O +
100 O +
formalin O -
- O -
fixed O +
paraffin O -
- O -
embedded O +
samples O +
of O +
invasive O +
ductal O +
carcinomas O -
. O +

p63-positive O +
cells O +
were O +
found O +
in O +
16 O -
% O +
of O +
carcinomas O -
. O +

p63-positive O +
carcinomas O +
were O +
poorly O +
differentiated O -
, O +
hormone O +
receptor O -
- O -
negative O +
neoplasms O +
with O +
a O +
high O +
proliferation O +
rate O -
. O +

p63 O +
also O +
correlated O +
with O +
advanced O +
pathological O +
stage O -
, O +
tumor O +
size O -
, O +
and O +
the O +
expression O +
of O +
human O +
telomerase O +
reverse O +
transcriptase O +
( O -
hTERT O -
) O -
, O +
tissue O +
inhibitor O +
of O +
matrix O +
metalloproteinase O +
1 O +
( O -
TIMP1 O -
) O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
. O +

The O +
expression O +
of O +
TIMP1 O +
suggests O +
that O +
the O +
anti O -
- O -
proteolytic O +
stimuli O +
may O +
be O +
preponderant O +
in O +
p63-positive O +
carcinomas O -
. O +

hTERT O +
activity O +
is O +
associated O +
with O +
nodal O +
metastases O +
and O +
cellular O +
proliferation O -
. O +

VEGF O +
regulates O +
angiogenesis O -
, O +
which O +
is O +
also O +
a O +
fundamental O +
event O +
in O +
the O +
process O +
of O +
tumor O +
growth O +
and O +
metastatic O +
dissemination O -
. O +

Thus O -
, O +
the O +
differential O +
regulation O +
of O +
hTERT O +
and O +
VEGF O +
in O +
p63-positive O +
breast O +
carcinomas O +
may O +
contribute O +
to O +
the O +
clinically O +
more O +
aggressive O +
behavior O +
of O +
these O +
neoplasms O -
. O +

Mechanisms O +
of O +
pericyte O +
recruitment O +
in O +
tumour O +
angiogenesis O -
: O +
a O +
new O +
role O +
for O +
metalloproteinases O -
. O +

Pericytes O +
occur O +
in O +
tumour O +
blood O +
vessels O +
and O +
are O +
critical O +
for O +
the O +
development O +
of O +
a O +
functional O +
vascular O +
network O -
. O +

Targeting O +
tumour O +
pericytes O +
is O +
a O +
promising O +
anti O -
- O -
angiogenic O +
therapy O +
but O +
requires O +
identifying O +
the O +
mechanisms O +
of O +
their O +
recruitment O +
in O +
tumour O +
and O +
addressing O +
whether O +
these O +
mechanisms O +
can O +
be O +
selectively O +
harnessed O -
. O +

Among O +
the O +
pathways O +
involved O +
in O +
pericyte O +
recruitment O +
during O +
embryonic O +
development O -
, O +
the O +
contribution O +
of O +
platelet O -
- O -
derived O +
growth O +
factor O +
B O +
and O +
sphingosine O +
1-phosphate O +
is O +
confirmed O +
in O +
tumour O +
angiogenesis O -
. O +

The O +
effect O +
of O +
angiopoietin O +
1 O +
depends O +
on O +
the O +
tumour O +
model O -
. O +

Transforming O +
growth O +
factor O -
- O -
beta1 O +
enhances O +
tumour O +
vascularization O +
and O +
microvessel O +
maturation O -
. O +

Recent O +
reports O +
suggest O +
a O +
participation O +
of O +
matrix O +
metalloproteinases O +
( O -
MMP O -
) O +
in O +
tumour O +
pericyte O +
recruitment O +
that O +
is O +
consistent O +
with O +
the O +
effect O +
of O +
certain O +
MMPs O +
in O +
the O +
development O +
of O +
microvasculature O +
in O +
embryonic O +
development O +
and O +
in O +
in O +
vitro O +
models O +
of O +
vascular O +
remodelling O -
. O +

Here O -
, O +
we O +
discuss O +
the O +
possibility O +
for O +
MMPs O +
to O +
contribute O +
to O +
pericyte O +
recruitment O +
at O +
six O +
levels O -
: O +
( O -
1 O -
) O +
direct O +
promotion O +
of O +
pericyte O +
invasion O +
by O +
extracellular O +
matrix O +
degradation O -
; O +
( O -
2 O -
) O +
stimulation O +
of O +
pericyte O +
proliferation O +
and O +
protection O +
against O +
apoptosis O +
by O +
modification O +
of O +
the O +
ECM O -
; O +
( O -
3 O -
) O +
activation O +
of O +
pericytes O +
through O +
the O +
release O +
of O +
growth O +
factor O +
bound O +
to O +
the O +
ECM O -
; O +
( O -
4 O -
) O +
transactivation O +
of O +
angiogenic O +
cell O +
surface O +
receptor O -
; O +
( O -
5 O -
) O +
propagation O +
of O +
angiogenic O +
signalling O +
as O +
cofactor O -
; O +
and O +
( O -
6 O -
) O +
recruitment O +
of O +
bone O +
marrow O -
- O -
derived O +
stem O +
cells O -
. O +

Regulation O +
of O +
the O +
composition O +
of O +
the O +
extracellular O +
matrix O +
by O +
low O +
density O +
lipoprotein O +
receptor O -
- O -
related O +
protein-1 O -
: O +
activities O +
based O +
on O +
regulation O +
of O +
mRNA O +
expression O -
. O +

Low O +
density O +
lipoprotein O +
receptor O -
- O -
related O +
protein-1 O +
( O -
LRP-1 O -
) O +
is O +
a O +
catabolic O +
receptor O +
for O +
extracellular O +
matrix O +
( O -
ECM O -
) O +
structural O +
proteins O +
and O +
for O +
proteins O +
that O +
bind O +
to O +
ECM O -
. O +

LRP-1 O +
also O +
is O +
implicated O +
in O +
integrin O +
maturation O -
. O +

In O +
this O +
study O -
, O +
we O +
applied O +
a O +
proteomics O +
strategy O +
to O +
identify O +
novel O +
proteins O +
involved O +
in O +
ECM O +
modeling O +
that O +
are O +
regulated O +
by O +
LRP-1 O -
. O +

We O +
show O +
that O +
LRP-1 O +
deficiency O +
in O +
murine O +
embryonic O +
fibroblasts O +
( O -
MEFs O -
) O +
is O +
associated O +
with O +
increased O +
levels O +
of O +
type O +
III O +
collagen O +
and O +
pigment O +
epithelium O -
- O -
derived O +
factor O -
, O +
which O +
accumulate O +
in O +
the O +
substratum O +
surrounding O +
cells O -
. O +

The O +
collagen O +
receptor O -
, O +
uPAR O -
- O -
AP O -
/ O -
Endo-180 O -
, O +
is O +
also O +
increased O +
in O +
LRP-1-deficient O +
MEFs O -
. O +

Human O +
LRP-1 O +
reversed O +
the O +
changes O +
in O +
protein O +
expression O +
associated O +
with O +
LRP-1 O +
deficiency O -
; O +
however O -
, O +
the O +
endocytic O +
activity O +
of O +
LRP-1 O +
was O +
not O +
involved O -
. O +

Instead O -
, O +
regulation O +
occurred O +
at O +
the O +
mRNA O +
level O -
. O +

Inhibition O +
of O +
c O -
- O -
Jun O +
amino O -
- O -
terminal O +
kinase O +
( O -
JNK O -
) O +
blocked O +
type O +
III O +
collagen O +
expression O +
in O +
LRP-1-deficient O +
MEFs O -
, O +
suggesting O +
regulation O +
of O +
JNK O +
activity O +
as O +
a O +
mechanism O +
by O +
which O +
LRP-1 O +
controls O +
mRNA O +
expression O -
. O +

The O +
ability O +
of O +
LRP-1 O +
to O +
regulate O +
expression O +
of O +
the O +
factors O +
identified O +
here O +
suggests O +
a O +
role O +
for O +
LRP-1 O +
in O +
determining O +
blood O +
vessel O +
structure O +
and O +
in O +
angiogenesis O -
. O +

Decrease O +
in O +
c O -
- O -
Myc O +
activity O +
enhances O +
cancer O +
cell O +
sensitivity O +
to O +
vinblastine B-Chemical -
. O +

The O +
c O -
- O -
myc O +
oncogene O +
encodes O +
for O +
a O +
transcriptional O +
factor O +
involved O +
in O +
many O +
cellular O +
processes O +
such O +
as O +
proliferation O -
, O +
differentiation O +
and O +
apoptosis O -
. O +

According O +
to O +
these O +
different O +
functions O -
, O +
the O +
role O +
of O +
c O -
- O -
Myc O +
protein O +
in O +
cellular O +
sensitivity O +
to O +
anti O -
- O -
cancer O +
drugs O +
is O +
controversial O -
. O +

We O +
defined O +
the O +
role O +
of O +
c O -
- O -
Myc O +
in O +
cancer O +
cell O +
sensitivity O +
to O +
vinblastine B-Chemical +
( O -
VLB B-Chemical -
) O +
using O +
human O +
colon O +
cancer O +
cells O -
: O +
LoVo O +
wild O -
- O -
type O +
or O +
transfected O +
with O +
a O +
plasmid O +
containing O +
the O +
human O +
c O -
- O -
myc O +
gene O +
in O +
antisense O +
orientation O +
( O -
LoVo O -
- O -
mycANS O -
) O -
. O +

Analysis O +
of O +
VLB B-Chemical +
cytotoxicity O +
demonstrated O +
a O +
3-fold O +
increase O +
in O +
VLB B-Chemical +
sensitivity O +
in O +
LoVo O -
- O -
mycANS O +
cells O -
. O +

Comparison O +
between O +
cells O +
revealed O +
different O +
apoptosis O +
kinetics O -
: O +
accumulation O +
of O +
cells O +
in O +
sub O -
- O -
G1 O +
phase O +
and O +
poly O -
( O -
ADP O -
- O -
ribose O -
) O +
polymerase O +
cleavage O +
occurred O +
earlier O +
in O +
LoVo O -
- O -
mycANS O -
. O +

Then O -
, O +
we O +
demonstrated O +
a O +
mitochondrial O +
membrane O +
potential O +
disruption O +
followed O +
by O +
cytochrome O +
c O +
release O +
that O +
indicates O +
the O +
involvement O +
of O +
mitochondria O +
in O +
this O +
apoptotic O +
signaling O +
pathway O -
. O +

This O +
earlier O +
apoptosis O +
was O +
accompanied O +
by O +
a O +
Bcl-2 O +
decrease O +
and O +
a O +
p53 O +
increase O -
. O +

In O +
conclusion O -
, O +
the O +
decrease O +
in O +
c O -
- O -
Myc O +
expression O +
enhanced O +
the O +
VLB B-Chemical +
sensitivity O -
, O +
triggering O +
earlier O +
apoptosis O +
through O +
induction O +
of O +
the O +
intrinsic O +
pathway O -
. O +

Thus O -
, O +
c O -
- O -
myc O +
induction O +
is O +
a O +
resistance O +
factor O +
and O +
our O +
findings O +
suggest O +
that O +
tumors O +
carrying O +
low O +
levels O +
of O +
c O -
- O -
Myc O +
protein O +
could O +
be O +
more O +
responsive O +
to O +
vinca B-Chemical +
alkaloids I-Chemical +
treatment O -
. O +

Moreover O -
, O +
the O +
downregulation O +
of O +
c O -
- O -
myc O +
oncogene O +
by O +
an O +
antisense O +
strategy O +
might O +
represent O +
a O +
useful O +
goal O +
for O +
improving O +
the O +
efficacy O +
of O +
this O +
anti O -
- O -
neoplastic O +
drug O +
family O -
. O +

Inhibition O +
of O +
the O +
mammalian O +
target O +
of O +
rapamycin O +
( O -
mTOR O -
) O +
by O +
rapamycin B-Chemical +
increases O +
chemosensitivity O +
of O +
CaSki O +
cells O +
to O +
paclitaxel B-Chemical -
. O +

Paclitaxel B-Chemical -
, O +
a O +
potent O +
anti O -
- O -
neoplastic O +
agent O -
, O +
has O +
been O +
found O +
to O +
be O +
effective O +
against O +
several O +
tumours O -
, O +
including O +
cervical O +
cancer O -
. O +

However O -
, O +
the O +
exact O +
mechanism O +
underlying O +
the O +
cytotoxic O +
effects O +
of O +
pacitaxel B-Chemical -
, O +
especially O +
in O +
the O +
survival O -
- O -
signalling O +
pathway O -
, O +
is O +
poorly O +
understood O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
molecular O +
pathway O +
of O +
the O +
cytotoxic O +
effect O +
of O +
paclitaxel B-Chemical +
in O +
human O +
cervical O +
cancer O +
cell O +
lines O -
. O +

Four O +
human O +
cervical O +
cancer O +
cell O +
lines O +
were O +
treated O +
for O +
24 O +
h O +
with O +
various O +
concentration O +
of O +
paclitaxel B-Chemical -
, O +
and O +
the O +
sensitivity O +
was O +
analysed O +
by O +
an O +
MTT O +
assay O -
. O +

The O +
cell O +
cycle O +
progression O +
and O +
sub O -
- O -
G1 O +
population O +
were O +
analysed O +
by O +
flow O +
cytometry O -
. O +

Apoptosis O +
was O +
further O +
measured O +
by O +
DNA O +
fragmentation O +
and O +
microscope O +
examination O -
. O +

The O +
protein O +
expression O +
was O +
determined O +
by O +
Western O +
blot O +
analysis O -
. O +

Our O +
results O +
showed O +
that O +
HeLa O +
cells O +
demonstrated O +
the O +
highest O +
sensitivity O +
to O +
paclitaxel B-Chemical -
, O +
whereas O +
CaSki O +
cells O +
showed O +
the O +
lowest O -
. O +

In O +
cervical O +
cancer O +
cells O -
, O +
paclitaxel B-Chemical +
induced O +
apoptosis O +
through O +
an O +
intrinsic O +
pathway O +
with O +
prior O +
G2 O -
/ O -
M O +
arrest O -
. O +

In O +
addition O -
, O +
we O +
showed O +
that O +
paclitaxel B-Chemical +
downregulated O +
the O +
phosphorylation O +
of O +
Akt O +
in O +
both O +
HeLa O +
and O +
CaSki O +
cells O -
. O +

Interestingly O -
, O +
in O +
CaSki O +
cells O -
, O +
which O +
were O +
more O +
suggestive O +
of O +
a O +
resistant O +
phenotype O -
, O +
paclitaxel B-Chemical +
induced O +
the O +
activation O +
of O +
mTOR O +
as O +
a O +
downstream O +
target O +
of O +
Akt O -
. O +

Pre O -
- O -
treatment O +
with O +
rapamycin B-Chemical +
inhibited O +
activation O +
of O +
mTOR O +
signalling O +
and O +
significantly O +
enhanced O +
the O +
sensitivity O +
of O +
CaSki O +
cells O +
to O +
paclitaxel B-Chemical +
by O +
increasing O +
apoptotic O +
cell O +
death O -
. O +

This O +
effect O +
was O +
mediated O -
, O +
at O +
least O +
partly O -
, O +
through O +
caspase O +
activation O -
. O +

Overall O -
, O +
paclitaxel B-Chemical +
exerts O +
its O +
anti O -
- O -
tumour O +
effects O +
on O +
cervical O +
cancer O +
cells O +
by O +
inducing O +
apoptosis O +
through O +
intrinsic O +
pathway O -
, O +
and O +
rapamycin B-Chemical +
targeted O +
to O +
mTOR O +
can O +
sensitise O +
paclitaxel B-Chemical -
- O -
resistant O +
cervical O +
cancer O +
cells O -
. O +

Ectopic O +
localization O +
of O +
mitochondrial O +
ATP O +
synthase O -
: O +
a O +
target O +
for O +
anti O -
- O -
angiogenesis O +
intervention O -
? O +

A O +
receptor O +
for O +
angiostatin O +
was O +
identified O +
on O +
the O +
surface O +
of O +
endothelial O +
cells O +
as O +
F O -
( O -
1 O -
) O -
-F O -
( O -
0 O -
) O +
ATP O +
synthase O +
( O -
Moser O +
et O +
al. O -
, O +
1999 O -
) O -
. O +

Proc O -
. O +

Natl O -
. O +

Acad O -
. O +

Sci O -
. O +

U.S.A. O +
96 O -
, O +
2811 O -
- O -
2816 O -
. O +

This O +
ectopic O +
ATP O +
synthase O +
catalyzes O +
ATP B-Chemical +
synthesis O +
and O +
is O +
inhibited O +
by O +
angiostatin O +
over O +
a O +
wide O +
pH O +
range O -
. O +

Endothelial O +
cells O +
grown O +
at O +
normal O +
pH O +
suffer O +
no O +
ill O +
effects O +
from O +
this O +
angiostatin O -
- O -
mediated O +
inhibition O +
of O +
ATP O +
synthase O -
, O +
whereas O +
endothelial O +
cells O +
grown O +
at O +
low O -
, O +
tumor O -
- O -
like O +
extracellular O +
pH O +
can O -
not O +
maintain O +
a O +
normal O +
intracellular O +
pH O +
and O +
die O -
. O +

Angiostatin O +
inhibits O +
both O +
ATP B-Chemical +
synthesis O +
and O +
ATP B-Chemical +
hydrolysis O +
( O -
Moser O +
et O +
al. O -
, O +
2001 O -
) O +
and O +
interferes O +
with O +
intracellular O +
pH O +
regulation O +
( O -
Wahl O +
and O +
Grant O -
, O +
2002 O -
; O +
Wahl O +
et O +
al. O -
, O +
2002 O -
) O -
. O +

Although O +
angiostatin O +
administered O +
intravenously O +
is O +
cleared O +
from O +
the O +
circulation O +
in O +
a O +
matter O +
of O +
minutes O -
, O +
angiostatin B-Chemical -
- I-Chemical -
mimetics I-Chemical +
that O +
are O +
more O +
stable O +
have O +
potential O +
for O +
clinical O +
application O -
. O +

An O +
angiostatin B-Chemical -
- I-Chemical -
mimetic I-Chemical +
activity O +
has O +
recently O +
been O +
observed O +
using O +
a O +
polyclonal O +
antibody O +
against O +
the O +
beta O +
catalytic O +
subunit O +
of O +
ATP O +
synthase O -
. O +

In O +
order O +
to O +
explore O +
the O +
mechanism O +
of O +
action O +
of O +
angiostatin O +
and O +
its O +
mimetics O -
, O +
further O +
work O +
needs O +
to O +
be O +
done O +
to O +
evaluate O +
clinical O +
applicability O -
, O +
specificity O -
, O +
and O +
contraindications O +
for O +
this O +
class O +
of O +
therapeutics O -
. O +

Defective O +
expression O +
of O +
HRK O +
is O +
associated O +
with O +
promoter O +
methylation O +
in O +
primary O +
central O +
nervous O +
system O +
lymphomas O -
. O +

OBJECTIVES O -
: O +
Recently O -
, O +
it O +
has O +
been O +
reported O +
that O +
expression O +
of O +
the O +
HRK O +
gene O +
was O +
significantly O +
reduced O +
by O +
hypermethylation O +
in O +
astrocytic O +
tumors O -
. O +

Our O +
aim O +
is O +
to O +
verify O +
the O +
alterations O +
in O +
the O +
HRK O +
gene O +
in O +
primary O +
central O +
nervous O +
system O +
lymphomas O +
( O -
PCNSLs O -
) O -
. O +

METHODS O -
: O +
We O +
analyzed O +
the O +
hypermethylation O +
status O +
and O +
expression O +
of O +
the O +
gene O +
and O +
12q13.1 O +
loss O +
of O +
heterozygosity O +
in O +
31 O +
PCNSLs O -
. O +

RESULTS O -
: O +
A O +
total O +
of O +
13 O +
PCNSLs O +
( O -
31 O -
% O -
) O +
demonstrated O +
hypermethylation O +
in O +
either O +
the O +
promoter O +
or O +
exon O +
1 O -
; O +
loss O +
of O +
HRK O +
expression O +
was O +
immunohistochemically O +
observed O +
in O +
9 O +
tumors O +
and O +
was O +
significantly O +
associated O +
with O +
promoter O +
methylation O -
. O +

In O +
addition O -
, O +
higher O +
apoptotic O +
counts O +
were O +
associated O +
with O +
HRK O +
positivity O -
. O +

PCNSLs O +
with O +
HRK O +
methylation O +
also O +
showed O +
methylation O +
of O +
multiple O +
genes O -
, O +
such O +
as O +
p14ARF O -
, O +
p16INK4a O -
, O +
RB1 O -
, O +
p27Kip1 O +
and O +
O6-MGMT O -
. O +

Patients O +
with O +
tumors O +
demonstrating O +
concurrent O +
methylation O +
of O +
more O +
than O +
half O +
of O +
their O +
genes O +
demonstrated O +
significantly O +
poorer O +
survival O +
and O +
earlier O +
recurrence O -
. O +

Hypermethylation O +
of O +
the O +
HRK O +
promoter O +
alone O +
was O +
not O +
associated O +
with O +
overall O +
outcome O -
, O +
but O +
relapse O -
- O -
free O +
survival O +
was O +
significantly O +
shorter O -
. O +

CONCLUSIONS O -
: O +
Our O +
findings O +
suggest O +
that O +
transcriptional O +
repression O +
of O +
HRK O +
is O +
caused O +
by O +
promoter O +
hypermethylation O +
in O +
PCNSL O -
, O +
and O +
that O +
the O +
loss O +
of O +
HRK O +
associated O +
with O +
the O +
methylation O +
profile O +
of O +
other O +
genes O +
is O +
a O +
potential O +
step O +
in O +
the O +
modulation O +
of O +
cellular O +
death O +
by O +
apoptosis O +
during O +
PCNSL O +
tumorigenesis O -
. O +

Heparin B-Chemical +
immobilized O +
porous O +
PLGA B-Chemical +
microspheres O +
for O +
angiogenic O +
growth O +
factor O +
delivery O -
. O +

PURPOSE O -
: O +
Heparin B-Chemical +
immobilized O +
porous O +
poly B-Chemical -
( I-Chemical -
D I-Chemical -
, I-Chemical -
L I-Chemical -
- I-Chemical -
lactic I-Chemical -
- I-Chemical -
co I-Chemical -
- I-Chemical -
glycolic I-Chemical +
acid I-Chemical -
) I-Chemical +
( O -
PLGA B-Chemical -
) O +
microspheres O +
were O +
prepared O +
for O +
sustained O +
release O +
of O +
basic O +
fibroblast O +
growth O +
factor O +
( O -
bFGF O -
) O +
to O +
induce O +
angiogenesis O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
Porous O +
PLGA B-Chemical +
microspheres O +
having O +
primary O +
amine O +
groups O +
on O +
the O +
surface O +
were O +
prepared O +
using O +
an O +
oil O -
- O -
in O -
- O -
water O +
( O -
O O -
/ O -
W O -
) O +
single O +
emulsion O +
method O +
using O +
Pluronic O +
F-127 O +
as O +
an O +
extractable O +
porogen O -
. O +

Heparin B-Chemical +
was O +
surface O +
immobilized O +
via O +
covalent O +
conjugation O -
. O +

bFGF O +
was O +
loaded O +
into O +
the O +
heparin B-Chemical +
functionalized O +
( O -
PLGA B-Chemical -
- O -
heparin B-Chemical -
) O +
microspheres O +
by O +
a O +
simple O +
dipping O +
method O -
. O +

The O +
bFGF O +
loaded O +
PLGA B-Chemical -
- O -
heparin B-Chemical +
microspheres O +
were O +
tested O +
for O +
in O +
vitro O +
release O +
and O +
in O +
vivo O +
angiogenic O +
activity O -
. O +

RESULTS O -
: O +
PLGA B-Chemical +
microspheres O +
with O +
an O +
open O -
- O -
porous O +
structure O +
were O +
formed O -
. O +

The O +
amount O +
of O +
conjugated O +
amine O +
group O +
onto O +
the O +
microspheres O +
was O +
1.93+ O -
/ O -
-0.01 O +
nmol O -
/ O -
mg O -
- O -
microspheres O -
, O +
while O +
the O +
amount O +
of O +
heparin B-Chemical +
was O +
95.8 O +
pmol O -
/ O -
mg O -
- O -
microspheres O -
. O +

PLGA B-Chemical -
- O -
heparin B-Chemical +
microspheres O +
released O +
out O +
bFGF O +
in O +
a O +
more O +
sustained O +
manner O +
with O +
a O +
smaller O +
extent O +
of O +
initial O +
burst O +
than O +
PLGA B-Chemical +
microspheres O -
, O +
indicating O +
that O +
surface O +
immobilized O +
heparin B-Chemical +
controlled O +
the O +
release O +
rate O +
of O +
bFGF O -
. O +

Subcutaneous O +
implantation O +
of O +
bFGF O +
loaded O +
PLGA B-Chemical -
- O -
heparin B-Chemical +
microspheres O +
in O +
mice O +
significantly O +
induced O +
the O +
formation O +
of O +
new O +
vascular O +
microvessels O -
. O +

CONCLUSIONS O -
: O +
PLGA B-Chemical +
microspheres O +
with O +
an O +
open O +
porous O +
structure O +
allowed O +
significant O +
amount O +
of O +
heparin B-Chemical +
immobilization O +
and O +
bFGF O +
loading O -
. O +

bFGF O +
loaded O +
PLGA B-Chemical -
- O -
HP B-Chemical +
microspheres O +
showed O +
sustained O +
release O +
profiles O +
of O +
bFGF O +
in O +
vitro O -
, O +
demonstrating O +
reversible O +
and O +
specific O +
binding O +
of O +
bFGF O +
to O +
immobilized O +
heparin B-Chemical -
. O +

They O +
also O +
induced O +
local O +
angiogenesis O +
in O +
vivo O +
in O +
an O +
animal O +
model O -
. O +

C O -
/ O -
EBPbeta O +
is O +
over O -
- O -
expressed O +
in O +
gastric O +
carcinogenesis O +
and O +
is O +
associated O +
with O +
COX-2 O +
expression O -
. O +

The O +
CCAAT O -
/ O -
enhancer O -
- O -
binding O +
protein O +
beta O +
( O -
C O -
/ O -
EBPbeta O -
) O +
transcription O +
factor O +
has O +
been O +
associated O +
with O +
several O +
cancer O +
models O -
. O +

In O +
this O +
study O -
, O +
the O +
expression O +
of O +
C O -
/ O -
EBPbeta O +
was O +
analysed O +
in O +
a O +
series O +
of O +
90 O +
gastric O +
carcinomas O +
( O -
GCs O -
) O -
. O +

We O +
also O +
assessed O +
the O +
effect O +
of O +
C O -
/ O -
EBPbeta O +
on O +
COX-2 O +
expression O -
. O +

In O +
normal O +
gastric O +
mucosa O -
, O +
C O -
/ O -
EBPbeta O +
expression O +
was O +
restricted O +
to O +
cells O +
in O +
the O +
proliferative O +
zone O -
. O +

In O +
intestinal O +
metaplasia O -
, O +
dysplasia O -
, O +
and O +
GC O +
of O +
the O +
intestinal O +
and O +
atypical O +
subtypes O -
, O +
C O -
/ O -
EBPbeta O +
was O +
over O -
- O -
expressed O +
( O -
p O +
< O +
0.0001 O -
, O +
for O +
the O +
association O +
with O +
histological O +
type O -
) O -
. O +

C O -
/ O -
EBPbeta O +
and O +
Ki67 O -
, O +
a O +
marker O +
of O +
cell O +
proliferation O -
, O +
were O +
also O +
co O -
- O -
expressed O +
in O +
primary O +
GC O -
. O +

We O +
also O +
observed O +
an O +
overlap O +
between O +
C O -
/ O -
EBPbeta O +
and O +
COX-2 O +
expression O +
in O +
GC O -
. O +

Using O +
GC O +
cell O +
lines O +
we O +
show O +
that O +
C O -
/ O -
EBPbeta O +
can O +
regulate O +
the O +
expression O +
of O +
endogenous O +
COX-2 O +
and O +
transactivate O +
the O +
promoter O +
of O +
the O +
COX-2 O +
gene O -
, O +
depending O +
on O +
its O +
methylation O +
status O -
. O +

These O +
results O +
suggest O +
that O +
C O -
/ O -
EBPbeta O +
may O +
be O +
a O +
marker O +
of O +
neoplastic O +
transformation O +
and O +
also O +
play O +
an O +
active O +
role O +
in O +
gastric O +
tumourigenesis O +
by O +
regulating O +
COX-2 O +
expression O -
. O +

Collagen O -
- O -
poly B-Chemical +
glycolic I-Chemical +
acid I-Chemical +
hybrid O +
matrix O +
with O +
basic O +
fibroblast O +
growth O +
factor O +
accelerated O +
angiogenesis O +
and O +
granulation O +
tissue O +
formation O +
in O +
diabetic O +
mice O -
. O +

Because O +
poor O +
skin O +
wound O +
healing O +
associated O +
with O +
diabetes O +
is O +
thought O +
to O +
be O +
partly O +
a O +
result O +
from O +
impaired O +
angiogenesis O -
, O +
treatments O +
that O +
improve O +
angiogenesis O +
could O +
have O +
important O +
clinical O +
applications O -
. O +

We O +
herein O +
report O +
the O +
effects O +
of O +
novel O +
developed O +
material O -
, O +
collagen O -
- O -
poly B-Chemical +
glycolic I-Chemical +
acid I-Chemical +
fiber O +
hybrid O +
matrix O -
, O +
being O +
used O +
together O +
with O +
basic O +
fibroblast O +
growth O +
factor O +
to O +
promote O +
wound O +
healing O +
of O +
full O -
- O -
thickness O +
skin O +
defects O +
on O +
the O +
back O +
of O +
type O +
2 O +
diabetic O +
Lepr O -
( O -
db O -
) O +
mice O -
. O +

Our O +
data O +
indicates O +
that O +
this O +
therapeutic O +
approach O +
markedly O +
promotes O +
angiogenesis O +
and O +
granulation O +
tissue O +
formation O +
in O +
comparison O +
with O +
other O +
conditions O +
14 O +
days O +
after O +
wounding O -
. O +

p18Ink4c O -
, O +
but O +
not O +
p27Kip1 O -
, O +
collaborates O +
with O +
Men1 O +
to O +
suppress O +
neuroendocrine O +
organ O +
tumors O -
. O +

Mutant O +
mice O +
lacking O +
both O +
cyclin O -
- O -
dependent O +
kinase O +
( O -
CDK O -
) O +
inhibitors O +
p18 O -
( O -
Ink4c O -
) O +
and O +
p27 O -
( O -
Kip1 O -
) O +
develop O +
a O +
tumor O +
spectrum O +
reminiscent O +
of O +
human O +
multiple O +
endocrine O +
neoplasia O +
( O -
MEN O -
) O +
syndromes O -
. O +

To O +
determine O +
how O +
p18 O +
and O +
p27 O +
genetically O +
interact O +
with O +
Men1 O -
, O +
the O +
tumor O +
suppressor O +
gene O +
mutated O +
in O +
familial O +
MEN1 O -
, O +
we O +
characterized O +
p18-Men1 O +
and O +
p27-Men1 O +
double O +
mutant O +
mice O -
. O +

Compared O +
with O +
their O +
corresponding O +
single O +
mutant O +
littermates O -
, O +
the O +
p18 O -
( O -
- O -
/ O -
- O -
) O -
; O +
Men1 O -
( O -
+ O -
/ O -
- O -
) O +
mice O +
develop O +
tumors O +
at O +
an O +
accelerated O +
rate O +
and O +
with O +
an O +
increased O +
incidence O +
in O +
the O +
pituitary O -
, O +
thyroid O -
, O +
parathyroid O -
, O +
and O +
pancreas O -
. O +

In O +
the O +
pituitary O +
and O +
pancreatic O +
islets O -
, O +
phosphorylation O +
of O +
the O +
retinoblastoma O +
( O -
Rb O -
) O +
protein O +
at O +
both O +
CDK2 O +
and O +
CDK4 O -
/ O -
6 O +
sites O +
was O +
increased O +
in O +
p18 O -
( O -
- O -
/ O -
- O -
) O +
and O +
Men1 O -
( O -
+ O -
/ O -
- O -
) O +
cells O +
and O +
was O +
further O +
increased O +
in O +
p18 O -
( O -
- O -
/ O -
- O -
) O -
; O +
Men1 O -
( O -
+ O -
/ O -
- O -
) O +
cells O -
. O +

The O +
remaining O +
wild O -
- O -
type O +
Men1 O +
allele O +
was O +
lost O +
in O +
most O +
tumors O +
from O +
Men1 O -
( O -
+ O -
/ O -
- O -
) O +
mice O +
but O +
was O +
retained O +
in O +
most O +
tumors O +
from O +
p18 O -
( O -
- O -
/ O -
- O -
) O -
; O +
Men1 O -
( O -
+ O -
/ O -
- O -
) O +
mice O -
. O +

Combined O +
mutations O +
of O +
p27 O -
( O -
- O -
/ O -
- O -
) O +
and O +
Men1 O -
( O -
+ O -
/ O -
- O -
) O -
, O +
in O +
contrast O -
, O +
did O +
not O +
exhibit O +
noticeable O +
synergistic O +
stimulation O +
of O +
Rb O +
kinase O +
activity O -
, O +
cell O +
proliferation O -
, O +
and O +
tumor O +
growth O -
. O +

These O +
results O +
demonstrate O +
that O +
functional O +
collaboration O +
exists O +
between O +
p18 O +
and O +
Men1 O +
and O +
suggest O +
that O +
Men1 O +
may O +
regulate O +
additional O +
factor O -
( O -
s O -
) O +
that O +
interact O +
with O +
p18 O +
and O +
p27 O +
differently O -
. O +

Punica O +
granatum O +
( O -
pomegranate O -
) O +
and O +
its O +
potential O +
for O +
prevention O +
and O +
treatment O +
of O +
inflammation O +
and O +
cancer O -
. O +

The O +
last O +
7 O +
years O +
have O +
seen O +
over O +
seven O +
times O +
as O +
many O +
publications O +
indexed O +
by O +
Medline O +
dealing O +
with O +
pomegranate O +
and O +
Punica O +
granatum O +
than O +
in O +
all O +
the O +
years O +
preceding O +
them O -
. O +

Because O +
of O +
this O -
, O +
and O +
the O +
virtual O +
explosion O +
of O +
interest O +
in O +
pomegranate O +
as O +
a O +
medicinal O +
and O +
nutritional O +
product O +
that O +
has O +
followed O -
, O +
this O +
review O +
is O +
accordingly O +
launched O -
. O +

The O +
pomegranate O +
tree O -
, O +
Punica O +
granatum O -
, O +
especially O +
its O +
fruit O -
, O +
possesses O +
a O +
vast O +
ethnomedical O +
history O +
and O +
represents O +
a O +
phytochemical O +
reservoir O +
of O +
heuristic O +
medicinal O +
value O -
. O +

The O +
tree O -
/ O -
fruit O +
can O +
be O +
divided O +
into O +
several O +
anatomical O +
compartments O -
: O +
( O -
1 O -
) O +
seed O -
, O +
( O -
2 O -
) O +
juice O -
, O +
( O -
3 O -
) O +
peel O -
, O +
( O -
4 O -
) O +
leaf O -
, O +
( O -
5 O -
) O +
flower O -
, O +
( O -
6 O -
) O +
bark O -
, O +
and O +
( O -
7 O -
) O +
roots O -
, O +
each O +
of O +
which O +
has O +
interesting O +
pharmacologic O +
activity O -
. O +

Juice O +
and O +
peels O -
, O +
for O +
example O -
, O +
possess O +
potent O +
antioxidant O +
properties O -
, O +
while O +
juice O -
, O +
peel O +
and O +
oil O +
are O +
all O +
weakly O +
estrogenic O +
and O +
heuristically O +
of O +
interest O +
for O +
the O +
treatment O +
of O +
menopausal O +
symptoms O +
and O +
sequellae O -
. O +

The O +
use O +
of O +
juice O -
, O +
peel O +
and O +
oil O +
have O +
also O +
been O +
shown O +
to O +
possess O +
anticancer O +
activities O -
, O +
including O +
interference O +
with O +
tumor O +
cell O +
proliferation O -
, O +
cell O +
cycle O -
, O +
invasion O +
and O +
angiogenesis O -
. O +

These O +
may O +
be O +
associated O +
with O +
plant O +
based O +
anti O -
- O -
inflammatory O +
effects O -
, O +
The O +
phytochemistry O +
and O +
pharmacological O +
actions O +
of O +
all O +
Punica O +
granatum O +
components O +
suggest O +
a O +
wide O +
range O +
of O +
clinical O +
applications O +
for O +
the O +
treatment O +
and O +
prevention O +
of O +
cancer O -
, O +
as O +
well O +
as O +
other O +
diseases O +
where O +
chronic O +
inflammation O +
is O +
believed O +
to O +
play O +
an O +
essential O +
etiologic O +
role O -
. O +

[ O -
Study O +
on O +
the O +
expression O +
of O +
angiogenesis O +
and O +
spontaneous O +
apoptosis O +
and O +
their O +
relevance O +
in O +
laryngeal O +
squamous O +
cell O +
carcinoma O -
] O +
OBJECTIVE O -
: O +
To O +
investigate O +
the O +
relationship O +
among O +
angiogenesis O -
, O +
spontaneous O +
apoptosis O +
and O +
clinicopathological O +
parameters O +
in O +
laryngeal O +
squamous O +
cell O +
carcinoma O +
( O -
LSCC O -
) O -
. O +

METHOD O -
: O +
The O +
intratumor O +
microvessel O +
density O +
( O -
IMVD O -
) O -
, O +
apoptotic O +
index O +
( O -
AI O -
) O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
expression O +
were O +
detected O +
by O +
immunohistochemistry O +
SABC O +
and O +
terminal O +
uridine O +
deoxynucleotidyl O +
transferase O +
mediated O +
nick O +
end O +
labeling O -
( O -
TUNEL O -
) O +
methods O +
in34 O +
LSCC O +
patients O -
. O +

RESULT O -
: O +
The O +
average O +
IMVD O +
was O +
( O -
21.50 O +
+ O -
/- O +

8.87 O -
) O -
, O +
and O +
median O +
of O +
AI O +
was O +
1.15 O -
% O -
. O +

The O +
average O +
IMVD O +
in O +
positive O +
and O +
negative O +
cervical O +
lymphatic O +
metastasis O +
was O +
( O -
26.33 O +
+ O -
/- O +

9.70 O -
) O +
and O +
( O -
17.68 O +
+ O -
/- O +

6.06 O -
) O +
respectively O -
, O +
and O +
the O +
IMVD O +
with O +
positive O +
lymphatic O +
metastasis O +
tumors O +
was O +
statistical O +
significantly O +
higher O +
than O +
those O +
with O +
negative O +
cervical O +
lymphatic O +
metastasis O +
tumors O +
( O -
P O +
less O +
than O +
0.01 O -
) O -
. O +

The O +
average O +
IMVD O +
had O +
statistical O +
difference O +
in O +
histological O +
grading O +
( O -
P O +
less O +
than O +
0.01 O -
) O -
, O +
and O +
analysis O +
by O +
one O +
to O +
one O -
, O +
the O +
average O +
IMVD O +
had O +
statistical O +
difference O +
between O +
high O +
and O +
median O +
grading O -
. O +

Expression O +
of O +
VEGF O +
had O +
a O +
significantly O +
positive O +
correlation O +
with O +
IMVD O +
( O -
r O +
= O +
0.51 O -
, O +
P O +
less O +
than O +
0.01 O -
) O -
. O +

Statistical O +
analysis O +
revealed O +
a O +
significantly O +
inverse O +
correlation O +
between O +
AI O +
and O +
IMVD O +
( O -
r O +
= O +
-0.53 O -
, O +
P O +
less O +
than O +
0.01 O -
) O -
. O +

We O +
failed O +
to O +
find O +
the O +
statistical O +
difference O +
between O +
IMVD O +
and O +
tumor O +
T O -
- O -
stage O +
in O +
LSCC O -
. O +

CONCLUSION O -
: O +
IMVD O +
may O +
be O +
an O +
important O +
indicator O +
to O +
predict O +
cervical O +
lymphatic O +
metastasis O +
in O +
LSCC O -
. O +

VEGF O +
might O +
be O +
an O +
important O +
angiogenic O +
factor O -
, O +
and O +
could O +
promote O +
tumor O +
angiogenesis O +
in O +
LSCC O -
. O +

Tumor O +
angiogenesis O +
might O +
contribute O +
to O +
tumor O +
malignant O +
progression O +
by O +
inhibiting O +
spontaneous O +
apoptosis O +
in O +
LSCC O -
. O +

Hyperforin B-Chemical +
blocks O +
neutrophil O +
activation O +
of O +
matrix O +
metalloproteinase-9 O -
, O +
motility O +
and O +
recruitment O -
, O +
and O +
restrains O +
inflammation O -
- O -
triggered O +
angiogenesis O +
and O +
lung O +
fibrosis O -
. O +

Hyperforin B-Chemical +
( O -
Hyp B-Chemical -
) O -
, O +
a O +
polyphenol B-Chemical -
- O -
derivative O +
of O +
St. O +
John O -
's O +
wort O +
( O -
Hypericum O +
perforatum O -
) O -
, O +
has O +
emerged O +
as O +
key O +
player O +
not O +
only O +
in O +
the O +
antidepressant O +
activity O +
of O +
the O +
plant O +
but O +
also O +
as O +
an O +
inhibitor O +
of O +
bacteria O +
lymphocyte O +
and O +
tumor O +
cell O +
proliferation O -
, O +
and O +
matrix O +
proteinases O -
. O +

We O +
tested O +
whether O +
as O +
well O +
as O +
inhibiting O +
leukocyte O +
elastase O +
( O -
LE O -
) O +
activity O -
, O +
Hyp B-Chemical +
might O +
be O +
effective O +
in O +
containing O +
both O +
polymorphonuclear O +
neutrophil O +
( O -
PMN O -
) O +
leukocyte O +
recruitment O +
and O +
unfavorable O +
eventual O +
tissue O +
responses O -
. O +

The O +
results O +
show O +
that O -
, O +
without O +
affecting O +
in O +
vitro O +
human O +
PMN O +
viability O +
and O +
chemokine O -
- O -
receptor O +
expression O -
, O +
Hyp B-Chemical +
( O -
as O +
stable O +
dicyclohexylammonium B-Chemical +
salt I-Chemical -
) O +
was O +
able O +
to O +
inhibit O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
their O +
chemotaxis O +
and O +
chemoinvasion O +
( O -
IC50=1 O +
microM O +
for O +
both O -
) O -
; O +
this O +
effect O +
was O +
associated O +
with O +
a O +
reduced O +
expression O +
of O +
the O +
adhesion O +
molecule O +
CD11b O +
by O +
formyl B-Chemical -
- I-Chemical -
Met I-Chemical -
- I-Chemical -
Leu I-Chemical -
- I-Chemical -
Phe I-Chemical -
- O -
stimulated O +
neutrophils O +
and O +
block O +
of O +
LE O -
- O -
triggered O +
activation O +
of O +
the O +
gelatinase O +
matrix O +
metalloproteinase-9 O -
. O +

PMN O -
- O -
triggered O +
angiogenesis O +
is O +
also O +
blocked O +
by O +
both O +
local O +
injection O +
and O +
daily O +
i.p O -
. O +

administration O +
of O +
the O +
Hyp B-Chemical +
salt O +
in O +
an O +
interleukin-8-induced O +
murine O +
model O -
. O +

Furthermore O -
, O +
i.p O -
. O +

treatment O +
with O +
Hyp B-Chemical +
reduces O +
acute O +
PMN O +
recruitment O +
and O +
enhances O +
resolution O +
in O +
a O +
pulmonary O +
bleomycin B-Chemical -
- O -
induced O +
inflammation O +
model O -
, O +
significantly O +
reducing O +
consequent O +
fibrosis O -
. O +

These O +
results O +
indicate O +
that O +
Hyp B-Chemical +
is O +
a O +
powerful O +
anti O -
- O -
inflammatory O +
compound O +
with O +
therapeutic O +
potential O -
, O +
and O +
they O +
elucidate O +
mechanistic O +
keys O -
. O +

An O +
antibody O +
directed O +
against O +
PDGF O +
receptor O +
beta O +
enhances O +
the O +
antitumor O +
and O +
the O +
anti O -
- O -
angiogenic O +
activities O +
of O +
an O +
anti O -
- O -
VEGF O +
receptor O +
2 O +
antibody O -
. O +

Platelet O -
- O -
derived O +
growth O +
factor O +
( O -
PDGF O -
) O +
and O +
its O +
receptors O +
( O -
PDGFR O -
) O +
play O +
important O +
roles O +
in O +
tumorigenesis O +
through O +
stimulating O +
tumor O +
growth O +
and O +
promoting O +
angiogenesis O +
via O +
enhancing O +
pericyte O +
recruitment O +
and O +
vessel O +
maturation O -
. O +

Here O +
we O +
produced O +
a O +
neutralizing O +
antibody O -
, O +
1B3 B-Chemical -
, O +
directed O +
against O +
mouse O +
PDGFRbeta O -
. O +

1B3 B-Chemical +
binds O +
to O +
PDGFRbeta O +
with O +
high O +
affinity O +
( O -
9x10 O -
( O -
-11 O -
) O -
M O -
) O +
and O +
blocks O +
PDGF O -
- O -
BB O +
from O +
binding O +
to O +
the O +
receptor O +
with O +
an O +
IC O -
( O -
50 O -
) O +
of O +
approximately O +
1.2 O +
nM. O +
The O +
antibody O +
also O +
blocks O +
ligand O -
- O -
stimulated O +
activation O +
of O +
PDGFRbeta O +
and O +
downstream O +
signaling O +
molecules O -
, O +
including O +
Akt O +
and O +
MAPK O +
p42 O -
/ O -
44 O -
, O +
in O +
tumor O +
cells O -
. O +

In O +
animal O +
studies O -
, O +
1B3 B-Chemical +
significantly O +
enhanced O +
the O +
antitumor O +
and O +
the O +
anti O -
- O -
angiogenic O +
activities O +
of O +
DC101 B-Chemical -
, O +
an O +
antibody O +
directed O +
against O +
mouse O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
2 O -
, O +
in O +
a O +
pancreatic O +
( O -
BxPC-3 O -
) O +
and O +
a O +
non O -
- O -
small O +
cell O +
lung O +
( O -
NCI O -
- O -
H460 O -
) O +
tumor O +
xenograft O +
models O -
. O +

Treatment O +
with O +
the O +
combination O +
of O +
1B3 B-Chemical +
and O +
DC101 B-Chemical +
in O +
BxPC-3 O +
xenograft O -
- O -
bearing O +
mice O +
resulted O +
in O +
tumor O +
regression O +
in O +
58 O -
% O +
of O +
mice O +
compared O +
to O +
that O +
in O +
18 O -
% O +
of O +
mice O +
treated O +
with O +
DC101 B-Chemical +
alone O -
. O +

Taken O +
together O -
, O +
these O +
results O +
lend O +
great O +
support O +
to O +
use O +
PDGFRbeta O +
antagonists O +
in O +
combinations O +
with O +
other O +
antitumor O +
and/or O +
anti O -
- O -
angiogenic O +
agents O +
in O +
the O +
treatment O +
of O +
a O +
variety O +
of O +
cancers O -
. O +

In O +
vivo O +
p53 O +
response O +
and O +
immune O +
reaction O +
underlie O +
highly O +
effective O +
low O -
- O -
dose O +
radiotherapy O +
in O +
follicular O +
lymphoma O -
. O +

Very O +
low O -
- O -
dose O +
irradiation O +
( O -
2 O +
x O +
2 O +
Gy O -
) O +
is O +
a O +
new O -
, O +
effective O -
, O +
and O +
safe O +
local O +
treatment O +
for O +
follicular O +
lymphoma O -
. O +

To O +
understand O +
the O +
biologic O +
mechanisms O +
of O +
this O +
extremely O +
effective O +
response O -
, O +
we O +
compared O +
by O +
microarray O +
the O +
gene O -
- O -
expression O +
profile O +
of O +
patients O -
' O +
biopsies O +
taken O +
before O +
and O +
after O +
radiation O -
. O +

In O +
all O +
patients O -
, O +
a O +
major O +
and O +
consistent O +
induction O +
of O +
p53 O +
target O +
genes O +
was O +
seen O -
. O +

p53 O +
targets O +
involved O +
in O +
cell O -
- O -
cycle O +
arrest O +
and O +
apoptosis O +
showed O +
the O +
same O +
mode O +
of O +
regulation O -
, O +
indicating O +
that O -
, O +
in O +
vivo O -
, O +
both O +
are O +
activated O +
simultaneously O -
. O +

p53 O +
up O -
- O -
regulation O +
and O +
p53-mediated O +
proliferation O +
arrest O +
and O +
apoptosis O +
were O +
substantiated O +
using O +
immunohistochemistry O -
, O +
with O +
activation O +
of O +
both O +
the O +
intrinsic O +
and O +
the O +
extrinsic O +
apoptotic O +
pathways O -
. O +

The O +
other O +
induced O +
genes O +
revealed O +
a O +
whole O +
set O +
of O +
biologically O +
meaningful O +
genes O +
related O +
to O +
macrophage O +
activation O +
and O +
TH1 O +
immune O +
response O -
. O +

Immunohistochemical O +
analysis O +
suggested O +
a O +
specific O +
activation O +
or O +
differentiation O +
of O +
resident O +
macrophages O +
by O +
apoptotic O +
cells O -
. O +

These O +
biologic O +
insights O +
are O +
important O +
arguments O +
to O +
advocate O +
the O +
use O +
of O +
low O -
- O -
dose O +
radiotherapy O +
as O +
an O +
effective O +
palliative O +
treatment O +
for O +
follicular O +
lymphoma O -
. O +

Moreover O -
, O +
this O +
study O +
is O +
the O +
first O +
in O +
vivo O +
report O +
of O +
the O +
radiation O -
- O -
induced O +
p53 O +
apoptotic O +
response O +
in O +
patients O +
and O +
suggests O +
that O +
this O +
apoptotic O +
response O +
is O +
not O +
immunologically O +
silent O -
. O +

Caffeine B-Chemical +
inhibits O +
adenosine B-Chemical -
- O -
induced O +
accumulation O +
of O +
hypoxia O -
- O -
inducible O +
factor-1alpha O -
, O +
vascular O +
endothelial O +
growth O +
factor O -
, O +
and O +
interleukin-8 O +
expression O +
in O +
hypoxic O +
human O +
colon O +
cancer O +
cells O -
. O +

Frequent O +
coffee O +
consumption O +
has O +
been O +
associated O +
with O +
a O +
reduced O +
risk O +
of O +
colorectal O +
cancer O +
in O +
a O +
number O +
of O +
case O -
- O -
control O +
studies O -
. O +

Coffee O +
is O +
a O +
leading O +
source O +
of O +
methylxanthines B-Chemical -
, O +
such O +
as O +
caffeine B-Chemical -
. O +

The O +
induction O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
and O +
interleukin-8 O +
( O -
IL-8 O -
) O +
is O +
an O +
essential O +
feature O +
of O +
tumor O +
angiogenesis O -
, O +
and O +
the O +
hypoxia O -
- O -
inducible O +
factor-1 O +
( O -
HIF-1 O -
) O +
transcription O +
factor O +
is O +
known O +
to O +
be O +
a O +
key O +
regulator O +
of O +
this O +
process O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
the O +
effects O +
of O +
caffeine B-Chemical +
on O +
HIF-1 O +
protein O +
accumulation O +
and O +
on O +
VEGF O +
and O +
IL-8 O +
expression O +
in O +
the O +
human O +
colon O +
cancer O +
cell O +
line O +
HT29 O +
under O +
hypoxic O +
conditions O -
. O +

Our O +
results O +
show O +
that O +
caffeine B-Chemical +
significantly O +
inhibits O +
adenosine B-Chemical -
- O -
induced O +
HIF-1alpha O +
protein O +
accumulation O +
in O +
cancer O +
cells O -
. O +

We O +
show O +
that O +
HIF-1alpha O +
and O +
VEGF O +
are O +
increased O +
through O +
A3 O +
adenosine O +
receptor O +
stimulation O -
, O +
whereas O +
the O +
effects O +
on O +
IL-8 O +
are O +
mediated O +
via O +
the O +
A2B O +
subtype O -
. O +

Pretreatment O +
of O +
cells O +
with O +
caffeine B-Chemical +
significantly O +
reduces O +
adenosine B-Chemical -
- O -
induced O +
VEGF O +
promoter O +
activity O +
and O +
VEGF O +
and O +
IL-8 O +
expression O -
. O +

The O +
mechanism O +
of O +
caffeine B-Chemical +
seems O +
to O +
involve O +
the O +
inhibition O +
of O +
the O +
extracellular O +
signal O -
- O -
regulated O +
kinase O +
1 O -
/ O -
2 O +
( O -
ERK1 O -
/ O -
2 O -
) O -
, O +
p38 O -
, O +
and O +
Akt O -
, O +
leading O +
to O +
a O +
marked O +
decrease O +
in O +
adenosine B-Chemical -
- O -
induced O +
HIF-1alpha O +
accumulation O -
, O +
VEGF O +
transcriptional O +
activation O -
, O +
and O +
VEGF O +
and O +
IL-8 O +
protein O +
accumulation O -
. O +

From O +
a O +
functional O +
perspective O -
, O +
we O +
observe O +
that O +
caffeine B-Chemical +
also O +
significantly O +
inhibits O +
the O +
A3 O +
receptor O -
- O -
stimulated O +
cell O +
migration O +
of O +
colon O +
cancer O +
cells O -
. O +

Conditioned O +
media O +
prepared O +
from O +
colon O +
cells O +
treated O +
with O +
an O +
adenosine B-Chemical +
analog O +
increased O +
human O +
umbilical O +
vein O +
endothelial O +
cell O +
migration O -
. O +

These O +
data O +
provide O +
evidence O +
that O +
adenosine B-Chemical +
could O +
modulate O +
the O +
migration O +
of O +
colon O +
cancer O +
cells O +
by O +
an O +
HIF-1alpha O -
/ O -
VEGF O -
/ O -
IL-8-dependent O +
mechanism O +
and O +
that O +
caffeine B-Chemical +
has O +
the O +
potential O +
to O +
inhibit O +
colon O +
cancer O +
cell O +
growth O -
. O +

Medical O +
therapy O +
for O +
intermittent O +
claudication O -
. O +

Medical O +
therapy O +
to O +
improve O +
symptoms O -
, O +
stabilise O +
the O +
underlying O +
vascular O +
disease O +
and O +
improve O +
lower O +
limb O +
outcomes O +
is O +
an O +
important O +
and O +
effective O +
adjunct O +
to O +
lifestyle O +
modification O +
and O +
surgical O +
or O +
endovascular O +
interventions O +
in O +
patients O +
with O +
IC O -
. O +

Randomised O +
placebo O +
controlled O +
trials O +
have O +
shown O +
that O +
the O +
phosphodiesterase O +
III O +
inhibitor O +
cilostazol B-Chemical +
100 O -
mg O +
bid O +
improves O +
pain O -
- O -
free O +
and O +
maximum O +
walking O +
distance O -
, O +
as O +
well O +
as O +
quality O +
of O +
life O -
, O +
in O +
a O +
range O +
of O +
patients O +
with O +
intermittent O +
claudication O +
in O +
whom O +
there O +
is O +
no O +
evidence O +
of O +
tissue O +
necrosis O +
or O +
rest O +
pain O -
. O +

This O +
review O +
summarises O +
the O +
evidence O +
from O +
8 O +
pivotal O +
trials O +
of O +
cilostazol B-Chemical +
involving O +
over O +
2000 O +
patients O +
with O +
intermittent O +
claudication O +
treated O +
for O +
up O +
to O +
6 O +
months O -
. O +

There O +
is O +
comparatively O +
less O +
evidence O +
to O +
support O +
the O +
use O +
of O +
other O +
treatment O +
modalities O +
for O +
relief O +
of O +
symptoms O +
in O +
intermittent O +
claudication O -
, O +
but O +
there O +
is O +
considerable O +
interest O +
in O +
therapeutic O +
angiogenesis O +
to O +
promote O +
new O +
vessel O +
formation O +
and O +
enhance O +
collateralisation O +
of O +
the O +
lower O +
limb O +
using O +
recombinant O +
growth O +
factor O +
proteins O +
or O +
gene O +
transfer O +
strategies O -
. O +

The O +
rationale O +
for O +
therapeutic O +
angiogenesis O +
is O +
discussed O -
, O +
together O +
with O +
the O +
most O +
recent O +
results O +
from O +
randomised O +
trials O +
in O +
patients O +
with O +
peripheral O +
arterial O +
disease O -
. O +

A O +
pivotal O +
role O +
for O +
p53 O -
: O +
balancing O +
aerobic O +
respiration O +
and O +
glycolysis O -
. O +

The O +
genetic O +
basis O +
of O +
increased O +
glycolytic O +
activity O +
observed O +
in O +
cancer O +
cells O +
is O +
likely O +
to O +
be O +
the O +
result O +
of O +
complex O +
interactions O +
of O +
multiple O +
regulatory O +
pathways O -
. O +

Here O +
we O +
review O +
the O +
recent O +
evidence O +
of O +
a O +
simple O +
genetic O +
mechanism O +
by O +
which O +
tumor O +
suppressor O +
p53 O +
regulates O +
mitochondrial O +
respiration O +
with O +
secondary O +
changes O +
in O +
glycolysis O +
that O +
are O +
reminiscent O +
of O +
the O +
Warburg O +
effect O -
. O +

The O +
biological O +
significance O +
of O +
this O +
regulation O +
of O +
the O +
two O +
major O +
pathways O +
of O +
energy O +
generation O +
by O +
p53 O +
remains O +
to O +
be O +
seen O -
. O +

Melissoidesin B-Chemical +
G I-Chemical -
, O +
a O +
diterpenoid O +
purified O +
from O +
Isodon O +
melissoides O -
, O +
induces O +
leukemic O -
- O -
cell O +
apoptosis O +
through O +
induction O +
of O +
redox O +
imbalance O +
and O +
exhibits O +
synergy O +
with O +
other O +
anticancer O +
agents O -
. O +

Melissoidesin B-Chemical +
G I-Chemical +
( O -
MOG B-Chemical -
) O +
is O +
a O +
new O +
diterpenoid O +
purified O +
from O +
Isodon O +
melissoides O -
, O +
a O +
plant O +
used O +
in O +
Chinese O +
traditional O +
medicine O +
as O +
antitumor O +
and O +
anti O -
- O -
inflammatory O +
agents O -
. O +

In O +
our O +
study O -
, O +
MOG B-Chemical +
was O +
shown O +
to O +
specifically O +
inhibit O +
the O +
growth O +
of O +
human O +
leukemia O +
cell O +
lines O +
and O +
primary O +
acute O +
myeloid O +
leukemia O +
( O -
AML O -
) O +
blasts O +
via O +
induction O +
of O +
apoptosis O -
, O +
with O +
the O +
evidence O +
of O +
mitochondrial O +
DeltaPsim O +
loss O -
, O +
reactive B-Chemical +
oxygen I-Chemical +
species I-Chemical +
production O -
, O +
caspases O +
activation O +
and O +
nuclear O +
fragmentation O -
. O +

Furthermore O -
, O +
it O +
was O +
shown O +
that O +
thiol B-Chemical -
- O -
containing O +
antioxidants O +
completely O +
blocked O +
MOG B-Chemical -
- O -
induced O +
mitochondrial O +
DeltaPsim O +
loss O +
and O +
subsequent O +
cell O +
apoptosis O -
, O +
while O +
the O +
inhibition O +
of O +
apoptosis O +
by O +
benzyloxy B-Chemical -
- I-Chemical -
carbonyl I-Chemical -
- I-Chemical -
Val I-Chemical -
- I-Chemical -
Ala I-Chemical -
- I-Chemical -
Asp I-Chemical -
- I-Chemical -
fluoromethylketone I-Chemical +
only O +
partially O +
attenuated O +
mitochondrial O +
DeltaPsim O +
loss O -
, O +
indicating O +
that O +
MOG B-Chemical -
- O -
induced O +
redox O +
imbalance O +
is O +
an O +
early O +
event O +
upstream O +
to O +
mitochondrial O +
DeltaPsim O +
loss O +
and O +
caspase-3 O +
activation O -
. O +

Consistently O -
, O +
it O +
was O +
found O +
that O +
MOG B-Chemical +
rapidly O +
decreased O +
the O +
intracellular O +
glutathione B-Chemical +
( O -
GSH B-Chemical -
) O +
content O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
and O +
the O +
significance O +
of O +
GSH B-Chemical +
depletion O +
in O +
MOG B-Chemical -
- O -
induced O +
apoptosis O +
was O +
further O +
supported O +
by O +
the O +
protective O +
effects O +
of O +
tert B-Chemical -
- I-Chemical -
butylhydroquinone I-Chemical +
( O -
tBHQ B-Chemical -
) O +
and O +
the O +
facilitative O +
effects O +
of O +
DL B-Chemical -
- I-Chemical -
buthionine I-Chemical +
( I-Chemical -
S I-Chemical -
, I-Chemical -
R I-Chemical -
) I-Chemical -
-sulfoximine I-Chemical +
( O -
BSO B-Chemical -
) O -
. O +

Furthermore O -
, O +
it O +
was O +
showed O +
that O +
GSH B-Chemical +
depletion O +
induced O +
by O +
MOG B-Chemical +
rendered O +
some O +
leukemia O +
cell O +
lines O +
more O +
sensitive O +
to O +
arsenic B-Chemical +
trioxide I-Chemical +
( O -
As2O3 B-Chemical -
) O -
, O +
doxorubicin B-Chemical +
or O +
cisplatin B-Chemical -
. O +

Additionally O -
, O +
the O +
synergistic O +
apoptotic O +
effects O +
of O +
MOG B-Chemical +
with O +
As2O3 B-Chemical +
were O +
detected O +
in O +
HL-60 O +
and O +
primary O +
AML O +
cells O -
, O +
but O +
not O +
in O +
normal O +
cells O -
, O +
suggesting O +
the O +
selective O +
toxicity O +
of O +
their O +
combination O +
to O +
the O +
malignant O +
cells O -
. O +

Together O -
, O +
we O +
proposed O +
that O +
MOG B-Chemical +
alone O +
or O +
administered O +
with O +
other O +
anticancer O +
agents O +
may O +
provide O +
a O +
novel O +
therapeutic O +
strategy O +
for O +
leukemia O -
. O +

Expression O +
of O +
epidermal O +
growth O +
factor O +
receptor O -
, O +
transforming O +
growth O +
factor O -
- O -
alpha O +
and O +
Ki-67 O +
in O +
relationship O +
to O +
malignant O +
transformation O +
of O +
pleomorphic O +
adenoma O -
. O +

CONCLUSION O -
: O +
Quantitative O +
assessment O +
is O +
more O +
sensitive O +
as O +
a O +
measure O +
of O +
cellular O +
protein O +
content O +
as O +
compared O +
with O +
standard O +
optical O +
density O +
measurements O -
. O +

The O +
data O +
support O +
the O +
hypothesis O +
that O +
increased O +
epidermal O +
growth O +
factor O +
receptor O +
( O -
EGFR O -
) O +
and O +
transforming O +
growth O +
factor O +
( O -
TGF O -
) O -
-alpha O +
expression O +
is O +
associated O +
with O +
early O +
events O +
in O +
malignant O +
transformation O +
of O +
pleomorphic O +
adenoma O +
( O -
PA O -
) O -
. O +

OBJECTIVE O -
: O +
In O +
the O +
present O +
study O -
, O +
we O +
attempted O +
to O +
identify O +
EGFR O +
and O +
TGF O -
- O -
alpha O +
expression O +
and O +
Ki-67 O +
index O +
in O +
carcinoma O +
ex O -
- O -
pleomorphic O +
adenoma O +
( O -
Ca O +
ex O -
- O -
PA O -
) O +
and O +
PA O -
. O +

We O +
also O +
compared O +
the O +
presence O +
of O +
EGFR O +
and O +
TGF O -
- O -
alpha O +
and O +
Ki-67 O +
index O +
with O +
clinical O +
data O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
The O +
tissues O +
were O +
stained O +
with O +
monoclonal O +
antibodies O +
to O +
EGFR O -
, O +
TGF O -
- O -
alpha O +
and O +
Ki-67 O -
. O +

The O +
results O +
were O +
analysed O +
using O +
quantitative O +
immunohistochemical O +
analysis O -
. O +

We O +
also O +
analysed O +
the O +
association O +
of O +
patients O -
' O +
prognosis O +
with O +
clinical O +
parameters O +
and O +
the O +
histological O +
classification O +
of O +
the O +
carcinomatous O +
component O -
. O +

RESULTS O -
: O +
As O +
regards O +
the O +
association O +
of O +
patients O -
' O +
prognosis O +
with O +
EGFR O +
staining O +
and O +
Ki-67 O +
index O -
, O +
a O +
significant O +
increase O +
was O +
observed O +
in O +
patients O +
who O +
died O +
or O +
had O +
residual O +
disease O +
compared O +
with O +
patients O +
who O +
were O +
alive O +
without O +
disease O -
. O +

In O +
the O +
immunohistochemical O +
analysis O +
of O +
EGFR O +
and O +
TGF O -
- O -
alpha O +
and O +
Ki67 O +
index O -
, O +
a O +
significant O +
increase O +
was O +
observed O +
in O +
Ca O +
ex O -
- O -
PA O -
, O +
especially O +
with O +
adenocarcinoma O -
, O +
compared O +
with O +
PA O +
and O +
sialadenitis O -
. O +

Ovarian O +
cancers O +
overexpress O +
the O +
antimicrobial O +
protein O +
hCAP-18 O +
and O +
its O +
derivative O +
LL-37 O +
increases O +
ovarian O +
cancer O +
cell O +
proliferation O +
and O +
invasion O -
. O +

The O +
role O +
of O +
the O +
pro O -
- O -
inflammatory O +
peptide O -
, O +
LL-37 O -
, O +
and O +
its O +
pro O -
- O -
form O -
, O +
human O +
cationic O +
antimicrobial O +
protein O +
18 O +
( O -
hCAP-18 O -
) O -
, O +
in O +
cancer O +
development O +
and O +
progression O +
is O +
poorly O +
understood O -
. O +

In O +
damaged O +
and O +
inflamed O +
tissue O -
, O +
LL-37 O +
functions O +
as O +
a O +
chemoattractant O -
, O +
mitogen O +
and O +
pro O -
- O -
angiogenic O +
factor O +
suggesting O +
that O +
the O +
peptide O +
may O +
potentiate O +
tumor O +
progression O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
characterize O +
the O +
distribution O +
of O +
hCAP-18 O -
/ O -
LL-37 O +
in O +
normal O +
and O +
cancerous O +
ovarian O +
tissue O +
and O +
to O +
examine O +
the O +
effects O +
of O +
LL-37 O +
on O +
ovarian O +
cancer O +
cells O -
. O +

Expression O +
of O +
hCAP-18 O -
/ O -
LL-37 O +
was O +
localized O +
to O +
immune O +
and O +
granulosa O +
cells O +
of O +
normal O +
ovarian O +
tissue O -
. O +

By O +
contrast O -
, O +
ovarian O +
tumors O +
displayed O +
significantly O +
higher O +
levels O +
of O +
hCAP-18 O -
/ O -
LL-37 O +
where O +
expression O +
was O +
observed O +
in O +
tumor O +
and O +
stromal O +
cells O -
. O +

Protein O +
expression O +
was O +
statistically O +
compared O +
to O +
the O +
degree O +
of O +
immune O +
cell O +
infiltration O +
and O +
microvessel O +
density O +
in O +
epithelial O -
- O -
derived O +
ovarian O +
tumors O +
and O +
a O +
significant O +
correlation O +
was O +
observed O +
for O +
both O -
. O +

It O +
was O +
demonstrated O +
that O +
ovarian O +
tumor O +
tissue O +
lysates O +
and O +
ovarian O +
cancer O +
cell O +
lines O +
express O +
hCAP-18 O -
/ O -
LL-37 O -
. O +

Treatment O +
of O +
ovarian O +
cancer O +
cell O +
lines O +
with O +
recombinant O +
LL-37 O +
stimulated O +
proliferation O -
, O +
chemotaxis O -
, O +
invasion O +
and O +
matrix O +
metalloproteinase O +
expression O -
. O +

These O +
data O +
demonstrate O +
for O +
the O +
first O +
time O +
that O +
hCAP-18 O -
/ O -
LL-37 O +
is O +
significantly O +
overexpressed O +
in O +
ovarian O +
tumors O +
and O +
suggest O +
LL-37 O +
may O +
contribute O +
to O +
ovarian O +
tumorigenesis O +
through O +
direct O +
stimulation O +
of O +
tumor O +
cells O -
, O +
initiation O +
of O +
angiogenesis O +
and O +
recruitment O +
of O +
immune O +
cells O -
. O +

These O +
data O +
provide O +
further O +
evidence O +
of O +
the O +
existing O +
relationship O +
between O +
pro O -
- O -
inflammatory O +
molecules O +
and O +
ovarian O +
cancer O +
progression O -
. O +

Ectopic O +
decorin O +
expression O +
up O -
- O -
regulates O +
VEGF O +
expression O +
in O +
mouse O +
cerebral O +
endothelial O +
cells O +
via O +
activation O +
of O +
the O +
transcription O +
factors O +
Sp1 O -
, O +
HIF1alpha O -
, O +
and O +
Stat3 O -
. O +

We O +
demonstrate O +
that O +
a O +
proteoglycan O +
decorin O +
( O -
DCN O -
) O +
up O -
- O -
regulates O +
the O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
expression O +
with O +
activation O +
of O +
VEGF O +
regulating O +
transcription O +
factors O +
Sp1 O -
, O +
hypoxia O -
- O -
inducible O +
factor O +
1alpha O +
( O -
HIF1alpha O -
) O -
, O +
and O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
3 O +
( O -
Stat3 O -
) O +
via O +
epidermal O +
growth O +
factor O +
receptor O +
( O -
EGFR O -
) O -
, O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
extracellular O +
signal O -
- O -
regulated O +
kinase O +
1 O -
/ O -
2 O +
( O -
ERK1 O -
/ O -
2 O -
) O -
, O +
and O +
protein O +
kinase O +
B O +
( O -
AKT O -
) O +
pathways O +
in O +
DCN O +
transfected O +
mouse O +
cerebral O +
endothelial O +
( O -
MCE O -
) O +
cells O -
. O +

Treatment O +
with O +
pharmacological O +
inhibitors O +
and O +
small O +
interfering O +
RNAs O +
reveal O +
that O +
induction O +
and O +
activation O +
of O +
Sp1 O -
, O +
HIF1alpha O -
, O +
and O +
Stat3 O +
facilitate O +
their O +
nuclear O +
localization O +
and O +
binding O +
to O +
their O +
specific O +
motifs O +
of O +
the O +
VEGF O +
promoter O +
and O +
induce O +
VEGF O +
expression O +
via O +
two O +
independent O +
pathways O -
, O +
DCN O -
/ O -
EGFR O -
/ O -
phosphoinositide-3 O +
kinase O -
/ O -
AKT O +
and O +
DCN O -
/ O -
EGFR O -
/ O -
ERK1 O -
/ O -
2 O -
, O +
respectively O -
, O +
in O +
DCN O +
synthesizing O +
MCE O +
cells O -
. O +

The O +
cell O +
type O +
specific O +
glycosylation O +
protects O +
Sp1 O +
and O +
HIF1alpha O +
from O +
proteosome O +
degradation O +
and O +
plays O +
an O +
important O +
and O +
novel O +
role O +
in O +
the O +
regulation O +
of O +
VEGF O +
in O +
DCN O +
transfected O +
MCE O +
cells O -
. O +

Induction O +
of O +
gelatinases O +
( O -
matrix O +
metalloproteinase O +
2 O +
and O +
9 O -
) O -
, O +
the O +
serine O +
protease O +
tissue O +
plasminogen O +
activator O +
and O +
plasmin O +
by O +
DCN O +
transfection O +
in O +
MCE O +
cells O +
leads O +
to O +
extracellular O +
proteolysis O +
and O +
to O +
release O +
of O +
matrix O -
- O -
bound O +
VEGF O +
and O +
activation O +
of O +
angiogenesis O -
. O +

In O +
this O +
study O -
, O +
we O +
demonstrate O +
that O +
two O +
independent O +
downstream O +
signal O +
pathways O -
, O +
DCN O -
/ O -
EGFR O -
/ O -
ERK1 O -
/ O -
2 O +
and O +
DCN O -
/ O -
EGFR O -
/ O -
phosphoinositide-3 O +
kinase O -
/ O -
AKT O -
, O +
mediate O +
up O -
- O -
regulation O +
and O +
activation O +
of O +
transcription O +
factors O +
of O +
VEGF O +
such O +
as O +
HIF1alpha O -
, O +
Stat3 O -
, O +
and O +
Sp1 O +
and O +
increase O +
VEGF O +
transcription O +
and O +
angiogenesis O +
in O +
MCE O +
cells O -
. O +

[ O -
Clinical O +
significance O +
of O +
interleukin-6 O +
( O -
IL-6 O -
) O +
as O +
a O +
prognostic O +
factor O +
of O +
cancer O +
disease O -
] O +
Interleukin-6 O +
( O -
IL-6 O -
) O +
is O +
proinflammatory O +
cytokine O +
that O +
produces O +
multifunctional O +
effects O -
. O +

It O +
is O +
also O +
involved O +
in O +
the O +
regulation O +
of O +
immune O +
reactions O -
, O +
hematopoiesis O +
and O +
inflammatory O +
state O -
. O +

Interleukin-6 O +
has O +
been O +
shown O +
to O +
be O +
associated O +
with O +
tumor O +
progression O +
including O +
inhibition O +
of O +
cancer O +
cells O +
apoptosis O +
and O +
stimulation O +
of O +
angiogenesis O -
. O +

Anti O -
- O -
IL-6 O +
therapy O +
is O +
a O +
new O +
strategy O +
in O +
the O +
inflammatory O +
autoimmune O +
diseases O +
and O +
cancer O -
. O +

Clinical O +
studies O +
have O +
shown O +
elevated O +
serum O +
IL-6 O +
concentrations O +
in O +
patients O +
with O +
endometrial O +
cancer O -
, O +
non O -
- O -
small O +
cell O +
lung O +
carcinoma O -
, O +
colorectal O +
cancer O -
, O +
renal O +
cell O +
carcinoma O -
, O +
breast O +
and O +
ovarian O +
cancer O -
. O +

Serum O +
IL-6 O +
levels O +
correlate O +
with O +
tumor O +
stage O -
, O +
and O +
survival O +
of O +
patients O -
. O +

In O +
this O +
article O +
we O +
have O +
focused O +
on O +
a O +
role O +
of O +
IL-6 O +
as O +
a O +
prognostic O +
factor O +
in O +
several O +
malignancies O +
such O +
as O +
colorectal O +
cancer O -
, O +
breast O +
cancer O -
, O +
gastric O +
cancer O +
and O +
pancreatic O +
cancer O -
. O +

Detection O +
of O +
lymphovascular O +
invasion O +
in O +
early O +
breast O +
cancer O +
by O +
D2 O -
- O -
40 O +
( O -
podoplanin O -
) O -
: O +
a O +
clinically O +
useful O +
predictor O +
for O +
axillary O +
lymph O +
node O +
metastases O -
. O +

PURPOSE O -
: O +
The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
use O +
of O +
D2 O -
- O -
40 O +
for O +
the O +
detection O +
of O +
lymphovascular O +
invasion O +
( O -
LVI O -
) O +
in O +
node O +
positive O +
and O +
negative O +
early O +
breast O +
cancer O -
. O +

LVI O +
is O +
associated O +
with O +
axillary O +
lymph O +
node O +
metastases O +
( O -
ALNM O -
) O +
and O +
a O +
long O -
- O -
term O +
prognostic O +
factor O -
. O +

A O +
precise O +
identification O +
of O +
LVI O +
would O +
have O +
a O +
strong O +
clinical O +
impact O +
for O +
breast O +
cancer O +
patients O -
. O +

METHODS O -
: O +
Immunohistochemical O +
staining O +
with O +
D2 O -
- O -
40 O +
and O +
CD34 O +
was O +
performed O +
on O +
formalin O -
- O -
fixed O -
, O +
paraffin O -
- O -
embedded O +
tissue O +
sections O +
of O +
254 O +
invasive O +
breast O +
tumors O +
of O +
247 O +
patients O +
with O +
node O +
negative O +
and O +
node O +
positive O +
early O +
breast O +
cancer O -
. O +

All O +
slides O +
were O +
screened O +
for O +
the O +
presence O +
of O +
LVI O -
. O +

Correlation O +
with O +
clinico O -
- O -
pathological O +
factors O +
including O +
LVI O +
as O +
retrieved O +
by O +
routine O +
haematoxylin B-Chemical +
and O +
eosin B-Chemical +
( O -
H.E. B-Chemical -
) O +
stained O +
sections O +
and O +
the O +
eligibility O +
for O +
the O +
prediction O +
of O +
ALNM O +
was O +
assessed O -
. O +

RESULTS O -
: O +
Using O +
the O +
D2 O -
- O -
40 O +
antibody O +
for O +
immunostaining O -
, O +
our O +
results O +
demonstrate O +
a O +
significant O +
higher O +
detection O +
( O -
P O +
< O +
0.001 O -
) O +
of O +
LVI O +
as O +
compared O +
with O +
routine O +
H.E B-Chemical -
.- I-Chemical -
staining O +
in O +
early O +
breast O +
cancer O -
. O +

LVI O +
was O +
correctly O +
identified O +
by O +
D2 O -
- O -
40 O +
( O -
D2 O -
- O -
40 O -
+ O -
) O +
in O +
70 O +
out O +
of O +
254 O +
tumors O +
( O -
28 O -
% O -
) O +
as O +
compared O +
to O +
40 O +
tumors O +
( O -
16 O -
% O -
) O +
by O +
routine O +
HE B-Chemical +
staining O +
( O -
HE+ B-Chemical -
) O -
. O +

There O +
was O +
a O +
significant O +
correlation O +
between O +
D2 O -
- O -
40 O +
+ O +
LVI O +
and O +
age O -
, O +
t O -
- O -
stage O -
, O +
nodal O +
status O -
, O +
grading O +
and O +
hormonreceptor O -
- O -
status O -
. O +

Correlation O +
between O +
D2 O -
- O -
40 O +
+ O +
LVI O +
and O +
menopausal O -
- O -
status O -
, O +
HER2-status O +
and O +
histological O +
type O +
was O +
not O +
significant O -
, O +
while O +
there O +
was O +
a O +
significant O +
correlation O +
of O +
D2 O -
- O -
40 O +
and O +
so O +
called O +
" O -
triple O +
negative O -
" O +
tumors O +
( O -
ER O -
/ O -
PR O +
and O +
HER2neu O -
- O -
negative O -
) O -
. O +

In O +
a O +
multivariate O +
analysis O +
D2 O -
- O -
40 O -
+ O +
was O +
the O +
strongest O +
predictor O +
for O +
ALNM O +
with O +
an O +
odds O +
ratio O +
of O +
3.489 O +
and O +
a O +
P O -
- O -
value O +
of O +
P O +
= O +
0.0003 O -
, O +
followed O +
only O +
by O +
T O -
- O -
stage O +
and O +
grading O +
with O +
odds O +
ratios O +
of O +
3.167 O +
and O +
1.953 O +
and O +
P O -
- O -
values O +
P O +
= O +
0.0003 O +
and O +
P O +
= O +
0.0352 O -
. O +

CONCLUSION O -
: O +
Immunostaining O +
with O +
D2 O -
- O -
40 O +
significantly O +
increased O +
the O +
frequency O +
of O +
detection O +
of O +
lymphatic O +
invasion O +
compared O +
to O +
conventional O +
H.E B-Chemical -
.- I-Chemical -
staining O +
in O +
early O +
breast O +
cancer O -
. O +

As O +
LVI O +
is O +
a O +
strong O +
predictive O +
and O +
prognostic O +
marker O -
, O +
the O +
monoclonal O +
antibody O +
D2 O -
- O -
40 O +
has O +
the O +
potential O +
to O +
play O +
a O +
significant O +
role O +
in O +
pathological O +
routine O +
workup O +
of O +
breast O +
tumors O -
. O +

Further O +
prospective O +
studies O +
are O +
needed O +
to O +
prove O +
the O +
clinical O +
impact O +
of O +
D2 O -
- O -
40 O -
. O +

Expression O +
of O +
CDK4 O +
or O +
CDK2 O +
in O +
mouse O +
oral O +
cavity O +
is O +
retained O +
in O +
adult O +
pituitary O +
with O +
distinct O +
effects O +
on O +
tumorigenesis O -
. O +

The O +
keratin O +
5 O +
( O -
K5 O -
) O +
promoter O +
drives O +
transgenic O +
expression O +
to O +
the O +
basal O +
cell O +
layer O +
of O +
stratified O +
epithelia O -
. O +

Surprisingly O -
, O +
analysis O +
of O +
K5CDK4 O +
and O +
K5CDK2 O +
transgenic O +
mouse O +
embryos O +
showed O +
CDK4 O +
and O +
CDK2 O +
expression O +
not O +
only O +
in O +
the O +
expected O +
tissues O -
, O +
but O +
also O +
in O +
the O +
adenohypophysis O -
. O +

This O +
organ O +
is O +
derived O +
from O +
an O +
upwards O +
growth O +
of O +
the O +
primitive O +
oropharynx O -
, O +
a O +
K5-expressing O +
tissue O -
. O +

We O +
show O +
that O +
transgenic O +
expression O +
of O +
CDKs O +
in O +
the O +
embryonic O +
oral O +
ectoderm O +
is O +
specifically O +
retained O +
in O +
undifferentiated O +
cells O +
from O +
the O +
pars O +
intermedia O +
of O +
the O +
adenohypophysis O -
. O +

Interestingly O -
, O +
we O +
found O +
that O +
K5CDK4 O +
mice O +
show O +
a O +
decreased O +
number O +
of O +
pituitary O +
stem O +
cells O -
, O +
even O +
though O +
CDK4 O +
is O +
not O +
expressed O +
in O +
the O +
stem O +
cells O +
but O +
in O +
transit O -
- O -
amplifying O +
( O -
TA O -
) O -
-like O +
cells O -
. O +

Interestingly O -
, O +
CDK4-expressing O +
cells O -
, O +
but O +
not O +
CDK2-expressing O +
cells O -
, O +
strongly O +
synergize O +
with O +
lack O +
of O +
p27 O -
( O -
Kip1 O -
) O +
to O +
generate O +
pituitary O +
carcinomas O +
that O +
appear O +
with O +
shortened O +
latency O +
and O +
are O +
drastically O +
more O +
aggressive O +
than O +
those O +
arising O +
in O +
p27 O -
( O -
- O -
/ O -
- O -
) O +
mice O -
. O +

Thus O -
, O +
we O +
show O +
that O +
deregulation O +
of O +
CDK O +
expression O +
in O +
the O +
primitive O +
oral O +
epithelium O +
plays O +
a O +
unique O +
function O -
, O +
providing O +
a O +
selective O +
advantage O +
that O +
gives O +
rise O +
to O +
transgene O -
- O -
positive O +
TA O -
- O -
like O +
pituitary O +
cells O -
. O +

Furthermore O -
, O +
retention O +
of O +
CDK4 O +
in O +
these O +
TA O -
- O -
like O +
pituitary O +
cells O +
synergizes O +
with O +
loss O +
of O +
p27 O -
( O -
Kip1 O -
) O +
to O +
induce O +
pituitary O +
adenocarcinomas O -
. O +

This O +
model O +
suggests O +
that O +
forced O +
expression O +
of O +
CDK4 O +
sensitizes O +
cells O +
and O +
synergizes O +
with O +
a O +
second O +
change O +
resulting O +
in O +
tumor O +
development O -
. O +

[ O -
Photodynamic O +
therapy O +
in O +
severe O +
chronic O +
central O +
serous O +
chorioretinopaty O -
] O +
OBJECTIVE O -
: O +
To O +
determine O +
the O +
efficacy O +
of O +
Photodynamic O +
Therapy O +
( O -
PDT O -
) O +
in O +
chronic O +
Central O +
Serous O +
Chorioretinopathy O +
( O -
CSC O -
) O -
. O +

METHODS O -
: O +
Patients O +
diagnosed O +
with O +
chronic O +
CSC O -
, O +
with O +
clinical O +
evidence O +
of O +
activity O +
and O +
treated O +
with O +
Photodynamic O +
Therapy O -
, O +
are O +
included O +
in O +
this O +
report O -
. O +

All O +
were O +
assessed O +
by O +
a O +
complete O +
ophthalmological O +
examination O -
, O +
including O +
assessment O +
of O +
the O +
best O +
corrected O +
visual O +
acuity O +
( O -
BCVA O -
) O +
using O +
an O +
ETDRS O +
chart O -
, O +
fluorescein B-Chemical +
and O +
indocyanine B-Chemical +
angiography O +
and O +
optical O +
coherence O +
tomography O +
( O -
OCT O -
) O -
. O +

The O +
main O +
objective O +
of O +
the O +
study O +
was O +
to O +
determine O +
the O +
mean O +
visual O +
acuity O +
change O -
. O +

RESULTS O -
: O +
11 O +
eyes O +
of O +
11 O +
patients O +
were O +
included O +
in O +
the O +
study O -
, O +
which O +
had O +
a O +
mean O +
follow O -
- O -
up O +
period O +
of O +
11 O +
months O -
. O +

The O +
mean O +
BCVA O +
increased O +
from O +
20 O -
/ O -
76 O +
to O +
20 O -
/ O -
64 O -
. O +

35 O -
% O +
of O +
eyes O +
improved O +
their O +
BCVA O +
by O +
2 O +
lines O +
or O +
more O -
, O +
45 O -
% O +
remained O +
stable O +
and O +
18 O -
% O +
lost O +
2 O +
lines O +
or O +
more O -
. O +

Choroidal O +
hyperpermeability O +
was O +
reduced O +
in O +
every O +
case O -
. O +

Neurosensorial O +
retinal O +
detachment O +
decreased O +
in O +
80 O -
% O +
of O +
cases O -
. O +

Only O +
one O +
eye O +
received O +
a O +
second O +
PDT O +
treatment O +
due O +
to O +
choroidal O +
neovascularization O -
. O +

An O +
increase O +
of O +
atrophy O +
over O +
the O +
Retinal O +
Pigment O +
Epithelium O +
( O -
RPE O -
) O +
was O +
observed O +
in O +
another O +
patient O -
. O +

CONCLUSIONS O -
: O +
PDT O +
can O +
reduce O +
the O +
clinical O +
signs O +
of O +
activity O -
, O +
such O +
as O +
choroidal O +
hyperpermeability O +
or O +
neurosensorial O +
retinal O +
detachment O -
, O +
in O +
patients O +
affected O +
by O +
chronic O +
CSC O -
. O +

However O -
, O +
the O +
increase O +
in O +
visual O +
acuity O +
is O +
variable O -
, O +
probably O +
due O +
to O +
the O +
extent O +
of O +
RPE O +
damage O -
. O +

Suppression O +
of O +
lung O +
tumor O +
growth O +
and O +
metastasis O +
in O +
mice O +
by O +
adeno O -
- O -
associated O +
virus O -
- O -
mediated O +
expression O +
of O +
vasostatin O -
. O +

PURPOSE O -
: O +
Angiogenesis O +
inhibitors O +
have O +
strong O +
therapeutic O +
potential O +
as O +
antitumor O +
agents O +
in O +
suppressing O +
tumor O +
growth O +
and O +
metastatic O +
progression O -
. O +

Vasostatin O -
, O +
the O +
N O -
- O -
terminal O +
domain O +
of O +
calreticulin O -
, O +
is O +
a O +
potent O +
angiogenesis O +
inhibitor O -
. O +

In O +
this O +
study O -
, O +
we O +
determined O +
the O +
effectiveness O +
of O +
vasostatin O +
delivered O +
by O +
recombinant O +
pseudotype O +
adeno O -
- O -
associated O +
virus O +
2 O -
/ O -
5 O +
( O -
rAAV2 O -
/ O -
5-VAS O -
) O +
as O +
a O +
gene O +
therapy O +
approach O +
for O +
lung O +
cancer O +
treatment O -
. O +

EXPERIMENTAL O +
DESIGN O -
: O +
We O +
used O +
rAAV2 O -
/ O -
5 O +
to O +
deliver O +
vasostatin O +
intratumorally O +
or O +
systemically O +
in O +
different O +
mouse O +
lung O +
tumor O +
models O -
-- O -
subcutaneous O -
, O +
orthotopic O +
xenograft O -
, O +
and O +
spontaneous O +
metastasis O +
lung O +
tumor O +
models O -
. O +

The O +
therapeutic O +
efficacy O +
of O +
rAAV2 O -
/ O -
5-VAS O +
was O +
determined O +
by O +
monitoring O +
tumor O +
volume O -
, O +
survival O +
rate O -
, O +
and O +
degree O +
of O +
neovascularization O +
after O +
treatment O +
in O +
these O +
models O -
. O +

RESULTS O -
: O +
Mice O +
bearing O +
subcutaneous O +
tumor O +
of O +
rAAV2 O -
/ O -
5-VAS O +
pretreated O +
Lewis O +
lung O +
carcinoma O +
cells O +
showed O +
> O -
50 O -
% O +
reduction O +
in O +
primary O +
tumor O +
volume O +
and O +
reduced O +
spontaneous O +
pulmonary O +
metastases O -
. O +

The O +
tumor O -
- O -
suppressive O +
action O +
of O +
rAAV2 O -
/ O -
5-VAS O +
in O +
subcutaneous O +
human O +
lung O +
tumor O +
A549 O +
xenograft O +
correlated O +
with O +
a O +
reduced O +
number O +
of O +
capillary O +
vessels O +
in O +
tumors O -
. O +

In O +
the O +
orthotopic O +
xenograft O +
model O -
, O +
rAAV2 O -
/ O -
5-VAS O +
suppressed O +
metastasis O +
of O +
A549 O +
tumors O +
to O +
mediastinal O +
lymph O +
nodes O +
and O +
contralateral O +
lung O -
. O +

Furthermore O -
, O +
treatment O +
of O +
immunocompetent O +
mice O +
in O +
the O +
spontaneous O +
lung O +
metastases O +
model O +
with O +
rAAV2 O -
/ O -
5-VAS O +
after O +
primary O +
tumor O +
excision O +
prolonged O +
their O +
median O +
survival O +
from O +
21 O +
to O +
51.5 O +
days O -
. O +

CONCLUSION O -
: O +
Our O +
results O +
show O +
the O +
effectiveness O +
of O +
rAAV2 O -
/ O -
5-VAS O +
as O +
an O +
angiogenesis O +
inhibitor O +
in O +
suppressing O +
tumor O +
growth O +
during O +
different O +
stages O +
of O +
tumor O +
progression O -
, O +
validating O +
the O +
application O +
of O +
rAAV2 O -
/ O -
5-VAS O +
gene O +
therapy O +
in O +
treatment O +
against O +
lung O +
cancer O -
. O +

Survivin O +
expression O +
in O +
breast O +
carcinoma O -
: O +
correlation O +
with O +
apoptosis O +
and O +
prognosis O -
. O +

BACKGROUND O -
: O +
Survivin O +
is O +
a O +
novel O +
inhibitor O +
of O +
apoptosis O +
commonly O +
detected O +
in O +
tissues O +
during O +
fetal O +
development O +
and O +
in O +
cancer O -
, O +
but O +
not O +
usually O +
in O +
normal O +
tissues O -
. O +

It O +
has O +
been O +
suggested O +
that O +
the O +
expression O +
of O +
this O +
protein O +
may O +
be O +
of O +
prognostic O +
significance O +
in O +
gastric O -
, O +
colorectal O -
, O +
and O +
bladder O +
carcinomas O -
. O +

We O +
assessed O +
survivin O +
expression O +
in O +
breast O +
carcinomas O +
correlating O +
results O +
with O +
expression O +
of O +
other O +
antiapoptotic O +
( O -
bcl-2 O -
, O +
bcl O -
- O -
x O -
) O +
and O +
proapoptotic O +
( O -
bax O -
) O +
markers O -
, O +
with O +
prognostic O +
parameters O -
, O +
and O +
with O +
prognosis O -
. O +

DESIGN O -
: O +
Paraffin B-Chemical -
- O -
embedded O +
sections O +
of O +
37 O +
breast O +
carcinomas O +
were O +
immunostained O +
for O +
survivin O -
, O +
bcl-2 O -
, O +
bcl O -
- O -
x O -
, O +
and O +
bax O -
. O +

Expression O +
was O +
evaluated O +
in O +
normal O +
breast O +
tissue O +
and O +
carcinoma O -
, O +
nuclei O +
and O +
cytoplasm O -
, O +
as O +
intensity O +
( O -
0 O +
to O +
3 O -
+ O -
) O -
, O +
and O +
percentage O +
of O +
positive O +
cells O -
. O +

RESULTS O -
: O +
Survivin O +
expression O +
was O +
noted O +
in O +
30 O +
( O -
81 O -
% O -
) O +
of O +
breast O +
carcinomas O -
, O +
and O +
in O +
normal O +
breast O +
tissue O -
, O +
in O +
nuclei O -
, O +
and O +
cytoplasm O -
. O +

There O +
was O +
a O +
significant O +
correlation O +
( O -
P=0.022 O -
) O +
between O +
survivin O +
and O +
bcl O -
- O -
x O +
expression O -
; O +
survivin O +
and O +
bcl O -
- O -
x O +
tended O +
to O +
correlate O +
with O +
overall O +
survival O +
( O -
P=0.072 O +
and O +
0.075 O -
, O +
respectively O -
) O -
, O +
but O +
not O +
with O +
disease O -
- O -
free O +
survival O +
( O -
P=0.19 O +
and O +
0.18 O -
, O +
respectively O -
) O -
. O +

There O +
was O +
no O +
correlation O +
of O +
survivin O +
with O +
bcl-2 O +
or O +
bax O +
expression O -
, O +
or O +
with O +
other O +
prognostic O +
parameters O +
( O -
age O -
, O +
tumor O +
size O -
, O +
histologic O +
type O -
, O +
histologic O +
grade O -
, O +
nodal O +
status O -
, O +
and O +
tumor O +
stage O -
) O +
( O -
P>0.05 O -
) O -
. O +

CONCLUSION O -
: O +
The O +
majority O +
( O -
81 O -
% O -
) O +
of O +
breast O +
carcinomas O +
show O +
survivin O +
expression O +
which O +
correlates O +
with O +
bcl O -
- O -
x O -
, O +
another O +
antiapoptotic O +
marker O -
, O +
and O +
both O +
markers O +
tend O +
to O +
correlate O +
with O +
prognosis O -
. O +

Radiation O +
retinopathy O +
is O +
treatable O +
with O +
anti O -
- O -
vascular O +
endothelial O +
growth O +
factor O +
bevacizumab B-Chemical +
( O -
Avastin B-Chemical -
) O -
. O +

PURPOSE O -
: O +
To O +
report O +
on O +
bevacizumab B-Chemical +
treatment O +
for O +
radiation O +
retinopathy O +
affecting O +
the O +
macula O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
Twenty O -
- O -
one O +
patients O +
with O +
radiation O +
retinopathy O +
( O -
edema O -
, O +
hemorrhages O -
, O +
capillary O +
dropout O -
, O +
and O +
neovascularization O -
) O +
and O +
a O +
subjective O +
or O +
objective O +
loss O +
of O +
vision O +
were O +
treated O -
. O +

Treatment O +
involved O +
intravitreal O +
injection O +
of O +
bevacizumab B-Chemical +
( O -
1.25 O +
mg O +
in O +
0.05 O +
mL O -
) O +
every O +
6 O -
- O -
12 O +
weeks O -
. O +

Treatment O +
was O +
discontinued O +
at O +
patient O +
request O +
or O +
if O +
there O +
was O +
no O +
measurable O +
response O +
to O +
therapy O -
. O +

Main O +
outcome O +
measures O +
included O +
best O +
corrected O +
visual O +
acuity O -
, O +
ophthalmic O +
examination O -
, O +
retinal O +
photography O -
, O +
and O +
angiography O -
. O +

RESULTS O -
: O +
Bevacizumab B-Chemical +
treatment O +
was O +
followed O +
by O +
reductions O +
in O +
retinal O +
hemorrhage O -
, O +
exudation O -
, O +
and O +
edema O -
. O +

Visual O +
acuities O +
were O +
stable O +
or O +
improved O +
in O +
86 O -
% O +
( O -
n=18 O -
) O -
. O +

Three O +
patients O +
discontinued O +
therapy O -
. O +

Each O +
was O +
legally O +
blind O +
before O +
treatment O +
( O -
n=1 O -
) O -
, O +
experienced O +
little O +
to O +
no O +
subjective O +
improvement O +
( O -
n=2 O -
) O -
, O +
or O +
was O +
poorly O +
compliant O +
( O -
n=2 O -
) O -
. O +

Three O +
patients O +
( O -
14 O -
% O -
) O +
regained O +
2 O +
or O +
more O +
lines O +
of O +
visual O +
acuity O -
. O +

No O +
ocular O +
or O +
systemic O +
bevacizumab B-Chemical -
- O -
related O +
side O +
effects O +
were O +
observed O -
. O +

CONCLUSIONS O -
: O +
Intravitreal O +
bevacizumab B-Chemical +
can O +
be O +
used O +
to O +
treat O +
radiation O +
retinopathy O -
. O +

In O +
most O +
cases O +
treatment O +
was O +
associated O +
with O +
decreased O +
vascular O +
leakage O -
, O +
stabilization O -
, O +
or O +
improved O +
vision O -
. O +

An O +
anti O -
- O -
vascular O +
endothelial O +
growth O +
factor O +
strategy O +
may O +
reduce O +
tissue O +
damage O +
associated O +
with O +
radiation O +
vasculopathy O +
and O +
neuropathy O -
. O +

Mitogen O -
- O -
activated O +
protein O +
kinase O +
kinase O +
signaling O +
promotes O +
growth O +
and O +
vascularization O +
of O +
fibrosarcoma O -
. O +

We O +
hypothesized O +
that O +
signaling O +
through O +
multiple O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
kinase O +
( O -
MKK O -
) O +
pathways O +
is O +
essential O +
for O +
the O +
growth O +
and O +
vascularization O +
of O +
soft O -
- O -
tissue O +
sarcomas O -
, O +
which O +
are O +
malignant O +
tumors O +
derived O +
from O +
mesenchymal O +
tissues O -
. O +

We O +
tested O +
this O +
using O +
HT-1080 O -
, O +
NCI O -
, O +
and O +
Shac O +
fibrosarcoma O -
- O -
derived O +
cell O +
lines O +
and O +
anthrax O +
lethal B-Chemical +
toxin I-Chemical +
( O -
LeTx B-Chemical -
) O -
, O +
a O +
bacterial O +
toxin O +
that O +
inactivates O +
MKKs O -
. O +

Western O +
blots O +
confirmed O +
that O +
LeTx B-Chemical +
treatment O +
reduced O +
the O +
levels O +
of O +
phosphorylated O +
extracellular O +
signal O -
- O -
regulated O +
kinase O +
and O +
p38 O +
MAPK O +
in O +
vitro O -
. O +

Although O +
short O +
treatments O +
with O +
LeTx B-Chemical +
only O +
modestly O +
affected O +
cell O +
proliferation O -
, O +
sustained O +
treatment O +
markedly O +
reduced O +
cell O +
numbers O -
. O +

LeTx B-Chemical +
also O +
substantially O +
inhibited O +
the O +
extracellular O +
release O +
of O +
angioproliferative O +
factors O +
including O +
vascular O +
endothelial O +
growth O +
factor O -
, O +
interleukin-8 O -
, O +
and O +
basic O +
fibroblast O +
growth O +
factor O -
. O +

Similar O +
results O +
were O +
obtained O +
with O +
cell O +
lines O +
derived O +
from O +
malignant O +
fibrous O +
histiocytomas O -
, O +
leiomyosarcomas O -
, O +
and O +
liposarcomas O -
. O +

In O +
vivo O -
, O +
LeTx B-Chemical +
decreased O +
MAPK O +
activity O +
and O +
blocked O +
fibrosarcoma O +
growth O -
. O +

Growth O +
inhibition O +
correlated O +
with O +
decreased O +
cellular O +
proliferation O +
and O +
extensive O +
necrosis O -
, O +
and O +
it O +
was O +
accompanied O +
by O +
a O +
decrease O +
in O +
tumor O +
mean O +
vessel O +
density O +
as O +
well O +
as O +
a O +
reduction O +
in O +
serum O +
expression O +
of O +
angioproliferative O +
cytokines O -
. O +

Vital O +
imaging O +
using O +
high O -
- O -
resolution O +
ultrasound O +
enhanced O +
with O +
contrast O +
microbubbles O +
revealed O +
that O +
the O +
effects O +
of O +
LeTx B-Chemical +
on O +
tumor O +
perfusion O +
were O +
remarkably O +
rapid O +
( O +
less O +
than O +
24 O +
h O -
) O +
and O +
resulted O +
in O +
a O +
marked O +
reduction O +
of O +
perfusion O +
within O +
the O +
tumor O +
but O +
not O +
in O +
nontumor O +
tissues O -
. O +

These O +
results O +
are O +
consistent O +
with O +
our O +
initial O +
hypothesis O +
and O +
lead O +
us O +
to O +
propose O +
that O +
MKK O +
inhibition O +
by O +
LeTx B-Chemical +
is O +
a O +
broadly O +
effective O +
strategy O +
for O +
targeting O +
neovascularization O +
in O +
fibrosarcomas O +
and O +
other O +
similar O +
proliferative O +
lesions O -
. O +

A O +
novel O +
role O +
of O +
thrombospondin-1 O +
in O +
cervical O +
carcinogenesis O -
: O +
inhibit O +
stroma O +
reaction O +
by O +
inhibiting O +
activated O +
fibroblasts O +
from O +
invading O +
cancer O -
. O +

Thrombospondin O +
( O -
TSP O -
) O -
-1 O -
, O +
a O +
potent O +
angiogenesis O +
inhibitor O -
, O +
has O +
been O +
shown O +
to O +
exert O +
different O +
biological O +
functions O +
on O +
various O +
cell O +
types O -
. O +

Here O -
, O +
we O +
investigate O +
the O +
role O +
of O +
TSP-1 O +
in O +
tumor O -
- O -
stroma O +
reaction O -
, O +
which O +
is O +
mainly O +
characterized O +
by O +
fibroblast O +
activation O +
to O +
create O +
a O +
permissive O +
microenvironment O +
for O +
tumor O +
progression O -
. O +

Immunohistochemistry O +
examinations O +
in O +
the O +
human O +
surgical O +
specimens O +
have O +
shown O +
that O +
a O +
downregulation O +
of O +
TSP-1 O +
during O +
the O +
progression O +
of O +
cervical O +
carcinogenesis O +
was O +
accompanied O +
by O +
an O +
emergence O +
in O +
the O +
upregulation O +
of O +
stroma O +
markers O -
, O +
alpha O -
- O -
smooth O +
muscle O +
actin O +
( O -
alpha O -
- O -
SMA O -
) O +
and O +
desmin O -
. O +

Transfection O +
of O +
SiHa O +
cervical O +
cancer O +
cells O +
with O +
a O +
plasmid O +
expressing O +
the O +
TSP-1 O +
protein O +
exhibited O +
antiangiogenic O +
activity O +
in O +
vitro O +
and O +
resulted O +
in O +
reduced O +
tumor O +
growth O +
in O +
severe O +
combined O +
immunodeficiency O +
( O -
SCID O -
) O +
mice O -
, O +
which O +
was O +
accompanied O +
by O +
a O +
decrease O +
in O +
tumor O +
vascularization O +
and O +
lower O +
expressions O +
of O +
alpha O -
- O -
SMA O +
and O +
desmin O +
than O +
those O +
in O +
the O +
vector O +
controls O -
. O +

Transfection O +
with O +
TSP-1 O +
and O +
purified O +
TSP-1 O +
added O +
to O +
NIH3T3 O +
cells O +
did O +
not O +
alter O +
the O +
protein O +
levels O +
of O +
alpha O -
- O -
SMA O +
and O +
desmin O +
but O +
significantly O +
inhibited O +
matrix O +
metalloprotease-2 O +
activity O -
. O +

Transforming O +
growth O +
factor O -
- O -
beta O +
( O -
TGF O -
- O -
beta O -
) O -
, O +
a O +
major O +
factor O +
in O +
the O +
activation O +
of O +
fibroblasts O -
, O +
increased O +
alpha O -
- O -
SMA O +
and O +
desmin O +
expression O +
and O +
the O +
ability O +
of O +
cell O +
migration O +
and O +
invasion O +
in O +
NIH3T3 O +
cells O -
. O +

The O +
increased O +
migration O +
ability O +
and O +
the O +
invasive O +
ability O +
into O +
tumor O +
cluster O +
of O +
TGF O -
- O -
beta O -
- O -
treated O +
NIH3T3 O +
cells O +
were O +
dose O +
dependently O +
inhibited O +
by O +
TSP-1 O -
. O +

In O +
contrast O -
, O +
ectopic O +
TSP-1 O +
expression O +
in O +
SiHa O +
cells O +
has O +
little O +
effect O +
on O +
the O +
invasive O +
ability O +
of O +
the O +
NIH3T3 O +
cells O -
. O +

Together O -
, O +
our O +
findings O +
demonstrate O +
a O +
novel O +
role O +
of O +
TSP-1 O +
to O +
inhibit O +
tumor O -
- O -
stroma O +
reaction O +
that O +
could O +
be O +
attributed O +
to O +
the O +
blockage O +
of O +
activated O +
fibroblasts O +
from O +
invading O +
cancer O +
cells O -
. O +

Targeting O +
a O +
tumor O -
- O -
specific O +
laminin O +
domain O +
critical O +
for O +
human O +
carcinogenesis O -
. O +

Laminin-332 O +
is O +
critical O +
for O +
squamous O +
cell O +
carcinoma O +
( O -
SCC O -
) O +
tumorigenesis O -
, O +
but O +
targeting O +
it O +
for O +
cancer O +
therapy O +
has O +
been O +
unachievable O +
due O +
to O +
key O +
role O +
of O +
laminin-332 O +
in O +
promoting O +
tissue O +
integrity O -
. O +

Here O -
, O +
we O +
show O +
that O +
a O +
portion O +
of O +
laminin-332 O -
, O +
termed O +
G45 O -
, O +
which O +
is O +
proteolytically O +
removed O +
and O +
absent O +
in O +
normal O +
tissues O -
, O +
is O +
prominently O +
expressed O +
in O +
most O +
human O +
SCC O +
tumors O +
and O +
plays O +
an O +
important O +
role O +
in O +
human O +
SCC O +
tumorigenesis O -
. O +

Primary O +
human O +
keratinocytes O +
lacking O +
G45 O +
( O -
DeltaG45 O -
) O +
showed O +
alterations O +
of O +
basal O +
receptor O +
organization O -
, O +
impaired O +
matrix O +
deposition O -
, O +
and O +
increased O +
migration O -
. O +

After O +
SCC O +
transformation O -
, O +
the O +
absence O +
of O +
G45 O +
domain O +
in O +
DeltaG45 O +
cells O +
was O +
associated O +
with O +
deficient O +
extracellular O +
signal O -
- O -
regulated O +
kinase O +
and O +
phosphotidylinositol O +
3-kinase O +
( O -
PI3 O -
K O -
) O +
pathway O +
activation O -
, O +
impaired O +
invasion O -
, O +
deficient O +
metalloproteinase O +
activity O -
, O +
and O +
absent O +
tumorgenicity O +
in O +
vivo O -
. O +

Expression O +
of O +
G45 O +
or O +
activated O +
PI3 O -
K O +
subunit O +
in O +
DeltaG45 O +
cells O +
reversed O +
these O +
abnormalities O -
. O +

G45 O +
antibody O +
treatment O +
induced O +
SCC O +
tumor O +
apoptosis O -
, O +
decreased O +
SCC O +
tumor O +
proliferation O -
, O +
and O +
markedly O +
impaired O +
human O +
SCC O +
tumorigenesis O +
in O +
vivo O +
without O +
affecting O +
normal O +
tissue O +
adhesion O -
. O +

These O +
results O +
show O +
a O +
remarkable O +
selectivity O +
of O +
expression O +
and O +
function O +
for O +
laminin-332 O +
G45 O +
in O +
human O +
SCC O +
tumorigenesis O +
and O +
implicate O +
it O +
as O +
a O +
specific O +
target O +
for O +
anticancer O +
therapy O -
. O +

Management O +
of O +
early O +
and O +
advanced O +
colorectal O +
cancer O -
: O +
therapeutic O +
issues O -
. O +

PURPOSE O -
: O +
The O +
staging O +
of O +
colorectal O +
cancer O -
, O +
therapeutic O +
decision O +
making O +
in O +
the O +
management O +
of O +
early O +
and O +
advanced O +
colorectal O +
cancer O -
, O +
and O +
dilemmas O +
posed O +
by O +
drug O -
- O -
related O +
toxicity O +
are O +
discussed O -
. O +

SUMMARY O -
: O +
Staging O +
of O +
colorectal O +
cancer O +
occurs O +
after O +
surgery O +
and O +
is O +
based O +
on O +
the O +
extent O +
of O +
disease O +
invasiveness O +
and O +
dissemination O -
. O +

Surgery O +
is O +
the O +
primary O +
treatment O +
for O +
stage O +
I O +
disease O -
. O +

Adjuvant O +
chemotherapy O +
is O +
recommended O +
after O +
resection O +
in O +
selected O +
high O -
- O -
risk O +
patients O +
with O +
stage O +
II O +
disease O +
and O +
in O +
all O +
patients O +
with O +
stage O +
III O +
disease O -
. O +

Convenience O +
of O +
administration O -
, O +
tolerability O -
, O +
and O +
patient O +
factors O +
not O +
necessarily O +
age O +
may O +
be O +
considerations O +
in O +
decisions O +
about O +
adjuvant O +
therapy O +
after O +
resection O -
. O +

Treatment O +
of O +
stage O +
IV O +
colorectal O +
cancer O +
is O +
based O +
on O +
the O +
type O +
of O +
prior O +
therapy O +
and O +
patient O -
- O -
specific O +
factors O -
. O +

Recently O -
, O +
significant O +
improvements O +
in O +
survival O +
have O +
been O +
achieved O +
through O +
the O +
use O +
of O +
combination O +
chemotherapy O +
and O +
monoclonal O +
antibody O +
regimens O -
. O +

Bevacizumab B-Chemical +
in O +
combination O +
with O +
chemotherapy O +
is O +
first O -
- O -
line O +
therapy O +
for O +
stage O +
IV O +
disease O -
. O +

Age O +
alone O +
should O +
not O +
preclude O +
the O +
use O +
of O +
chemotherapy O +
in O +
stage O +
IV O +
colorectal O +
cancer O -
, O +
although O +
the O +
ability O +
to O +
tolerate O +
drug O -
- O -
related O +
toxicity O +
may O +
be O +
a O +
consideration O -
. O +

The O +
optimal O +
duration O +
of O +
chemotherapy O +
in O +
patients O +
with O +
early O +
and O +
metastatic O +
colorectal O +
cancer O +
is O +
unclear O -
. O +

CONCLUSION O -
: O +
The O +
optimal O +
approach O +
to O +
the O +
treatment O +
of O +
colorectal O +
cancer O +
depends O +
on O +
several O +
considerations O -
, O +
including O +
patient O -
- O -
specific O +
factors O -
. O +

Adenomatoid O +
tumour O +
of O +
the O +
liver O -
. O +

An O +
unusual O +
primary O +
adenomatoid O +
tumour O +
arising O +
in O +
the O +
normal O +
liver O +
is O +
described O -
. O +

Hepatectomy O +
was O +
performed O -
, O +
and O +
the O +
patient O +
is O +
alive O +
and O +
free O +
of O +
disease O +
1 O +
year O +
postsurgery O -
. O +

Grossly O -
, O +
the O +
tumour O +
showed O +
a O +
haemorrhagic O +
cut O +
surface O +
with O +
numerous O +
microcystic O +
structures O -
. O +

Histological O +
examination O +
revealed O +
cystic O +
or O +
angiomatoid O +
spaces O +
of O +
various O +
sizes O +
lined O +
by O +
cuboidal O -
, O +
low O -
- O -
columnar O -
, O +
or O +
flattened O +
epithelioid O +
cells O +
with O +
vacuolated O +
cytoplasm O +
and O +
round O +
to O +
oval O +
nuclei O -
. O +

The O +
epithelioid O +
cells O +
were O +
entirely O +
supported O +
by O +
proliferated O +
capillaries O +
and O +
arteries O +
together O +
with O +
collagenous O +
stroma O -
. O +

Immunohistochemical O +
studies O +
showed O +
that O +
the O +
epithelioid O +
cells O +
were O +
strongly O +
positive O +
for O +
a O +
broad O +
spectrum O +
of O +
cytokeratins O +
( O -
AE1 O -
/ O -
AE3 O -
, O +
CAM5.2 O -
, O +
epithelial O +
membrane O +
antigen O +
and O +
cytokeratin O +
7 O -
) O +
and O +
mesothelial O +
markers O +
( O -
calretinin O -
, O +
Wilms O -
' O +
tumour O +
1 O +
and O +
D2 O -
- O -
40 O -
) O -
. O +

These O +
cells O +
were O +
negative O +
for O +
Hep O +
par-1 O -
, O +
carcinoembryonic O +
antigen O -
, O +
neural O +
cell O +
adhesion O +
molecule O -
, O +
CD34 O -
, O +
CD31 O +
and O +
HMB45 O -
. O +

Atypically O -
, O +
abundant O +
capillaries O +
were O +
observed O -
; O +
however O -
, O +
the O +
cystic O +
proliferation O +
of O +
epithelioid O +
cells O +
with O +
vacuoles O +
and O +
immunohistochemical O +
profile O +
of O +
the O +
epithelioid O +
element O +
were O +
consistent O +
with O +
hepatic O +
adenomatoid O +
tumour O -
. O +

The O +
tyrosine O +
kinase O +
inhibitor O +
cediranib B-Chemical +
blocks O +
ligand O -
- O -
induced O +
vascular O +
endothelial O +
growth O +
factor O +
receptor-3 O +
activity O +
and O +
lymphangiogenesis O -
. O +

Solid O +
tumors O +
express O +
a O +
range O +
of O +
factors O +
required O +
to O +
sustain O +
their O +
growth O +
and O +
promote O +
their O +
dissemination O -
. O +

Among O +
these O +
are O +
vascular O +
endothelial O +
growth O +
factor O -
- O -
A O +
( O -
VEGF O -
- O -
A O -
) O -
, O +
the O +
key O +
angiogenic O +
stimulant O -
, O +
and O +
VEGF O -
- O -
C O -
, O +
a O +
primary O +
mediator O +
of O +
lymphangiogenesis O -
. O +

Small O +
molecule O +
tyrosine B-Chemical +
kinase I-Chemical +
inhibitors I-Chemical +
offer O +
the O +
potential O +
to O +
inhibit O +
more O +
than O +
one O +
kinase O +
and O +
impede O +
tumor O +
growth O +
by O +
multiple O +
mechanisms O -
. O +

However O -
, O +
their O +
potency O +
toward O +
individual O +
targets O +
can O +
vary O -
. O +

Cediranib B-Chemical +
( O -
RECENTIN B-Chemical -
; O +
AZD2171 B-Chemical -
) O +
is O +
an O +
inhibitor O +
of O +
VEGF O +
signaling O +
that O +
has O +
been O +
shown O +
in O +
experimental O +
models O +
to O +
prevent O +
VEGF O -
- O -
A O -
- O -
induced O +
angiogenesis O +
and O +
primary O +
tumor O +
growth O -
, O +
yet O +
the O +
effects O +
of O +
cediranib B-Chemical +
on O +
VEGF O +
receptor O +
( O -
VEGFR O -
) O -
-3-mediated O +
endothelial O +
cell O +
function O +
and O +
lymphangiogenesis O +
are O +
unknown O -
. O +

To O +
better O +
understand O +
the O +
activity O +
of O +
cediranib B-Chemical +
against O +
VEGFR-3 O +
and O +
its O +
associated O +
signaling O +
events O +
compared O +
with O +
its O +
activity O +
against O +
VEGFR-2 O -
, O +
we O +
used O +
the O +
receptor O -
- O -
specific O +
ligands O +
VEGF O -
- O -
E O +
and O +
VEGF O -
- O -
C156S O -
. O +

In O +
human O +
endothelial O +
cells O -
, O +
cediranib B-Chemical +
inhibited O +
VEGF O -
- O -
E O -
- O -
induced O +
phosphorylation O +
of O +
VEGFR-2 O +
and O +
VEGF O -
- O -
C156S O -
- O -
induced O +
phosphorylation O +
of O +
VEGFR-3 O +
at O +
concentrations O +
of O +
less O +
than O +
/=1nmol O -
/ O -
L O +
and O +
inhibited O +
activation O +
of O +
downstream O +
signaling O +
molecules O -
. O +

Additionally O -
, O +
cediranib B-Chemical +
blocked O +
VEGF O -
- O -
C156S O -
- O -
induced O +
and O +
VEGF O -
- O -
E O -
- O -
induced O +
proliferation O -
, O +
survival O -
, O +
and O +
migration O +
of O +
lymphatic O +
and O +
blood O +
vascular O +
endothelial O +
cells O -
. O +

In O +
vivo O -
, O +
cediranib B-Chemical +
( O -
6 O +
mg O -
/ O -
kg O -
/ O -
d O -
) O +
prevented O +
angiogenesis O +
and O +
lymphangiogenesis O +
induced O +
by O +
VEGF O -
- O -
E O -
- O -
expressing O +
and O +
VEGF O -
- O -
C156S O -
- O -
expressing O +
adenoviruses O -
, O +
respectively O -
. O +

Cediranib B-Chemical +
( O -
6 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O +
also O +
blocked O +
angiogenesis O +
and O +
lymphangiogenesis O +
induced O +
by O +
adenoviruses O +
expressing O +
VEGF O -
- O -
A O +
or O +
VEGF O -
- O -
C O +
and O +
compromised O +
the O +
blood O +
and O +
lymphatic O +
vasculatures O +
of O +
VEGF O -
- O -
C O -
- O -
expressing O +
tumors O -
. O +

Cediranib B-Chemical +
may O -
, O +
therefore O -
, O +
be O +
an O +
effective O +
means O +
of O +
preventing O +
tumor O +
progression O -
, O +
not O +
only O +
by O +
inhibiting O +
VEGFR-2 O +
activity O +
and O +
angiogenesis O -
, O +
but O +
also O +
by O +
concomitantly O +
inhibiting O +
VEGFR-3 O +
activity O +
and O +
lymphangiogenesis O -
. O +

Endosialin O -
/ O -
TEM O +
1 O -
/ O -
CD248 O +
is O +
a O +
pericyte O +
marker O +
of O +
embryonic O +
and O +
tumor O +
neovascularization O -
. O +

The O +
formation O +
of O +
functional O -
, O +
mature O +
blood O +
vessels O +
depends O +
on O +
the O +
interaction O +
between O +
endothelial O +
cells O +
and O +
pericytes O -
. O +

Commonality O +
exists O +
in O +
the O +
processes O +
involved O +
in O +
vasculature O +
development O +
between O +
tissues O +
whether O +
healthy O +
or O +
diseased O -
. O +

Endosialin O -
/ O -
TEM O +
1 O +
is O +
a O +
cell O +
membrane O +
protein O +
that O +
is O +
expressed O +
in O +
blood O +
vessels O +
during O +
embryogenesis O +
and O +
tumorigenesis O +
but O +
not O +
in O +
normal O +
mature O +
vessels O -
. O +

Antibodies O +
developed O +
to O +
human O +
endosialin O +
were O +
used O +
to O +
investigate O +
endosialin O +
expression O +
and O +
function O +
in O +
human O +
prenatal O +
brain O +
pericytes O +
and O +
pericytes O +
residing O +
in O +
tumors O -
. O +

Anti O -
- O -
endosialin O +
was O +
capable O +
of O +
preventing O +
pericyte O +
tube O +
formation O +
in O +
culture O +
and O +
inhibited O +
migration O -
. O +

Brain O +
pericytes O +
in O +
culture O +
had O +
higher O +
levels O +
of O +
endosialin O -
/ O -
TEM O +
1 O +
than O +
TEMs-2 O -
, O +
-3 O -
, O +
-4 O -
, O +
-5 O -
, O +
-7 O -
, O +
and O +
-8 O -
. O +

Immunocytochemistry O +
revealed O +
that O +
endosialin O +
was O +
present O +
in O +
the O +
cytoplasmic O +
body O +
and O +
in O +
the O +
elongated O +
extensions O +
essential O +
to O +
pericyte O +
function O -
. O +

Transgenic O +
mice O +
engineered O +
to O +
express O +
human O +
endosialin O +
bred O +
on O +
an O +
immunocompromised O +
background O +
allowed O +
the O +
growth O +
of O +
human O +
tumor O +
xenografts O -
. O +

In O +
human O +
colon O +
carcinoma O +
Colo205 O +
and O +
HT29 O +
xenografts O +
grown O +
in O +
human O +
endosialin O -
- O -
transgenic O +
mice O -
, O +
endosialin O +
expression O +
was O +
largely O +
confined O +
to O +
NG2-expressing O +
perivascular O +
cells O +
and O +
not O +
CD31-positive O +
endothelial O +
cells O -
. O +

Similar O +
methods O +
applied O +
to O +
human O +
ovarian O +
and O +
colon O +
tumors O +
confirmed O +
endosialin O +
expression O +
by O +
pericytes O -
. O +

The O +
data O +
indicate O +
that O +
endosialin O +
is O +
strongly O +
expressed O +
by O +
pericytes O +
during O +
periods O +
of O +
active O +
angiogenesis O +
during O +
embryonic O +
and O +
tumor O +
development O -
. O +

Anti O -
- O -
endosialin O +
antibodies O +
may O +
have O +
value O +
in O +
identifying O +
vasculature O +
in O +
malignant O +
tissues O -
. O +

With O +
the O +
appropriate O +
agent O -
, O +
targeting O +
endosialin O +
may O +
interfere O +
with O +
blood O +
vessel O +
growth O +
during O +
tumor O +
development O -
. O +

The O +
role O +
of O +
p53 O +
in O +
pigmentation O -
, O +
tanning O +
and O +
melanoma O -
. O +

p53 O +
has O +
a O +
central O +
role O +
in O +
skin O +
pigmentation O +
and O +
may O +
impact O +
on O +
melanoma O +
at O +
all O +
stages O -
, O +
however O -
, O +
as O +
it O -
's O +
mutation O +
frequency O +
in O +
melanoma O +
is O +
low O -
, O +
it O -
's O +
role O +
has O +
been O +
somewhat O +
under O -
- O -
appreciated O -
. O +

During O +
normal O +
skin O +
function O -
, O +
p53 O +
in O +
the O +
keratinocyte O +
is O +
a O +
transducer O +
of O +
the O +
skin O +
tanning O +
signal O +
and O +
an O +
essential O +
component O +
of O +
what O +
is O +
effectively O +
a O +
keratinocyte O -
- O -
melanocyte O +
signaling O +
cycle O +
that O +
regulates O +
skin O +
pigmentation O -
. O +

It O +
is O +
clear O +
that O +
this O +
cycle O +
functions O +
optimally O +
in O +
skin O +
of O +
dark O +
pigmentation O -
. O +

When O +
melanin B-Chemical +
biosynthesis O +
is O +
genetically O +
disrupted O +
in O +
skin O +
of O +
white O +
complexion O -
, O +
we O +
propose O +
that O +
this O +
cycle O +
operates O +
as O +
a O +
promoter O +
of O +
melanocyte O +
proliferation O -
. O +

The O +
cell O +
autonomous O +
function O +
of O +
p53 O +
in O +
melanocytes O +
is O +
not O +
well O +
described O -
, O +
however O -
, O +
the O +
balance O +
of O +
the O +
evidence O +
suggests O +
that O +
p53 O +
is O +
an O +
effective O +
tumor O +
suppressor O +
and O +
the O +
myriad O +
of O +
mechanisms O +
by O +
which O +
the O +
p53 O +
pathway O +
may O +
be O +
dysregulated O +
in O +
tumors O +
attests O +
to O +
it O +
importance O +
as O +
a O +
tumor O +
suppressor O -
. O +

In O +
this O +
review O -
, O +
we O +
outline O +
the O +
known O +
mechanisms O +
that O +
impair O +
p53 O +
itself O +
and O +
its O +
immediate O +
regulators O +
or O +
target O +
genes O +
during O +
melanomagenesis O -
. O +

Due O +
to O +
the O +
importance O +
of O +
this O +
pathway O -
, O +
it O +
is O +
clear O +
that O +
p53 O +
disruptions O +
may O +
relate O +
directly O +
to O +
a O +
patient O -
's O +
prognosis O -
. O +

This O +
pathway O +
will O +
continue O +
to O +
be O +
a O +
focus O +
of O +
investigation O -
, O +
particularly O +
with O +
respect O +
to O +
targeted O +
experimental O +
chemotherapeutics O -
. O +

Allergic O +
pulmonary O +
inflammation O +
promotes O +
the O +
recruitment O +
of O +
circulating O +
tumor O +
cells O +
to O +
the O +
lung O -
. O +

Allergen O -
- O -
induced O +
respiratory O +
inflammation O +
facilitates O +
and/or O +
elicits O +
the O +
extravasation O +
of O +
proinflammatory O +
leukocytes O +
by O +
well O -
- O -
understood O +
mechanisms O +
that O +
mediate O +
the O +
movement O +
of O +
multiple O +
cell O +
types O -
. O +

The O +
nonspecific O +
character O +
of O +
these O +
pathways O +
led O +
us O +
to O +
hypothesize O +
that O +
circulating O +
cancer O +
cells O +
use O +
similar O +
mechanisms O -
, O +
promoting O +
secondary O +
tumor O +
formation O +
at O +
distal O +
sites O -
. O +

To O +
test O +
this O +
hypothesis O -
, O +
the O +
frequency O +
of O +
metastasis O +
to O +
the O +
lung O +
as O +
a O +
function O +
of O +
allergic O +
pulmonary O +
inflammation O +
was O +
assessed O +
following O +
the O +
i.v O -
. O +

injection O +
of O +
B16-F10 O +
melanoma O +
cells O +
in O +
mice O -
. O +

These O +
studies O +
showed O +
that O +
allergen O -
- O -
induced O +
pulmonary O +
inflammation O +
resulted O +
in O +
a O +
> O -
3-fold O +
increase O +
in O +
lung O +
metastases O -
. O +

This O +
increase O +
was O +
dependent O +
on O +
CD4 O -
( O -
+ O -
) O +
T O -
- O -
cell O +
activities O -
; O +
however O -
, O +
it O +
occurred O +
independent O +
of O +
the O +
induced O +
eosinophilia O +
associated O +
with O +
allergen O +
provocation O -
. O +

Interventional O +
strategies O +
showed O +
that O +
existing O +
therapeutic O +
modalities O +
for O +
asthma O -
, O +
such O +
as O +
inhaled O +
corticosteroids B-Chemical -
, O +
were O +
sufficient O +
to O +
block O +
the O +
enhanced O +
pulmonary O +
recruitment O +
of O +
cancer O +
cells O +
from O +
circulation O -
. O +

Additional O +
mechanistic O +
studies O +
further O +
suggested O +
that O +
the O +
ability O +
of O +
circulating O +
cancer O +
cells O +
to O +
extravasate O +
to O +
surrounding O +
lung O +
tissues O +
was O +
linked O +
to O +
the O +
activation O +
of O +
the O +
vascular O +
endothelium O +
via O +
one O +
or O +
more O +
Galpha O -
( O -
i O -
) O -
-coupled O +
receptors O -
. O +

Interestingly O -
, O +
a O +
survey O +
of O +
a O +
clinical O +
breast O +
cancer O +
surgical O +
database O +
showed O +
that O +
the O +
incidence O +
of O +
asthma O +
was O +
higher O +
among O +
patients O +
with O +
lung O +
metastases O -
. O +

Thus O -
, O +
our O +
data O +
show O +
that O +
allergic O +
respiratory O +
inflammation O +
may O +
represent O +
a O +
risk O +
factor O +
for O +
the O +
development O +
of O +
lung O +
metastases O +
and O +
suggest O +
that O +
amelioration O +
of O +
the O +
pulmonary O +
inflammation O +
associated O +
with O +
asthma O +
will O +
have O +
a O +
direct O +
and O +
immediate O +
benefit O +
to O +
the O +
7 O -
% O +
to O +
8 O -
% O +
of O +
breast O +
cancer O +
patients O +
with O +
this O +
lung O +
disease O -
. O +

PI3K O -
/ O -
Akt O -
- O -
dependent O +
transcriptional O +
regulation O +
and O +
activation O +
of O +
BMP-2-Smad O +
signaling O +
by O +
NF O -
- O -
kappaB O +
in O +
metastatic O +
prostate O +
cancer O +
cells O -
. O +

BACKGROUND O -
: O +
Bone O +
morphogenetic O +
proteins O +
( O -
BMPs O -
) O +
exert O +
osteoinductive O +
effects O +
in O +
prostate O +
cancer O +
( O -
PC O -
) O +
via O +
uncharacterized O +
mechanisms O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
whether O +
the O +
nuclear O +
transcription O +
factor O +
NF O -
- O -
kappaB O -
, O +
implicated O +
in O +
PC O +
metastasis O -
, O +
is O +
involved O +
in O +
transcriptional O +
regulation O +
and O +
activation O +
of O +
BMP-2 O +
or O +
BMP-4 O -
/ O -
Smad O +
signaling O +
in O +
PC O +
cells O -
. O +

METHODS O -
: O +
NF O -
- O -
kappaB O +
inhibition O +
was O +
achieved O +
by O +
IkappaBalpha O +
super O -
- O -
repressor O +
adenoviral O +
vector O +
and O +
activation O +
was O +
monitored O +
by O +
EMSA O +
and O +
reporter O +
assays O -
. O +

BMP O +
expression O +
and O +
activation O +
was O +
measured O +
by O +
PCR O +
and O +
reporter O +
assays O -
. O +

Promoter O +
binding O +
assay O +
was O +
performed O +
by O +
chromatin O +
immunoprecipitation O +
( O -
ChIP O -
) O +
assay O -
. O +

Smad1 O -
/ O -
5 O -
/ O -
8 O +
phosphorylation O +
was O +
measured O +
by O +
Western O +
blot O +
analysis O -
. O +

RESULTS O -
: O +
PCR O +
and O +
chimeric O +
BMP-2 O +
and O +
BMP-4 O +
luciferase O +
assays O +
demonstrate O +
that O +
NF O -
- O -
kappaB O +
confers O +
robust O +
and O +
selective O +
activation O +
of O +
BMP-2 O +
in O +
p65 O +
overexpressing O +
or O +
rhTNF O -
- O -
alpha O -
- O -
stimulated O +
PC O +
cells O -
. O +

Inhibition O +
of O +
NF O -
- O -
kappaB O +
significantly O +
reduced O +
transcript O +
levels O +
and O +
autocrine O +
production O +
of O +
BMP-2 O +
by O +
rhTNF O -
- O -
alpha O +
stimulated O +
C4 O -
- O -
2B O +
cells O +
and O +
to O +
a O +
lesser O +
extent O +
by O +
the O +
parental O +
LNCaP O +
cells O -
. O +

Selective O +
inhibition O +
of O +
PI3K O -
/ O -
Akt O +
suppressed O +
the O +
NF O -
- O -
kappaB O -
- O -
induced O +
BMP-2 O +
promoter O +
activity O -
. O +

Furthermore O -
, O +
suppression O +
of O +
NF O -
- O -
kappaB O +
activation O +
decreased O +
the O +
transcript O +
levels O +
and O +
BMP-2-induced O +
phosphorylation O +
of O +
Smad1 O -
/ O -
5 O -
/ O -
8 O -
, O +
critical O +
downstream O +
targets O +
of O +
BMP-2 O +
signaling O +
in O +
PC O +
cells O -
. O +

Notably O -
, O +
the O +
activation O +
of O +
BMPRII O +
by O +
BMP-2 O +
is O +
required O +
for O +
modulation O +
of O +
Smad O +
activation O +
by O +
NF O -
- O -
kappaB O +
in O +
PC O +
cells O -
. O +

Based O +
on O +
ChIP O +
analysis O -
, O +
the O +
transcriptional O +
regulation O +
of O +
BMP-2 O +
gene O +
by O +
NF O -
- O -
kappaB O +
may O +
be O +
partially O +
attributed O +
to O +
binding O +
to O +
kappab O +
site O +
on O +
the O +
BMP-2 O +
promoter O -
. O +

CONCLUSIONS O -
: O +
The O +
data O +
suggest O +
that O +
PI3K O -
/ O -
Akt O -
- O -
NF O -
- O -
kappaB O +
axis O +
may O +
promote O +
PC O +
bone O +
metastasis O +
in O +
part O +
by O +
regulating O +
transcription O +
and O +
activation O +
of O +
the O +
BMP-2-Smad O +
signaling O +
cascade O +
in O +
osteotropic O +
PC O +
cells O -
. O +

Inhibition O +
of O +
energy O -
- O -
producing O +
pathways O +
of O +
HepG2 O +
cells O +
by O +
3-bromopyruvate B-Chemical -
. O +

3-BrPA B-Chemical +
( O -
3-bromopyruvate B-Chemical -
) O +
is O +
an O +
alkylating O +
agent O +
with O +
anti O -
- O -
tumoral O +
activity O +
on O +
hepatocellular O +
carcinoma O -
. O +

This O +
compound O +
inhibits O +
cellular O +
ATP B-Chemical +
production O +
owing O +
to O +
its O +
action O +
on O +
glycolysis O +
and O +
oxidative O +
phosphorylation O -
; O +
however O -
, O +
the O +
specific O +
metabolic O +
steps O +
and O +
mechanisms O +
of O +
3-BrPA B-Chemical +
action O +
in O +
human O +
hepatocellular O +
carcinomas O -
, O +
particularly O +
its O +
effects O +
on O +
mitochondrial O +
energetics O -
, O +
are O +
poorly O +
understood O -
. O +

In O +
the O +
present O +
study O +
it O +
was O +
found O +
that O +
incubation O +
of O +
HepG2 O +
cells O +
with O +
a O +
low O +
concentration O +
of O +
3-BrPA B-Chemical +
for O +
a O +
short O +
period O +
( O -
150 O +
microM O +
for O +
30 O +
min O -
) O +
significantly O +
affected O +
both O +
glycolysis O +
and O +
mitochondrial O +
respiratory O +
functions O -
. O +

The O +
activity O +
of O +
mitochondrial O +
hexokinase O +
was O +
not O +
inhibited O +
by O +
150 O +
microM O +
3-BrPA B-Chemical -
, O +
but O +
this O +
concentration O +
caused O +
more O +
than O +
70 O -
% O +
inhibition O +
of O +
GAPDH O +
( O -
glyceraldehyde-3-phosphate O +
dehydrogenase O -
) O +
and O +
3-phosphoglycerate O +
kinase O +
activities O -
. O +

Additionally O -
, O +
3-BrPA B-Chemical +
treatment O +
significantly O +
impaired O +
lactate B-Chemical +
production O +
by O +
HepG2 O +
cells O -
, O +
even O +
when O +
glucose B-Chemical +
was O +
withdrawn O +
from O +
the O +
incubation O +
medium O -
. O +

Oxygen B-Chemical +
consumption O +
of O +
HepG2 O +
cells O +
supported O +
by O +
either O +
pyruvate B-Chemical -
/ O -
malate B-Chemical +
or O +
succinate B-Chemical +
was O +
inhibited O +
when O +
cells O +
were O +
pre O -
- O -
incubated O +
with O +
3-BrPA B-Chemical +
in O +
glucose B-Chemical -
- O -
free O +
medium O -
. O +

On O +
the O +
other O +
hand O -
, O +
when O +
cells O +
were O +
pre O -
- O -
incubated O +
in O +
glucose B-Chemical -
- O -
supplemented O +
medium O -
, O +
oxygen B-Chemical +
consumption O +
was O +
affected O +
only O +
when O +
succinate B-Chemical +
was O +
used O +
as O +
the O +
oxidizable O +
substrate O -
. O +

An O +
increase O +
in O +
oligomycin B-Chemical -
- O -
independent O +
respiration O +
was O +
observed O +
in O +
HepG2 O +
cells O +
treated O +
with O +
3-BrPA B-Chemical +
only O +
when O +
incubated O +
in O +
glucose B-Chemical -
- O -
supplemented O +
medium O -
, O +
indicating O +
that O +
3-BrPA B-Chemical +
induces O +
mitochondrial O +
proton B-Chemical +
leakage O +
as O +
well O +
as O +
blocking O +
the O +
electron B-Chemical +
transport O +
system O -
. O +

The O +
activity O +
of O +
succinate O +
dehydrogenase O +
was O +
inhibited O +
by O +
70 O -
% O +
by O +
3-BrPA B-Chemical +
treatment O -
. O +

These O +
results O +
suggest O +
that O +
the O +
combined O +
action O +
of O +
3-BrPA B-Chemical +
on O +
succinate O +
dehydrogenase O +
and O +
on O +
glycolysis O -
, O +
inhibiting O +
steps O +
downstream O +
of O +
the O +
phosphorylation O +
of O +
glucose B-Chemical -
, O +
play O +
an O +
important O +
role O +
in O +
HepG2 O +
cell O +
death O -
. O +

A O +
novel O +
integrin O +
alpha5beta1 O +
antagonistic O +
peptide O -
, O +
A5 O -
- O -
1 O -
, O +
screened O +
by O +
Protein O +
Chip O +
system O +
as O +
a O +
potent O +
angiogenesis O +
inhibitor O -
. O +

Integrin O +
alpha5beta1 O +
immobilized O +
on O +
a O +
ProteoChip O +
was O +
used O +
to O +
screen O +
new O +
antagonistic O +
peptides O +
from O +
multiple O +
hexapeptide O +
sub O -
- O -
libraries O +
of O +
the O +
positional O +
scanning O +
synthetic O +
peptide O +
combinatorial O +
library O +
( O -
PS O -
- O -
SPCL O -
) O -
. O +

The O +
integrin O +
alpha5beta1-Fibronectin O +
interaction O +
was O +
demonstrated O +
on O +
the O +
chip O -
. O +

A O +
novel O +
peptide O +
ligand O -
, O +
A5 O -
- O -
1 O +
( O -
VILVLF O -
) O -
, O +
with O +
high O +
affinity O +
to O +
integrin O +
alpha5beta1 O +
was O +
identified O +
from O +
the O +
hexapeptide O +
libraries O +
with O +
this O +
chip O -
- O -
based O +
screening O +
method O +
on O +
the O +
basis O +
of O +
a O +
competitive O +
inhibition O +
assay O -
. O +

A5 O -
- O -
1 O +
inhibits O +
the O +
integrin O -
- O -
fibronectin O +
interaction O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
( O -
IC O -
( O -
50 O -
) O -
; O +
1.56+ O -
/ O -
-0.28 O +
microM. O +
In O +
addition O -
, O +
it O +
inhibits O +
human O +
umbilical O +
vein O +
endothelial O +
cell O +
proliferation O -
, O +
migration O -
, O +
adhesion O -
, O +
tubular O +
network O +
formation O -
, O +
and O +
bFGF O -
- O -
induced O +
neovascularization O +
in O +
a O +
chick O +
chorioallantoic O +
membrane O -
. O +

These O +
results O +
suggest O +
that O +
A5 O -
- O -
1 O +
will O +
be O +
a O +
potent O +
inhibitor O +
of O +
neovascularization O -
. O +

Evaluation O +
of O +
electrical O +
stimulation O +
for O +
ischemic O +
wound O +
therapy O -
: O +
a O +
feasibility O +
study O +
using O +
the O +
lapine O +
wound O +
model O -
. O +

Chronic O +
wounds O +
are O +
a O +
major O +
secondary O +
complication O +
for O +
many O +
people O +
with O +
impaired O +
mobility O -
. O +

Electrical O +
stimulation O +
( O -
ES O -
) O +
has O +
been O +
recommended O +
as O +
a O +
adjunctive O +
therapy O -
, O +
however O +
optimal O +
treatment O +
paradigms O +
have O +
not O +
been O +
established O -
. O +

Our O +
group O +
seeks O +
to O +
determine O +
the O +
basic O +
mechanisms O +
underlying O +
ES O +
wound O +
therapy O -
, O +
an O +
area O +
where O +
understanding O +
is O +
currently O +
limited O -
. O +

A O +
feasibility O +
study O +
was O +
carried O +
out O +
to O +
develop O +
the O +
Ahn O -
/ O -
Mustoe O +
lapine O +
wound O +
model O +
for O +
systematic O +
investigation O +
of O +
the O +
effects O +
of O +
electrical O +
stimulation O +
on O +
ischemic O +
wound O +
therapy O -
. O +

A O +
standardized O +
surgical O +
procedure O +
incorporated O +
a O +
hybrid O +
stimulation O +
system O +
comprising O +
an O +
implantable O +
mini O -
- O -
stimulator O +
and O +
surface O +
electrodes O -
, O +
with O +
creation O +
of O +
repeatable O +
ischemic O +
wounds O -
. O +

Twenty O +
mature O +
male O +
New O +
Zealand O +
white O +
rabbits O +
( O -
3 O +
kg O +
weight O -
) O +
were O +
employed O +
to O +
evaluate O +
the O +
effects O +
of O +
two O +
empirically O +
selected O +
stimulation O +
paradigms O +
applied O +
continuously O +
for O +
7 O -
- O -
21 O +
days O -
, O +
using O +
each O +
animal O +
as O +
its O +
own O +
control O -
. O +

Outcomes O +
measures O +
included O +
transcutaneous O +
blood O +
gas O +
levels O -
, O +
histology O -
, O +
total O +
RNA O +
content O +
and O +
analysis O +
of O +
alpha2 O +
( O -
I O -
) O +
collagen O +
( O -
COL O -
- O -
I O -
) O -
, O +
type O +
IV O +
collagen O +
( O -
COL O -
- O -
IV O -
) O -
, O +
alpha1 O +
( O -
V O -
) O +
collagen O +
( O -
COL O -
- O -
V O -
) O -
, O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
expression O +
using O +
real O -
- O -
time O +
quantitative O +
PCR O -
. O +

All O +
markers O +
for O +
stimulated O +
wounds O +
showed O +
increased O +
activity O +
relative O +
to O +
non O -
- O -
stimulated O +
control O +
wounds O +
between O +
7 O +
and O +
14 O +
days O +
following O +
injury O -
, O +
with O +
peak O +
activity O +
at O +
14 O +
days O -
. O +

By O +
21 O +
days O +
post O -
- O -
injury O -
, O +
all O +
activity O +
had O +
returned O +
to O +
near O +
baseline O +
level O -
. O +

VEGF O +
and O +
COL O -
- O -
IV O +
levels O +
were O +
found O +
to O +
be O +
significantly O +
higher O +
for O +
pattern O +
A O +
( O -
110 O +
mus O +
pulse O +
width O -
) O +
compared O +
to O +
pattern O +
B O +
( O -
5 O +
mus O +
pulse O +
width O -
) O +
at O +
14 O +
days O -
, O +
implying O +
that O +
pattern O +
A O +
may O +
be O +
more O +
effective O +
at O +
promoting O +
angiogenesis O -
. O +

All O +
wounds O +
were O +
fully O +
re O -
- O -
epithelialized O +
by O +
10 O +
days O +
post O -
- O -
injury O -
. O +

Both O +
COL O -
- O -
I O +
and O +
COL O -
- O -
V O +
showed O +
statistically O +
significant O +
( O -
P O +
less O +
than O +
0.05 O -
) O +
increased O +
activity O +
between O +
day O +
7 O +
and O +
day O +
14 O +
for O +
pattern O +
A O -
, O +
potentially O +
indicating O +
a O +
continued O +
effect O +
on O +
matrix O +
remodeling O -
. O +

The O +
early O +
closure O +
of O +
all O +
wounds O +
implies O +
that O +
the O +
rabbit O +
ear O +
model O +
may O +
not O +
be O +
valid O +
for O +
chronic O +
wound O +
studies O -
. O +

VEGF O -
, O +
angiopoietin-1 O +
and O +
-2 O +
in O +
bronchial O +
asthma O -
: O +
new O +
molecular O +
targets O +
in O +
airway O +
angiogenesis O +
and O +
microvascular O +
remodeling O -
. O +

Airway O +
angiogenesis O +
and O +
microvascular O +
remodeling O +
are O +
known O +
features O +
of O +
bronchial O +
asthma O -
, O +
but O +
the O +
mechanisms O +
of O +
these O +
structural O +
alterations O +
are O +
just O +
beginning O +
to O +
be O +
elucidated O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
, O +
one O +
of O +
the O +
most O +
potent O +
angiogenic O +
factors O -
, O +
stimulates O +
endothelial O +
cell O +
proliferation O +
and O +
induces O +
the O +
angiogenesis O -
. O +

Recently O -
, O +
considerable O +
attentions O +
have O +
been O +
devoted O +
to O +
the O +
physiological O +
roles O +
of O +
angiopoietin O +
( O -
Ang O -
) O -
-1 O +
and O +
-2 O +
as O +
regulatory O +
factors O +
of O +
VEGF O -
. O +

Ang-1 O +
has O +
been O +
shown O +
to O +
induce O +
the O +
migration O +
and O +
sprouting O +
of O +
endothelial O +
cells O -
, O +
and O +
coexpression O +
of O +
Ang-1 O +
and O +
VEGF O +
enhanced O +
angiogenesis O -
. O +

In O +
the O +
presence O +
of O +
high O +
levels O +
of O +
VEGF O -
, O +
Ang-2 O +
also O +
promotes O +
rapid O +
increase O +
in O +
capillary O +
diameter O -
, O +
remodeling O +
of O +
the O +
basal O +
lamina O -
, O +
proliferation O +
and O +
migration O +
of O +
endothelial O +
cells O -
, O +
and O +
stimulates O +
sprouting O +
of O +
new O +
blood O +
vessels O -
. O +

Thus O -
, O +
VEGF O -
, O +
Ang-1 O +
and O +
-2 O +
may O +
play O +
complementary O +
and O +
coordinated O +
roles O +
in O +
airway O +
angiogenesis O +
and O +
microvascular O +
remodeling O -
, O +
and O +
these O +
structural O +
changes O +
are O +
potentially O +
reversible O +
by O +
therapeutic O +
intervention O -
. O +

The O +
scope O +
of O +
the O +
present O +
review O +
is O +
to O +
discuss O +
from O +
a O +
clinical O +
point O +
of O +
view O +
the O +
potential O +
interactions O +
between O +
VEGF O +
and O +
angiopoietins O +
in O +
the O +
asthmatic O +
airways O -
, O +
and O +
focus O +
on O +
the O +
therapeutic O +
implications O +
targeting O +
for O +
these O +
angiogenic O +
factors O -
. O +

Recently O -
, O +
there O +
is O +
an O +
increasing O +
number O +
of O +
patents O +
which O +
have O +
been O +
focused O +
on O +
the O +
inhibitors O +
of O +
VEGF O +
action O -
. O +

These O +
inhibitors O +
are O +
directed O +
towards O +
the O +
receptors O +
of O +
VEGF O +
or O +
intracellular O +
substrates O +
for O +
the O +
receptors O -
. O +

We O +
will O +
also O +
discuss O +
several O +
patents O +
regarding O +
inhibitors O +
of O +
VEGF O +
action O +
in O +
the O +
present O +
review O -
. O +

p53 O +
hot O -
- O -
spot O +
mutants O +
increase O +
tumor O +
vascularization O +
via O +
ROS B-Chemical -
- O -
mediated O +
activation O +
of O +
the O +
HIF1 O -
/ O -
VEGF O -
- O -
A O +
pathway O -
. O +

The O +
function O +
of O +
p53 O +
tumor O +
suppressor O +
is O +
often O +
altered O +
in O +
various O +
human O +
tumors O +
predominantly O +
through O +
missense O -
- O -
mutations O +
resulting O +
in O +
accumulation O +
of O +
mutant O +
proteins O -
. O +

We O +
revealed O +
that O +
expression O +
of O +
p53 O +
proteins O +
with O +
amino O -
- O -
acid O +
substitutions O +
at O +
codons O +
175 O +
( O -
R175H O -
) O -
, O +
248 O +
( O -
R248W O -
) O -
, O +
and O +
273 O +
( O -
R273H O -
) O -
, O +
representing O +
the O +
hot O -
- O -
spots O +
of O +
mutations O +
in O +
various O +
human O +
tumors O -
, O +
increased O +
the O +
number O +
of O +
vessels O +
in O +
HCT116 O +
human O +
colon O +
carcinoma O +
xenografts O +
and O -
, O +
as O +
a O +
result O -
, O +
accelerated O +
their O +
growth O -
. O +

Stimulation O +
of O +
tumor O +
angiogenesis O +
was O +
connected O +
with O +
about O +
2-fold O +
increase O +
in O +
intracellular O +
level O +
of O +
reactive B-Chemical +
oxygen I-Chemical +
species I-Chemical +
( O -
ROS B-Chemical -
) O -
. O +

Antioxidant O +
N B-Chemical -
- I-Chemical -
acetyl I-Chemical -
- I-Chemical -
l I-Chemical -
- I-Chemical -
aspartate I-Chemical +
( O -
NAC B-Chemical -
) O +
decreased O +
vessels O +
number O +
in O +
tumors O +
formed O +
by O +
cells O +
with O +
inactivated O +
p53 O +
and O +
inhibited O +
their O +
growth O -
. O +

Effect O +
of O +
ROS B-Chemical +
on O +
angiogenesis O +
in O +
tumors O +
expressing O +
hot O -
- O -
spot O +
p53 O +
mutants O +
was O +
correlated O +
with O +
their O +
ability O +
to O +
increase O +
a O +
content O +
of O +
HIF1 O +
transcriptional O +
factor O +
responsible O +
for O +
up O -
- O -
regulation O +
of O +
VEGF O -
- O -
A O +
mRNAs O -
. O +

The O +
Akt O -
/ O -
mTOR O +
pathway O +
assures O +
the O +
synthesis O +
of O +
HIF-1alpha O +
protein O +
in O +
a O +
glucose- B-Chemical +
and O +
reoxygenation O -
- O -
dependent O +
manner O +
in O +
irradiated O +
tumors O -
. O +

Transcriptional O +
activity O +
of O +
HIF-1 O +
( O -
hypoxia O -
- O -
inducible O +
factor-1 O -
) O +
has O +
been O +
reported O +
to O +
be O +
up O -
- O -
regulated O +
in O +
solid O +
tumors O +
after O +
ionizing O +
radiation O -
; O +
however O -
, O +
the O +
molecular O +
mechanism O +
underlying O +
the O +
response O +
remains O +
to O +
be O +
elucidated O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
performed O +
a O +
series O +
of O +
molecular O +
imaging O +
experiments O +
using O +
a O +
HIF-1-dependent O +
reporter O +
gene O -
, O +
5HREp O -
- O -
ODD O -
- O -
luc O -
, O +
and O +
found O +
an O +
essential O +
role O +
of O +
the O +
Akt O -
/ O -
mTOR O +
pathway O -
. O +

Hypoxic O +
tumor O +
cells O +
distant O +
from O +
blood O +
vessels O +
were O +
dramatically O +
reoxygenated O +
at O +
24 O +
h O +
postirradiation O -
, O +
and O +
HIF-1 O +
activity O +
increased O +
as O +
HIF-1alpha O +
accumulated O +
in O +
the O +
reoxygenated O +
regions O -
. O +

The O +
accumulation O +
was O +
inhibited O +
with O +
a O +
nonmetabolizable O +
glucose B-Chemical +
analog O -
, O +
2-deoxy B-Chemical -
- I-Chemical -
d I-Chemical -
- I-Chemical -
glucose I-Chemical -
, O +
through O +
the O +
suppression O +
of O +
radiation O -
- O -
induced O +
phosphorylation O +
of O +
Akt O +
in O +
the O +
reoxygenated O +
regions O -
. O +

Akt O +
knockdown O +
and O +
an O +
mTOR O +
inhibitor O +
revealed O +
the O +
importance O +
of O +
the O +
Akt O -
/ O -
mTOR O +
pathway O +
in O +
the O +
postirradiation O +
accumulation O +
of O +
HIF-1alpha O -
. O +

In O +
vitro O +
experiments O +
confirmed O +
that O +
an O +
increase O +
in O +
glucose B-Chemical +
availability O +
induced O +
Akt O +
phosphorylation O +
under O +
reoxygenated O +
conditions O +
and O +
consequently O +
up O -
- O -
regulated O +
HIF-1alpha O +
translation O -
. O +

Moreover O -
, O +
both O +
the O +
accelerated O +
translation O +
and O +
the O +
previously O +
reported O +
reactive B-Chemical +
oxygen I-Chemical +
species I-Chemical -
- O -
mediated O +
stabilization O +
of O +
HIF-1alpha O +
protein O +
were O +
essential O +
to O +
the O +
activation O +
of O +
HIF-1 O -
. O +

All O +
of O +
these O +
results O +
indicate O +
that O +
Akt O -
/ O -
mTOR O -
- O -
dependent O +
translation O +
of O +
HIF-1alpha O +
plays O +
a O +
critical O +
role O +
in O +
the O +
postirradiation O +
up O -
- O -
regulation O +
of O +
intratumoral O +
HIF-1 O +
activity O +
in O +
response O +
to O +
radiation O -
- O -
induced O +
alterations O +
of O +
glucose B-Chemical +
and O +
oxygen B-Chemical +
availability O +
in O +
a O +
solid O +
tumor O -
. O +

Involvement O +
of O +
PTEN O +
promoter O +
methylation O +
in O +
cerebral O +
cavernous O +
malformations O -
. O +

BACKGROUND O +
AND O +
PURPOSE O -
: O +
Cerebral O +
cavernous O +
malformations O +
( O -
CCMs O -
) O +
are O +
prevalent O +
cerebral O +
vascular O +
lesions O +
involving O +
aberrant O +
angiogenesis O -
. O +

However O -
, O +
the O +
underlying O +
mechanism O +
is O +
poorly O +
understood O -
. O +

Phosphatase O +
and O +
tension O +
homolog O +
deleted O +
on O +
chromosome O +
10 O +
( O -
PTEN O -
) O -
, O +
a O +
tumor O +
suppressor O -
, O +
is O +
frequently O +
deficient O +
in O +
various O +
pathologies O +
due O +
to O +
mutation O +
or O +
epigenetic O +
alterations O -
. O +

PTEN O +
promoter O +
hypermethylation O +
is O +
a O +
major O +
epigenetic O +
silencing O +
mechanism O +
leading O +
to O +
activation O +
of O +
angiogenesis O +
in O +
tumors O -
. O +

The O +
present O +
study O +
aimed O +
to O +
investigate O +
whether O +
PTEN O +
promoter O +
methylation O +
was O +
involved O +
in O +
CCMs O -
. O +

METHODS O -
: O +
PTEN O +
promoter O +
methylation O +
was O +
detected O +
in O +
surgical O +
specimens O +
of O +
CCMs O +
( O -
n=69 O -
) O +
by O +
methylation O -
- O -
specific O +
polymerase O +
chain O +
reaction O -
. O +

The O +
methylation O +
status O +
was O +
correlated O +
to O +
the O +
clinical O +
manifestations O +
and O +
to O +
PTEN O +
expression O -
, O +
which O +
was O +
analyzed O +
by O +
both O +
Western O +
blot O +
and O +
immunohistochemistry O -
. O +

To O +
investigate O +
the O +
endothelial O +
proliferation O +
and O +
the O +
potential O +
signaling O +
pathways O +
affected O +
by O +
PTEN O +
methylation O -
, O +
proliferating O +
cell O +
nuclear O +
antigen O +
as O +
well O +
as O +
phosphor O -
- O -
Akt O +
and O +
phosphor O -
- O -
Erk1,2 O +
were O +
detected O +
by O +
immunofluorescence O +
and O +
Western O +
blot O -
, O +
respectively O -
, O +
in O +
CCM O +
specimens O -
. O +

RESULTS O -
: O +
Methylation O -
- O -
specific O +
polymerase O +
chain O +
reaction O +
revealed O +
PTEN O +
promoter O +
methylation O +
in O +
15.9 O -
% O +
CCMs O -
. O +

Strikingly O -
, O +
5 O +
of O +
6 O +
familial O +
CCMs O +
showed O +
PTEN O +
promoter O +
methylation O +
( O -
83.3 O -
% O -
) O -
, O +
which O +
was O +
significantly O +
higher O +
than O +
in O +
sporadic O +
cases O +
( O -
9.4 O -
% O -
; O +
P<0.001 O -
) O -
. O +

In O +
addition O -
, O +
PTEN O +
promoter O +
methylation O +
appeared O +
more O +
frequently O +
in O +
multiple O +
CCMs O -
, O +
including O +
familial O +
cases O +
( O -
46.7 O -
% O -
) O -
, O +
than O +
that O +
in O +
single O -
- O -
lesioned O +
CCMs O +
( O -
11.8 O -
% O -
; O +
P<0.05 O -
) O -
. O +

Immunostaining O +
and O +
Western O +
blot O +
revealed O +
a O +
more O +
significant O +
PTEN O +
downregulation O +
in O +
PTEN O -
- O -
methylated O +
CCMs O +
in O +
comparison O +
to O +
PTEN O -
- O -
unmethylated O +
CCMs O -
. O +

Reduced O +
PTEN O +
expression O +
was O +
inversely O +
correlated O +
to O +
the O +
expression O +
of O +
proliferating O +
cell O +
nuclear O +
antigen O +
and O +
to O +
the O +
activation O +
of O +
Erk1,2 O -
, O +
but O +
not O +
of O +
Akt O -
. O +

CONCLUSIONS O -
: O +
We O +
reported O +
here O +
for O +
the O +
first O +
time O +
the O +
involvement O +
of O +
PTEN O +
promoter O +
methylation O +
in O +
CCMs O -
, O +
particularly O +
in O +
familial O +
CCMs O -
, O +
suggesting O +
this O +
epigenetic O +
alteration O +
as O +
a O +
potential O +
pathomechanism O +
of O +
CCMs O -
. O +

The O +
identification O +
of O +
Erk1,2 O +
as O +
triggered O +
signaling O +
in O +
the O +
lesions O +
may O +
be O +
valuable O +
for O +
the O +
development O +
of O +
effective O +
therapy O +
for O +
this O +
disease O -
. O +

Effect O +
of O +
platelet O -
- O -
rich O +
plasma O +
and O +
fibrin O +
glue O +
on O +
healing O +
of O +
critical O -
- O -
size O +
calvarial O +
bone O +
defects O -
. O +

Despite O +
the O +
insufficient O +
number O +
of O +
experimental O +
studies O -
, O +
platelet O -
- O -
rich O +
plasma O +
( O -
PRP O -
) O +
including O +
high O +
amounts O +
of O +
growth O +
factors O +
is O +
introduced O +
to O +
clinical O +
use O +
rapidly O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
compare O +
the O +
effects O +
of O +
PRP O +
and O +
platelet O -
- O -
poor O +
plasma O +
( O -
PPP O -
) O +
on O +
healing O +
of O +
critical O -
- O -
size O +
bone O +
defects O -
. O +

Bilateral O +
full O -
- O -
thickness O -
, O +
critical O -
- O -
size O +
bone O +
defects O +
were O +
created O +
in O +
the O +
parietal O +
bones O +
of O +
32 O +
rabbits O -
, O +
which O +
had O +
been O +
studied O +
in O +
4 O +
groups O -
. O +

Saline B-Chemical -
, O +
thrombin O +
solution O -
, O +
PPP O -
, O +
and O +
PRP O +
were O +
applied O +
to O +
the O +
created O +
defects O +
before O +
closure O -
. O +

Radiologic O +
defect O +
area O +
measurement O +
results O +
at O +
0 O -
, O +
4 O -
, O +
and O +
16 O +
weeks O +
were O +
compared O +
between O +
the O +
groups O -
. O +

In O +
addition O -
, O +
densities O +
of O +
the O +
newly O +
formed O +
bones O +
at O +
16th O +
week O +
were O +
studied O -
. O +

Histologic O +
parameters O +
( O -
primary O +
and O +
secondary O +
bone O +
trabecula O -
, O +
neovascularization O -
, O +
and O +
bone O +
marrow O +
and O +
connective O +
tissue O +
formation O -
) O +
were O +
compared O +
between O +
4- O +
and O +
16-week O +
groups O -
. O +

More O +
rapid O +
decrease O +
in O +
defect O +
size O +
was O +
observed O +
in O +
groups O +
3 O +
and O +
4 O +
than O +
in O +
groups O +
1 O +
and O +
2 O -
, O +
both O +
in O +
the O +
4th O +
and O +
16th O +
weeks O -
. O +

Newly O +
formed O +
bone O +
densities O +
were O +
also O +
found O +
to O +
be O +
higher O +
in O +
these O +
2 O +
groups O -
. O +

New O +
bone O +
formation O +
was O +
detected O +
to O +
be O +
more O +
rapid O +
considering O +
histologic O +
parameters O -
, O +
in O +
groups O +
3 O +
and O +
4 O +
at O +
4th O +
and O +
16th O +
weeks O -
. O +

Study O +
demonstrates O +
that O +
PRP O +
and O +
PPP O +
might O +
have O +
favorable O +
effects O +
on O +
bone O +
healing O -
. O +

Although O +
we O +
can O -
not O +
reveal O +
any O +
statistical O +
difference O +
between O +
these O +
2 O +
substances O +
considering O +
osteoinductive O +
potential O -
, O +
PRP O +
group O +
has O +
demonstrated O +
superior O +
results O +
compared O +
with O +
fibrin O +
glue O +
group O -
. O +

Higher O +
platelet O +
concentrations O +
may O +
expose O +
beneficial O +
effects O +
of O +
PRP O -
. O +

Host O -
- O -
derived O +
angiopoietin-2 O +
affects O +
early O +
stages O +
of O +
tumor O +
development O +
and O +
vessel O +
maturation O +
but O +
is O +
dispensable O +
for O +
later O +
stages O +
of O +
tumor O +
growth O -
. O +

The O +
angiopoietin O -
/ O -
Tie2 O +
system O +
has O +
been O +
identified O +
as O +
the O +
second O +
vascular O -
- O -
specific O +
receptor O +
tyrosine O +
kinase O +
system O +
controlling O +
vessel O +
assembly O -
, O +
maturation O -
, O +
and O +
quiescence O -
. O +

Angiopoietin-2 O +
( O -
Ang-2 O -
) O +
is O +
prominently O +
up O -
- O -
regulated O +
in O +
the O +
host O -
- O -
derived O +
vasculature O +
of O +
most O +
tumors O -
, O +
making O +
it O +
an O +
attractive O +
candidate O +
for O +
antiangiogenic O +
intervention O -
. O +

Yet O -
, O +
the O +
net O +
outcome O +
of O +
Ang-2 O +
functions O +
on O +
tumor O +
angiogenesis O +
is O +
believed O +
to O +
be O +
contextual O +
depending O +
on O +
the O +
local O +
cytokine O +
milieu O -
. O +

Correspondingly O -
, O +
Ang-2 O +
manipulatory O +
therapies O +
have O +
been O +
shown O +
to O +
exert O +
protumorigenic O +
as O +
well O +
as O +
antitumorigenic O +
effects O -
. O +

To O +
clarify O +
the O +
role O +
of O +
Ang-2 O +
for O +
angiogenesis O +
and O +
tumor O +
growth O +
in O +
a O +
definite O +
genetic O +
experimental O +
setting O -
, O +
the O +
present O +
study O +
was O +
aimed O +
at O +
comparatively O +
studying O +
the O +
growth O +
of O +
different O +
tumors O +
in O +
wild O -
- O -
type O +
and O +
Ang-2-deficient O +
mice O -
. O +

Lewis O +
lung O +
carcinomas O -
, O +
MT O -
- O -
ret O +
melanomas O -
, O +
and O +
B16F10 O +
melanomas O +
all O +
grew O +
slower O +
in O +
Ang-2-deficient O +
mice O -
. O +

Yet O -
, O +
tumor O +
growth O +
in O +
wild O -
- O -
type O +
and O +
Ang-2-deficient O +
mice O +
dissociated O +
during O +
early O +
stages O +
of O +
tumor O +
development O -
, O +
whereas O +
tumor O +
growth O +
rates O +
during O +
later O +
stages O +
of O +
primary O +
tumor O +
progression O +
were O +
similar O -
. O +

Analysis O +
of O +
the O +
intratumoral O +
vascular O +
architecture O +
revealed O +
no O +
major O +
differences O +
in O +
microvessel O +
density O +
and O +
perfusion O +
characteristics O -
. O +

However O -
, O +
diameters O +
of O +
intratumoral O +
microvessels O +
were O +
smaller O +
in O +
tumors O +
grown O +
in O +
Ang-2-deficient O +
mice O -
, O +
and O +
the O +
vasculature O +
had O +
an O +
altered O +
pattern O +
of O +
pericyte O +
recruitment O +
and O +
maturation O -
. O +

Ang-2-deficient O +
tumor O +
vessels O +
had O +
higher O +
pericyte O +
coverage O +
indices O -
. O +

Recruited O +
pericytes O +
were O +
desmin O +
and O +
NG2 O +
positive O +
and O +
predominately O +
alpha O -
- O -
smooth O +
muscle O +
actin O +
negative O -
, O +
indicative O +
of O +
a O +
more O +
mature O +
pericyte O +
phenotype O -
. O +

Collectively O -
, O +
the O +
experiments O +
define O +
the O +
role O +
of O +
Ang-2 O +
during O +
tumor O +
angiogenesis O +
and O +
establish O +
a O +
better O +
rationale O +
for O +
combination O +
therapies O +
involving O +
Ang-2 O +
manipulatory O +
therapies O -
. O +

PTTG O +
overexpression O +
promotes O +
lymph O +
node O +
metastasis O +
in O +
human O +
esophageal O +
squamous O +
cell O +
carcinoma O -
. O +

Human O +
pituitary O +
tumor O +
transforming O +
gene O +
( O -
PTTG O -
) O +
overexpression O +
correlates O +
with O +
metastasis O +
in O +
multiple O +
tumors O -
, O +
and O +
yet O +
its O +
molecular O +
mechanisms O +
of O +
action O +
remain O +
elusive O -
. O +

We O +
detected O +
PTTG O +
overexpression O +
in O +
66 O -
% O +
( O -
111 O +
of O +
169 O -
) O +
of O +
primary O +
esophageal O +
squamous O +
cell O +
carcinoma O +
( O -
ESCC O -
) O +
tumor O +
tissues O +
by O +
in O +
situ O +
hybridization O -
. O +

PTTG O +
overexpression O +
correlated O +
with O +
lymph O +
node O +
metastasis O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

Ectopic O +
PTTG O +
overexpression O +
in O +
a O +
representative O +
ESCC O +
cell O +
line O -
, O +
EC9706 O -
, O +
increased O +
in O +
vitro O +
cell O +
migration O +
and O +
invasion O +
and O +
promoted O +
in O +
vivo O +
lymph O +
node O +
metastasis O -
. O +

Suppressing O +
PTTG O +
expression O +
by O +
siRNA O +
decreased O +
cell O +
motility O +
in O +
both O +
PTTG O -
- O -
HA O -
/ O -
EC9706 O +
and O +
KYSE150 O +
cells O -
. O +

By O +
using O +
mass O +
spectrometric O +
analysis O -
, O +
we O +
identified O +
that O +
PTTG O +
up O -
- O -
regulated O +
S100A4 O +
and O +
galectin-1 O +
secretion O +
and O +
down O -
- O -
regulated O +
tissue O +
inhibitor O +
of O +
metalloproteinase-2 O +
secretion O +
to O +
the O +
culture O +
media O -
. O +

PTTG O +
induced O +
S100A4 O +
and O +
galectin-1 O +
mRNA O +
and O +
protein O +
expression O +
as O +
assessed O +
by O +
Western O +
blot O +
and O +
reverse O +
transcription O -
- O -
PCR O -
. O +

Attenuating O +
galectin-1 O +
expression O +
by O +
siRNA O +
constrained O +
PTTG O -
- O -
HA O -
/ O -
EC9706 O +
cell O +
motility O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

PTTG O +
activated O +
E O -
- O -
box O +
transcription O +
and O +
induced O +
c O -
- O -
Myc O +
protein O +
expression O +
in O +
EC9706 O +
cells O -
, O +
which O +
in O +
turn O +
may O +
act O +
on O +
an O +
E O -
- O -
box O +
motif O +
within O +
the O +
galectin-1 O +
promoter O -
. O +

Chromatin O +
immunoprecipitation O +
assays O +
further O +
confirmed O +
specific O +
c O -
- O -
Myc O +
binding O +
to O +
galectin-1 O +
promoter O -
. O +

PTTG O -
- O -
induced O +
galectin-1 O +
transactivation O +
and O +
expression O +
were O +
mediated O +
by O +
c O -
- O -
Myc O -
, O +
and O +
both O +
inductions O +
were O +
suppressed O +
by O +
c O -
- O -
Myc O +
RNAi O +
cotranfection O -
. O +

These O +
findings O +
elucidate O +
the O +
molecular O +
mechanisms O +
of O +
PTTG O +
overexpression O +
in O +
promoting O +
tumor O +
metastasis O -
, O +
whereby O +
up O -
- O -
regulated O +
PTTG O +
modulates O +
expression O +
and O +
secretion O +
of O +
metastasis O -
- O -
related O +
factors O +
to O +
facilitate O +
cell O +
motility O -
. O +

Characterization O +
of O +
the O +
metabolic O +
changes O +
underlying O +
growth O +
factor O +
angiogenic O +
activation O -
: O +
identification O +
of O +
new O +
potential O +
therapeutic O +
targets O -
. O +

Angiogenesis O +
is O +
a O +
fundamental O +
process O +
to O +
normal O +
and O +
abnormal O +
tissue O +
growth O +
and O +
repair O -
, O +
which O +
consists O +
of O +
recruiting O +
endothelial O +
cells O +
toward O +
an O +
angiogenic O +
stimulus O -
. O +

The O +
cells O +
subsequently O +
proliferate O +
and O +
differentiate O +
to O +
form O +
endothelial O +
tubes O +
and O +
capillary O -
- O -
like O +
structures O -
. O +

Little O +
is O +
known O +
about O +
the O +
metabolic O +
adaptation O +
of O +
endothelial O +
cells O +
through O +
such O +
a O +
transformation O -
. O +

We O +
studied O +
the O +
metabolic O +
changes O +
of O +
endothelial O +
cell O +
activation O +
by O +
growth O +
factors O +
using O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
( O -
HUVECs O -
) O -
, O +
[ B-Chemical -
1,2- I-Chemical -
( I-Chemical -
13 I-Chemical -
) I-Chemical -
C I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
] I-Chemical -
-glucose I-Chemical +
and O +
mass O +
isotopomer O +
distribution O +
analysis O -
. O +

The O +
metabolism O +
of O +
[ B-Chemical -
1,2- I-Chemical -
( I-Chemical -
13 I-Chemical -
) I-Chemical -
C I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
] I-Chemical -
-glucose I-Chemical +
by O +
HUVEC O +
allows O +
us O +
to O +
trace O +
many O +
of O +
the O +
main O +
glucose B-Chemical +
metabolic O +
pathways O -
, O +
including O +
glycogen B-Chemical +
synthesis O -
, O +
the O +
pentose B-Chemical +
cycle O +
and O +
the O +
glycolytic O +
pathways O -
. O +

So O +
we O +
established O +
that O +
these O +
pathways O +
were O +
crucial O +
to O +
endothelial O +
cell O +
proliferation O +
under O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
and O +
fibroblast O +
growth O +
factor O +
( O -
FGF O -
) O +
stimulation O -
. O +

A O +
specific O +
VEGF O +
receptor-2 O +
inhibitor O +
demonstrated O +
the O +
importance O +
of O +
glycogen B-Chemical +
metabolism O +
and O +
pentose B-Chemical +
cycle O +
pathway O -
. O +

Furthermore O -
, O +
we O +
showed O +
that O +
glycogen B-Chemical +
was O +
depleted O +
in O +
a O +
low O +
glucose B-Chemical +
medium O -
, O +
but O +
conserved O +
under O +
hypoxic O +
conditions O -
. O +

Finally O -
, O +
we O +
demonstrated O +
that O +
direct O +
inhibition O +
of O +
key O +
enzymes O +
to O +
glycogen B-Chemical +
metabolism O +
and O +
pentose B-Chemical +
phosphate O +
pathways O +
reduced O +
HUVEC O +
viability O +
and O +
migration O -
. O +

In O +
this O +
regard O -
, O +
inhibitors O +
of O +
these O +
pathways O +
have O +
been O +
shown O +
to O +
be O +
effective O +
antitumoral O +
agents O -
. O +

To O +
sum O +
up O -
, O +
our O +
data O +
suggest O +
that O +
the O +
inhibition O +
of O +
metabolic O +
pathways O +
offers O +
a O +
novel O +
and O +
powerful O +
therapeutic O +
approach O -
, O +
which O +
simultaneously O +
inhibits O +
tumor O +
cell O +
proliferation O +
and O +
tumor O -
- O -
induced O +
angiogenesis O -
. O +

Bmi-1 O +
over O -
- O -
expression O +
in O +
neural O +
stem O -
/ O -
progenitor O +
cells O +
increases O +
proliferation O +
and O +
neurogenesis O +
in O +
culture O +
but O +
has O +
little O +
effect O +
on O +
these O +
functions O +
in O +
vivo O -
. O +

The O +
polycomb O +
gene O +
Bmi-1 O +
is O +
required O +
for O +
the O +
self O -
- O -
renewal O +
of O +
stem O +
cells O +
from O +
diverse O +
tissues O -
, O +
including O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O -
. O +

Bmi-1 O +
expression O +
is O +
elevated O +
in O +
most O +
human O +
gliomas O -
, O +
irrespective O +
of O +
grade O -
, O +
raising O +
the O +
question O +
of O +
whether O +
Bmi-1 O +
over O -
- O -
expression O +
is O +
sufficient O +
to O +
promote O +
self O -
- O -
renewal O +
or O +
tumorigenesis O +
by O +
CNS O +
stem O -
/ O -
progenitor O +
cells O -
. O +

To O +
test O +
this O +
we O +
generated O +
Nestin O -
- O -
Bmi-1-GFP O +
transgenic O +
mice O -
. O +

Analysis O +
of O +
two O +
independent O +
lines O +
with O +
expression O +
in O +
the O +
fetal O +
and O +
adult O +
CNS O +
demonstrated O +
that O +
transgenic O +
neural O +
stem O +
cells O +
formed O +
larger O +
colonies O -
, O +
more O +
self O -
- O -
renewing O +
divisions O -
, O +
and O +
more O +
neurons O +
in O +
culture O -
. O +

However O -
, O +
in O +
vivo O -
, O +
Bmi-1 O +
over O -
- O -
expression O +
had O +
little O +
effect O +
on O +
CNS O +
stem O +
cell O +
frequency O -
, O +
subventricular O +
zone O +
proliferation O -
, O +
olfactory O +
bulb O +
neurogenesis O -
, O +
or O +
neurogenesis O -
/ O -
gliogenesis O +
during O +
development O -
. O +

Bmi-1 O +
transgenic O +
mice O +
were O +
born O +
with O +
enlarged O +
lateral O +
ventricles O +
and O +
a O +
minority O +
developed O +
idiopathic O +
hydrocephalus O +
as O +
adults O -
, O +
but O +
none O +
of O +
the O +
transgenic O +
mice O +
formed O +
detectable O +
CNS O +
tumors O -
, O +
even O +
when O +
aged O -
. O +

The O +
more O +
pronounced O +
effects O +
of O +
Bmi-1 O +
over O -
- O -
expression O +
in O +
culture O +
were O +
largely O +
attributable O +
to O +
the O +
attenuated O +
induction O +
of O +
p16 O -
( O -
Ink4a O -
) O +
and O +
p19 O -
( O -
Arf O -
) O +
in O +
culture O -
, O +
proteins O +
that O +
are O +
generally O +
not O +
expressed O +
by O +
neural O +
stem O -
/ O -
progenitor O +
cells O +
in O +
young O +
mice O +
in O +
vivo O -
. O +

Bmi-1 O +
over O -
- O -
expression O +
therefore O +
has O +
more O +
pronounced O +
effects O +
in O +
culture O +
and O +
does O +
not O +
appear O +
to O +
be O +
sufficient O +
to O +
induce O +
tumorigenesis O +
in O +
vivo O -
. O +

AngiomiRs O -
-- O -
key O +
regulators O +
of O +
angiogenesis O -
. O +

The O +
formation O +
of O +
new O +
blood O +
vessels O +
through O +
the O +
process O +
of O +
angiogenesis O +
is O +
critical O +
in O +
vascular O +
development O +
and O +
homeostasis O -
. O +

Aberrant O +
angiogenesis O +
leads O +
to O +
a O +
variety O +
of O +
diseases O -
, O +
such O +
as O +
ischemia O +
and O +
cancer O -
. O +

Recent O +
studies O +
have O +
revealed O +
important O +
roles O +
for O +
miRNAs O +
in O +
regulating O +
endothelial O +
cell O +
( O -
EC O -
) O +
function O -
, O +
especially O +
angiogenesis O -
. O +

Mice O +
with O +
EC O -
- O -
specific O +
deletion O +
of O +
Dicer O -
, O +
a O +
key O +
enzyme O +
for O +
generating O +
miRNAs O -
, O +
display O +
defective O +
postnatal O +
angiogenesis O -
. O +

Specific O +
miRNAs O +
( O -
angiomiRs O -
) O +
have O +
recently O +
been O +
shown O +
to O +
regulate O +
angiogenesis O +
in O +
vivo O -
. O +

miRNA-126 O -
, O +
an O +
EC O -
- O -
restricted O +
miRNA O -
, O +
regulates O +
vascular O +
integrity O +
and O +
developmental O +
angiogenesis O -
. O +

miR-378 O -
, O +
miR-296 O -
, O +
and O +
the O +
miR-17 O -
- O -
92 O +
cluster O +
contribute O +
to O +
tumor O +
angiogenesis O -
. O +

Manipulating O +
angiomiRs O +
in O +
the O +
settings O +
of O +
pathological O +
vascularization O +
represents O +
a O +
new O +
therapeutic O +
approach O -
. O +

The O +
modulation O +
of O +
platelet O +
and O +
endothelial O +
cell O +
adhesion O +
to O +
vascular O +
graft O +
materials O +
by O +
perlecan O -
. O +

Controlled O +
neo O -
- O -
endothelialisation O +
is O +
critical O +
to O +
the O +
patency O +
of O +
small O +
diameter O +
vascular O +
grafts O -
. O +

Endothelialisation O +
and O +
platelet O +
adhesion O +
to O +
purified O +
endothelial O +
cell O -
- O -
derived O +
perlecan O -
, O +
the O +
major O +
heparan O +
sulfate O +
( O -
HS O -
) O +
proteoglycan O +
in O +
basement O +
membranes O -
, O +
were O +
investigated O +
using O +
in O +
vivo O +
and O +
in O +
vitro O +
assays O -
. O +

Expanded O +
polytetrafluoroethylene B-Chemical +
( O -
ePTFE O -
) O +
vascular O +
grafts O +
were O +
coated O +
with O +
perlecan O +
and O +
tested O +
in O +
an O +
ovine O +
carotid O +
interposition O +
model O +
for O +
a O +
period O +
of O +
6 O +
weeks O +
and O +
assessed O +
using O +
light O +
and O +
scanning O +
microscopy O -
. O +

Enhanced O +
endothelial O +
cell O +
growth O +
and O +
reduced O +
platelet O +
adhesion O +
were O +
observed O +
on O +
the O +
perlecan O +
coated O +
grafts O +
when O +
compared O +
to O +
uncoated O +
controls O +
implanted O +
in O +
the O +
same O +
sheep O +
( O -
n=5 O -
) O -
. O +

Perlecan O +
was O +
also O +
found O +
to O +
stimulate O +
endothelial O +
cell O +
proliferation O +
in O +
vitro O +
over O +
a O +
period O +
of O +
6 O +
days O +
in O +
the O +
presence O +
of O +
plasma O +
proteins O +
and O +
fibroblastic O +
growth O +
factor O +
2 O +
( O -
FGF-2 O -
) O -
, O +
however O +
in O +
the O +
absence O +
of O +
FGF-2 O +
endothelial O +
cell O +
growth O +
could O +
not O +
be O +
maintained O +
during O +
this O +
period O -
. O +

Perlecan O +
was O +
found O +
to O +
be O +
anti O -
- O -
adhesive O +
for O +
platelets O -
, O +
however O +
after O +
removal O +
of O +
the O +
HS O +
chains O +
attached O +
to O +
perlecan O -
, O +
platelet O +
adhesion O +
and O +
aggregation O +
were O +
supported O -
. O +

These O +
results O +
suggest O +
a O +
role O +
for O +
HS O +
chains O +
of O +
perlecan O +
in O +
improving O +
graft O +
patency O +
by O +
selectively O +
promoting O +
endothelial O +
cell O +
proliferation O +
while O +
modulating O +
platelet O +
adhesion O -
. O +

Angiogenesis O +
in O +
platelet O +
endothelial O +
cell O +
adhesion O +
molecule-1-null O +
mice O -
. O +

Platelet O +
endothelial O +
cell O +
adhesion O +
molecule O +
( O -
PECAM O -
) O -
-1 O +
has O +
been O +
previously O +
implicated O +
in O +
endothelial O +
cell O +
migration O -
; O +
additionally O -
, O +
anti O -
- O -
PECAM-1 O +
antibodies O +
have O +
been O +
shown O +
to O +
inhibit O +
in O +
vivo O +
angiogenesis O -
. O +

Studies O +
were O +
therefore O +
performed O +
with O +
PECAM-1-null O +
mice O +
to O +
further O +
define O +
the O +
involvement O +
of O +
PECAM-1 O +
in O +
blood O +
vessel O +
formation O -
. O +

Vascularization O +
of O +
subcutaneous O +
Matrigel O +
implants O +
as O +
well O +
as O +
tumor O +
angiogenesis O +
were O +
both O +
inhibited O +
in O +
PECAM-1-null O +
mice O -
. O +

Reciprocal O +
bone O +
marrow O +
transplants O +
that O +
involved O +
both O +
wild O -
- O -
type O +
and O +
PECAM-1-deficient O +
mice O +
revealed O +
that O +
the O +
impaired O +
angiogenic O +
response O +
resulted O +
from O +
a O +
loss O +
of O +
endothelial O -
, O +
but O +
not O +
leukocyte O -
, O +
PECAM-1 O -
. O +

In O +
vitro O +
wound O +
migration O +
and O +
single O -
- O -
cell O +
motility O +
by O +
PECAM-1-null O +
endothelial O +
cells O +
were O +
also O +
compromised O -
. O +

In O +
addition O -
, O +
filopodia O +
formation O -
, O +
a O +
feature O +
of O +
motile O +
cells O -
, O +
was O +
inhibited O +
in O +
PECAM-1-null O +
endothelial O +
cells O +
as O +
well O +
as O +
in O +
human O +
endothelial O +
cells O +
treated O +
with O +
either O +
anti O -
- O -
PECAM-1 O +
antibody O +
or O +
PECAM-1 O +
siRNA O -
. O +

Furthermore O -
, O +
the O +
expression O +
of O +
PECAM-1 O +
promoted O +
filopodia O +
formation O +
and O +
increased O +
the O +
protein O +
expression O +
levels O +
of O +
Cdc42 O -
, O +
a O +
Rho O +
GTPase O +
that O +
is O +
known O +
to O +
promote O +
the O +
formation O +
of O +
filopodia O -
. O +

In O +
the O +
developing O +
retinal O +
vasculature O -
, O +
numerous O -
, O +
long O +
filamentous O +
filopodia O -
, O +
emanating O +
from O +
endothelial O +
cells O +
at O +
the O +
tips O +
of O +
angiogenic O +
sprouts O -
, O +
were O +
observed O +
in O +
wild O -
- O -
type O +
animals O -
, O +
but O +
to O +
a O +
lesser O +
extent O +
in O +
the O +
PECAM-1-null O +
mice O -
. O +

Together O -
, O +
these O +
data O +
further O +
establish O +
the O +
involvement O +
of O +
endothelial O +
PECAM-1 O +
in O +
angiogenesis O +
and O +
suggest O +
that O -
, O +
in O +
vivo O -
, O +
PECAM-1 O +
may O +
stimulate O +
endothelial O +
cell O +
motility O +
by O +
promoting O +
the O +
formation O +
of O +
filopodia O -
. O +

Desipramine B-Chemical +
inhibits O +
the O +
growth O +
of O +
a O +
mouse O +
skin O +
squamous O +
cell O +
carcinoma O +
cell O +
line O +
and O +
affects O +
glucocorticoid O +
receptor O -
- O -
mediated O +
transcription O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
examine O +
the O +
effect O +
of O +
tricyclic O +
antidepressant O +
desipramine B-Chemical +
( O -
DMI B-Chemical -
) O +
on O +
the O +
growth O +
inhibition O +
and O +
translocation O +
of O +
the O +
glucocorticoid O +
receptor O +
( O -
GR O -
) O +
from O +
the O +
cytoplasm O +
to O +
the O +
nucleus O +
in O +
cancerous O +
and O +
noncancerous O +
cell O +
lines O +
and O +
the O +
effect O +
of O +
DMI B-Chemical +
on O +
GR O -
- O -
mediated O +
transcription O -
. O +

Nontumorigenic O -
, O +
immortalized O +
keratinocytes O +
cell O +
line O +
( O -
3PC O -
) O -
, O +
papilloma O +
( O -
MT1 O -
/ O -
2 O -
) O -
, O +
and O +
squamous O +
cell O +
carcinoma O +
( O -
Ca3 O -
/ O -
7 O -
) O +
cell O +
lines O +
were O +
initially O +
used O +
to O +
study O +
the O +
cell O +
growth O +
inhibition O +
by O +
DMI B-Chemical -
. O +

Although O -
, O +
the O +
growth O +
of O +
all O +
three O +
cell O +
lines O +
was O +
suppressed O +
by O +
DMI B-Chemical -
, O +
it O +
was O +
more O +
effective O +
in O +
Ca3 O -
/ O -
7 O +
cells O -
. O +

Therefore O -
, O +
we O +
next O +
examined O +
the O +
effect O +
of O +
DMI B-Chemical +
on O +
Ca3 O -
/ O -
7 O +
cells O -
, O +
resistant O +
to O +
growth O +
inhibition O +
by O +
the O +
synthetic O +
glucocorticoid B-Chemical +
fluocinolone I-Chemical +
acetonide I-Chemical +
( O -
FA B-Chemical -
) O -
. O +

DMI B-Chemical +
inhibited O +
cell O +
proliferation O +
in O +
a O +
time O -
- O -
dependent O +
manner O -
. O +

The O +
translocation O +
of O +
GR O +
was O +
induced O +
by O +
FA B-Chemical +
alone O -
, O +
DMI B-Chemical +
alone O -
, O +
and O +
combination O +
of O +
both O +
agents O -
. O +

FA B-Chemical +
induced O +
GR O -
- O -
mediated O +
transcription O +
in O +
Ca3 O -
/ O -
7 O +
cells O +
transfected O +
with O +
a O +
luciferase O +
reporter O +
gene O +
under O +
the O +
control O +
of O +
glucocorticoid O +
response O +
element O +
( O -
GRE O -
) O -
, O +
but O +
DMI B-Chemical +
alone O +
did O +
not O +
affect O +
GR O -
- O -
mediated O +
transcription O -
. O +

However O -
, O +
DMI B-Chemical +
inhibited O +
FA B-Chemical -
- O -
induced O -
, O +
GR O -
- O -
mediated O +
transcription O +
when O +
both O +
agents O +
were O +
given O +
together O -
. O +

Pretreatment O +
with O +
DMI B-Chemical +
followed O +
by O +
combination O +
of O +
DMI B-Chemical +
and O +
FA B-Chemical +
decreased O +
GR O -
- O -
mediated O +
transcription O +
more O +
than O +
pretreatment O +
with O +
FA B-Chemical -
. O +

The O +
expression O +
of O +
metallothionein-1 O +
( O -
Mt-1 O -
) O +
gene O -
, O +
which O +
is O +
regulated O +
by O +
GR O -
, O +
was O +
induced O +
significantly O +
by O +
the O +
combination O +
of O +
DMI B-Chemical +
and O +
FA B-Chemical -
, O +
and O +
enhanced O +
significantly O +
by O +
pretreatment O +
with O +
FA B-Chemical +
but O +
not O +
DMI B-Chemical -
. O +

DMI B-Chemical +
is O +
suggested O +
to O +
inhibit O +
the O +
growth O +
of O +
Ca3 O -
/ O -
7 O +
cells O +
and O +
to O +
affect O +
GR O -
- O -
mediated O +
transcription O -
. O +

c O -
- O -
Ski O +
overexpression O +
promotes O +
tumor O +
growth O +
and O +
angiogenesis O +
through O +
inhibition O +
of O +
transforming O +
growth O +
factor O -
- O -
beta O +
signaling O +
in O +
diffuse O -
- O -
type O +
gastric O +
carcinoma O -
. O +

c O -
- O -
Ski O -
, O +
originally O +
identified O +
as O +
a O +
proto O -
- O -
oncogene O +
product O -
, O +
is O +
an O +
important O +
negative O +
regulator O +
of O +
transforming O +
growth O +
factor O +
( O -
TGF O -
) O -
-beta O +
family O +
signaling O +
through O +
interaction O +
with O +
Smad2 O -
, O +
Smad3 O -
, O +
and O +
Smad4 O -
. O +

High O +
expression O +
of O +
c O -
- O -
Ski O +
has O +
been O +
found O +
in O +
some O +
cancers O -
, O +
including O +
gastric O +
cancer O -
. O +

We O +
previously O +
showed O +
that O +
disruption O +
of O +
TGF O -
- O -
beta O +
signaling O +
by O +
dominant O -
- O -
negative O +
TGF O -
- O -
beta O +
type O +
II O +
receptor O +
in O +
a O +
diffuse O -
- O -
type O +
gastric O +
carcinoma O +
model O +
accelerated O +
tumor O +
growth O +
through O +
induction O +
of O +
tumor O +
angiogenesis O +
by O +
decreased O +
expression O +
of O +
the O +
anti O -
- O -
angiogenic O +
factor O +
thrombospondin O +
( O -
TSP O -
) O -
-1 O -
. O +

Here O -
, O +
we O +
examined O +
the O +
function O +
of O +
c O -
- O -
Ski O +
in O +
human O +
diffuse O -
- O -
type O +
gastric O +
carcinoma O +
OCUM-2MLN O +
cells O -
. O +

Overexpression O +
of O +
c O -
- O -
Ski O +
inhibited O +
TGF O -
- O -
beta O +
signaling O +
in O +
OCUM-2MLN O +
cells O -
. O +

Interestingly O -
, O +
c O -
- O -
Ski O +
overexpression O +
resulted O +
in O +
extensive O +
acceleration O +
of O +
the O +
growth O +
of O +
subcutaneous O +
xenografts O +
in O +
BALB O -
/ O -
c O +
nu O -
/ O -
nu O +
female O +
mice O +
( O -
6 O +
weeks O +
of O +
age O -
) O -
. O +

Similar O +
to O +
tumors O +
expressing O +
dominant O -
- O -
negative O +
TGF O -
- O -
beta O +
type O +
II O +
receptor O -
, O +
histochemical O +
studies O +
revealed O +
less O +
fibrosis O +
and O +
increased O +
angiogenesis O +
in O +
xenografted O +
tumors O +
expressing O +
c O -
- O -
Ski O +
compared O +
to O +
control O +
tumors O -
. O +

Induction O +
of O +
TSP-1 O +
mRNA O +
by O +
TGF O -
- O -
beta O +
was O +
attenuated O +
by O +
c O -
- O -
Ski O +
in O +
vitro O -
, O +
and O +
expression O +
of O +
TSP-1 O +
mRNA O +
was O +
decreased O +
in O +
tumors O +
expressing O +
c O -
- O -
Ski O +
in O +
vivo O -
. O +

These O +
findings O +
suggest O +
that O +
c O -
- O -
Ski O +
overexpression O +
promotes O +
the O +
growth O +
of O +
diffuse O -
- O -
type O +
gastric O +
carcinoma O +
through O +
induction O +
of O +
angiogenesis O -
. O +

EPOX B-Chemical +
inhibits O +
angiogenesis O +
by O +
degradation O +
of O +
Mcl-1 O +
through O +
ERK O +
inactivation O -
. O +

PURPOSE O -
: O +
Antiangiogenic O +
therapy O +
is O +
considered O +
as O +
an O +
effective O +
strategy O +
for O +
controlling O +
the O +
growth O +
and O +
metastasis O +
of O +
tumors O -
. O +

Among O +
a O +
myriad O +
of O +
biological O +
activities O +
described O +
for O +
xanthone B-Chemical +
derivatives I-Chemical -
, O +
the O +
anticancer O +
activity O +
is O +
quite O +
remarkable O -
, O +
but O +
the O +
molecular O +
mechanism O +
is O +
not O +
clearly O +
resolved O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
investigated O +
the O +
antiangiogenic O +
mechanism O +
of O +
3,6-di B-Chemical -
( I-Chemical -
2,3-epoxypropoxy I-Chemical -
) I-Chemical -
xanthone I-Chemical +
( O -
EPOX B-Chemical -
) O -
, O +
a O +
novel O +
Mcl-1 O +
targeting O +
drug O -
. O +

EXPERIMENTAL O +
DESIGN O -
: O +
To O +
evaluate O +
the O +
antiangiogenic O +
activity O +
of O +
EPOX B-Chemical -
, O +
we O +
did O +
cell O +
viability O -
, O +
cell O +
cycle O -
, O +
tube O +
formation O +
assay O +
in O +
vitro O -
, O +
and O +
Matrigel O +
plug O +
assay O +
in O +
vivo O -
. O +

To O +
evaluate O +
the O +
effect O +
of O +
EPOX B-Chemical +
on O +
the O +
endothelial O +
signaling O +
pathway O -
, O +
we O +
did O +
immunoblotting O -
, O +
immunoprecipitation O -
, O +
and O +
immunofluorescence O +
analysis O -
. O +

Intracellular O +
glutathione B-Chemical +
levels O +
were O +
determined O +
with O +
the O +
use O +
of O +
monochlorobimane B-Chemical -
, O +
a O +
glutathione B-Chemical -
- O -
specific O +
probe O -
. O +

RESULTS O -
: O +
EPOX B-Chemical +
induced O +
endothelial O +
cell O +
apoptosis O +
in O +
association O +
with O +
proteasome O -
- O -
dependent O +
Mcl-1 O +
degradation O -
. O +

Down O -
- O -
regulation O +
of O +
Mcl-1 O +
resulted O +
in O +
an O +
increase O +
in O +
Mcl-1-free O +
Bim O -
, O +
activation O +
of O +
Bax O -
, O +
and O +
then O +
signaling O +
of O +
mitochondria O -
- O -
mediated O +
apoptosis O -
. O +

Additionally O -
, O +
glutathione B-Chemical +
depletion O +
and O +
extracellular O +
signal O -
- O -
regulated O +
kinase O +
( O -
ERK O -
) O +
inactivation O +
was O +
observed O +
in O +
EPOX B-Chemical -
- O -
treated O +
cells O -
. O +

Glutathione B-Chemical +
supplementation O +
reversed O +
the O +
inhibitory O +
effects O +
of O +
EPOX B-Chemical +
on O +
ERK O -
, O +
which O +
increases O +
the O +
phosphorylation O +
of O +
Mcl-1 O +
at O +
T O -
( O -
163 O -
. O -
) O +

Overexpression O +
of O +
mitogen O -
- O -
activated O +
protein O -
/ O -
ERK O +
kinase O +
( O -
MEK O -
) O +
partially O +
reversed O +
the O +
effect O +
of O +
EPOX B-Chemical +
on O +
Mcl-1 O +
dephosphorylation O -
, O +
ubiquitination O -
, O +
and O +
degradation O -
, O +
further O +
implicating O +
ERK O +
in O +
the O +
regulation O +
of O +
Mcl-1 O +
stability O -
. O +

CONCLUSIONS O -
: O +
This O +
study O +
provides O +
evidence O +
that O +
EPOX B-Chemical +
induces O +
glutathione B-Chemical +
depletion O -
, O +
ERK O +
inactivation O -
, O +
and O +
Mcl-1 O +
degradation O +
on O +
endothelial O +
cells O -
, O +
which O +
leads O +
to O +
inhibition O +
of O +
angiogenesis O -
. O +

Our O +
results O +
suggest O +
that O +
EPOX B-Chemical +
is O +
a O +
novel O +
antiangiogenic O +
agent O -
, O +
making O +
it O +
a O +
promising O +
lead O +
compound O +
for O +
further O +
development O +
in O +
the O +
treatment O +
of O +
angiogenesis O -
- O -
related O +
pathologies O -
. O +

Nicked O +
{ O -
beta O -
} O -
2-glycoprotein O +
I O +
binds O +
angiostatin O +
4.5 O +
( O -
plasminogen O +
kringle O +
1 O -
- O -
5 O -
) O +
and O +
attenuates O +
its O +
antiangiogenic O +
property O -
. O +

Angiostatin O +
was O +
first O +
discovered O +
as O +
a O +
plasminogen O +
fragment O +
with O +
antitumor O -
/ O -
antiangiogenic O +
property O -
. O +

One O +
of O +
the O +
angiostatin O +
isoforms O -
, O +
that O +
is O -
, O +
angiostatin O +
4.5 O +
( O -
AS4.5 O -
) O -
, O +
consisting O +
of O +
plasminogen O +
kringle O +
1 O +
to O +
4 O +
and O +
a O +
most O +
part O +
of O +
kringle O +
5 O -
, O +
is O +
produced O +
by O +
autoproteolysis O +
and O +
present O +
in O +
human O +
plasma O -
. O +

beta2-glycoprotein O +
I O +
( O -
beta2GPI O -
) O +
is O +
proteolytically O +
cleaved O +
by O +
plasmin O +
in O +
its O +
domain O +
V O +
( O -
nicked O +
beta2GPI O -
) O -
, O +
resulting O +
in O +
binding O +
to O +
plasminogen O -
. O +

Antiangiogenic O +
properties O +
have O +
been O +
recently O +
reported O +
in O +
nicked O +
beta2GPI O +
as O +
well O +
as O +
in O +
intact O +
beta2GPI O +
at O +
higher O +
concentrations O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
found O +
significant O +
binding O +
of O +
nicked O +
beta2GPI O +
to O +
AS4.5 O +
( O -
K O -
( O -
D O -
) O +
= O +
3.27 O +
x O +
10 O -
( O -
6 O -
) O +
M O -
( O -
-1 O -
) O -
) O -
. O +

Via O +
this O +
binding O -
, O +
nicked O +
beta2GPI O +
attenuates O +
the O +
antiangiogenic O +
functions O +
of O +
AS4.5 O +
in O +
the O +
proliferation O +
of O +
arterial O -
/ O -
venous O +
endothelial O +
cells O -
, O +
in O +
the O +
extracellular O +
matrix O +
invasion O +
and O +
the O +
tube O +
formation O +
of O +
venous O +
endothelial O +
cells O -
, O +
and O +
in O +
vivo O +
angiogenesis O -
. O +

In O +
contrast O -
, O +
intact O +
beta2GPI O +
does O +
not O +
bind O +
to O +
AS4.5 O +
or O +
inhibit O +
its O +
antiangiogenic O +
activity O -
. O +

Thus O -
, O +
nicked O +
beta2GPI O +
exerts O +
dual O +
effects O +
on O +
angiogenesis O -
, O +
that O +
is O -
, O +
nicked O +
beta2GPI O +
promotes O +
angiogenesis O +
in O +
the O +
presence O +
of O +
AS4.5 O -
, O +
whereas O +
nicked O +
beta2GPI O +
inhibits O +
angiogenesis O +
at O +
concentrations O +
high O +
enough O +
to O +
neutralize O +
AS4.5 O -
. O +

Our O +
data O +
suggest O +
that O +
plasmin O -
- O -
nicked O +
beta2GPI O +
promotes O +
angiogenesis O +
by O +
interacting O +
with O +
plasmin O -
- O -
generated O +
AS4.5 O +
in O +
sites O +
of O +
increased O +
fibrinolysis O +
such O +
as O +
thrombus O -
. O +

Use O +
of O +
uteroglobin O +
for O +
the O +
engineering O +
of O +
polyvalent O -
, O +
polyspecific O +
fusion O +
proteins O -
. O +

We O +
report O +
a O +
novel O +
strategy O +
to O +
engineer O +
and O +
express O +
stable O +
and O +
soluble O +
human O +
recombinant O +
polyvalent O -
/ O -
polyspecific O +
fusion O +
proteins O -
. O +

The O +
procedure O +
is O +
based O +
on O +
the O +
use O +
of O +
a O +
central O +
skeleton O +
of O +
uteroglobin O -
, O +
a O +
small O +
and O +
very O +
soluble O +
covalently O +
linked O +
homodimeric O +
protein O +
that O +
is O +
very O +
resistant O +
to O +
proteolytic O +
enzymes O +
and O +
to O +
pH O +
variations O -
. O +

Using O +
a O +
human O +
recombinant O +
antibody O +
( O -
scFv O -
) O +
specific O +
for O +
the O +
angiogenesis O +
marker O +
domain O +
B O +
of O +
fibronectin O -
, O +
interleukin O +
2 O -
, O +
and O +
an O +
scFv O +
able O +
to O +
neutralize O +
tumor O +
necrosis O +
factor O -
- O -
alpha O -
, O +
we O +
expressed O +
various O +
biologically O +
active O +
uteroglobin O +
fusion O +
proteins O -
. O +

The O +
results O +
demonstrate O +
the O +
possibility O +
to O +
generate O +
monospecific O +
divalent O +
and O +
tetravalent O +
antibodies O -
, O +
immunocytokines O -
, O +
and O +
dual O +
specificity O +
tetravalent O +
antibodies O -
. O +

Furthermore O -
, O +
compared O +
with O +
similar O +
fusion O +
proteins O +
in O +
which O +
uteroglobin O +
was O +
not O +
used O -
, O +
the O +
use O +
of O +
uteroglobin O +
improved O +
properties O +
of O +
solubility O +
and O +
stability O -
. O +

Indeed O -
, O +
in O +
the O +
reported O +
cases O +
it O +
was O +
possible O +
to O +
vacuum O +
dry O +
and O +
reconstitute O +
the O +
proteins O +
without O +
any O +
aggregation O +
or O +
loss O +
in O +
protein O +
and O +
biological O +
activity O -
. O +

Targeting O +
angiogenesis O -
: O +
progress O +
with O +
anti O -
- O -
VEGF O +
treatment O +
with O +
large O +
molecules O -
. O +

Angiogenesis O -
-- O -
one O +
of O +
the O +
hallmarks O +
of O +
cancer O -
-- O -
has O +
emerged O +
as O +
a O +
valid O +
therapeutic O +
target O +
in O +
oncology O -
. O +

The O +
VEGF O +
system O +
represents O +
a O +
key O +
mediator O +
of O +
tumor O -
- O -
initiated O +
angiogenesis O +
and O +
the O +
first O +
target O +
of O +
antiangiogenesis O +
agents O +
introduced O +
in O +
clinical O +
practice O -
. O +

Although O +
anti O -
- O -
VEGF O +
therapies O +
have O +
clearly O +
demonstrated O +
antitumor O +
efficacy O +
in O +
various O +
malignancies O -
, O +
especially O +
when O +
combined O +
with O +
conventional O +
cytotoxic O +
chemotherapy O -
, O +
their O +
mechanism O +
of O +
action O +
is O +
not O +
fully O +
understood O -
. O +

This O +
Review O +
will O +
discuss O +
the O +
rationale O +
for O +
using O +
antiangiogenic O +
compounds O +
and O +
will O +
focus O +
on O +
large O +
molecules O -
, O +
such O +
as O +
antibodies O -
, O +
that O +
target O +
the O +
VEGF O +
system O -
. O +

Clinical O +
data O +
on O +
bevacizumab B-Chemical +
is O +
discussed O +
in O +
detail O -
. O +

Predictive O +
markers O +
for O +
anti O -
- O -
VEGF O +
agents O +
have O +
not O +
yet O +
been O +
identified O +
and O +
questions O +
regarding O +
the O +
usefulness O +
of O +
bevacizumab B-Chemical +
in O +
the O +
adjuvant O +
setting O +
as O +
well O +
as O +
its O +
continued O +
use O +
beyond O +
progression O +
remain O +
unanswered O -
, O +
in O +
spite O +
of O +
negative O +
data O +
on O +
bevacizumab B-Chemical +
in O +
treating O +
patients O +
with O +
adjuvant O +
colon O +
cancer O -
. O +

Nonetheless O -
, O +
anti O -
- O -
VEGF O +
therapy O +
has O +
enhanced O +
the O +
arsenal O +
of O +
anticancer O +
therapies O +
and O +
has O +
provided O +
new O +
insights O +
into O +
the O +
biology O +
of O +
malignancy O -
. O +

[ O -
An O +
experimental O +
study O +
on O +
angiogenesis O +
of O +
non O -
- O -
vascularized O +
autogenous O +
bone O +
graft O +
with O +
vascular O +
bundle O +
implantation O -
] O +
OBJECTIVE O -
: O +
To O +
investigate O +
the O +
effect O +
of O +
vascular O +
bundle O +
implantation O +
in O +
autogenous O +
bone O +
graft O +
on O +
angiogenesis O -
. O +

METHODS O -
: O +
Thirty O -
- O -
six O +
New O +
Zealand O +
white O +
rabbits O +
were O +
evaluated O +
in O +
this O +
study O -
. O +

A O +
portion O +
of O +
bilateral O +
radial O +
bones O +
of O +
a O +
rabbit O +
were O +
removed O +
as O +
free O +
bone O +
grafts O -
, O +
whose O +
periostea O +
were O +
peeled O +
off O -
. O +

In O +
test O +
group O -
, O +
the O +
external O +
maxillary O +
artery O +
bundle O +
was O +
passed O +
through O +
the O +
marrow O +
cavity O +
of O +
the O +
bone O -
. O +

In O +
control O +
group O -
, O +
there O +
was O +
no O +
vascular O +
bundle O +
implantation O -
. O +

Each O +
bone O +
was O +
placed O +
in O +
masseter O +
muscle O +
separately O -
. O +

The O +
rabbits O +
were O +
sacrificed O +
and O +
the O +
specimens O +
were O +
procured O +
at O +
3 O +
days O -
, O +
1 O -
, O +
2 O -
, O +
3 O -
, O +
4 O +
and O +
6 O +
weeks O +
after O +
surgery O +
for O +
histological O +
observation O -
, O +
Chinese O +
ink O +
perfusion O +
and O +
CD34 O +
immunohistochemistry O -
. O +

Microvessel O +
density O +
( O -
MVD O -
) O +
was O +
assessed O +
in O +
order O +
to O +
evaluate O +
angiogenesis O +
of O +
autogenous O +
bone O +
grafts O -
. O +

RESULTS O -
: O +
The O +
bone O +
grafts O +
were O +
found O +
revascularization O +
in O +
3 O +
days O +
after O +
surgery O +
in O +
the O +
test O +
group O -
, O +
whereas O +
at O +
2 O +
weeks O +
in O +
the O +
control O +
group O -
. O +

In O +
3 O +
days O -
, O +
1 O +
week O -
, O +
2 O +
weeks O -
, O +
3 O +
weeks O +
and O +
4 O +
weeks O +
after O +
surgery O -
, O +
the O +
MVD O +
of O +
test O +
group O +
was O +
significantly O +
higher O +
than O +
that O +
of O +
control O +
group O -
. O +

In O +
4 O +
weeks O +
after O +
surgery O -
, O +
angiogenesis O +
of O +
test O +
group O +
reached O +
to O +
peak O -
. O +

CONCLUSION O -
: O +
Vascular O +
bundle O +
implantation O +
improved O +
angiogenesis O +
in O +
non O -
- O -
vascularized O +
autogenous O +
bone O +
graft O +
in O +
this O +
study O -
. O +

[ O -
Ambiguity O +
role O +
of O +
neutrophils O +
in O +
oncogenesis O -
] O +
The O +
review O +
is O +
focused O +
on O +
the O +
participation O +
of O +
polymorphonuclear O +
granulocytes O +
( O -
neutrophils O -
) O +
in O +
development O +
and O +
spreading O +
of O +
a O +
tumor O -
. O +

We O +
consider O +
both O +
the O +
well O +
known O +
functions O +
of O +
neutrophils O +
( O -
degranulation O -
, O +
production O +
of O +
reactive B-Chemical +
oxygen I-Chemical +
species I-Chemical +
( O -
ROS B-Chemical -
) O -
) O +
and O +
the O +
recently O +
shown O +
one O +
( O -
presentation O +
of O +
an O +
antigene O -
) O -
. O +

The O +
special O +
attention O +
is O +
focused O +
on O +
the O +
ambiguity O +
of O +
the O +
neutrophil O +
role O +
in O +
oncogenesis O -
. O +

The O +
dominant O +
view O +
is O +
that O +
neutrophils O +
display O +
exclusively O +
antitumor O +
properties O -
. O +

The O +
update O +
information O +
testifies O +
about O +
protumoral O +
activity O +
of O +
neutrophils O -
: O +
they O +
migrate O +
to O +
a O +
tumor O +
and O +
promote O +
angiogenesis O +
and O +
metastasis O +
at O +
late O +
stages O +
of O +
the O +
tumor O -
. O +

It O +
is O +
interesting O +
that O +
certain O +
components O +
of O +
neutrophil O +
cytotoxic O +
arsenal O +
( O -
ROS B-Chemical -
, O +
cytokines O -
, O +
specific O +
enzymes O -
) O +
participate O +
both O +
in O +
antitumoral O +
defenses O +
of O +
an O +
organism O +
and O +
protumoral O +
activity O -
. O +

Targeting O +
glucose B-Chemical +
consumption O +
and O +
autophagy O +
in O +
myeloma O +
with O +
the O +
novel O +
nucleoside B-Chemical +
analogue I-Chemical +
8-aminoadenosine I-Chemical -
. O +

Multiple O +
myeloma O -
, O +
an O +
incurable O +
plasma O +
cell O +
malignancy O -
, O +
is O +
characterized O +
by O +
altered O +
cellular O +
metabolism O +
and O +
resistance O +
to O +
apoptosis O -
. O +

Recent O +
connections O +
between O +
glucose B-Chemical +
metabolism O +
and O +
resistance O +
to O +
apoptosis O +
provide O +
a O +
compelling O +
rationale O +
for O +
targeting O +
metabolic O +
changes O +
in O +
cancer O -
. O +

In O +
this O +
study O -
, O +
we O +
have O +
examined O +
the O +
ability O +
of O +
the O +
purine B-Chemical +
analogue I-Chemical +
8-aminoadenosine I-Chemical +
to O +
acutely O +
reduce O +
glucose B-Chemical +
consumption O +
by O +
regulating O +
localization O +
and O +
expression O +
of O +
key O +
glucose O +
transporters O -
. O +

Myeloma O +
cells O +
counteracted O +
the O +
metabolic O +
stress O +
by O +
activating O +
autophagy O -
. O +

Co O -
- O -
treatment O +
with O +
inhibitors O +
of O +
autophagy O +
results O +
in O +
marked O +
enhancement O +
of O +
cell O +
death O -
. O +

Glucose B-Chemical +
consumption O +
by O +
drug O -
- O -
resistant O +
myeloma O +
cells O +
was O +
unaffected O +
by O +
8-aminoadenosine B-Chemical -
, O +
and O +
accordingly O -
, O +
no O +
activation O +
of O +
autophagy O +
was O +
observed O -
. O +

However O -
, O +
these O +
cells O +
can O +
be O +
sensitized O +
to O +
8-aminoadenosine B-Chemical +
under O +
glucose B-Chemical -
- O -
limiting O +
conditions O -
. O +

The O +
prosurvival O +
autophagic O +
response O +
of O +
myeloma O +
to O +
nutrient O +
deprivation O +
or O +
to O +
nucleoside B-Chemical +
analogue I-Chemical +
treatment O +
has O +
not O +
been O +
described O +
previously O -
. O +

This O +
study O +
establishes O +
the O +
potential O +
of O +
metabolic O +
targeting O +
as O +
a O +
broader O +
means O +
to O +
kill O +
and O +
sensitize O +
myeloma O +
and O +
identifies O +
a O +
compound O +
that O +
can O +
achieve O +
this O +
goal O -
. O +

Endothelial O +
cell O +
migration O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
expression O +
are O +
the O +
result O +
of O +
loss O +
of O +
breast O +
tissue O +
polarity O -
. O +

Recruiting O +
a O +
new O +
blood O +
supply O +
is O +
a O +
rate O -
- O -
limiting O +
step O +
in O +
tumor O +
progression O -
. O +

In O +
a O +
three O -
- O -
dimensional O +
model O +
of O +
breast O +
carcinogenesis O -
, O +
disorganized O -
, O +
proliferative O +
transformed O +
breast O +
epithelial O +
cells O +
express O +
significantly O +
higher O +
expression O +
of O +
angiogenic O +
genes O +
compared O +
with O +
their O +
polarized O -
, O +
growth O -
- O -
arrested O +
nonmalignant O +
counterparts O -
. O +

Elevated O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
secretion O +
by O +
malignant O +
cells O +
enhanced O +
recruitment O +
of O +
endothelial O +
cells O +
( O -
EC O -
) O +
in O +
heterotypic O +
cocultures O -
. O +

Significantly O -
, O +
phenotypic O +
reversion O +
of O +
malignant O +
cells O +
via O +
reexpression O +
of O +
HoxD10 O -
, O +
which O +
is O +
lost O +
in O +
malignant O +
progression O -
, O +
significantly O +
attenuated O +
VEGF O +
expression O +
in O +
a O +
hypoxia O -
- O -
inducible O +
factor O +
1alpha O -
- O -
independent O +
fashion O +
and O +
reduced O +
EC O +
migration O -
. O +

This O +
was O +
due O +
primarily O +
to O +
restoring O +
polarity O -
: O +
forced O +
proliferation O +
of O +
polarized O -
, O +
nonmalignant O +
cells O +
did O +
not O +
induce O +
VEGF O +
expression O +
and O +
EC O +
recruitment O -
, O +
whereas O +
disrupting O +
the O +
architecture O +
of O +
growth O -
- O -
arrested O -
, O +
reverted O +
cells O +
did O -
. O +

These O +
data O +
show O +
that O +
disrupting O +
cytostructure O +
activates O +
the O +
angiogenic O +
switch O +
even O +
in O +
the O +
absence O +
of O +
proliferation O +
and/or O +
hypoxia O +
and O +
restoring O +
organization O +
of O +
malignant O +
clusters O +
reduces O +
VEGF O +
expression O +
and O +
EC O +
activation O +
to O +
levels O +
found O +
in O +
quiescent O +
nonmalignant O +
epithelium O -
. O +

These O +
data O +
confirm O +
the O +
importance O +
of O +
tissue O +
architecture O +
and O +
polarity O +
in O +
malignant O +
progression O -
. O +

Islet O +
endothelial O +
activation O +
and O +
oxidative O +
stress O +
gene O +
expression O +
is O +
reduced O +
by O +
IL-1Ra B-Chemical +
treatment O +
in O +
the O +
type O +
2 O +
diabetic O +
GK O +
rat O -
. O +

BACKGROUND O -
: O +
Inflammation O +
followed O +
by O +
fibrosis O +
is O +
a O +
component O +
of O +
islet O +
dysfunction O +
in O +
both O +
rodent O +
and O +
human O +
type O +
2 O +
diabetes O -
. O +

Because O +
islet O +
inflammation O +
may O +
originate O +
from O +
endothelial O +
cells O -
, O +
we O +
assessed O +
the O +
expression O +
of O +
selected O +
genes O +
involved O +
in O +
endothelial O +
cell O +
activation O +
in O +
islets O +
from O +
a O +
spontaneous O +
model O +
of O +
type O +
2 O +
diabetes O -
, O +
the O +
Goto O -
- O -
Kakizaki O +
( O -
GK O -
) O +
rat O -
. O +

We O +
also O +
examined O +
islet O +
endotheliuml O -
/ O -
oxidative O +
stress O +
( O -
OS O -
) O -
/ O -
inflammation O -
- O -
related O +
gene O +
expression O -
, O +
islet O +
vascularization O +
and O +
fibrosis O +
after O +
treatment O +
with O +
the O +
interleukin-1 B-Chemical +
( I-Chemical -
IL-1 I-Chemical -
) I-Chemical +
receptor I-Chemical +
antagonist I-Chemical +
( O -
IL-1Ra B-Chemical -
) O -
. O +

METHODOLOGY O -
/ O -
PRINCIPAL O +
FINDINGS O -
: O +
Gene O +
expression O +
was O +
analyzed O +
by O +
quantitative O +
RT O -
- O -
PCR O +
on O +
islets O +
isolated O +
from O +
10-week O -
- O -
old O +
diabetic O +
GK O +
and O +
control O +
Wistar O +
rats O -
. O +

Furthermore O -
, O +
GK O +
rats O +
were O +
treated O +
s.c O +
twice O +
daily O +
with O +
IL-1Ra B-Chemical +
( O -
Kineret B-Chemical -
, O +
Amgen O -
, O +
100 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O +
or O +
saline B-Chemical -
, O +
from O +
4 O +
weeks O +
of O +
age O +
onwards O +
( O -
onset O +
of O +
diabetes O -
) O -
. O +

Four O +
weeks O +
later O -
, O +
islet O +
gene O +
analysis O +
and O +
pancreas O +
immunochemistry O +
were O +
performed O -
. O +

Thirty O -
- O -
two O +
genes O +
were O +
selected O +
encoding O +
molecules O +
involved O +
in O +
endothelial O +
cell O +
activation O -
, O +
particularly O +
fibrinolysis O -
, O +
vascular O +
tone O -
, O +
OS O -
, O +
angiogenesis O +
and O +
also O +
inflammation O -
. O +

All O +
genes O +
except O +
those O +
encoding O +
angiotensinogen O +
and O +
epoxide O +
hydrolase O +
( O -
that O +
were O +
decreased O -
) O -
, O +
and O +
12-lipoxygenase O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
that O +
showed O +
no O +
change O -
) O -
, O +
were O +
significantly O +
up O -
- O -
regulated O +
in O +
GK O +
islets O -
. O +

After O +
IL-1Ra B-Chemical +
treatment O +
of O +
GK O +
rats O +
in O +
vivo O -
, O +
most O +
selected O +
genes O +
implied O +
in O +
endothelium O -
/ O -
OS O -
/ O -
immune O +
cells O -
/ O -
fibrosis O +
were O +
significantly O +
down O -
- O -
regulated O -
. O +

IL-1Ra B-Chemical +
also O +
improved O +
islet O +
vascularization O -
, O +
reduced O +
fibrosis O +
and O +
ameliorated O +
glycemia O -
. O +

CONCLUSIONS O -
/ O -
SIGNIFICANCE O -
: O +
GK O +
rat O +
islets O +
have O +
increased O +
mRNA O +
expression O +
of O +
markers O +
of O +
early O +
islet O +
endothelial O +
cell O +
activation O -
, O +
possibly O +
triggered O +
by O +
several O +
metabolic O +
factors O -
, O +
and O +
also O +
some O +
defense O +
mechanisms O -
. O +

The O +
beneficial O +
effect O +
of O +
IL-1Ra B-Chemical +
on O +
most O +
islet O +
endothelial O -
/ O -
OS O -
/ O -
immune O +
cells O -
/ O -
fibrosis O +
parameters O +
analyzed O +
highlights O +
a O +
major O +
endothelial O -
- O -
related O +
role O +
for O +
IL-1 O +
in O +
GK O +
islet O +
alterations O -
. O +

Thus O -
, O +
metabolically O -
- O -
altered O +
islet O +
endothelium O +
might O +
affect O +
the O +
beta O -
- O -
cell O +
microenvironment O +
and O +
contribute O +
to O +
progressive O +
type O +
2 O +
diabetic O +
beta O -
- O -
cell O +
dysfunction O +
in O +
GK O +
rats O -
. O +

Counteracting O +
islet O +
endothelial O +
cell O +
inflammation O +
might O +
be O +
one O +
way O +
to O +
ameliorate O -
/ O -
prevent O +
beta O -
- O -
cell O +
dysfunction O +
in O +
type O +
2 O +
diabetes O -
. O +

[ O -
Prognostic O +
significance O +
of O +
cellular O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
expression O +
in O +
the O +
course O +
of O +
chronic O +
myeloid O +
leukaemia O -
] O +
INTRODUCTION O -
: O +
Increased O +
angiogenesis O +
in O +
bone O +
marrow O +
is O +
one O +
of O +
the O +
characteristics O +
of O +
chronic O +
myeloid O +
leukaemia O +
( O -
CML O -
) O -
, O +
a O +
clonal O +
myeloproliferative O +
disorder O +
that O +
expresses O +
a O +
chimeric O +
bcr O -
/ O -
abl O +
protein O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
is O +
one O +
of O +
the O +
most O +
potent O +
and O +
a O +
specific O +
regulator O +
of O +
angiogenesis O +
which O +
principally O +
targets O +
endothelial O +
cells O +
and O +
regulates O +
several O +
of O +
their O +
functions O -
, O +
including O +
mitogenesis O -
, O +
permeability O +
and O +
migration O -
. O +

The O +
impact O +
of O +
elevated O +
VEGF O +
expression O +
on O +
the O +
course O +
of O +
chronic O +
myeloid O +
leukaemia O +
is O +
unknown O -
. O +

OBJECTIVE O -
: O +
The O +
aim O +
of O +
this O +
study O +
was O +
the O +
follow O -
- O -
up O +
of O +
VEGF O +
expression O +
during O +
the O +
course O +
of O +
CML O -
. O +

METHODS O -
: O +
We O +
studied O +
VEGF O +
expression O +
of O +
85 O +
CML O +
patients O +
( O -
median O +
age O +
50 O +
years O -
, O +
range O +
16 O -
- O -
75 O +
years O -
) O -
. O +

At O +
the O +
commencement O +
of O +
the O +
study O -
, O +
29 O +
patients O +
were O +
in O +
chronic O +
phase O +
( O -
CP O -
) O -
, O +
25 O +
in O +
an O +
accelerated O +
phase O +
( O -
AP O -
) O -
, O +
and O +
31 O +
in O +
the O +
blast O +
crisis O +
( O -
BC O -
) O -
. O +

The O +
temporal O +
expression O +
( O -
percentage O +
positivity O +
per O +
1000 O +
analysed O +
cells O -
) O +
VEGF O +
proteins O +
over O +
the O +
course O +
of O +
CML O +
were O +
studied O +
using O +
the O +
immunohistochemical O +
technique O +
utilizing O +
relevant O +
monoclonal O +
antibodies O -
. O +

It O +
was O +
correlated O +
with O +
the O +
laboratory O +
( O -
Hb O -
, O +
WBC O +
and O +
platelet O +
counts O -
, O +
and O +
the O +
percentage O +
of O +
blasts O -
) O +
and O +
clinical O +
parameters O +
( O -
organomegaly O -
, O +
duration O +
of O +
CP O -
, O +
AP O -
, O +
and O +
BC O -
) O +
of O +
disease O +
progression O -
. O +

RESULTS O -
: O +
The O +
expression O +
ofVEGF O +
protein O +
was O +
most O +
pronounced O +
in O +
AP O +
( O -
ANOVA O -
, O +
p=0.033 O -
) O -
. O +

The O +
level O +
of O +
VEGF O +
expression O +
correlated O +
inversely O +
with O +
the O +
degree O +
of O +
splenomegaly O +
( O -
Pearson O -
, O +
r=-0.400 O -
, O +
p=0.011 O -
) O -
. O +

High O +
expression O +
of O +
VEGF O +
correlated O +
with O +
a O +
shorter O +
overall O +
survival O +
( O -
log O +
rank O -
, O +
p=0.042 O -
) O -
. O +

CONCLUSION O -
: O +
Immunohistochemically O +
confirmed O +
significance O +
of O +
the O +
expression O +
of O +
VEGF O +
in O +
dependence O +
of O +
the O +
CML O +
stage O +
could O +
be O +
of O +
clinical O +
importance O +
in O +
deciding O +
on O +
the O +
timing O +
therapy O -
. O +

These O +
data O +
suggest O +
that O +
VEGF O +
plays O +
a O +
role O +
in O +
the O +
biology O +
of O +
CML O +
and O +
that O +
VEGF O +
inhibitors O +
should O +
be O +
investigated O +
in O +
CML O -
. O +

Inducible O +
nitric O +
oxide O +
synthase O +
modulates O +
angiogenesis O +
in O +
ischemic O +
hindlimb O +
of O +
rat O -
. O +

BACKGROUND O -
: O +
Angiogenesis O +
plays O +
an O +
important O +
role O +
in O +
maintaining O +
adequate O +
oxygen B-Chemical +
delivery O -
, O +
and O +
nitric B-Chemical +
oxide I-Chemical +
( O -
NO B-Chemical -
) O +
is O +
a O +
potential O +
regulator O +
of O +
angiogenesis O -
. O +

NO B-Chemical +
is O +
synthesized O +
through O +
three O +
isoforms O +
of O +
NO O +
synthase O +
( O -
NOS O -
) O -
. O +

It O +
is O +
hypothesized O +
that O +
the O +
NO B-Chemical +
derived O +
from O +
inducible O +
NOS O +
( O -
iNOS O -
) O +
may O +
promote O +
survival O +
of O +
ischemic O +
tissue O +
through O +
angiogenesis O -
. O +

To O +
test O +
this O +
hypothesis O -
, O +
we O +
investigated O +
the O +
effect O +
of O +
iNOS O +
deficiency O +
( O -
by O +
L B-Chemical -
- I-Chemical -
NIL I-Chemical -
) O +
on O +
angiogenesis O +
in O +
a O +
hindlimb O +
ischemia O +
model O -
. O +

METHODS O -
: O +
Thirty O -
- O -
two O +
male O +
wistar O +
rats O +
randomly O +
divided O +
into O +
four O +
groups O -
. O +

In O +
groups O +
1 O +
& O +
2 O -
, O +
hindlimb O +
ischemia O +
was O +
induced O +
by O +
ligation O +
of O +
femoral O +
artery O +
and O +
they O +
received O +
L B-Chemical -
- I-Chemical -
NIL I-Chemical +
and O +
saline B-Chemical +
respectively O -
. O +

The O +
animals O +
in O +
groups O +
3 O +
and O +
4 O +
also O +
received O +
L B-Chemical -
- I-Chemical -
NIL I-Chemical +
and O +
saline B-Chemical +
respectively O +
without O +
surgical O +
procedure O -
. O +

After O +
21 O +
days O -
, O +
the O +
serum O +
concentration O +
of O +
nitrite B-Chemical -
, O +
capillary O +
density O +
and O +
expression O +
of O +
HIF1alpha O +
were O +
determined O -
. O +

RESULTS O -
: O +
Serum O +
nitrite B-Chemical +
levels O +
were O +
significantly O +
lower O +
in O +
L B-Chemical -
- I-Chemical -
NIL I-Chemical +
groups O +
( O -
p<0.05 O -
) O -
. O +

The O +
capillary O +
density O +
in O +
group O +
1 O +
( O -
ischemia+L O -
- B-Chemical -
NIL I-Chemical -
) O +
was O +
significantly O +
different O +
from O +
group O +
2 O +
( O -
ischemia+saline O -
) O -
; O +
group O +
1 O -
: O +
360.33+ O -
/ O -
-77.02 O -
, O +
group O +
2 O -
: O +
549+ O -
/ O -
-81.85 O +
/mm2 O -
, O +
p<0.05 O -
) O +
.In O +
addition O -
, O +
expression O +
of O +
HIF1alpha O +
was O +
significantly O +
increased O +
in O +
ischemic O +
groups O +
( O -
p<0.05 O -
) O -
. O +

CONCLUSION O -
: O +
Selective O +
inhibition O +
of O +
iNOS O +
by O +
L B-Chemical -
- I-Chemical -
NIL I-Chemical +
inhibits O +
angiogenesis O +
in O +
a O +
hindlimb O +
ischemic O +
rat O +
model O -
. O +

In O +
addition O -
, O +
ischemia O +
induces O +
expression O +
of O +
HIF1alpha O +
in O +
hypoxic O +
tissue O -
. O +

Tumor O +
Angiogenesis O -
: O +
Initiation O +
and O +
Targeting O +
- O +
Therapeutic O +
Targeting O +
of O +
an O +
FGF O -
- O -
Binding O +
Protein O -
, O +
an O +
Angiogenic O +
Switch O +
Molecule O -
, O +
and O +
Indicator O +
of O +
Early O +
Stages O +
of O +
Gastrointestinal O +
Adenocarcinomas O +
- O -
. O +

Tumor O +
angiogenesis O +
has O +
been O +
related O +
to O +
the O +
initiation O +
as O +
well O +
as O +
progression O +
toward O +
more O +
aggressive O +
behavior O +
of O +
human O +
tumors O -
. O +

In O +
particular O -
, O +
the O +
activity O +
of O +
angiogenic O +
factors O +
is O +
crucial O +
for O +
tumor O +
progression O -
. O +

We O +
previously O +
characterized O +
a O +
secreted O +
fibroblast O +
growth O +
factor O -
- O -
binding O +
protein O +
( O -
FGF O -
- O -
BP O -
) O +
as O +
a O +
chaperone O +
molecule O -
, O +
which O +
binds O +
to O +
various O +
FGFs O -
, O +
enhances O +
FGF O -
- O -
mediated O +
biochemical O +
and O +
biologic O +
events O +
and O +
importantly O +
is O +
a O +
crucial O +
rate O -
- O -
limiting O +
factor O +
for O +
tumor O -
- O -
dependent O +
angiogenesis O -
. O +

We O +
generated O +
monoclonal O +
antibodies O +
that O +
target O +
FGF O -
- O -
BP O +
protein O +
and O +
used O +
them O +
as O +
a O +
tool O +
to O +
evaluate O +
frequency O +
and O +
pattern O +
of O +
FGF O -
- O -
BP O +
expression O +
during O +
the O +
malignant O +
progression O +
of O +
pancreas O +
and O +
colorectal O +
carcinoma O +
in O +
archival O +
tissue O +
samples O -
. O +

We O +
found O +
that O +
FGF O -
- O -
BP O +
is O +
dramatically O +
upregulated O +
during O +
the O +
initiation O +
of O +
colorectal O +
and O +
pancreatic O +
adenocarcinoma O -
. O +

Crucial O +
genetic O +
events O +
underlying O +
the O +
initiation O +
and O +
progression O +
of O +
colorectal O +
and O +
pancreatic O +
adenocarcinoma O +
with O +
a O +
particular O +
focus O +
on O +
the O +
modulation O +
of O +
angiogenesis O +
and O +
antiangiogenic O +
therapies O +
are O +
discussed O -
. O +

We O +
propose O +
that O +
the O +
upregulation O +
of O +
the O +
secreted O +
FGF O -
- O -
BP O +
protein O +
during O +
early O +
phases O +
of O +
pancreas O +
and O +
colon O +
cancer O +
could O +
make O +
this O +
protein O +
a O +
possible O +
serum O +
marker O +
indicating O +
the O +
presence O +
of O +
high O -
- O -
risk O +
premalignant O +
lesions O -
. O +

Furthermore O -
, O +
the O +
biological O +
activity O +
of O +
FGF O -
- O -
BP O +
is O +
neutralized O +
by O +
monoclonal O +
antibodies O +
suggesting O +
the O +
potential O +
for O +
antibody O -
- O -
based O +
therapeutic O +
targeting O -
. O +

[ O -
Effect O +
of O +
osteopontin O +
silencing O +
by O +
lentivirus O -
- O -
mediated O +
delivery O +
of O +
siRNA O +
on O +
glioma O +
cell O +
invasion O +
and O +
apoptosis O -
] O -
. O +

OBJECTIVE O -
: O +
To O +
investigate O +
the O +
effect O +
of O +
osteopontin O +
silencing O +
on O +
the O +
invasion O +
and O +
apoptosis O +
of O +
U251 O +
cells O -
. O +

METHODS O -
: O +
The O +
invasion O -
, O +
apoptosis O +
and O +
levels O +
of O +
uPA O -
, O +
MMP-2 O +
and O +
MMP-9 O +
were O +
determined O +
by O +
invasion O +
assay O -
, O +
flow O +
cytometry O -
, O +
Western O +
blot O +
and O +
real O -
- O -
time O +
fluorescence O +
quantitative O +
PCR O +
respectively O -
. O +

RESULTS O -
: O +
Osteopontin O +
small O +
interference O +
RNA O +
( O -
siRNA O -
) O +
inhibited O +
osteopontin O +
expression O +
and O +
cell O +
invasion O -
, O +
promoted O +
apoptosis O +
in O +
U251 O +
cells O -
. O +

In O +
addition O -
, O +
the O +
expression O +
of O +
Bcl-2 O -
, O +
uPA O -
, O +
MMP-2 O +
and O +
MMP-9 O +
was O +
decreased O -
, O +
while O +
Bax O +
level O +
was O +
elevated O -
. O +

CONCLUSION O -
: O +
Osteopontin O +
siRNA O +
can O +
inhibit O +
U251 O +
cells O +
invasion O +
via O +
the O +
down O -
- O -
regulation O +
of O +
uPA O -
, O +
MMP-2 O +
and O +
MMP-9 O +
levels O -
, O +
and O +
promote O +
apoptosis O +
through O +
induction O +
of O +
Bax O +
expression O +
and O +
inhibition O +
of O +
Bcl O +
2 O +
level O -
. O +

It O +
suggests O +
that O +
osteopontin O +
plays O +
an O +
important O +
role O +
in O +
human O +
glioma O +
progression O -
. O +

Pancreatic O +
endocrine O +
tumors O -
: O +
expression O +
profiling O +
evidences O +
a O +
role O +
for O +
AKT O -
- O -
mTOR O +
pathway O -
. O +

PURPOSE O -
: O +
We O +
investigated O +
the O +
global O +
gene O +
expression O +
in O +
a O +
large O +
panel O +
of O +
pancreatic O +
endocrine O +
tumors O +
( O -
PETs O -
) O +
aimed O +
at O +
identifying O +
new O +
potential O +
targets O +
for O +
therapy O +
and O +
biomarkers O +
to O +
predict O +
patient O +
outcome O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
Using O +
a O +
custom O +
microarray O -
, O +
we O +
analyzed O +
72 O +
primary O +
PETs O -
, O +
seven O +
matched O +
metastases O -
, O +
and O +
10 O +
normal O +
pancreatic O +
samples O -
. O +

Relevant O +
differentially O +
expressed O +
genes O +
were O +
validated O +
by O +
either O +
quantitative O +
real O -
- O -
time O +
polymerase O +
chain O +
reaction O +
or O +
immunohistochemistry O +
on O +
tissue O +
microarrays O -
. O +

RESULTS O -
: O +
Our O +
data O +
showed O +
that O -
: O +
tuberous O +
sclerosis O +
2 O +
( O -
TSC2 O -
) O +
and O +
phosphatase O +
and O +
tensin O +
homolog O +
( O -
PTEN O -
) O +
were O +
downregulated O +
in O +
most O +
of O +
the O +
primary O +
tumors O -
, O +
and O +
their O +
low O +
expression O +
was O +
significantly O +
associated O +
with O +
shorter O +
disease O -
- O -
free O +
and O +
overall O +
survival O -
; O +
somatostatin O +
receptor O +
2 O +
( O -
SSTR2 O -
) O +
was O +
absent O +
or O +
very O +
low O +
in O +
insulinomas O +
compared O +
with O +
nonfunctioning O +
tumors O -
; O +
and O +
expression O +
of O +
fibroblast O +
growth O +
factor O +
13 O +
( O -
FGF13 O -
) O +
gene O +
was O +
significantly O +
associated O +
with O +
the O +
occurrence O +
of O +
liver O +
metastasis O +
and O +
shorter O +
disease O -
- O -
free O +
survival O -
. O +

TSC2 O +
and O +
PTEN O +
are O +
two O +
key O +
inhibitors O +
of O +
the O +
Akt O -
/ O -
mammalian O +
target O +
of O +
rapamycin O +
( O -
mTOR O -
) O +
pathway O +
and O +
the O +
specific O +
inhibition O +
of O +
mTOR O +
with O +
rapamycin B-Chemical +
or O +
RAD001 B-Chemical +
inhibited O +
cell O +
proliferation O +
of O +
PET O +
cell O +
lines O -
. O +

CONCLUSION O -
: O +
Our O +
results O +
strongly O +
support O +
a O +
role O +
for O +
PI3K O -
/ O -
Akt O -
/ O -
mTOR O +
pathway O +
in O +
PET O -
, O +
which O +
ties O +
in O +
with O +
the O +
fact O +
that O +
mTOR O +
inhibitors O +
have O +
reached O +
phase O +
III O +
trials O +
in O +
neuroendocrine O +
tumors O -
. O +

The O +
finding O +
of O +
differential O +
SSTR O +
expression O +
raises O +
the O +
potential O +
for O +
SSTR O +
expression O +
to O +
be O +
evaluated O +
as O +
a O +
marker O +
of O +
response O +
to O +
somatostatin O +
analogs O -
. O +

Finally O -
, O +
we O +
identified O +
FGF13 O +
as O +
a O +
new O +
prognostic O +
marker O +
that O +
predicted O +
poorer O +
outcome O +
in O +
patients O +
who O +
were O +
clinically O +
considered O +
free O +
from O +
disease O -
. O +

Hormonal O +
regulation O +
and O +
distinct O +
functions O +
of O +
semaphorin-3B O +
and O +
semaphorin-3F O +
in O +
ovarian O +
cancer O -
. O +

Semaphorins O +
comprise O +
a O +
family O +
of O +
molecules O +
that O +
influence O +
neuronal O +
growth O +
and O +
guidance O -
. O +

Class-3 O +
semaphorins O -
, O +
semaphorin-3B O +
( O -
SEMA3B O -
) O +
and O +
semaphorin-3F O +
( O -
SEMA3F O -
) O -
, O +
illustrate O +
their O +
effects O +
by O +
forming O +
a O +
complex O +
with O +
neuropilins O +
( O -
NP-1 O +
or O +
NP-2 O -
) O +
and O +
plexins O -
. O +

We O +
examined O +
the O +
status O +
and O +
regulation O +
of O +
semaphorins O +
and O +
their O +
receptors O +
in O +
human O +
ovarian O +
cancer O +
cells O -
. O +

A O +
significantly O +
reduced O +
expression O +
of O +
SEMA3B O +
( O -
83 O +
kDa O -
) O -
, O +
SEMA3F O +
( O -
90 O +
kDa O -
) O -
, O +
and O +
plexin O -
- O -
A3 O +
was O +
observed O +
in O +
ovarian O +
cancer O +
cell O +
lines O +
when O +
compared O +
with O +
normal O +
human O +
ovarian O +
surface O +
epithelial O +
cells O -
. O +

The O +
expression O +
of O +
NP-1 O -
, O +
NP-2 O -
, O +
and O +
plexin O -
- O -
A1 O +
was O +
not O +
altered O +
in O +
human O +
ovarian O +
surface O +
epithelial O +
and O +
ovarian O +
cancer O +
cells O -
. O +

The O +
decreased O +
expression O +
of O +
SEMA3B O -
, O +
SEMA3F O -
, O +
and O +
plexin O -
- O -
A3 O +
was O +
confirmed O +
in O +
stage O +
3 O +
ovarian O +
tumors O -
. O +

The O +
treatment O +
of O +
ovarian O +
cancer O +
cells O +
with O +
luteinizing O +
hormone O -
, O +
follicle O -
- O -
stimulating O +
hormone O -
, O +
and O +
estrogen B-Chemical +
induced O +
a O +
significant O +
upregulation O +
of O +
SEMA3B O -
, O +
whereas O +
SEMA3F O +
was O +
upregulated O +
only O +
by O +
estrogen B-Chemical -
. O +

Cotreatment O +
of O +
cell O +
lines O +
with O +
a O +
hormone O +
and O +
its O +
specific O +
antagonist O +
blocked O +
the O +
effect O +
of O +
the O +
hormone O -
. O +

Ectopic O +
expression O +
of O +
SEMA3B O +
or O +
SEMA3F O +
reduced O +
soft O -
- O -
agar O +
colony O +
formation O -
, O +
adhesion O -
, O +
and O +
cell O +
invasion O +
of O +
ovarian O +
cancer O +
cell O +
cultures O -
. O +

Forced O +
expression O +
of O +
SEMA3B O -
, O +
but O +
not O +
SEMA3F O -
, O +
inhibited O +
viability O +
of O +
ovarian O +
cancer O +
cells O -
. O +

Overexpression O +
of O +
SEMA3B O +
and O +
SEMA3F O +
reduced O +
focal O +
adhesion O +
kinase O +
phosphorylation O +
and O +
matrix O +
metalloproteinase-2 O +
and O +
matrix O +
metalloproteinase-9 O +
expression O +
in O +
ovarian O +
cancer O +
cells O -
. O +

Forced O +
expression O +
of O +
SEMA3F O -
, O +
but O +
not O +
SEMA3B O +
in O +
ovarian O +
cancer O +
cells O -
, O +
significantly O +
inhibited O +
endothelial O +
cell O +
tube O +
formation O -
. O +

Collectively O -
, O +
our O +
results O +
suggest O +
that O +
the O +
loss O +
of O +
SEMA3 O +
expression O +
could O +
be O +
a O +
hallmark O +
of O +
cancer O +
progression O -
. O +

Furthermore O -
, O +
gonadotropin- O +
and/or O +
estrogen B-Chemical -
- O -
mediated O +
maintenance O +
of O +
SEMA3 O +
expression O +
could O +
control O +
ovarian O +
cancer O +
angiogenesis O +
and O +
metastasis O -
. O +

Tobacco O +
smoke O +
promotes O +
lung O +
tumorigenesis O +
by O +
triggering O +
IKKbeta- O +
and O +
JNK1-dependent O +
inflammation O -
. O +

Chronic O +
exposure O +
to O +
tobacco O +
smoke O -
, O +
which O +
contains O +
over O +
60 O +
tumor O -
- O -
initiating O +
carcinogens O -
, O +
is O +
the O +
major O +
risk O +
factor O +
for O +
development O +
of O +
lung O +
cancer O -
, O +
accounting O +
for O +
a O +
large O +
portion O +
of O +
cancer O -
- O -
related O +
deaths O +
worldwide O -
. O +

It O +
is O +
well O +
established O +
that O +
tobacco O +
smoke O +
is O +
a O +
tumor O +
initiator O -
, O +
but O +
we O +
asked O +
whether O +
it O +
also O +
acts O +
as O +
a O +
tumor O +
promoter O +
once O +
malignant O +
initiation O -
, O +
such O +
as O +
caused O +
by O +
K O -
- O -
ras O +
activation O -
, O +
has O +
taken O +
place O -
. O +

Here O +
we O +
demonstrate O +
that O +
repetitive O +
exposure O +
to O +
tobacco O +
smoke O +
promotes O +
tumor O +
development O +
both O +
in O +
carcinogen O -
- O -
treated O +
mice O +
and O +
in O +
transgenic O +
mice O +
undergoing O +
sporadic O +
K O -
- O -
ras O +
activation O +
in O +
lung O +
epithelial O +
cells O -
. O +

Tumor O +
promotion O +
is O +
due O +
to O +
induction O +
of O +
inflammation O +
that O +
results O +
in O +
enhanced O +
pneumocyte O +
proliferation O +
and O +
is O +
abrogated O +
by O +
IKKbeta O +
ablation O +
in O +
myeloid O +
cells O +
or O +
inactivation O +
of O +
JNK1 O -
. O +

Telomere O -
/ O -
telomerase O +
interplay O +
in O +
virus O -
- O -
driven O +
and O +
virus O -
- O -
independent O +
lymphomagenesis O -
: O +
pathogenic O +
and O +
clinical O +
implications O -
. O +

Telomerase O +
is O +
a O +
ribonucleoprotein O +
complex O +
critically O +
involved O +
in O +
extending O +
and O +
maintaining O +
telomeres O -
. O +

Unlike O +
the O +
majority O +
of O +
somatic O +
cells O -
, O +
in O +
which O +
hTERT O +
and O +
telomerase O +
activity O +
are O +
generally O +
silent O -
, O +
normal O +
lymphocytes O +
show O +
transient O +
physiological O +
hTERT O +
expression O +
and O +
telomerase O +
activity O +
according O +
to O +
their O +
differentiation O -
/ O -
activation O +
status O -
. O +

During O +
lymphomagenesis O -
, O +
induction O +
of O +
persistent O +
telomerase O +
expression O +
and O +
activity O +
may O +
occur O +
before O +
or O +
after O +
telomere O +
shortening O -
, O +
as O +
a O +
consequence O +
of O +
the O +
different O +
mechanisms O +
through O +
which O +
transforming O +
factors O -
/ O -
agents O +
may O +
activate O +
telomerase O -
. O +

Available O +
data O +
indicate O +
that O +
the O +
timing O +
of O +
telomerase O +
activation O +
may O +
allow O +
the O +
distinction O +
of O +
two O +
different O +
lymphomagenetic O +
models O -
: O +
( O -
i O -
) O +
an O +
early O +
activation O +
of O +
telomerase O +
via O +
exogenous O +
regulators O +
of O +
hTERT O -
, O +
along O +
with O +
an O +
increased O +
lymphocyte O +
growth O +
and O +
a O +
subsequent O +
selection O +
of O +
cells O +
with O +
increased O +
transforming O +
potential O +
may O +
characterize O +
several O +
virus O -
- O -
related O +
lymphoid O +
malignancies O -
; O +
( O -
ii O -
) O +
a O +
progressive O +
shortening O +
of O +
telomeres O -
, O +
leading O +
to O +
genetic O +
instability O +
which O +
favors O +
a O +
subsequent O +
activation O +
of O +
telomerase O +
via O +
endogenous O +
regulators O +
may O +
occur O +
in O +
most O +
virus O -
- O -
unrelated O +
lymphoid O +
tumors O -
. O +

These O +
models O +
may O +
have O +
clinically O +
relevant O +
implications O -
, O +
particularly O +
for O +
the O +
tailoring O +
of O +
therapeutic O +
strategies O +
targeting O +
telomerase O -
. O +

1,4-phenylenebis B-Chemical -
( I-Chemical -
methylene I-Chemical -
) I-Chemical -
selenocyanate I-Chemical -
, O +
but O +
not O +
selenomethionine B-Chemical -
, O +
inhibits O +
androgen O +
receptor O +
and O +
Akt O +
signaling O +
in O +
human O +
prostate O +
cancer O +
cells O -
. O +

The O +
lack O +
of O +
treatment O +
for O +
worried O -
- O -
well O +
patients O +
with O +
high O -
- O -
grade O +
prostatic O +
intraepithelial O +
neoplasia O +
combined O +
with O +
issues O +
of O +
recurrence O +
and O +
hormone O +
resistance O +
in O +
prostate O +
cancer O +
survivors O +
remains O +
a O +
major O +
public O +
health O +
obstacle O -
. O +

The O +
long O +
latency O +
of O +
prostate O +
cancer O +
development O +
provides O +
an O +
opportunity O +
to O +
intervene O +
with O +
agents O +
of O +
known O +
mechanisms O +
at O +
various O +
stages O +
of O +
disease O +
progression O -
. O +

A O +
number O +
of O +
signaling O +
cascades O +
have O +
been O +
shown O +
to O +
play O +
important O +
roles O +
in O +
prostate O +
cancer O +
development O +
and O +
progression O -
, O +
including O +
the O +
androgen O +
receptor O +
( O -
AR O -
) O +
and O +
phosphatidylinositol O +
3-kinase O -
/ O -
Akt O +
signaling O +
pathways O -
. O +

Crosstalk O +
between O +
these O +
two O +
pathways O +
is O +
also O +
thought O +
to O +
contribute O +
to O +
progression O +
and O +
hormone O -
- O -
refractory O +
prostate O +
disease O -
. O +

Our O +
initial O +
investigations O +
show O +
that O +
the O +
naturally O +
occurring O +
organoselenium O +
compound O +
selenomethionine B-Chemical +
( O -
SM B-Chemical -
) O +
and O +
the O +
synthetic O +
1,4-phenylenebis B-Chemical -
( I-Chemical -
methylene I-Chemical -
) I-Chemical -
selenocyanate I-Chemical +
( O -
p B-Chemical -
- I-Chemical -
XSC I-Chemical -
) O +
can O +
inhibit O +
human O +
prostate O +
cancer O +
cell O +
viability O -
; O +
however O -
, O +
in O +
contrast O +
to O +
SM B-Chemical -
, O +
p B-Chemical -
- I-Chemical -
XSC I-Chemical +
is O +
active O +
at O +
physiologically O +
relevant O +
doses O -
. O +

In O +
the O +
current O +
investigation O -
, O +
we O +
show O +
that O +
p B-Chemical -
- I-Chemical -
XSC I-Chemical -
, O +
but O +
not O +
an O +
equivalent O +
dose O +
of O +
SM B-Chemical -
, O +
alters O +
molecular O +
targets O +
and O +
induces O +
apoptosis O +
in O +
androgen B-Chemical -
- O -
responsive O +
LNCaP O +
and O +
androgen B-Chemical -
- O -
independent O +
LNCaP O +
C4 O -
- O -
2 O +
human O +
prostate O +
cancer O +
cells O -
. O +

p B-Chemical -
- I-Chemical -
XSC I-Chemical +
effectively O +
inhibits O +
AR O +
expression O +
and O +
transcriptional O +
activity O +
in O +
both O +
cell O +
lines O -
. O +

p B-Chemical -
- I-Chemical -
XSC I-Chemical +
also O +
decreases O +
Akt O +
phosphorylation O +
as O +
well O +
as O +
Akt O -
- O -
specific O +
phosphorylation O +
of O +
the O +
AR O -
. O +

Inhibition O +
of O +
Akt O -
, O +
however O -
, O +
does O +
not O +
fully O +
attenuate O +
p B-Chemical -
- I-Chemical -
XSC I-Chemical -
- O -
mediated O +
downregulation O +
of O +
AR O +
activity O -
, O +
suggesting O +
that O +
inhibition O +
of O +
AR O +
signaling O +
by O +
p B-Chemical -
- I-Chemical -
XSC I-Chemical +
does O +
not O +
occur O +
solely O +
through O +
alterations O +
in O +
the O +
phosphatidylinositol O +
3-kinase O -
/ O -
Akt O +
survival O +
pathway O -
. O +

Our O +
data O +
suggest O +
that O +
p B-Chemical -
- I-Chemical -
XSC I-Chemical +
inhibits O +
multiple O +
signaling O +
pathways O +
in O +
prostate O +
cancer O -
, O +
likely O +
accounting O +
for O +
the O +
downstream O +
effects O +
on O +
proliferation O +
and O +
apoptosis O -
. O +

Ras O +
p21 O +
onco O -
- O -
protein O +
in O +
the O +
sera O +
of O +
mice O +
carrying O +
an O +
experimentally O +
induced O +
tumor O +
and O +
in O +
human O +
cancer O +
patients O -
. O +

We O +
have O +
established O +
a O +
model O +
system O +
to O +
detect O +
the O +
presence O +
of O +
ras O +
p21 O +
in O +
the O +
sera O +
of O +
Balb O -
/ O -
c O +
mice O +
carrying O +
tumors O +
induced O +
by O +
a O +
mouse O +
cell O +
line O +
transformed O +
with O +
the O +
Harvey O +
murine O +
sarcoma O +
virus O +
in O +
the O +
presence O +
of O +
a O +
helper O +
Friend O +
murine O +
leukemia O +
virus O -
. O +

As O +
determined O +
by O +
ELISA O +
and O +
immunoblot O +
assays O -
, O +
ras O +
p21 O +
in O +
the O +
serum O +
increased O +
with O +
increased O +
tumor O +
growth O -
. O +

Since O +
ras O +
genes O +
have O +
been O +
found O +
to O +
be O +
frequently O +
activated O +
in O +
human O +
tumours O -
, O +
we O +
examined O +
the O +
levels O +
of O +
ras O +
p21 O +
in O +
the O +
sera O +
of O +
a O +
variety O +
of O +
human O +
cancer O +
patients O -
. O +

In O +
only O +
3 O +
out O +
of O +
13 O +
cases O -
, O +
representing O +
patients O +
with O +
adenocarcinomas O +
of O +
the O +
stomach O +
receiving O +
chemotherapy O -
, O +
was O +
ras O +
p21 O +
detected O +
at O +
elevated O +
levels O -
, O +
whereas O +
in O +
patients O +
with O +
the O +
following O +
types O +
of O +
cancer O +
no O +
substantial O +
change O +
in O +
serum O +
ras O +
p21 O +
was O +
observed O -
; O +
nine O +
with O +
breast O -
, O +
5 O +
colon O -
, O +
5 O +
lung O -
, O +
5 O +
ovarian O +
and O +
5 O +
hepatocellular O +
carcinomas O -
. O +

High O -
- O -
mobility O +
group O +
A2 O +
protein O +
modulates O +
hTERT O +
transcription O +
to O +
promote O +
tumorigenesis O -
. O +

The O +
high O -
- O -
mobility O +
group O +
A2 O +
gene O +
( O -
HMGA2 O -
) O +
is O +
one O +
of O +
the O +
most O +
frequently O +
amplified O +
genes O +
in O +
human O +
cancers O -
. O +

However O -
, O +
functions O +
of O +
HMGA2 O +
in O +
tumorigenesis O +
are O +
not O +
fully O +
understood O +
due O +
to O +
limited O +
knowledge O +
of O +
its O +
targets O +
in O +
tumor O +
cells O -
. O +

Our O +
study O +
reveals O +
a O +
novel O +
link O +
between O +
HMGA2 O +
and O +
the O +
regulation O +
of O +
human O +
telomerase O +
reverse O +
transcriptase O +
( O -
hTERT O -
) O -
, O +
the O +
catalytic O +
subunit O +
of O +
telomerase O -
, O +
which O +
offers O +
critical O +
insight O +
into O +
how O +
HMGA2 O +
contributes O +
to O +
tumorigenesis O -
. O +

The O +
expression O +
of O +
HMGA2 O +
modulates O +
the O +
expression O +
of O +
hTERT O -
, O +
resulting O +
in O +
cells O +
with O +
enhanced O +
telomerase O +
activities O +
and O +
increased O +
telomere O +
length O -
. O +

Treatment O +
with O +
suberoylanilide B-Chemical +
hydroxamide I-Chemical +
( O -
SAHA B-Chemical -
) O -
, O +
a O +
histone O +
deacetylase O +
( O -
HDAC O -
) O +
inhibitor O -
, O +
causes O +
dose O -
- O -
dependent O +
hTERT O +
reporter O +
activation O -
, O +
mimicking O +
HMGA2 O +
overexpression O -
. O +

By O +
interacting O +
with O +
Sp1 O -
, O +
HMGA2 O +
interferes O +
with O +
the O +
recruitment O +
of O +
HDAC2 O +
to O +
the O +
hTERT O +
proximal O +
promoter O -
, O +
enhancing O +
localized O +
histone O +
H3-K9 O +
acetylation O +
and O +
thereby O +
stimulating O +
hTERT O +
expression O +
and O +
telomerase O +
activity O -
. O +

Moreover O -
, O +
HMGA2 O +
knockdown O +
by O +
short O +
hairpin O +
HMGA2 O +
in O +
HepG2 O +
cells O +
leads O +
to O +
progressive O +
telomere O +
shortening O +
and O +
a O +
concurrent O +
decrease O +
of O +
steady O -
- O -
state O +
hTERT O +
mRNA O +
levels O -
, O +
attenuating O +
their O +
ability O +
to O +
form O +
colonies O +
in O +
soft O +
agar O -
. O +

Importantly O -
, O +
HMGA2 O +
partially O +
replaces O +
the O +
function O +
of O +
hTERT O +
during O +
the O +
tumorigenic O +
transformation O +
of O +
normal O +
human O +
fibroblasts O -
. O +

These O +
findings O +
are O +
potentially O +
clinically O +
relevant O -
, O +
because O +
HMGA2 O +
expression O +
is O +
reported O +
to O +
be O +
upregulated O +
in O +
a O +
number O +
of O +
human O +
cancers O +
as O +
telomere O +
maintenance O +
is O +
essential O +
for O +
tumorigenesis O -
. O +

KISS1 O +
methylation O +
and O +
expression O +
as O +
tumor O +
stratification O +
biomarkers O +
and O +
clinical O +
outcome O +
prognosticators O +
for O +
bladder O +
cancer O +
patients O -
. O +

KISS1 O +
is O +
a O +
metastasis O +
suppressor O +
gene O +
that O +
is O +
lost O +
in O +
several O +
malignancies O -
, O +
including O +
bladder O +
cancer O -
. O +

We O +
tested O +
the O +
epigenetic O +
silencing O +
hypothesis O +
and O +
evaluated O +
the O +
biological O +
influence O +
of O +
KISS1 O +
methylation O +
on O +
its O +
expression O +
and O +
clinical O +
relevance O +
in O +
bladder O +
cancer O -
. O +

KISS1 O +
hypermethylation O +
was O +
frequent O +
in O +
bladder O +
cancer O +
cells O +
analyzed O +
by O +
methylation O -
- O -
specific O +
PCR O +
and O +
bisulfite B-Chemical +
sequencing O +
and O +
was O +
associated O +
with O +
low O +
gene O +
expression O -
, O +
being O +
restored O +
in O +
vitro O +
by O +
demethylating O +
azacytidine B-Chemical -
. O +

Hypermethylation O +
was O +
also O +
frequently O +
observed O +
in O +
a O +
large O +
series O +
of O +
bladder O +
tumors O +
( O -
83.1 O -
% O -
, O +
n O +
= O +
804 O -
) O -
. O +

KISS1 O +
methylation O +
was O +
associated O +
with O +
increasing O +
stage O +
( O -
P O +
= O +
0.001 O -
) O +
and O +
tumor O +
grade O +
( O -
P O +
= O +
0.010 O -
) O -
. O +

KISS1 O +
methylation O +
was O +
associated O +
with O +
low O +
KISS1 O +
transcript O +
expression O +
by O +
quantitative O +
RT O -
- O -
PCR O +
( O -
P O +
= O +
0.037 O -
) O -
. O +

KISS1 O +
transcript O +
expression O +
was O +
also O +
associated O +
with O +
histopathological O +
tumor O +
stage O +
( O -
P O +
< O +
0.0005 O -
) O -
. O +

Low O +
transcript O +
expression O +
alone O +
( O -
P O +
= O +
0.003 O -
) O +
or O +
combined O +
with O +
methylation O +
( O -
P O +
= O +
0.019 O -
) O +
was O +
associated O +
with O +
poor O +
disease O -
- O -
specific O +
survival O +
( O -
n O +
= O +
205 O -
) O -
. O +

KISS1 O +
transcript O +
expression O +
remained O +
an O +
independent O +
prognosticator O +
in O +
multivariate O +
analyses O +
( O -
P O +
= O +
0.017 O -
) O -
. O +

KISS1 O +
hypermethylation O +
was O +
identified O +
in O +
bladder O +
cancer O -
, O +
providing O +
a O +
potential O +
mechanistic O +
explanation O +
( O -
epigenetic O +
silencing O -
) O +
for O +
the O +
observed O +
loss O +
of O +
KISS1 O +
in O +
uroepithelial O +
malignancies O -
. O +

Associations O +
of O +
KISS1 O +
methylation O +
and O +
its O +
expression O +
with O +
histopathological O +
variables O +
and O +
poor O +
survival O +
suggest O +
the O +
utility O +
of O +
incorporating O +
KISS1 O +
measurement O +
using O +
paraffin B-Chemical -
- O -
embedded O +
material O +
for O +
tumor O +
stratification O +
and O +
clinical O +
outcome O +
prognosis O +
of O +
patients O +
with O +
uroepithelial O +
neoplasias O -
. O +

The O +
members O +
of O +
an O +
Epstein O -
- O -
Barr O +
virus O +
microRNA O +
cluster O +
cooperate O +
to O +
transform O +
B O +
lymphocytes O -
. O +

Epstein O -
- O -
Barr O +
virus O +
( O -
EBV O -
) O +
transforms O +
B O +
lymphocytes O +
through O +
the O +
expression O +
of O +
the O +
latent O +
viral O +
proteins O +
EBNA O +
and O +
latent O +
membrane O +
protein O +
( O -
LMP O -
) O -
. O +

Recently O -
, O +
it O +
has O +
become O +
apparent O +
that O +
microRNAs O +
( O -
miRNAs O -
) O +
also O +
contribute O +
to O +
EBV O -
's O +
oncogenic O +
properties O -
; O +
recombinant O +
EBVs O +
that O +
lack O +
the O +
BHRF1 O +
miRNA O +
cluster O +
display O +
a O +
reduced O +
ability O +
to O +
transform O +
B O +
lymphocytes O +
in O +
vitro O -
. O +

Furthermore O -
, O +
infected O +
cells O +
evince O +
a O +
marked O +
upregulation O +
of O +
the O +
EBNA O +
genes O -
. O +

Using O +
recombinant O +
viruses O +
that O +
lack O +
only O +
one O +
member O +
of O +
the O +
cluster O -
, O +
we O +
now O +
show O +
that O +
all O +
three O +
BHRF1 O +
miRNAs O +
contribute O +
to O +
B O -
- O -
cell O +
transformation O -
. O +

Recombinants O +
that O +
lacked O +
miR O -
- O -
BHRF1 O -
- O -
2 O +
or O +
miR O -
- O -
BHRF1 O -
- O -
3 O +
displayed O +
enhanced O +
EBNA O +
expression O +
initiated O +
at O +
the O +
Cp O +
and O +
Wp O +
promoters O -
. O +

Interestingly O -
, O +
we O +
find O +
that O +
the O +
deletion O +
of O +
miR O -
- O -
BHRF1 O -
- O -
2 O +
reduced O +
the O +
expression O +
level O +
of O +
miR O -
- O -
BHRF1 O -
- O -
3 O +
and O +
possibly O +
that O +
of O +
miR O -
- O -
BHRF1 O -
- O -
1 O -
, O +
demonstrating O +
that O +
the O +
expression O +
of O +
one O +
miRNA O +
can O +
potentiate O +
the O +
expression O +
of O +
other O +
miRNAs O +
located O +
in O +
the O +
same O +
cluster O -
. O +

Therefore O -
, O +
the O +
phenotypic O +
traits O +
of O +
the O +
miR O -
- O -
BHRF1 O -
- O -
2 O +
null O +
mutant O +
could O +
result O +
partly O +
from O +
reduced O +
miR O -
- O -
BHRF1 O -
- O -
1 O +
and O +
miR O -
- O -
BHRF1 O -
- O -
3 O +
expression O +
levels O -
. O +

Nevertheless O -
, O +
using O +
an O +
miR O -
- O -
BHRF1 O -
- O -
1 O +
and O +
miR O -
- O -
BHRF1 O -
- O -
3 O +
double O +
mutant O -
, O +
we O +
could O +
directly O +
assess O +
and O +
confirm O +
the O +
contribution O +
of O +
miR O -
- O -
BHRF1 O -
- O -
2 O +
to O +
B O -
- O -
cell O +
transformation O -
. O +

Furthermore O -
, O +
we O +
found O +
that O +
the O +
potentiating O +
effect O +
of O +
miR O -
- O -
BHRF1 O -
- O -
2 O +
on O +
miR O -
- O -
BHRF1 O -
- O -
3 O +
synthesis O +
can O +
be O +
reproduced O +
with O +
simple O +
expression O +
plasmids O -
, O +
provided O +
that O +
both O +
miRNAs O +
are O +
processed O +
from O +
the O +
same O +
transcript O -
. O +

Therefore O -
, O +
this O +
enhancing O +
effect O +
does O +
not O +
result O +
from O +
an O +
idiosyncrasy O +
of O +
the O +
EBV O +
genome O +
but O +
rather O +
reflects O +
a O +
general O +
property O +
of O +
these O +
miRNAs O -
. O +

This O +
study O +
highlights O +
the O +
advantages O +
of O +
arranging O +
the O +
BHRF1 O +
miRNAs O +
in O +
clusters O -
: O +
it O +
allows O +
the O +
synchronous O +
and O +
synergistic O +
expression O +
of O +
genetic O +
elements O +
that O +
cooperate O +
to O +
transform O +
their O +
target O +
cells O -
. O +

Correlation O +
of O +
lymphatic O +
vessel O +
density O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
with O +
nodal O +
metastasis O +
in O +
papillary O +
thyroid O +
microcarcinoma O -
. O +

BACKGROUND O -
: O +
The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
not O +
only O +
the O +
intratumoral O +
and O +
peritumoral O +
lymphatic O +
vessel O +
density O +
( O -
ILD O +
and O +
PLD O -
) O +
but O +
also O +
the O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factors O +
( O -
VEGFs O -
) O +
and O +
to O +
test O +
their O +
correlation O +
with O +
regional O +
lymph O +
nodal O +
metastases O +
in O +
papillary O +
thyroid O +
microcarcinoma O +
( O -
PTMC O -
) O -
. O +

METHODS O -
: O +
A O +
clinicopathologic O +
data O +
review O +
was O +
performed O +
in O +
60 O +
patients O +
with O +
PTMC O +
treated O +
with O +
total O +
thyroidectomies O +
involving O +
neck O +
dissections O -
. O +

The O +
patterns O +
of O +
lymphatic O +
vessels O -
, O +
the O +
expression O +
of O +
VEGFs O -
, O +
and O +
their O +
correlation O +
with O +
neck O +
metastases O +
were O +
assessed O -
. O +

RESULTS O -
: O +
PLD O +
was O +
significantly O +
higher O +
than O +
ILD O +
( O -
p O +
< O +
.001 O -
) O -
. O +

Patients O +
with O +
high O +
PLD O +
( O -
> O -
8.0 O -
) O +
showed O +
higher O +
rates O +
of O +
neck O +
metastases O +
than O +
low O +
PLD O +
( O -
< O -
= O +
8.0 O -
) O +
( O -
74.0 O -
% O +
vs O +
46.8 O -
% O -
, O +
p O +
= O +
.03 O -
) O -
. O +

Univariate O +
and O +
multivariate O +
analyses O +
revealed O +
high O +
PLD O +
as O +
the O +
only O +
independent O +
variable O +
predictive O +
of O +
neck O +
metastasis O -
. O +

The O +
expression O +
of O +
VEGFs O +
did O +
not O +
correlate O +
with O +
either O +
lymphatic O +
density O +
or O +
neck O +
metastasis O -
. O +

CONCLUSIONS O -
: O +
PLD O +
may O +
be O +
of O +
potential O +
benefit O +
in O +
the O +
prediction O +
of O +
neck O +
metastasis O +
in O +
PTMC O -
. O +

Sunitinib B-Chemical +
induces O +
apoptosis O +
in O +
pheochromocytoma O +
tumor O +
cells O +
by O +
inhibiting O +
VEGFR2 O -
/ O -
Akt O -
/ O -
mTOR O -
/ O -
S6K1 O +
pathways O +
through O +
modulation O +
of O +
Bcl-2 O +
and O +
BAD O -
. O +

Sunitinib B-Chemical +
is O +
an O +
oral O +
multitargeted O +
receptor O +
tyrosine O +
kinase O +
inhibitor O +
with O +
antiangiogenic O +
and O +
antitumor O +
activity O +
that O +
mainly O +
targets O +
vascular O +
endothelial O +
growth O +
factor O +
receptors O +
( O -
VEGFRs O -
) O -
. O +

Very O +
recently O -
, O +
sunitinib B-Chemical +
has O +
been O +
shown O +
to O +
be O +
an O +
active O +
agent O +
for O +
the O +
treatment O +
of O +
malignant O +
pheochromocytomas O -
. O +

However O -
, O +
it O +
is O +
unclear O +
whether O +
sunitinib B-Chemical +
acts O +
only O +
through O +
an O +
antiangiogenic O +
mechanism O +
or O +
whether O +
it O +
may O +
also O +
directly O +
target O +
tumor O +
cells O -
. O +

Sunitinib B-Chemical +
markedly O +
induced O +
apoptosis O +
of O +
PC12 O +
cells O +
in O +
a O +
dose O -
- O -
dependent O +
and O +
time O -
- O -
dependent O +
manner O -
. O +

Furthermore O -
, O +
in O +
support O +
of O +
these O +
findings O -
, O +
we O +
found O +
that O +
sunitinib B-Chemical +
induced O +
a O +
reduction O +
in O +
the O +
expression O +
of O +
the O +
antiapoptotic O +
molecule O +
Bcl-2 O +
as O +
well O +
as O +
dephosphorylation O +
of O +
the O +
proapoptotic O +
molecule O +
BAD O -
, O +
which O +
results O +
in O +
the O +
activation O +
of O +
BAD O +
in O +
these O +
cells O -
. O +

Consistent O +
with O +
these O +
apoptotic O +
effects O -
, O +
our O +
results O +
showed O +
that O +
sunitinib B-Chemical +
inhibited O +
phosphorylation O +
of O +
Akt O +
and O +
mTOR O +
and O +
was O +
followed O +
by O +
a O +
reduction O +
of O +
S6K1 O -
, O +
which O +
is O +
a O +
well O -
- O -
known O +
target O +
of O +
mTOR O -
. O +

Knockdown O +
of O +
VEGFR-2 O +
attenuated O +
the O +
sunitinib B-Chemical -
- O -
induced O +
effects O -
, O +
including O +
apoptosis O +
and O +
inhibition O +
of O +
signaling O +
pathways O +
such O +
as O +
the O +
phosphorylation O +
of O +
Akt O +
as O +
well O +
as O +
mTOR O -
, O +
and O +
Bcl-2 O -
, O +
which O +
confirmed O +
that O +
these O +
effects O +
could O +
be O +
mediated O +
by O +
VEGFR-2 O -
. O +

In O +
addition O -
, O +
silencing O +
of O +
S6K1 O +
induced O +
apoptosis O +
accompanied O +
by O +
a O +
decrease O +
in O +
the O +
phosphorylation O +
of O +
BAD O +
and O +
Bcl-2 O -
, O +
similar O +
to O +
that O +
observed O +
with O +
sunitinib B-Chemical +
treatment O -
. O +

Thus O -
, O +
these O +
results O +
together O +
suggest O +
that O +
sunitinib B-Chemical +
initially O +
exerts O +
its O +
apoptotic O +
effect O +
through O +
the O +
inhibition O +
of O +
VEGFR-2 O -
, O +
which O -
, O +
when O +
followed O +
by O +
reduction O +
of O +
its O +
downstream O +
effectors O -
, O +
including O +
Akt O -
/ O -
mTOR O -
/ O -
S6K1 O -
, O +
may O +
lead O +
to O +
inhibition O +
of O +
the O +
antiapoptotic O +
molecule O +
Bcl-2 O +
and O +
activation O +
of O +
the O +
proapoptotic O +
molecule O +
BAD O +
in O +
PC12 O +
cells O -
. O +

However O -
, O +
PC12 O +
cells O +
do O +
not O +
precisely O +
reflect O +
the O +
pathogenesis O +
of O +
malignant O +
cells O -
. O +

Therefore O -
, O +
we O +
confirmed O +
the O +
key O +
findings O +
by O +
replicating O +
these O +
experiments O +
in O +
human O +
neuroblastoma O +
SK O -
- O -
N O -
- O -
SH O +
cells O -
. O +

Development O +
of O +
a O +
mouse O +
model O +
for O +
lymph O +
node O +
metastasis O +
with O +
endometrial O +
cancer O -
. O +

Controlling O +
lymph O +
node O +
metastasis O +
is O +
currently O +
a O +
key O +
issue O +
in O +
cancer O +
therapy O -
. O +

Lymph O +
node O +
metastasis O +
is O +
one O +
of O +
the O +
most O +
important O +
prognostic O +
factors O +
in O +
various O +
types O +
of O +
cancers O -
, O +
including O +
endometrial O +
cancer O -
. O +

Vascular O +
endothelial O +
growth O +
factor O -
- O -
C O +
( O -
VEGF O -
- O -
C O -
) O +
plays O +
a O +
crucial O +
role O +
in O +
lymphangiogenesis O -
, O +
and O +
is O +
implicated O +
to O +
play O +
an O +
important O +
role O +
in O +
lymph O +
node O +
metastasis O -
. O +

To O +
evaluate O +
the O +
role O +
of O +
VEGF O -
- O -
C O +
in O +
lymph O +
node O +
metastasis O -
, O +
we O +
developed O +
an O +
animal O +
model O +
by O +
using O +
an O +
endometrial O +
cancer O +
cell O +
line O -
, O +
HEC1A O -
. O +

This O +
cell O +
line O +
is O +
not O +
invasive O +
by O +
nature O +
and O +
secretes O +
moderate O +
amounts O +
of O +
VEGF O -
- O -
C O -
; O +
intrauterine O +
injection O +
of O +
HEC1A O +
cells O +
into O +
Balb O -
/ O -
c O +
nude O +
mice O +
resulted O +
in O +
uterine O +
cancer O +
with O +
lymph O +
node O +
metastasis O +
after O +
8 O +
weeks O -
. O +

To O +
analyze O +
the O +
contribution O +
of O +
VEGF O -
- O -
C O +
to O +
lymph O +
node O +
metastasis O -
, O +
its O +
corresponding O +
gene O +
was O +
stably O +
introduced O +
into O +
HEC1A O +
cells O +
( O -
HEC1A O -
/ O -
VEGF O -
- O -
C O -
) O -
, O +
which O +
then O +
produced O +
more O +
than O +
10 O +
times O +
the O +
amount O +
of O +
VEGF O -
- O -
C. O +
The O +
number O +
of O +
lymph O +
node O +
metastases O +
was O +
significantly O +
higher O +
in O +
HEC1A O -
/ O -
VEGF O -
- O -
C O +
cells O +
than O +
in O +
HEC1A O +
cells O +
( O -
3.2 O +
vs O +
1.1 O +
nodes O -
/ O -
animal O -
, O +
respectively O -
) O -
. O +

Augmented O +
lymphangiogenesis O +
was O +
observed O +
within O +
tumors O +
when O +
HEC1A O -
/ O -
VEGF O -
- O -
C O +
cells O +
were O +
inoculated O -
. O +

These O +
results O +
indicate O +
that O +
VEGF O -
- O -
C O +
plays O +
a O +
critical O +
role O +
in O +
lymph O +
node O +
metastasis O -
, O +
in O +
addition O +
to O +
serving O +
as O +
a O +
platform O +
to O +
test O +
the O +
efficacy O +
of O +
various O +
therapeutic O +
modalities O +
against O +
lymph O +
node O +
metastasis O -
. O +

Curcumin B-Chemical +
inhibits O +
metastatic O +
progression O +
of O +
breast O +
cancer O +
cell O +
through O +
suppression O +
of O +
urokinase O -
- O -
type O +
plasminogen O +
activator O +
by O +
NF O -
- O -
kappa O +
B O +
signaling O +
pathways O -
. O +

Curcumin B-Chemical +
( O -
1,7-bis B-Chemical -
( I-Chemical -
4-hydroxy-3-methoxyphenyl I-Chemical -
) I-Chemical -
-1,6-heptadiene-3,5-dione I-Chemical -
) O -
, O +
is O +
extracted O +
from O +
the O +
plant O +
Curcuma O +
longa O -
. O +

It O +
was O +
recently O +
reported O +
for O +
its O +
anticancer O +
effect O +
on O +
several O +
types O +
of O +
cancer O +
cells O +
in O +
vitro O +
however O -
, O +
the O +
molecular O +
mechanisms O +
of O +
this O +
anticancer O +
effect O +
are O +
not O +
fully O +
understood O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
evaluated O +
the O +
effects O +
of O +
curcumin B-Chemical +
on O +
human O +
mammary O +
epithelial O +
carcinoma O +
MCF-7 O +
cells O -
. O +

Cells O +
were O +
treated O +
with O +
curcumin B-Chemical +
and O +
examined O +
for O +
cell O +
viability O +
by O +
MTT O +
assay O -
. O +

The O +
cells O +
invasion O +
was O +
demonstrated O +
by O +
transwell O +
assay O -
. O +

The O +
binding O +
activity O +
of O +
NF O -
- O -
kappaB O +
to O +
DNA O +
was O +
examined O +
in O +
nuclear O +
extracts O +
using O +
Trans O -
- O -
AM O +
NF O -
- O -
kappaB O +
ELISA O +
kit O -
. O +

Western O +
blot O +
was O +
performed O +
to O +
detect O +
the O +
effect O +
of O +
curcumin B-Chemical +
on O +
the O +
expression O +
of O +
uPA O -
. O +

Our O +
results O +
showed O +
that O +
curcumin B-Chemical +
dose O -
- O -
dependently O +
inhibited O +
( O -
P O +
< O +
0.05 O -
) O +
the O +
proliferation O +
of O +
MCF-7 O +
cells O -
. O +

Meanwhile O -
, O +
the O +
adhesion O +
and O +
invasion O +
ability O +
of O +
MCF-7 O +
cells O +
were O +
sharply O +
inhibited O +
when O +
treated O +
with O +
different O +
concentrations O +
of O +
curcumin B-Chemical -
. O +

Curcumin B-Chemical +
also O +
significantly O +
decreased O +
( O -
P O +
< O +
0.05 O -
) O +
the O +
expression O +
of O +
uPA O +
and O +
NF O -
- O -
kappaB O +
DNA O +
binding O +
activity O -
, O +
respectively O -
. O +

It O +
is O +
concluded O +
that O +
curcumin B-Chemical +
inhibits O +
the O +
adhesion O +
and O +
invasion O +
of O +
MCF-7 O +
cells O +
through O +
down O -
- O -
regulating O +
the O +
protein O +
expression O +
of O +
uPA O +
via O +
of O +
NF O -
- O -
kappaB O +
activation O -
. O +

Accordingly O -
, O +
the O +
therapeutic O +
potential O +
of O +
curcumin B-Chemical +
for O +
breast O +
cancer O +
deserves O +
further O +
study O -
. O +

Aglycon B-Chemical +
of O +
rhizochalin B-Chemical +
from O +
the O +
Rhizochalina O +
incrustata O +
induces O +
apoptosis O +
via O +
activation O +
of O +
AMP O -
- O -
activated O +
protein O +
kinase O +
in O +
HT-29 O +
colon O +
cancer O +
cells O -
. O +

Rhizochalin B-Chemical +
is O +
a O +
two O -
- O -
headed O +
sphingolipid B-Chemical -
- O -
like O +
compound O +
isolated O +
from O +
the O +
sponge O +
Rhizochalina O +
incrustata O -
. O +

It O +
has O +
been O +
reported O +
that O +
rhizocalin B-Chemical +
and O +
its O +
derivates O +
have O +
a O +
chemopreventive O +
and O +
chemotherapeutic O +
effect O -
. O +

However O -
, O +
the O +
molecular O +
mechanism O +
of O +
these O +
effects O +
is O +
not O +
understood O -
. O +

Here O -
, O +
we O +
demonstrate O +
that O +
aglycon B-Chemical +
of O +
rhizochalin B-Chemical +
( O -
AglRhz B-Chemical -
) O +
from O +
the O +
Rhizochalina O +
incrustata O +
induces O +
AMP O -
- O -
activated O +
protein O +
kinase O +
( O -
AMPK O -
) O +
phosphorylation O -
, O +
and O +
thereby O +
inhibits O +
mammalian O +
target O +
of O +
rapamycin O +
( O -
mTOR O -
) O -
-p70S6 O +
kinase O -
- O -
extracellular O +
signal O -
- O -
regulated O +
kinase O +
( O -
ERK O -
) O +
signaling O +
and O +
activator O +
protein O +
1 O +
( O -
AP-1 O -
) O +
activity O +
via O +
phosphorylation O +
of O +
Raptor O +
in O +
HT-29 O +
cells O -
. O +

In O +
addition O -
, O +
AglRhz B-Chemical +
induced O +
activation O +
of O +
caspase-3 O +
and O +
poly O -
( O -
ADP O -
- O -
ribose O -
) O +
polymerase O +
( O -
PARP O -
) O -
, O +
and O +
DNA O +
fragmentation O +
in O +
HT-29 O +
cells O -
, O +
leads O +
to O +
induction O +
of O +
apoptosis O +
as O +
well O +
as O +
suppression O +
of O +
tumorigenicity O +
of O +
HT-29 O +
cells O -
. O +

Notably O -
, O +
AglRhz B-Chemical +
inhibits O +
insulin O -
- O -
like O +
growth O +
factor O +
( O -
IGF O -
) O -
-1-induced O +
AP-1 O +
activity O +
and O +
cell O +
transformation O +
in O +
JB6 O +
Cl41 O +
cells O -
. O +

Overall O -
, O +
our O +
findings O +
identify O +
AMPK O +
as O +
an O +
important O +
target O +
protein O +
for O +
mediating O +
the O +
anti O -
- O -
tumor O +
properties O +
of O +
AglRhz B-Chemical +
in O +
HT-29 O +
colon O +
cancer O +
cells O +
and O +
have O +
important O +
implication O +
for O +
sponges O -
, O +
the O +
most O +
important O +
marine O +
source O -
, O +
in O +
colon O +
cancer O -
. O +

c O -
- O -
MYC O +
functions O +
as O +
a O +
molecular O +
switch O +
to O +
alter O +
the O +
response O +
of O +
human O +
mammary O +
epithelial O +
cells O +
to O +
oncostatin O +
M. O +
Cytokines O +
play O +
an O +
important O +
role O +
in O +
creating O +
an O +
inflammatory O +
microenvironment O -
, O +
which O +
is O +
now O +
considered O +
a O +
hallmark O +
of O +
cancer O -
. O +

Although O +
tumor O +
cells O +
can O +
exploit O +
cytokine O +
signaling O +
to O +
promote O +
growth O -
, O +
invasion O -
, O +
and O +
metastasis O -
, O +
the O +
response O +
of O +
normal O +
and O +
premalignant O +
epithelial O +
cells O +
to O +
cytokines O +
present O +
in O +
a O +
developing O +
tumor O +
microenvironment O +
remains O +
unclear O -
. O +

Oncostatin O +
M O +
( O -
OSM O -
) O -
, O +
an O +
IL-6 O +
family O +
cytokine O +
responsible O +
for O +
STAT3 O +
activation O -
, O +
has O +
been O +
implicated O +
in O +
cancer O +
development O -
, O +
progression O -
, O +
invasion O -
, O +
and O +
metastasis O -
. O +

Paradoxically O -
, O +
OSM O +
can O +
also O +
suppress O +
the O +
growth O +
of O +
normal O +
cells O +
and O +
certain O +
tumor O -
- O -
derived O +
cell O +
lines O -
. O +

Using O +
isogenic O +
human O +
mammary O +
epithelial O +
cells O +
( O -
HMEC O -
) O +
at O +
different O +
stages O +
of O +
neoplastic O +
transformation O -
, O +
we O +
found O +
that O +
OSM O +
signaling O +
suppressed O +
c O -
- O -
MYC O +
expression O +
and O +
engaged O +
a O +
p16- O +
and O +
p53-independent O +
growth O +
arrest O +
that O +
required O +
STAT3 O +
activity O -
. O +

Inhibition O +
of O +
STAT3 O +
activation O +
by O +
expressing O +
a O +
dominant O -
- O -
negative O +
STAT3 O +
protein O +
or O +
a O +
STAT3-shRNA O +
prevented O +
the O +
OSM O -
- O -
mediated O +
arrest O -
. O +

In O +
addition O -
, O +
expression O +
of O +
c O -
- O -
MYC O +
from O +
a O +
constitutive O +
promoter O +
also O +
abrogated O +
the O +
STAT3-mediated O +
arrest O -
, O +
and O +
strikingly O -
, O +
cooperated O +
with O +
OSM O +
to O +
promote O +
anchorage O -
- O -
independent O +
growth O +
( O -
AIG O -
) O -
, O +
a O +
property O +
associated O +
with O +
malignant O +
transformation O -
. O +

Cooperative O +
transformation O +
by O +
c O -
- O -
MYC O +
and O +
OSM O +
required O +
PI3 O -
K O +
and O +
AKT O +
signaling O -
, O +
showing O +
the O +
importance O +
of O +
multiple O +
signaling O +
pathways O +
downstream O +
of O +
the O +
OSM O +
receptor O +
in O +
defining O +
the O +
cellular O +
response O +
to O +
cytokines O -
. O +

These O +
findings O +
identify O +
c O -
- O -
MYC O +
as O +
an O +
important O +
molecular O +
switch O +
that O +
alters O +
the O +
cellular O +
response O +
to O +
OSM O -
- O -
mediated O +
signaling O +
from O +
tumor O +
suppressive O +
to O +
tumor O +
promoting O -
. O +

PTHrP O +
drives O +
breast O +
tumor O +
initiation O -
, O +
progression O -
, O +
and O +
metastasis O +
in O +
mice O +
and O +
is O +
a O +
potential O +
therapy O +
target O -
. O +

Parathyroid O +
hormone O -
- O -
related O +
protein O +
( O -
PTHrP O -
) O +
is O +
a O +
secreted O +
factor O +
expressed O +
in O +
almost O +
all O +
normal O +
fetal O +
and O +
adult O +
tissues O -
. O +

It O +
is O +
involved O +
in O +
a O +
wide O +
range O +
of O +
developmental O +
and O +
physiological O +
processes O -
, O +
including O +
serum O +
calcium B-Chemical +
regulation O -
. O +

PTHrP O +
is O +
also O +
associated O +
with O +
the O +
progression O +
of O +
skeletal O +
metastases O -
, O +
and O +
its O +
dysregulated O +
expression O +
in O +
advanced O +
cancers O +
causes O +
malignancy O -
- O -
associated O +
hypercalcemia O -
. O +

Although O +
PTHrP O +
is O +
frequently O +
expressed O +
by O +
breast O +
tumors O +
and O +
other O +
solid O +
cancers O -
, O +
its O +
effects O +
on O +
tumor O +
progression O +
are O +
unclear O -
. O +

Here O -
, O +
we O +
demonstrate O +
in O +
mice O +
pleiotropic O +
involvement O +
of O +
PTHrP O +
in O +
key O +
steps O +
of O +
breast O +
cancer O +
- O +
it O +
influences O +
the O +
initiation O +
and O +
progression O +
of O +
primary O +
tumors O +
and O +
metastases O -
. O +

Pthrp O +
ablation O +
in O +
the O +
mammary O +
epithelium O +
of O +
the O +
PyMT O -
- O -
MMTV O +
breast O +
cancer O +
mouse O +
model O +
caused O +
a O +
delay O +
in O +
primary O +
tumor O +
initiation O -
, O +
inhibited O +
tumor O +
progression O -
, O +
and O +
reduced O +
metastasis O +
to O +
distal O +
sites O -
. O +

Mechanistically O -
, O +
it O +
reduced O +
expression O +
of O +
molecular O +
markers O +
of O +
cell O +
proliferation O +
( O -
Ki67 O -
) O +
and O +
angiogenesis O +
( O -
factor O +
VIII O -
) O -
, O +
antiapoptotic O +
factor O +
Bcl-2 O -
, O +
cell O -
- O -
cycle O +
progression O +
regulator O +
cyclin O +
D1 O -
, O +
and O +
survival O +
factor O +
AKT1 O -
. O +

PTHrP O +
also O +
influenced O +
expression O +
of O +
the O +
adhesion O +
factor O +
CXCR4 O -
, O +
and O +
coexpression O +
of O +
PTHrP O +
and O +
CXCR4 O +
was O +
crucial O +
for O +
metastatic O +
spread O -
. O +

Importantly O -
, O +
PTHrP O -
- O -
specific O +
neutralizing O +
antibodies O +
slowed O +
the O +
progression O +
and O +
metastasis O +
of O +
human O +
breast O +
cancer O +
xenografts O -
. O +

Our O +
data O +
identify O +
what O +
we O +
believe O +
to O +
be O +
new O +
functions O +
for O +
PTHrP O +
in O +
several O +
key O +
steps O +
of O +
breast O +
cancer O +
and O +
suggest O +
that O +
PTHrP O +
may O +
constitute O +
a O +
novel O +
target O +
for O +
therapeutic O +
intervention O -
. O +

Overexpression O +
confers O +
an O +
oncogenic O +
potential O +
upon O +
the O +
eph O +
gene O -
. O +

The O +
eph O +
gene O +
encodes O +
a O +
putative O +
receptor O +
tyrosine O +
kinase O +
for O +
an O +
as O +
yet O +
unknown O +
ligand O -
. O +

Some O +
human O +
cancer O +
cells O +
have O +
been O +
found O +
to O +
overexpress O +
eph O +
mRNAs O +
without O +
gene O +
amplification O -
. O +

We O +
show O +
here O +
that O +
NIH3T3 O +
cells O +
acquire O +
tumorigenic O +
ability O +
in O +
nude O +
mice O +
and O +
make O +
colonies O +
in O +
soft O +
agar O +
with O +
a O +
viral O +
LTR O +
( O -
Long O +
Terminal O +
Repeat O -
) O -
-driven O +
artificial O +
expression O +
of O +
the O +
eph O +
gene O +
to O +
a O +
high O +
level O -
. O +

This O +
result O +
supports O +
the O +
alleged O +
contribution O +
of O +
overexpressed O +
receptor O +
tyrosine O +
kinases O +
to O +
cell O +
transformation O -
. O +

Inhibition O +
by O +
retinoic B-Chemical +
acid I-Chemical +
of O +
type O +
IV O +
collagenolysis O +
and O +
invasion O +
through O +
reconstituted O +
basement O +
membrane O +
by O +
metastatic O +
rat O +
mammary O +
adenocarcinoma O +
cells O -
. O +

The O +
activity O +
of O +
type O +
IV O +
collagenase O -
, O +
which O +
enables O +
tumor O +
cells O +
to O +
degrade O +
collagen O +
type O +
IV O +
found O +
in O +
the O +
subendothelial O +
basement O +
membrane O -
, O +
has O +
been O +
correlated O +
with O +
the O +
metastatic O +
potential O +
in O +
several O +
tumor O +
types O -
, O +
including O +
the O +
rat O +
13762NF O +
mammary O +
adenocarcinoma O +
cell O +
line O +
and O +
its O +
clones O -
. O +

In O +
this O +
study O -
, O +
we O +
examined O +
whether O +
all B-Chemical -
- I-Chemical -
trans I-Chemical -
- I-Chemical -
retinoic I-Chemical +
acid I-Chemical +
( O -
all B-Chemical -
- I-Chemical -
trans I-Chemical -
- I-Chemical -
RA I-Chemical -
) O +
and O +
other O +
retinoids O -
, O +
which O +
exhibit O +
antitumor O +
activity O +
in O +
vitro O +
and O +
in O +
vivo O -
, O +
affect O +
the O +
collagenolytic O +
activity O +
of O +
metastatic O +
rat O +
13762NF O +
mammary O +
adenocarcinoma O +
cells O -
. O +

Cells O +
of O +
the O +
highly O +
metastatic O +
lung O -
- O -
colonizing O +
clone O +
MTF7.T35.3 O -
, O +
derived O +
from O +
the O +
13762NF O +
cell O +
line O -
, O +
were O +
treated O +
for O +
3 O +
days O +
with O +
0.1 O -
, O +
1 O -
, O +
or O +
10 O +
microM O +
all B-Chemical -
- I-Chemical -
trans I-Chemical -
- I-Chemical -
RA I-Chemical -
, O +
harvested O -
, O +
and O +
seeded O +
on O +
[ B-Chemical -
3H I-Chemical -
] I-Chemical -
proline I-Chemical -
- O -
labeled O +
extracellular O +
matrix O +
deposited O +
by O +
cultured O +
rat O +
lung O +
endothelial O +
cells O +
or O +
on O +
a O +
film O +
of O +
purified O +
[ B-Chemical -
3H I-Chemical -
] I-Chemical -
proline I-Chemical -
- O -
labeled O +
type O +
IV O +
collagen O -
. O +

The O +
amount O +
of O +
radioactivity O +
released O +
into O +
the O +
medium O +
during O +
the O +
subsequent O +
24 O +
to O +
72 O +
h O +
was O +
measured O -
, O +
and O +
it O +
was O +
found O +
that O +
all B-Chemical -
- I-Chemical -
trans I-Chemical -
- I-Chemical -
RA I-Chemical +
treatment O +
inhibited O +
degradation O +
of O +
extracellular O +
matrix O +
and O +
type O +
IV O +
collagen O +
by O +
50 O +
to O +
60 O -
% O -
. O +

This O +
effect O +
was O +
observed O +
whether O +
the O +
cells O +
had O +
been O +
treated O +
with O +
all B-Chemical -
- I-Chemical -
trans I-Chemical -
- I-Chemical -
RA I-Chemical +
in O +
serum O -
- O -
free O +
medium O +
or O +
in O +
medium O +
supplemented O +
with O +
heat O -
- O -
inactivated O +
or O +
acid O -
- O -
treated O +
fetal O +
bovine O +
serum O -
. O +

The O +
growth O +
of O +
the O +
cells O +
was O +
not O +
inhibited O +
under O +
these O +
conditions O -
, O +
except O +
after O +
treatment O +
with O +
10 O +
microM O +
all B-Chemical -
- I-Chemical -
trans I-Chemical -
- I-Chemical -
RA I-Chemical +
in O +
serum O -
- O -
free O +
medium O -
. O +

The O +
reduction O +
in O +
collagenolytic O +
activity O +
was O +
observed O +
in O +
viable O +
cells O +
as O +
well O +
as O +
in O +
conditioned O +
medium O -
. O +

A O +
24-h O +
exposure O +
of O +
cells O +
to O +
all B-Chemical -
- I-Chemical -
trans I-Chemical -
- I-Chemical -
RA I-Chemical +
was O +
sufficient O +
to O +
cause O +
a O +
30 O -
% O +
decrease O +
in O +
the O +
collagenolytic O +
activity O -
, O +
and O +
this O +
inhibitory O +
effect O +
was O +
reversible O -
. O +

The O +
direct O +
addition O +
of O +
all B-Chemical -
- I-Chemical -
trans I-Chemical -
- I-Chemical -
RA I-Chemical +
to O +
conditioned O +
medium O +
had O +
no O +
effect O +
on O +
secreted O +
collagenase O +
activity O -
. O +

The O +
apparent O +
molecular O +
weights O +
of O +
the O +
collagenolytic O +
enzymes O +
were O +
determined O +
by O +
electrophoresis O +
of O +
cell O +
extracts O +
and O +
concentrated O +
conditioned O +
medium O +
in O +
type O +
IV O +
collagen O -
- O -
embedded O +
polyacrylamide B-Chemical +
gels O +
followed O +
by O +
renaturation O +
and O +
activation O +
of O +
the O +
enzymes O +
within O +
the O +
gels O -
. O +

Two O +
major O +
type O +
IV O +
collagenolytic O +
metalloproteinases O +
exhibiting O +
molecular O +
weights O +
of O +
64,000 O +
and O +
88,000 O -
, O +
respectively O -
, O +
were O +
detected O +
by O +
this O +
method O -
. O +

These O +
two O +
enzymes O +
were O +
also O +
found O +
to O +
have O +
specificity O +
for O +
gelatin O -
. O +

The O +
Mr O +
64,000 O +
enzyme O +
could O +
be O +
extracted O +
from O +
viable O +
cells O +
( O -
presumably O +
from O +
the O +
cell O +
membrane O -
) O +
by O +
2 O -
% O +
1-butanol B-Chemical -
. O +

Treatment O +
with O +
all B-Chemical -
- I-Chemical -
trans I-Chemical -
- I-Chemical -
RA I-Chemical +
decreased O +
the O +
level O +
of O +
these O +
enzymes O +
in O +
the O +
cellular O -
, O +
cell O +
membrane O -
, O +
and O +
conditioned O +
medium O +
compartments. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
400 O +
WORDS O -
) O +

Elevated O +
levels O +
of O +
diacylglycerol B-Chemical +
and O +
decreased O +
phorbol B-Chemical +
ester I-Chemical +
sensitivity O +
in O +
ras O -
- O -
transformed O +
fibroblasts O -
. O +

Diacylglycerol B-Chemical +
( O -
DG B-Chemical -
) O +
plays O +
a O +
central O +
role O +
in O +
phospholipid B-Chemical +
metabolism O +
and O +
is O +
an O +
endogenous O +
activator O +
of O +
protein O +
kinase O +
C. O +
We O +
have O +
suggested O +
that O +
constitutive O +
activation O +
of O +
this O +
kinase O +
is O +
one O +
mechanism O +
by O +
which O +
oncogenes O +
transform O +
cells O -
. O +

The O +
ras O -
- O -
encoded O +
proteins O +
are O +
similar O +
to O +
regulatory O +
G O -
- O -
proteins O +
and O +
are O +
candidates O +
for O +
the O +
unknown O +
G O -
- O -
protein O +
that O +
modulates O +
phosphatidylinositol B-Chemical +
( O -
PI B-Chemical -
) O +
turnover O -
. O +

Differences O +
in O +
polyphosphoinositide B-Chemical +
metabolism O +
have O +
been O +
reported O +
for O +
ras O -
- O -
transformed O +
cells O -
. O +

But O +
because O +
these O +
experiments O +
were O +
performed O +
on O +
confluent O +
cultures O +
of O +
established O +
cell O +
lines O -
, O +
the O +
differences O +
are O +
difficult O +
to O +
attribute O +
to O +
ras O +
transformation O -
. O +

Here O +
we O +
show O +
that O +
exponentially O +
growing O +
NIH O +
3T3 O +
fibroblasts O +
recently O +
transformed O +
by O +
Ha O -
- O -
ras O +
or O +
Ki O -
- O -
ras O +
possess O +
elevated O +
DG B-Chemical +
concentrations O +
without O +
significant O +
alterations O +
in O +
the O +
levels O +
of O +
other O +
polyphosphoinositide B-Chemical +
metabolites O -
. O +

The O +
basal O +
phosphorylation O +
of O +
protein O +
kinase O +
C O +
substrate O +
of O +
relative O +
molecular O +
mass O +
( O -
Mr O -
) O +
80,000 O +
( O -
80 O -
K O -
) O +
is O +
significantly O +
increased O +
in O +
all O +
the O +
ras O -
- O -
transformed O +
cell O +
lines O -
. O +

Surprisingly O -
, O +
however O -
, O +
further O +
phosphorylation O +
of O +
this O +
protein O +
on O +
addition O +
of O +
phorbol B-Chemical +
ester I-Chemical +
was O +
greatly O +
reduced O -
. O +

Ha O -
- O -
ras O +
cells O +
also O +
show O +
less O +
binding O +
of O +
phorbol B-Chemical +
ester I-Chemical +
than O +
control O +
cells O -
, O +
suggesting O +
that O +
elevation O +
of O +
DG B-Chemical +
causes O +
partial O +
down O -
- O -
regulation O +
in O +
addition O +
to O +
activation O +
of O +
protein O +
kinase O +
C. O +

Malate B-Chemical -
- O -
citrate B-Chemical +
cycle O +
during O +
glycolysis O +
and O +
glutaminolysis O +
in O +
Ehrlich O +
ascites O +
tumor O +
cells O -
. O +

The O +
malate B-Chemical -
- O -
citrate B-Chemical +
cycle O +
was O +
studied O +
during O +
aerobic O +
glycolysis O +
and O +
glutaminolysis O +
in O +
a O +
strain O +
of O +
Ehrlich O +
ascites O +
tumor O +
cells O +
which O +
showed O +
a O +
very O +
low O +
malate B-Chemical -
- O -
aspartate B-Chemical +
shuttle O +
system O +
activity O -
. O +

The O +
experimental O +
approach O +
includes O -
: O +
estimation O +
of O +
mitochondrial O +
NAD B-Chemical -
[ I-Chemical -
P I-Chemical -
] I-Chemical -
+-dependent O +
malic O +
enzyme O +
activity O -
; O +
respiratory O +
activity O +
of O +
freshly O +
harvested O +
or O +
fasted O +
cells O -
, O +
and O +
of O +
isolated O +
mitochondria O -
; O +
and O +
determination O +
of O +
the O +
metabolites O +
involved O +
in O +
the O +
glycolytic O +
and O +
glutaminolytic O +
pathways O -
. O +

The O +
results O +
suggest O +
that O +
in O +
this O +
strain O -
, O +
the O +
malate B-Chemical -
- O -
citrate B-Chemical +
shuttle O +
is O +
not O +
an O +
effective O +
pathway O +
for O +
transferring O +
glycolytic O +
reducing O +
equivalents O +
from O +
cytosol O +
to O +
mitochondria O -
. O +

Less O +
than O +
15 O -
% O +
of O +
the O +
glucose B-Chemical +
uptake O +
was O +
affected O +
by O +
the O +
1,2,3-benzenetricarboxylate B-Chemical +
inhibition O +
of O +
the O +
malate B-Chemical -
- O -
citrate B-Chemical +
shuttle O -
. O +

Moreover O -
, O +
in O +
the O +
presence O +
of O +
glucose B-Chemical -
, O +
the O +
malate B-Chemical -
- O -
citrate B-Chemical +
cycle O +
did O +
not O +
appear O +
to O +
play O +
an O +
important O +
role O +
in O +
the O +
glutaminolytic O +
process O -
. O +

The O +
present O +
work O +
supports O +
and O +
extends O +
the O +
finding O +
of O +
previous O +
studies O -
, O +
since O +
the O +
results O +
showed O +
that O +
the O +
glucose B-Chemical +
metabolism O +
depressed O +
the O +
oxidative O +
processes O +
in O +
Ehrlich O +
ascites O +
tumor O +
mitochondria O -
, O +
not O +
only O +
alone O -
, O +
but O +
also O +
in O +
the O +
presence O +
of O +
glutamine O -
. O +

Interestingly O -
, O +
the O +
high O +
glutamine O +
uptake O +
was O +
maintained O +
in O +
the O +
presence O +
of O +
glucose B-Chemical -
. O +

N B-Chemical -
- I-Chemical -
methyl I-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
nitrosourea I-Chemical -
- O -
induced O +
transformation O +
of O +
rat O +
urothelial O +
cells O +
in O +
vitro O +
is O +
not O +
mediated O +
by O +
activation O +
of O +
ras O +
oncogenes O -
. O +

Adult O +
rat O +
urothelial O +
cells O +
were O +
transformed O +
in O +
vitro O +
following O +
treatment O +
with O +
a O +
single O +
dose O +
of O +
N B-Chemical -
- I-Chemical -
methyl I-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
nitrosourea I-Chemical +
( O -
MNU B-Chemical -
) O +
or O +
MNU B-Chemical +
treatment O +
followed O +
by O +
promotion O +
with O +
sodium B-Chemical +
saccharin I-Chemical -
. O +

This O +
in O +
vitro O +
transformation O +
process O +
involves O +
multiple O +
steps O -
: O +
slow O -
- O -
growing O +
' O -
pre O -
- O -
neoplastic O -
' O +
epithelial O +
foci O +
are O +
induced O +
70 O -
- O -
100 O +
days O +
after O +
MNU B-Chemical +
treatment O +
and O +
from O +
such O +
foci O +
rapidly O +
proliferating O +
immortal O +
cell O +
lines O +
were O +
established O -
, O +
some O +
of O +
which O +
became O +
tumorigenic O +
after O +
a O +
further O +
latent O +
period O -
. O +

A O +
series O +
of O +
epithelial O +
cell O +
lines O +
and O +
a O +
single O +
fibroblast O +
cell O +
line O +
established O +
in O +
this O +
way O +
were O +
analysed O +
for O +
the O +
presence O +
of O +
transforming O +
genes O +
by O +
DNA O +
transfection O +
into O +
NIH3T3 O +
cells O -
. O +

None O +
of O +
the O +
epithelial O +
cell O +
lines O +
induced O +
foci O +
in O +
a O +
focus O +
formation O +
assay O -
. O +

The O +
single O +
non O -
- O -
epithelial O +
line O +
induced O +
foci O +
and O +
was O +
found O +
to O +
contain O +
an O +
activated O +
c O -
- O -
Ki O -
- O -
ras O +
gene O +
with O +
a O +
G----A B-Chemical +
transition O +
in O +
codon O +
12 O -
. O +

To O +
assay O +
for O +
the O +
possible O +
presence O +
of O +
transforming O +
genes O +
which O +
were O +
not O +
active O +
in O +
a O +
focus O +
formation O +
assay O -
, O +
two O +
of O +
the O +
epithelial O +
lines O +
were O +
analysed O +
further O +
by O +
co O -
- O -
transfection O +
with O +
a O +
dominant O +
selectable O +
marker O -
, O +
followed O +
by O +
selection O +
and O +
inoculation O +
into O +
nude O +
mice O -
. O +

No O +
tumours O +
were O +
induced O +
within O +
the O +
latent O +
period O +
for O +
tumour O +
production O +
by O +
control O +
cells O +
transfected O +
with O +
NIH3T3 O +
cell O +
DNA O +
( O -
40 O -
- O -
60 O +
days O -
) O -
. O +

These O +
results O +
suggest O +
that O +
there O +
is O +
cell O +
type O +
specificity O +
for O +
oncogene O +
activation O +
during O +
in O +
vitro O +
rat O +
bladder O +
transformation O +
initiated O +
by O +
a O +
single O +
carcinogen O +
and O +
that O +
ras O +
gene O +
activation O +
is O +
not O +
a O +
necessary O +
step O +
in O +
urothelial O +
transformation O +
in O +
vitro O -
. O +

New O +
functions O +
of O +
epidermal O +
growth O +
factor O -
: O +
stimulation O +
of O +
capillary O +
endothelial O +
cell O +
migration O +
and O +
matrix O +
dependent O +
proliferation O -
. O +

The O +
proliferative O +
response O +
of O +
bovine O +
retinal O +
capillary O +
endothelial O +
cells O +
to O +
EGF O +
is O +
dependent O +
upon O +
attaching O +
the O +
cells O +
to O +
a O +
matrix O +
of O +
fibronectin O -
. O +

Bovine O +
capillary O +
endothelial O +
cells O +
are O +
also O +
stimulated O +
to O +
actively O +
migrate O +
when O +
exposed O +
to O +
EGF O +
in O +
vitro O -
. O +

These O +
activities O +
provide O +
an O +
explanation O +
for O +
the O +
angiogenic O +
properties O +
of O +
EGF O +
in O +
vivo O -
. O +

Capillary O +
cell O +
migration O +
and O +
proliferation O +
are O +
proposed O +
as O +
sensitive O +
quantifiable O +
bioassays O +
to O +
explore O +
the O +
functional O +
domains O +
of O +
the O +
EGF O +
molecule O -
. O +

Studies O +
on O +
the O +
inactivation O +
of O +
these O +
properties O +
of O +
EGF O +
by O +
specific O +
cleavage O +
of O +
the O +
molecule O +
with O +
CNBr B-Chemical +
or O +
proteases O +
suggest O +
that O +
an O +
intact O +
loop O +
composed O +
in O +
part O +
by O +
amino O +
acid O +
residues O +
20 O +
to O +
31 O +
is O +
essential O +
for O +
at O +
least O +
some O +
functions O -
. O +

Scanning O +
electron O +
microscopy O +
of O +
vascular O +
casts O +
in O +
experimental O +
ocular O +
vasoproliferation O -
. O +

Scanning O +
electron O +
microscopy O +
of O +
vascular O +
casts O +
was O +
used O +
to O +
investigate O +
three O +
experimental O +
models O +
of O +
neovascularization O -
. O +

In O +
each O +
experimental O +
situation O -
, O +
the O +
casts O +
provided O +
a O +
valuable O +
three O +
dimensional O +
representation O +
of O +
the O +
newly O +
formed O +
blood O +
vessels O +
and O +
permitted O +
subclassification O +
of O +
the O +
vessels O +
within O +
normal O +
and O +
proliferating O +
vascular O +
networks O -
. O +

They O +
defined O +
also O +
the O +
predominant O +
origin O +
of O +
new O +
vessels O +
from O +
venules O +
and O +
capillaries O -
, O +
and O +
enabled O +
the O +
evolution O +
of O +
proliferating O +
vessels O +
into O +
arterioles O +
and O +
venules O +
to O +
be O +
documented O -
. O +

Although O +
vascular O +
casts O +
must O +
be O +
interpreted O +
with O +
caution O +
in O +
light O +
of O +
the O +
possibility O +
of O +
incomplete O +
filling O +
and O +
other O +
artifacts O -
, O +
they O +
are O +
a O +
valuable O +
tool O +
in O +
the O +
study O +
of O +
ocular O +
vasoproliferation O -
. O +

Interaction O +
between O +
cellular O +
and O +
viral O +
genes O +
in O +
the O +
expression O +
of O +
the O +
RSV O -
- O -
induced O +
transformation O -
- O -
specific O +
cell O -
- O -
surface O +
antigen O +
VCSA O -
. O +

Transformation O +
of O +
BHK O +
hamster O +
fibroblasts O +
by O +
an O +
env- O +
strain O +
of O +
Rous O +
sarcoma O +
virus O +
( O -
RSV O -
) O +
leads O +
to O +
the O +
appearance O +
at O +
the O +
cell O +
surface O +
of O +
a O +
virus O -
- O -
induced O +
nonvirion O +
antigen O +
( O -
VCSA O -
) O -
, O +
specific O +
for O +
transformation O -
, O +
whose O +
expression O +
is O +
controlled O +
by O +
the O +
transforming O +
src O +
gene O -
. O +

Previous O +
work O +
has O +
shown O +
that O +
a O +
rabbit O +
anti O -
- O -
VCSA O +
serum O +
lyses O +
specifically O -
, O +
in O +
the O +
presence O +
of O +
complement O -
, O +
51Cr B-Chemical -
- O -
labelled O +
RSV O -
- O -
transformed O +
cells O +
from O +
different O +
animal O +
species O -
. O +

Now O -
, O +
by O +
competition O +
experiments O +
with O +
a O +
panel O +
of O +
different O +
unlabelled O +
cells O +
we O +
show O +
that O +
the O +
VCSA O +
expressed O +
on O +
RSV O -
- O -
transformed O +
hamster O +
fibroblasts O +
is O +
a O +
complex O +
of O +
at O +
least O +
three O +
distinct O +
antigenic O +
specificities O -
: O +
( O -
1 O -
) O +
one O +
expressed O +
on O +
all O +
RSV O -
- O -
transformed O +
fibroblasts O -
, O +
regardless O +
their O +
species O +
and O +
the O +
subgroup O +
or O +
strain O +
of O +
the O +
transforming O +
virus O -
; O +
( O -
2 O -
) O +
one O +
cross O -
- O -
reacting O +
with O +
a O +
cell O -
- O -
surface O +
antigen O +
( O -
CSA O -
) O +
expressed O +
at O +
various O +
degrees O +
on O +
untransformed O +
avian O +
fibroblasts O -
, O +
but O +
not O +
on O +
mammalian O +
fibroblasts O -
; O +
( O -
3 O -
) O +
one O +
species O -
- O -
specific O -
, O +
present O +
only O +
on O +
RSV O -
- O -
transformed O +
hamster O +
fibroblasts O -
. O +

It O +
is O +
concluded O +
that O +
VCSA O +
is O +
a O +
complex O +
of O +
several O +
antigenic O +
determinants O -
, O +
and O +
that O +
some O +
of O +
these O +
differ O +
in O +
different O +
cells O +
transformed O +
by O +
RSV O -
. O +

This O +
observation O +
indicates O +
that O +
VCSA O +
expression O +
at O +
the O +
cell O +
surface O +
is O +
likely O +
to O +
be O +
the O +
result O +
of O +
the O +
interaction O +
between O +
the O +
viral O +
src O +
gene O +
product O +
pp60src O +
with O +
host O +
cell O +
gene O -
( O -
s O -
) O +
or O +
gene O +
product O -
( O -
s O -
) O -
, O +
rather O +
than O +
the O +
simple O +
expression O +
of O +
this O +
molecule O +
at O +
the O +
cell O +
surface O -
. O +

Angiogenesis O -
: O +
initiation O +
and O +
control O -
. O +

From O +
in O +
vivo O +
experiments O +
using O +
new O +
methods O +
such O +
as O +
the O +
rabbit O +
cornea O -
, O +
it O +
is O +
now O +
becoming O +
clear O +
that O +
the O +
growth O +
of O +
a O +
capillary O +
involves O +
an O +
ordered O +
sequence O +
of O +
events O +
that O +
includes O +
lysis O +
of O +
the O +
basement O +
membrane O +
of O +
a O +
parent O +
venule O -
, O +
directional O +
migration O +
of O +
capillary O +
endothelial O +
cells O +
toward O +
the O +
angiogenic O +
stimulus O -
, O +
lumen O +
formation O -
, O +
development O +
of O +
branches O -
, O +
and O +
anastomosis O +
of O +
the O +
tip O +
of O +
one O +
tube O +
with O +
another O +
to O +
form O +
a O +
loop O -
. O +

It O +
is O +
also O +
clear O +
that O +
diffusible O +
angiogenic O +
stimuli O +
can O +
be O +
released O +
not O +
only O +
from O +
most O +
solid O +
tumors O -
, O +
but O +
also O +
from O +
at O +
least O +
three O +
non O -
- O -
neoplastic O +
cells O -
. O +

These O +
include O +
activated O +
macrophages O -
, O +
sensitized O +
lymphocytes O -
, O +
and O +
adipocytes O -
. O +

Other O +
normal O +
tissues O +
can O +
also O +
stimulate O +
angiogenesis O -
, O +
but O +
the O +
type O +
of O +
cell O +
giving O +
rise O +
to O +
the O +
angiogenic O +
stimulus O +
is O +
unknown O -
, O +
and O +
the O +
period O +
of O +
angiogenic O +
stimulation O +
is O +
brief O -
. O +

With O +
the O +
recent O +
ability O +
to O +
clone O +
capillary O +
endothelial O +
cells O +
and O +
to O +
carry O +
them O +
in O +
long O -
- O -
term O +
culture O -
, O +
it O +
has O +
been O +
possible O +
to O +
further O +
delineate O +
the O +
mechanism O +
of O +
capillary O +
growth O -
. O +

In O +
vitro O +
studies O +
have O +
shown O +
that O +
the O +
mast O +
cell O +
seems O +
to O +
behave O +
as O +
a O +
helper O +
cell O +
for O +
capillary O +
endothelial O +
cells O -
, O +
in O +
some O +
way O +
speeding O +
up O +
their O +
rate O +
of O +
directional O +
migration O -
. O +

At O +
this O +
writing O -
, O +
heparin B-Chemical +
appears O +
to O +
be O +
the O +
principal O +
mast O +
cell O +
factor O +
responsible O +
for O +
this O +
effect O +
on O +
capillary O +
endothelial O +
cells O -
. O +

One O +
theoretical O +
possibility O +
is O +
that O +
mast O +
cells O +
may O +
prepare O +
the O +
matrix O -
, O +
perhaps O +
by O +
slow O +
release O +
of O +
heparin B-Chemical -
, O +
so O +
that O +
capillary O +
sprouts O +
can O +
more O +
easily O +
move O +
through O +
it O +
toward O +
their O +
angiogenic O +
target O -
. O +

While O +
the O +
study O +
of O +
angiogenesis O +
as O +
a O +
phenomenon O +
is O +
still O +
in O +
an O +
early O +
phase O -
, O +
it O +
has O +
become O +
possible O -
, O +
by O +
using O +
a O +
combination O +
of O +
in O +
vitro O +
and O +
in O +
vivo O +
techniques O -
, O +
to O +
more O +
thoroughly O +
understand O +
the O +
initiation O +
and O +
control O +
of O +
capillary O +
growth O -
. O +

Molecular O +
events O +
leading O +
to O +
enhanced O +
glucose B-Chemical +
transport O +
in O +
Rous O +
sarcoma O +
virus O -
- O -
transformed O +
cells O -
. O +

Transformation O +
by O +
Rous O +
sarcoma O +
virus O +
results O +
in O +
a O +
dramatic O +
increase O +
in O +
the O +
rate O +
at O +
which O +
the O +
transformed O +
cells O +
transport O +
glucose B-Chemical +
across O +
the O +
cell O +
membrane O -
. O +

The O +
increased O +
transport O +
rate O +
is O +
a O +
consequence O +
of O +
an O +
increased O +
number O +
of O +
transporters O +
in O +
the O +
transformed O +
cells O -
. O +

Utilizing O +
antibody O +
raised O +
against O +
the O +
purified O +
human O +
erythrocyte O +
glucose B-Chemical +
transporter O -
, O +
we O +
have O +
identified O +
the O +
glucose B-Chemical +
transporter O +
as O +
a O +
membrane O +
glycoprotein O +
with O +
a O +
monomer O +
Mr O +
of O +
approximately O +
41,000 O -
. O +

The O +
increased O +
rate O +
of O +
glucose B-Chemical +
transport O +
is O +
dependent O +
on O +
the O +
activity O +
of O +
pp60src O -
, O +
the O +
transforming O +
protein O +
of O +
Rous O +
sarcoma O +
virus O -
. O +

This O +
protein O +
has O +
been O +
shown O +
to O +
be O +
a O +
protein O +
kinase O +
that O +
phosphorylates O +
on O +
tyrosine O +
residues O -
. O +

We O +
have O +
examined O +
the O +
tyrosine O +
phosphorylation O +
of O +
a O +
major O +
cellular O +
protein O +
of O +
Mr O +
36,000 O +
in O +
cells O +
infected O +
with O +
a O +
panel O +
of O +
partially O +
transforming O +
mutants O +
of O +
Rous O +
sarcoma O +
virus O -
. O +

One O +
of O +
these O +
mutants O +
( O -
CU2 O -
) O +
increases O +
the O +
rate O +
of O +
glucose B-Chemical +
transport O +
only O +
slightly O +
and O +
does O +
not O +
render O +
the O +
infected O +
cells O +
fully O +
anchorage O +
independent O +
or O +
tumorigenic O +
( O -
although O +
other O +
transformation O +
parameters O +
are O +
fully O +
induced O -
) O -
. O +

Cells O +
infected O +
with O +
this O +
mutant O +
display O +
a O +
36,000-dalton O +
protein O +
that O +
is O +
phosphorylated O +
to O +
a O +
considerably O +
lesser O +
extent O +
than O +
cells O +
infected O +
with O +
wild O -
- O -
type O +
virus O -
. O +

Analyses O +
of O +
this O +
sort O +
may O +
help O +
to O +
identify O +
the O +
cellular O +
targets O +
of O +
pp60src O +
whose O +
phosphorylation O +
is O +
necessary O +
for O +
the O +
increased O +
glucose B-Chemical +
transport O +
rate O -
. O +

Hemostasis O +
and O +
mechanism O +
of O +
action O +
of O +
selective O +
antimetastatic O +
drugs O +
in O +
mice O +
bearing O +
Lewis O +
lung O +
carcinoma O -
. O +

The O +
selective O +
antimetastatic O +
agents O +
p- B-Chemical -
( I-Chemical -
3,3-dimethyl-1-triazeno I-Chemical -
) I-Chemical -
benzoic I-Chemical +
acid I-Chemical +
potassium I-Chemical +
salt I-Chemical +
( O -
DM B-Chemical -
- I-Chemical -
COOK I-Chemical -
) O -
, O +
5- B-Chemical -
( I-Chemical -
3,3-dimethyl-1-triazeno I-Chemical -
) I-Chemical -
imidazole-4-carboxamide I-Chemical +
( O -
DTIC B-Chemical -
) O +
and O +
( B-Chemical -
+ I-Chemical -
/- I-Chemical -
) I-Chemical -
1,2-di I-Chemical -
( I-Chemical -
3,5-dioxopiperazin-1-yl I-Chemical -
) I-Chemical -
propane I-Chemical +
( O -
ICRF-159 B-Chemical -
) O +
have O +
been O +
shown O +
to O +
markedly O +
depress O +
the O +
formation O +
of O +
spontaneous O +
hematogenous O +
metastases O +
in O +
mice O +
bearing O +
s.c O -
. O +

Lewis O +
lung O +
carcinoma O -
, O +
with O +
a O +
mechanism O +
unrelated O +
to O +
cytotoxicity O +
for O +
tumor O +
cells O -
. O +

The O +
effects O +
on O +
hemostasis O +
of O +
DM B-Chemical -
- I-Chemical -
COOK I-Chemical -
, O +
DTIC B-Chemical +
and O +
ICRF-159 B-Chemical +
have O +
thus O +
been O +
examined O +
in O +
comparison O +
with O +
those O +
of O +
a O +
purely O +
cytotoxic O +
agent O -
, O +
cyclophosphamide B-Chemical -
, O +
in O +
mice O +
bearing O +
i.m O -
. O +

Lewis O +
lung O +
carcinoma O -
. O +

The O +
parameters O +
considered O +
are O +
the O +
number O +
of O +
platelets O +
and O +
their O +
aggregability O -
, O +
prothrombin O +
and O +
partial O +
thromboplastin O +
times O -
, O +
plasma O +
fibrinogen O +
concentration O +
and O +
tumor O +
cell O +
procoagulant O +
activity O -
. O +

Slight O +
variations O +
are O +
caused O +
by O +
drug O +
treatment O +
in O +
tumor O -
- O -
bearing O +
mice O +
as O +
compared O +
with O +
untreated O +
tumor O -
- O -
bearing O +
controls O -
; O +
the O +
pattern O +
of O +
effects O +
of O +
the O +
selective O +
antimetastatic O +
agents O +
does O +
not O +
differ O +
from O +
that O +
of O +
the O +
reference O +
cytotoxic O +
compound O +
used O -
, O +
cyclophosphamide B-Chemical -
. O +

These O +
data O +
thus O +
indicate O +
that O +
the O +
effects O +
on O +
hemostasis O +
of O +
the O +
drugs O +
examined O +
can O +
contribute O +
only O +
marginally O +
to O +
their O +
antimetastatic O +
action O -
, O +
since O +
more O +
pronounced O +
effects O +
on O +
hemostasis O +
have O +
been O +
shown O +
to O +
be O +
required O +
to O +
significantly O +
affect O +
metastasis O +
formation O -
. O +

Inhibition O +
by O +
N- B-Chemical -
( I-Chemical -
phosphonacetyl I-Chemical -
) I-Chemical -
-L I-Chemical -
- I-Chemical -
aspartate I-Chemical +
of O +
Ehrlich O +
ascites O +
tumour O +
growth O +
and O +
glucose B-Chemical +
transport O -
. O +

N- B-Chemical -
( I-Chemical -
Phosphonacetyl I-Chemical -
) I-Chemical -
-L I-Chemical -
- I-Chemical -
aspartate I-Chemical +
( O -
PALA B-Chemical -
) O +
suppressed O +
the O +
growth O +
of O +
Ehrlich O +
ascites O +
tumour O +
cells O +
in O +
vivo O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

Simultaneously O +
as O +
the O +
growth O +
rate O +
decreased O -
, O +
the O +
cellular O +
uptake O +
of O +
glucose B-Chemical +
and O +
the O +
density O +
of O +
a O +
class O +
of O +
glucose B-Chemical -
- O -
reversible O +
binding O +
sites O +
for O +
cytochalasin B-Chemical +
B I-Chemical +
on O +
the O +
cell O +
surface O +
were O +
also O +
found O +
to O +
be O +
reduced O -
. O +

There O +
is O +
a O +
highly O +
significant O +
correlation O +
between O +
the O +
magnitude O +
of O +
changes O +
in O +
the O +
number O +
of O +
cytochalasin B-Chemical +
B I-Chemical +
binding O +
sites O +
and O +
the O +
magnitude O +
of O +
changes O +
in O +
glucose B-Chemical +
uptake O -
. O +

The O +
physiological O +
significance O +
of O +
these O +
observations O +
are O +
discussed O -
. O +

A O +
transcript O +
from O +
the O +
long O +
terminal O +
repeats O +
of O +
a O +
murine O +
retrovirus O +
associated O +
with O +
trans O +
activation O +
of O +
cellular O +
genes O -
. O +

Infection O +
of O +
human O +
or O +
murine O +
cells O +
with O +
murine O +
leukemia O +
viruses O +
rapidly O +
increases O +
the O +
expression O +
of O +
a O +
number O +
of O +
genes O +
that O +
belong O +
to O +
the O +
immunoglobulin O +
superfamily O +
and O +
are O +
involved O +
in O +
T O -
- O -
lymphocyte O +
activation O -
, O +
including O +
the O +
class O +
I O +
major O +
histocompatibility O +
complex O +
antigens O -
. O +

We O +
have O +
reported O +
recently O +
that O +
the O +
long O +
terminal O +
repeat O +
( O -
LTR O -
) O +
of O +
Moloney O +
murine O +
leukemia O +
virus O +
encodes O +
a O +
trans O +
activator O +
which O +
induces O +
transcription O +
and O +
expression O +
of O +
class O +
I O +
major O +
histocompatibility O +
complex O +
genes O +
and O +
certain O +
cytokine O +
genes O -
. O +

The O +
portion O +
of O +
the O +
LTR O +
responsible O +
for O +
trans O +
activation O +
was O +
mapped O +
by O +
deletions O +
to O +
lie O +
within O +
the O +
U3 O +
region O -
. O +

We O +
demonstrate O +
here O +
that O +
a O +
transcript O +
is O +
initiated O +
within O +
the O +
U3 O +
region O +
and O +
that O +
its O +
presence O +
correlates O +
with O +
the O +
trans O -
- O -
activating O +
activity O -
. O +

Analysis O +
of O +
the O +
LTR O +
region O +
reveals O +
a O +
potential O +
internal O +
promoter O +
element O +
for O +
RNA O +
polymerase O +
III O +
transcription O +
within O +
the O +
U3 O +
region O -
. O +

Studies O +
with O +
polymerase O +
inhibitors O +
suggest O +
that O +
this O +
LTR O +
transcript O -
, O +
designated O +
let O +
( O -
LTR O -
- O -
encoded O +
trans O +
activator O -
) O -
, O +
is O +
a O +
product O +
of O +
RNA O +
polymerase O +
III O -
. O +

The O +
mechanisms O +
whereby O +
RNA O +
leukemia O +
viruses O +
cause O +
lymphoid O +
neoplasia O +
after O +
a O +
long O +
latent O +
period O +
have O +
been O +
extensively O +
studied O +
but O +
are O +
only O +
partially O +
understood O -
. O +

The O +
region O +
of O +
the O +
LTR O +
identified O +
here O +
as O +
being O +
important O +
in O +
trans O +
activation O +
has O +
recently O +
been O +
shown O +
to O +
be O +
a O +
critical O +
determinant O +
of O +
the O +
leukemogenicity O +
and O +
latency O +
of O +
Moloney O +
murine O +
leukemia O +
virus O -
. O +

These O +
findings O +
suggest O +
a O +
novel O +
mechanism O +
of O +
retrovirus O -
- O -
induced O +
activation O +
of O +
cellular O +
gene O +
expression O -
, O +
potentially O +
contributing O +
to O +
leukemogenesis O -
. O +

Ultraviolet O +
B O +
irradiation O +
promotes O +
tumorigenic O +
and O +
metastatic O +
properties O +
in O +
primary O +
cutaneous O +
melanoma O +
via O +
induction O +
of O +
interleukin O +
8 O -
. O +

UV O +
radiation O +
has O +
been O +
shown O +
to O +
play O +
a O +
role O +
in O +
the O +
initiation O +
of O +
human O +
cutaneous O +
melanoma O -
, O +
but O +
its O +
role O +
in O +
the O +
development O +
of O +
malignant O +
melanoma O +
to O +
the O +
metastatic O +
state O +
is O +
not O +
very O +
well O +
defined O -
. O +

Although O +
previous O +
studies O +
have O +
concentrated O +
on O +
the O +
effect O +
of O +
UV O -
- O -
B O +
on O +
the O +
host O +
immune O +
response O -
, O +
the O +
effect O +
of O +
UV O -
- O -
B O +
on O +
the O +
tumor O +
cells O +
was O +
not O +
elucidated O -
. O +

Here O +
we O +
show O +
that O +
UV O -
- O -
B O +
can O +
induce O +
interleukin O +
8 O +
( O -
IL-8 O -
) O +
mRNA O +
and O +
protein O +
secretion O +
in O +
human O +
cutaneous O +
melanoma O +
with O +
negligible O +
expression O +
of O +
IL-8 O -
. O +

UV O -
- O -
B O -
- O -
induced O +
IL-8 O +
was O +
constitutively O +
expressed O +
60 O +
days O +
after O +
irradiation O +
in O +
tumors O +
implanted O +
in O +
mice O -
. O +

Induction O +
of O +
IL-8 O +
was O +
UV O -
- O -
B O +
dose O +
dependent O +
and O +
blocked O +
by O +
cyclohexamide B-Chemical -
, O +
indicating O +
that O +
de O +
novo O +
protein O +
synthesis O +
is O +
required O +
for O +
its O +
expression O -
. O +

The O +
UV O -
- O -
irradiated O +
cells O +
demonstrated O +
enhanced O +
tumorigenicity O +
and O +
metastatic O +
potential O +
in O +
nude O +
mice O -
. O +

The O +
increase O +
in O +
tumorigenicity O +
and O +
metastatic O +
ability O +
could O +
be O +
explained O +
by O +
the O +
increase O +
in O +
Mr O +
72,000 O +
type O +
IV O +
collagenase O +
activity O +
and O +
angiogenesis O +
attributed O +
to O +
the O +
induction O +
of O +
IL-8 O +
after O +
irradiation O -
. O +

The O +
acquisition O +
of O +
the O +
metastatic O +
phenotype O +
induced O +
by O +
UV O -
- O -
B O +
could O +
not O +
be O +
attributed O +
to O +
abnormalities O +
in O +
the O +
p53 O +
or O +
MTS-1 O +
( O -
p16INK4 O -
) O +
genes O -
. O +

To O +
the O +
best O +
of O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
report O +
to O +
show O +
that O +
UV O -
- O -
B O +
can O +
increase O +
the O +
aggressiveness O +
of O +
human O +
cutaneous O +
melanoma O +
for O +
growth O +
and O +
metastasis O -
. O +

Down O -
- O -
regulation O +
of O +
collagen O +
XII O +
in O +
transformed O +
mesenchymal O +
cells O -
. O +

Collagen O +
XII O +
is O +
a O +
complex O +
multidomain O +
protein O +
associated O +
with O +
the O +
surface O +
of O +
interstitial O +
collagen O +
fibrils O -
. O +

This O +
protein O +
is O +
produced O +
in O +
large O +
amounts O +
by O +
fibroblasts O +
cultivated O +
in O +
vitro O -
. O +

However O -
, O +
it O +
is O +
completely O +
absent O +
from O +
cells O +
transformed O +
by O +
the O +
oncogene O +
v O -
- O -
myc O +
or O +
v O -
- O -
src O +
and O +
from O +
cells O +
derived O +
from O +
a O +
methylcholanthrene B-Chemical -
- O -
induced O +
fibrosarcoma O -
. O +

Since O +
all O +
these O +
cells O +
lack O +
any O +
mRNA O +
for O +
collagen O -
, O +
XII O -
, O +
it O +
seems O +
likely O +
that O +
the O +
synthesis O +
is O +
blocked O +
at O +
the O +
transcriptional O +
level O -
. O +

Experiments O +
with O +
a O +
temperature O -
- O -
sensitive O +
mutant O +
of O +
Rous O +
sarcoma O +
virus O +
demonstrated O +
that O +
a O +
single O +
oncogene O +
product O +
is O +
sufficient O +
to O +
inhibit O +
the O +
synthesis O -
. O +

A O +
reduction O +
in O +
the O +
expression O +
of O +
collagen O +
XII O +
might O +
have O +
profound O +
effects O +
on O +
the O +
stability O +
of O +
the O +
extracellular O +
matrix O +
of O +
transformed O +
cells O -
. O +

Modulation O +
of O +
apoptosis O +
in O +
human O +
myeloid O +
leukemic O +
cells O +
by O +
GM O -
- O -
CSF O -
. O +

Apoptosis O +
( O -
programmed O +
cell O +
death O -
) O +
regulates O +
cell O +
population O +
size O -
. O +

To O +
determine O +
the O +
mechanisms O +
whereby O +
hematopoietic O +
growth O +
factors O +
( O -
HGFs O -
) O +
modulate O +
apoptosis O +
in O +
human O +
myeloid O +
leukemic O +
cells O -
, O +
we O +
evaluated O +
the O +
roles O +
of O +
protein O +
and O +
mRNA O +
synthesis O +
for O +
altering O +
apoptosis O +
in O +
growth O +
factor O -
- O -
stimulated O +
vs. O +
quiescent O +
leukemic O +
TF1 O +
cells O -
. O +

Lysates O +
of O +
cells O +
from O +
the O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O -
GM O -
- O -
CSF O -
) O -
-dependent O +
myeloid O +
leukemic O +
cell O +
line O +
TF1 O +
were O +
separated O +
into O +
high O +
molecular O +
weight O +
( O -
HMW O -
) O +
pellets O +
of O +
intact O +
DNA O +
and O +
supernatants O +
of O +
fragmented O +
low O +
MW O +
( O -
LMW O -
) O +
DNA O -
, O +
and O +
the O +
DNA O +
purified O +
from O +
these O +
fractions O +
was O +
quantified O -
. O +

In O +
the O +
absence O +
of O +
both O +
GM O -
- O -
CSF O +
and O +
fetal O +
bovine O +
serum O +
( O -
FBS O -
) O -
, O +
70 O -
% O +
of O +
the O +
DNA O +
was O +
fragmented O +
after O +
3 O +
days O +
in O +
culture O -
, O +
with O +
a O +
characteristic O +
apoptotic O +
ladder O -
- O -
like O +
pattern O +
on O +
agarose B-Chemical +
gel O +
electrophoresis O -
, O +
whereas O +
this O +
proportion O +
had O +
initially O +
been O +
< O +
5 O -
% O -
. O +

In O +
contrast O -
, O +
less O +
than O +
5 O -
% O +
of O +
the O +
DNA O +
was O +
fragmented O +
in O +
cells O +
incubated O +
with O +
GM O -
- O -
CSF O +
plus O +
FBS O +
or O +
GM O -
- O -
CSF O +
alone O -
. O +

Delayed O +
addition O +
of O +
GM O -
- O -
CSF O -
, O +
but O +
not O +
FBS O -
, O +
permitted O +
partial O +
rescue O +
of O +
the O +
cells O -
, O +
inhibiting O +
increasing O +
rates O +
of O +
accumulation O +
of O +
fragmented O +
DNA O -
. O +

When O +
the O +
macro O -
- O -
molecular O +
synthesis O +
inhibitor O +
cycloheximide B-Chemical +
( O -
CHX B-Chemical -
) O +
or O +
actinomycin B-Chemical +
D I-Chemical +
( O -
Act B-Chemical +
D I-Chemical -
) O +
was O +
present O +
for O +
26 O +
hours O +
in O +
the O +
absence O +
of O +
GM O -
- O -
CSF O +
and O +
FBS O -
, O +
apoptosis O +
was O +
inhibited O -
. O +

In O +
contrast O -
, O +
in O +
the O +
presence O +
of O +
GM O -
- O -
CSF O +
or O +
FBS O -
, O +
apoptosis O +
was O +
enhanced O +
upon O +
addition O +
of O +
CHX B-Chemical +
or O +
Act B-Chemical +
D. I-Chemical +
The O +
latter O +
effect O +
persisted O +
even O +
with O +
the O +
late O +
addition O +
of O +
CHX B-Chemical -
. O +

These O +
findings O +
indicate O +
that O +
disparate O +
mechanisms O +
of O +
enhancing O +
or O +
inhibiting O +
apoptosis O +
exist O +
in O +
myeloid O +
leukemic O +
cells O +
related O +
to O +
environmental O +
conditions O -
, O +
including O +
HGF O -
- O -
regulated O +
cellular O +
synthesis O +
of O +
distinct O +
proteins O +
and O +
mRNA O -
. O +

[ O -
The O +
erbB O +
gene O +
family O -
: O +
significance O +
for O +
tumor O +
development O -
, O +
prognosis O +
and O +
new O +
therapeutic O +
modalities O -
] O -
. O +

RNA O +
and O +
DNA O +
viruses O +
can O +
be O +
transforming O +
and O +
tumourigenic O +
agents O -
. O +

The O +
transformation O +
is O +
a O +
consequence O +
of O +
the O +
ability O +
of O +
viruses O +
to O +
integrate O +
into O +
the O +
host O +
cell O -
's O +
DNA O +
and O +
to O +
produce O +
transforming O +
proteins O -
. O +

These O +
proteins O +
are O +
mainly O +
produced O +
by O +
specific O +
integral O +
parts O +
of O +
the O +
viral O +
genome O -
, O +
the O +
oncogenes O -
. O +

Comparison O +
between O +
RNA O -
/ O -
DNA O +
sequence O +
of O +
viral O +
oncogenes O +
and O +
normal O +
human O +
genome O +
of O +
non O -
- O -
transformed O +
cells O +
revealed O +
high O +
sequence O +
similarities O +
in O +
specific O +
genomic O +
areas O -
, O +
which O +
were O +
named O +
cellular O +
proto O -
- O -
oncogens O -
. O +

They O +
are O +
important O +
components O +
of O +
the O +
growth O +
regulatory O +
pathways O +
in O +
normal O +
cells O -
. O +

The O +
accumulation O +
of O +
genetic O +
alterations O +
of O +
some O +
proto O -
- O -
oncogens O -
, O +
like O +
the O +
erbB O -
- O -
family O -
, O +
may O +
be O +
part O +
of O +
the O +
mechanism O -
, O +
by O +
which O +
malignant O +
cells O +
can O +
acquire O +
a O +
selective O +
growth O +
advantage O -
. O +

The O +
epidermal O +
growth O +
factor O +
receptor O +
( O -
EGF O -
- O -
R O -
, O +
c O -
- O -
erbB1 O -
) O -
, O +
Her-2 O -
/ O -
neu O +
( O -
c O -
- O -
erbB2 O -
) O -
, O +
and O +
c O -
- O -
erbB3 O +
are O +
members O +
of O +
the O +
erbB O -
- O -
family O -
. O +

The O +
detection O +
of O +
increased O +
abundance O +
of O +
EGF O -
- O -
R O +
or O +
Her-2 O -
/ O -
neu O +
proteins O +
in O +
human O +
tumours O +
can O +
provide O +
additional O +
information O +
on O +
the O +
disease O -
- O -
free O +
survival O +
and O +
overall O +
survival O +
for O +
patients O +
with O +
breast O -
, O +
ovarian O -
, O +
endometrial O +
or O +
cervical O +
cancer O -
. O +

Molecular O +
and O +
cell O -
- O -
physiological O +
analyses O +
have O +
improved O +
the O +
understanding O +
of O +
tumour O +
biology O +
and O +
provide O +
the O +
opportunity O +
for O +
new O +
therapeutic O +
approaches O -
. O +

Monoclonal O +
antibody O +
targeted O +
therapy O +
directed O +
against O +
EGF O -
- O -
R O +
or O +
Her-2 O -
/ O -
neu O -
, O +
the O +
use O +
of O +
anti O -
- O -
sense O +
oligonucleotides O +
and O +
oligodeoxynucleotides O -
, O +
and O +
the O +
application O +
of O +
tyrosine O +
kinase O +
and O +
protein O +
C O -
- O -
kinase O +
inhibitors O +
are O +
currently O +
being O +
investigated O -
. O +

Transforming O +
growth O +
factor O +
beta O +
1 O +
promotes O +
spontaneous O +
transformation O +
of O +
cultured O +
rat O +
liver O +
epithelial O +
cells O -
. O +

The O +
neoplastic O +
transformation O +
of O +
cultured O +
rat O +
liver O +
epithelial O +
cells O +
by O +
various O +
means O +
has O +
consistently O +
been O +
associated O +
with O +
the O +
development O +
of O +
resistance O +
to O +
the O +
mito O -
- O -
inhibitory O +
effect O +
of O +
transforming O +
growth O +
factor O +
beta O +
( O -
TGF O -
- O -
beta O -
) O -
, O +
suggesting O +
that O +
such O +
phenotype O +
plays O +
a O +
mechanistic O +
role O +
during O +
the O +
transformation O +
of O +
these O +
cells O -
. O +

We O +
have O +
studied O +
the O +
induction O +
of O +
the O +
" O -
TGF O -
- O -
beta O -
- O -
resistant O -
" O +
phenotype O +
in O +
a O +
clonal O +
strain O +
of O +
early O +
passage O +
WB O -
- O -
F344 O +
normal O +
cultured O +
rat O +
liver O +
epithelial O +
cells O -
, O +
the O +
proliferation O +
of O +
which O +
was O +
markedly O +
inhibited O +
by O +
TGF O -
- O -
beta O -
. O +

The O +
control O +
WB O +
cells O +
in O +
continuous O +
culture O +
slowly O +
developed O +
TGF O -
- O -
beta O +
resistance O -
. O +

However O -
, O +
when O +
the O +
same O +
cells O +
were O +
exposed O +
to O +
step O -
- O -
wise O +
increases O +
of O +
TGF O -
- O -
beta O +
concentration O +
in O +
their O +
culture O +
medium O -
, O +
the O +
development O +
of O +
TGF O -
- O -
beta O +
resistance O +
was O +
accelerated O -
. O +

Cells O +
which O +
had O +
been O +
grown O +
in O +
medium O +
containing O +
1 O +
ng O -
/ O -
ml O +
TGF O -
- O -
beta O +
developed O +
colony O -
- O -
forming O +
capacity O +
in O +
soft O +
agar O +
containing O +
epidermal O +
growth O +
factor O -
. O +

Cells O +
which O +
were O +
grown O +
in O +
media O +
containing O +
5 O +
and O +
10 O +
ng O -
/ O -
ml O +
TGF O -
- O -
beta O +
demonstrated O +
a O +
low O +
level O +
of O +
colony O -
- O -
forming O +
efficiency O +
in O +
soft O +
agar O +
medium O +
without O +
added O +
epidermal O +
growth O +
factor O +
and O +
tumorigenicity O +
in O +
isogeneic O +
rats O -
. O +

These O +
TGF O -
- O -
beta O -
- O -
resistant O +
cells O +
also O +
exhibited O +
progressively O +
increasing O +
levels O +
of O +
expression O +
of O +
the O +
c O -
- O -
fos O +
and O +
and O +
myc O +
mRNA O -
, O +
and O +
increased O +
resistance O +
to O +
the O +
cytotoxicity O +
of O +
Adriamycin B-Chemical +
and O +
melphalan B-Chemical -
. O +

The O +
latter O +
phenomenon O +
was O +
accompanied O +
by O +
an O +
increase O +
in O +
the O +
mdr-1 O +
mRNA O +
expression O -
, O +
cellular O +
glutathione B-Chemical +
level O -
, O +
and O +
glutathione O +
S O -
- O -
transferase O +
activity O -
. O +

The O +
results O +
suggest O +
that O +
chronic O +
exposure O +
to O +
high O +
concentration O +
of O +
TGF O -
- O -
beta O +
promotes O +
the O +
spontaneous O +
neoplastic O +
transformation O +
of O +
cultured O +
rat O +
liver O +
epithelial O +
cells O -
, O +
and O +
that O +
this O +
process O +
may O +
represent O +
one O +
of O +
the O +
mechanisms O +
of O +
cellular O +
adaptation O +
for O +
induction O +
of O +
the O +
multidrug O -
- O -
resistant O +
phenotype O +
during O +
the O +
carcinogenesis O +
of O +
epithelial O +
cells O -
. O +

Elevated O +
expression O +
of O +
the O +
junB O +
proto O -
- O -
oncogene O +
is O +
essential O +
for O +
v O -
- O -
fos O +
induced O +
transformation O +
of O +
Rat-1 O +
cells O -
. O +

We O +
previously O +
described O +
the O +
isolation O +
of O +
non O -
- O -
tumorigenic O +
revertants O +
from O +
mutagenized O +
populations O +
of O +
v O -
- O -
fos O -
- O -
transformed O +
Rat-1 O +
cells O +
( O -
Zarbl O +
et O +
al. O -
, O +
1987 O -
) O -
. O +

In O +
the O +
present O +
study O +
we O +
examined O +
the O +
possibility O +
that O +
the O +
revertant O +
phenotype O +
resulted O +
from O +
mutations O +
that O +
altered O +
the O +
expression O +
or O +
activities O +
of O +
the O +
c O -
- O -
jun O +
or O +
junB O +
proto O -
- O -
oncogenes O -
. O +

The O +
results O +
demonstrated O +
that O +
levels O +
of O +
the O +
c O -
- O -
jun O +
mRNA O +
and O +
protein O +
were O +
unchanged O +
in O +
the O +
revertants O +
when O +
compared O +
to O +
the O +
transformed O +
parental O +
cells O -
, O +
and O +
ectopic O +
overexpression O +
of O +
c O -
- O -
jun O +
failed O +
to O +
retransform O +
the O +
revertants O -
. O +

Although O +
one O +
mutant O +
allele O +
was O +
detected O +
in O +
revertant O +
EMS-1 O -
- O -
19 O -
, O +
overexpression O +
of O +
this O +
mutant O +
allele O +
failed O +
to O +
inhibit O +
v O -
- O -
fos O +
induced O +
cell O +
transformation O -
. O +

Together O +
these O +
results O +
indicated O +
that O +
the O +
revertant O +
phenotype O +
did O +
not O +
result O +
from O +
altered O +
expression O +
or O +
mutations O +
in O +
the O +
c O -
- O -
jun O +
gene O -
. O +

In O +
contrast O +
to O +
the O +
results O +
obtained O +
with O +
c O -
- O -
jun O -
, O +
the O +
levels O +
of O +
junB O +
mRNA O +
and O +
protein O +
were O +
found O +
to O +
be O +
reduced O +
two- O +
or O +
threefold O +
in O +
revertant O +
EMS-1 O -
- O -
19 O -
. O +

Ectopic O +
overexpression O +
of O +
junB O +
induced O +
transformation O +
of O +
revertant O +
EMS-1 O -
- O -
19 O -
, O +
but O +
failed O +
to O +
transform O +
Rat-1 O +
cells O -
. O +

Moreover O -
, O +
about O +
10 O -
% O +
of O +
v O -
- O -
fos O +
transformed O +
cells O +
transfected O +
with O +
vectors O +
that O +
express O +
antisense O +
junB O +
mRNA O +
acquired O +
a O +
non O -
- O -
transformed O +
phenotype O -
. O +

Together O +
these O +
results O +
indicate O +
that O +
expression O +
of O +
junB O +
above O +
a O +
threshold O +
level O +
is O +
essential O +
for O +
v O -
- O -
fos O -
- O -
induced O +
transformation O +
of O +
Rat-1 O +
fibroblasts O -
. O +

H O -
- O -
ras O +
mutations O +
in O +
human O +
pituitary O +
carcinoma O +
metastases O -
. O +

Molecular O +
mechanisms O +
of O +
pituitary O +
tumorigenesis O +
were O +
studied O +
using O +
Polymerase O +
chain O +
reaction O -
- O -
single O +
stranded O +
conformational O +
polymorphism O +
with O +
DNA O +
sequencing O +
to O +
identify O +
potential O +
mutations O +
in O +
the O +
ras O +
protooncogenes O +
and O +
the O +
tumor O +
suppressor O +
gene O +
p53 O +
in O +
invasive O +
pituitary O +
adenomas O +
and O +
carcinomas O -
. O +

Sequencing O +
of O +
exons O +
5 O +
through O +
8 O +
of O +
the O +
p53 O +
gene O +
revealed O +
no O +
mutations O -
, O +
nor O +
were O +
mutations O +
detected O +
in O +
the O +
N- O +
or O +
K O -
- O -
ras O +
protooncogenes O +
in O +
four O +
of O +
the O +
carcinomas O +
and O +
their O +
respective O +
metastatic O +
deposits O -
. O +

Point O +
mutations O +
of O +
H O -
- O -
ras O +
however O -
, O +
were O +
identified O +
in O +
three O +
distant O +
metastatic O +
pituitary O +
tumor O +
secondaries O -
, O +
but O +
not O +
in O +
their O +
respective O +
primary O +
pituitary O +
carcinomas O -
, O +
or O +
in O +
six O +
invasive O +
adenomas O -
. O +

Two O +
of O +
the O +
mutations O +
included O +
a O +
G B-Chemical +
to O +
C B-Chemical +
substitution O +
at O +
codon O +
12 O -
, O +
and O +
a O +
G B-Chemical +
to O +
A B-Chemical +
substitution O +
at O +
codon O +
18 O -
, O +
resulting O +
in O +
a O +
glycine O +
to O +
arginine O -
, O +
and O +
an O +
alanine O +
to O +
threonine O +
change O +
at O +
these O +
amino O +
acids O -
, O +
respectively O -
. O +

A O +
third O +
mutation O +
involved O +
a O +
single O +
base O +
pair O +
( O -
adenine B-Chemical -
) O +
deletion O +
in O +
codon O +
3 O +
of O +
H O -
- O -
ras O +
which O +
causes O +
a O +
frame O +
shift O -
, O +
resulting O +
in O +
a O +
termination O +
signal O +
at O +
codon O +
19 O -
. O +

These O +
results O +
suggest O +
that O +
point O +
mutations O +
in O +
p53 O +
and O +
ras O +
are O +
not O +
associated O +
with O +
pituitary O +
tumorigenesis O -
, O +
however O -
, O +
point O +
mutations O +
of O +
the O +
H O -
- O -
ras O +
gene O +
may O +
be O +
important O +
in O +
the O +
formation O +
and O +
or O +
growth O +
of O +
pituitary O +
metastases O -
. O +

This O +
observed O +
genomic O +
instability O +
will O +
be O +
of O +
value O +
in O +
predicting O +
the O +
potential O +
metastatic O +
behavior O +
of O +
these O +
aggressive O +
pituitary O +
tumors O -
. O +

Overexpression O +
of O +
Glut-1 O +
glucose B-Chemical +
transporter O +
in O +
human O +
breast O +
cancer O -
. O +

An O +
immunohistochemical O +
study O -
. O +

BACKGROUND O -
: O +
Breast O +
cancers O +
have O +
higher O +
than O +
normal O +
glucose B-Chemical +
metabolism O -
, O +
but O +
the O +
mechanism O +
of O +
glucose B-Chemical +
entry O +
into O +
these O +
tumors O +
is O +
not O +
well O +
understood O -
. O +

METHODS O -
: O +
The O +
expression O +
of O +
five O +
facilitative O +
glucose B-Chemical +
transporters O -
, O +
Glut-1 O +
( O -
erythrocyte O +
type O -
) O -
, O +
Glut-2 O +
( O -
liver O +
type O -
) O -
, O +
Glut-3 O +
( O -
brain O +
type O -
) O -
, O +
Glut-4 O +
( O -
muscle O -
/ O -
fat O +
type O -
) O -
, O +
and O +
Glut-5 O +
( O -
small O +
intestine O +
type O -
) O -
, O +
was O +
studied O +
by O +
immunohistochemistry O +
of O +
paraffin B-Chemical +
sections O +
from O +
12 O +
primary O +
human O +
breast O +
cancers O +
and O +
8 O +
lymph O +
node O +
metastases O +
from O +
2 O +
patients O -
. O +

Rat O +
tissues O +
known O +
to O +
express O +
these O +
glucose B-Chemical +
transporters O +
were O +
used O +
as O +
controls O -
. O +

RESULTS O -
: O +
All O +
the O +
primary O +
breast O +
cancers O +
and O +
the O +
lymph O +
node O +
metastases O +
were O +
positive O +
for O +
Glut-1 O -
. O +

This O +
transporter O +
was O +
expressed O +
on O +
the O +
cell O +
membrane O +
and O +
in O +
the O +
cytoplasm O +
of O +
the O +
tumor O +
cells O -
, O +
but O +
exhibited O +
marked O +
intratumoral O +
and O +
intertumoral O +
variability O +
in O +
the O +
proportions O +
of O +
positive O +
cells O +
and O +
the O +
intensity O +
of O +
staining O -
. O +

Staining O +
of O +
the O +
normal O +
mammary O +
epithelium O -
, O +
if O +
present O -
, O +
was O +
much O +
lower O +
than O +
observed O +
in O +
tumor O +
cells O +
from O +
the O +
same O +
patient O -
. O +

Glut-2 O +
was O +
expressed O +
in O +
all O +
of O +
the O +
tumors O -
, O +
but O +
the O +
intensity O +
of O +
staining O +
was O +
not O +
consistently O +
stronger O +
than O +
that O +
seen O +
in O +
healthy O +
breast O -
. O +

Clusters O +
of O +
Glut-4-positive O +
granule O +
were O +
observed O +
in O +
cells O +
in O +
six O +
of O +
the O +
tumors O -
. O +

None O +
of O +
the O +
tumors O +
or O +
the O +
healthy O +
breast O +
in O +
the O +
tissues O +
studied O +
expressed O +
Glut-3 O +
or O +
Glut-5 O -
. O +

CONCLUSIONS O -
: O +
Higher O +
expression O +
of O +
the O +
glucose B-Chemical +
transporter O +
Glut-1 O +
by O +
breast O +
cancer O +
cells O +
compared O +
with O +
the O +
healthy O +
breast O +
tissue O +
is O +
common O -
. O +

Increased O +
glucose B-Chemical +
transporter O +
protein O +
expression O +
may O +
contribute O +
to O +
the O +
increased O +
uptake O +
of O +
2- B-Chemical -
[ I-Chemical -
18F I-Chemical -
] I-Chemical -
-fluoro-2-deoxy I-Chemical -
- I-Chemical -
D I-Chemical -
- I-Chemical -
glucose I-Chemical +
( O -
FDG B-Chemical -
) O +
by O +
these O +
tumors O +
observed O +
by O +
positron O +
emission O +
tomography O +
( O -
PET O -
) O +
imaging O -
. O +

Transformation O -
- O -
associated O +
cytokine O +
9E3 O -
/ O -
CEF4 O +
is O +
chemotactic O +
for O +
chicken O +
peripheral O +
blood O +
mononuclear O +
cells O -
. O +

9E3 O -
/ O -
CEF4 O -
, O +
which O +
is O +
released O +
from O +
transformed O +
chicken O +
embryo O +
fibroblasts O +
( O -
CEF O -
) O -
, O +
is O +
a O +
member O +
of O +
the O +
platelet O +
factor O +
4 O +
family O +
of O +
inflammatory O +
proteins O +
and O +
may O +
be O +
the O +
avian O +
homolog O +
of O +
interleukin-8 O -
. O +

Since O +
the O +
function O +
of O +
9E3 O -
/ O -
CEF4 O +
is O +
unknown O -
, O +
we O +
examined O +
the O +
effect O +
of O +
the O +
protein O +
on O +
mitogenicity O +
and O +
chemotaxis O -
, O +
as O +
well O +
as O +
its O +
expression O -
, O +
in O +
fibroblasts O +
and O +
peripheral O +
blood O +
cells O -
. O +

9E3 O -
/ O -
CEF4 O +
mRNA O +
was O +
expressed O +
in O +
chicken O +
peripheral O +
blood O +
monocytes O -
, O +
and O +
its O +
expression O +
was O +
stimulated O +
by O +
incubation O +
of O +
the O +
monocytes O +
with O +
lipopolysaccharide B-Chemical +
or O +
phorbol B-Chemical +
myristic I-Chemical +
acetate I-Chemical -
. O +

Boyden O +
double O -
- O -
membrane O +
analysis O +
of O +
chemotaxis O +
showed O +
that O +
9E3 O -
/ O -
CEF4 O +
was O +
chemotactic O +
for O +
chicken O +
peripheral O +
blood O +
mononuclear O +
cells O -
, O +
as O +
well O +
as O +
for O +
heterophils O -
. O +

Untransformed O +
CEF O +
and O +
CEF O +
transformed O +
with O +
Rous O +
sarcoma O +
virus O +
also O +
migrated O +
to O +
9E3 O -
/ O -
CEF4 O +
protein O -
, O +
as O +
measured O +
by O +
Boyden O +
single O -
- O -
membrane O +
analysis O -
. O +

9E3 O -
/ O -
CEF4 O +
was O +
slightly O +
mitogenic O +
for O +
CEF O -
, O +
causing O +
a O +
doubling O +
of O +
[ B-Chemical -
3H I-Chemical -
] I-Chemical -
thymidine I-Chemical +
uptake O +
when O +
added O +
to O +
serum O -
- O -
starved O +
CEF.9E3 O -
/ O -
CEF4 O +
was O +
found O +
associated O +
not O +
only O +
with O +
the O +
cell O +
and O +
in O +
the O +
culture O +
medium O +
of O +
Rous O +
sarcoma O +
virus O -
- O -
transformed O +
CEF O +
but O +
also O +
with O +
the O +
extracellular O +
matrix O -
. O +

The O +
in O +
vivo O +
role O +
of O +
9E3 O -
/ O -
CEF4 O +
may O +
be O +
involved O +
with O +
chemotaxis O +
and O +
metastasis O -
, O +
rather O +
than O +
with O +
direct O +
stimulation O +
of O +
mitogenicity O -
. O +

Appearance O +
of O +
tumorous O +
phenotypes O +
in O +
goldfish O +
erythrophores O +
transfected O +
with O +
ras O -
, O +
src O -
, O +
and O +
myc O +
oncogenes O +
and O +
spontaneous O +
differentiation O +
of O +
the O +
transformants O +
in O +
vitro O -
. O +

When O +
goldfish O +
erythrophores O +
isolated O +
from O +
the O +
skin O +
by O +
tissue O +
digestion O +
and O +
centrifugation O +
in O +
a O +
Percoll O +
density O +
gradient O +
were O +
transfected O +
in O +
a O +
monolayer O -
- O -
culture O +
with O +
v O -
- O -
Ha O -
- O -
ras O +
or O +
v O -
- O -
src O +
oncogene O +
either O +
singly O +
or O +
in O +
combination O +
with O +
v O -
- O -
myc O +
by O +
means O +
of O +
calcium B-Chemical +
phosphate I-Chemical -
- O -
DNA O +
co O -
- O -
precipitation O -
, O +
there O +
appeared O +
a O +
certain O +
number O +
of O +
transformants O +
manifesting O +
a O +
chromatoblast O -
- O -
like O +
profile O +
and O +
tumorous O +
phenotypes O +
as O +
seen O +
in O +
the O +
capability O +
for O +
unlimited O +
growth O -
, O +
and O +
piling O -
- O -
up O +
in O +
a O +
monolayer O -
- O -
culture O +
or O +
colony O +
formation O +
in O +
semi O -
- O -
solid O +
soft O +
agar O -
. O +

After O +
successive O +
growth O +
in O +
vitro O +
for O +
longer O +
than O +
one O +
month O +
which O +
was O +
scarcely O +
observed O +
with O +
the O +
erythrophores O -
, O +
the O +
vast O +
majority O +
of O +
such O +
transformants O +
began O +
to O +
differentiate O +
into O +
erythrophores O +
and O +
ceased O +
proliferation O +
spontaneously O -
. O +

The O +
onset O +
of O +
their O +
differentiation O +
was O +
ascertained O +
by O +
the O +
deposition O +
of O +
marker O +
pteridine B-Chemical +
pigments O -
. O +

None O +
of O +
the O +
transformants O +
differentiated O +
into O +
melanophores O +
or O +
iridophores O +
or O +
other O +
neural O +
crest O +
derivatives O +
as O +
seen O +
in O +
goldfish O +
erythrophoroma O +
cells O -
. O +

Little O +
difference O +
was O +
observed O +
in O +
their O +
transforming O +
efficiency O +
( O -
0.2 O -
- O -
0.3 O +
transformants O -
/ O -
micrograms O +
DNA O -
) O +
between O +
the O +
combinations O +
of O +
oncogenes O +
applied O +
but O +
a O +
tendency O +
was O +
noted O +
that O +
cells O +
transfected O +
with O +
ras O +
or O +
src O +
in O +
combination O +
with O +
myc O +
developed O +
the O +
capacity O +
to O +
grow O +
for O +
a O +
longer O +
period O +
and O +
differentiated O +
at O +
a O +
later O +
stage O +
than O +
those O +
transfected O +
solely O +
with O +
ras O +
or O +
src O -
. O +

One O +
cell O +
line O +
( O -
ESM-1 O -
) O +
derived O +
from O +
the O +
erythrophores O +
transfected O +
with O +
src O -
/ O -
myc O +
grew O +
successively O +
over O +
nine O +
months O -
, O +
indicating O +
its O +
acquisition O +
of O +
immortality O -
. O +

The O +
expression O +
of O +
the O +
transfected O +
oncogenes O +
in O +
this O +
cell O +
line O +
was O +
examined O +
in O +
comparison O +
with O +
the O +
erythrophoroma O +
cells O +
by O +
Western O +
and O +
Northern O +
blot O +
analyses O -
. O +

Autocrine O +
angiogenic O +
vascular O +
prosthesis O +
with O +
bone O +
marrow O +
transplantation O -
. O +

Synthetic O +
vascular O +
prostheses O +
are O +
foreign O +
bodies O -
, O +
so O +
that O +
blood O +
coagulation O +
can O +
occur O +
on O +
their O +
luminal O +
surfaces O -
, O +
causing O +
graft O +
occlusion O +
very O +
frequently O +
in O +
prostheses O +
of O +
small O +
diameter O -
. O +

A O +
vascular O +
prosthesis O +
needs O +
angiogenesis O +
for O +
endothelialization O +
of O +
the O +
luminal O +
surface O -
, O +
as O +
endothelial O +
cells O +
have O +
natural O +
and O +
permanent O +
antithrombogenic O +
properties O -
. O +

To O +
induce O +
capillary O +
growth O +
into O +
the O +
graft O -
, O +
we O +
developed O +
a O +
method O +
of O +
transplanting O +
bone O +
marrow O +
cells O -
, O +
which O +
are O +
primitive O -
, O +
strong O +
enough O +
to O +
survive O -
, O +
and O +
create O +
blood O +
cells O -
, O +
resulting O +
in O +
the O +
inducement O +
of O +
capillary O +
growth O -
. O +

In O +
an O +
animal O +
experiment O -
, O +
marrow O +
cells O +
were O +
infiltrated O +
into O +
the O +
walls O +
of O +
long O -
- O -
fibril O +
expanded O +
polytetrafluoroethylene B-Chemical +
( O -
ePTFE B-Chemical -
) O +
vascular O +
grafts O -
. O +

The O +
grafts O +
were O +
implanted O +
in O +
the O +
abdominal O +
aortic O +
position O +
of O +
24 O +
dogs O +
autologously O -
. O +

Marrow O +
cells O +
survived O +
and O +
continued O +
exogenous O +
hemopoiesis O +
for O +
up O +
to O +
six O +
months O +
and O +
were O +
immunohistochemically O +
reactive O +
to O +
basic O +
fibroblast O +
growth O +
factor O +
( O -
bFGF O -
) O -
. O +

All O +
the O +
grafts O +
older O +
than O +
three O +
weeks O +
had O +
complete O +
endothelialization O +
and O +
maintained O +
their O +
patency O -
. O +

Twenty O +
grafts O +
without O +
bone O +
marrow O +
were O +
implanted O +
as O +
controls O -
. O +

Endothelialization O +
was O +
present O +
at O +
anastomotic O +
sites O -
, O +
but O +
other O +
areas O +
were O +
covered O +
with O +
fresh O +
thrombi O -
. O +

Four O +
out O +
of O +
seven O +
control O +
grafts O +
were O +
patent O +
with O +
endothelial O +
cell O +
lining O +
at O +
six O +
months O -
, O +
but O +
three O +
were O +
occluded O +
and O +
one O +
of O +
the O +
four O +
grafts O +
was O +
still O +
covered O +
with O +
a O +
thrombus O +
layer O -
. O +

Bone O +
marrow O +
with O +
its O +
unique O +
native O +
properties O +
produced O +
autocrine O +
angiogenicity O +
in O +
the O +
graft O -
. O +

Molecular O +
biology O +
of O +
cervical O +
cancer O +
and O +
its O +
precursors O -
. O +

Cervical O +
cancer O +
develops O +
from O +
well O -
- O -
defined O +
precursor O +
lesions O +
referred O +
to O +
as O +
either O +
cervical O +
intraepithelial O +
neoplasia O +
or O +
squamous O +
intraepithelial O +
lesions O -
. O +

It O +
is O +
now O +
known O +
that O +
specific O +
types O +
of O +
human O +
papillomaviruses O +
( O -
HPV O -
) O +
are O +
the O +
principal O +
etiologic O +
agents O +
for O +
both O +
cervical O +
cancer O +
and O +
its O +
precursors O -
. O +

The O +
high O -
- O -
oncogenic O -
- O -
risk O +
HPV O +
types O +
associated O +
with O +
invasive O +
cervical O +
cancer O +
produce O +
two O +
oncoproteins O -
, O +
designated O +
E6 O +
and O +
E7 O -
, O +
which O +
interact O +
with O +
endogenous O +
cell O +
cycle O +
regulatory O +
proteins O -
, O +
including O +
p53 O +
and O +
Rb O -
. O +

The O +
interaction O +
of O +
virally O +
derived O +
and O +
endogenous O +
cellular O +
proteins O +
converges O +
in O +
deregulation O +
of O +
cell O +
cycle O +
progression O +
and O +
appears O +
to O +
be O +
critical O +
for O +
the O +
development O +
of O +
cervical O +
cancers O -
. O +

However O -
, O +
the O +
development O +
of O +
cervical O +
cancer O +
is O +
a O +
multistep O +
process O +
that O +
can O -
not O +
be O +
explained O +
simply O +
by O +
infection O +
with O +
specific O +
types O +
of O +
HPV O -
. O +

One O +
additional O +
event O +
that O +
appears O +
to O +
play O +
a O +
role O +
in O +
tumor O +
progression O +
is O +
integration O +
of O +
HPV O +
DNA O +
into O +
the O +
host O +
genome O -
. O +

Integration O +
of O +
HPV O +
DNA O +
frequently O +
disrupts O +
the O +
E2 O +
open O +
reading O +
frames O -
, O +
resulting O +
in O +
overexpression O +
of O +
the O +
E6 O +
and O +
E7 O +
oncoproteins O +
and O +
possibly O +
causing O +
genomic O +
instability O -
. O +

Additional O +
cofactors O +
and O +
mutational O +
events O +
may O +
be O +
important O +
in O +
the O +
pathogenesis O +
of O +
invasive O +
cervical O +
cancers O +
and O +
may O +
include O +
chromosomal O +
rearrangements O -
, O +
loss O +
of O +
constitutional O +
heterozygosity O -
, O +
and O +
proto O -
- O -
oncogene O +
activation O -
. O +

Stimulation O +
of O +
endothelial O +
cell O +
migration O +
by O +
vascular O +
permeability O +
factor O -
/ O -
vascular O +
endothelial O +
growth O +
factor O +
through O +
cooperative O +
mechanisms O +
involving O +
the O +
alphavbeta3 O +
integrin O -
, O +
osteopontin O -
, O +
and O +
thrombin O -
. O +

We O +
have O +
identified O +
several O +
mechanisms O +
by O +
which O +
the O +
angiogenic O +
cytokine O +
vascular O +
permeability O +
factor O -
/ O -
vascular O +
endothelial O +
growth O +
factor O +
( O -
VPF O -
/ O -
VEGF O -
) O +
likely O +
regulates O +
endothelial O +
cells O +
( O -
EC O -
) O +
migration O -
. O +

VPF O -
/ O -
VEGF O +
induced O +
dermal O +
microvascular O +
EC O +
expression O +
of O +
mRNAs O +
encoding O +
the O +
alphav O +
and O +
beta3 O +
integrin O +
subunits O +
resulting O +
in O +
increased O +
levels O +
of O +
the O +
alphavbeta3 O +
heterodimer O +
at O +
the O +
cell O +
surface O -
, O +
and O +
VPF O -
/ O -
VEGF O +
also O +
induced O +
mRNA O +
encoding O +
osteopontin O +
( O -
OPN O -
) O -
, O +
an O +
alphavbeta3 O +
ligand O -
. O +

OPN O +
promoted O +
EC O +
migration O +
in O +
vitro O -
; O +
and O +
VPF O -
/ O -
VEGF O +
induction O +
of O +
alphavbeta3 O +
was O +
accompanied O +
by O +
increased O +
EC O +
migration O +
toward O +
OPN O -
. O +

Because O +
thrombin O +
cleavage O +
of O +
OPN O +
results O +
in O +
substantial O +
enhancement O +
of O +
OPN O -
's O +
adhesive O +
properties O -
, O +
and O +
because O +
VPF O -
/ O -
VEGF O +
promotes O +
increased O +
microvascular O +
permeability O +
leading O +
to O +
activation O +
of O +
the O +
extrinsic O +
coagulation O +
pathway O -
, O +
we O +
also O +
investigated O +
whether O +
VPF O -
/ O -
VEGF O +
facilitates O +
thrombin O +
cleavage O +
of O +
OPN O +
in O +
vivo O -
. O +

Consistent O +
with O +
this O +
hypothesis O -
, O +
co O -
- O -
injection O +
of O +
VPF O -
/ O -
VEGF O +
together O +
with O +
OPN O +
resulted O +
in O +
rapid O +
cleavage O +
of O +
OPN O +
by O +
endogenous O +
thrombin O -
. O +

Furthermore O -
, O +
in O +
comparison O +
with O +
native O +
OPN O -
, O +
thrombin O -
- O -
cleaved O +
OPN O +
stimulated O +
a O +
greater O +
rate O +
of O +
EC O +
migration O +
in O +
vitro O -
, O +
which O +
was O +
additive O +
to O +
the O +
increased O +
migration O +
associated O +
with O +
induction O +
of O +
alpha O +
v O +
beta O +
3 O -
. O +

Thus O -
, O +
these O +
data O +
demonstrate O +
cooperative O +
mechanisms O +
for O +
VPF O -
/ O -
VEGF O +
regulation O +
of O +
EC O +
migration O +
involving O +
the O +
alphavbeta3 O +
integrin O -
, O +
the O +
alphavbeta3 O +
ligand O +
OPN O -
, O +
and O +
thrombin O +
cleavage O +
of O +
OPN O -
. O +

These O +
findings O +
also O +
illustrate O +
an O +
operational O +
link O +
between O +
VPF O -
/ O -
VEGF O +
induction O +
of O +
EC O +
gene O +
expression O +
and O +
VPF O -
/ O -
VEGF O +
enhancement O +
of O +
microvascular O +
permeability O -
, O +
suggesting O +
that O +
these O +
distinct O +
biological O +
activities O +
may O +
act O +
accordingly O +
to O +
stimulate O +
EC O +
migration O +
during O +
angiogenesis O -
. O +

Prognostic O +
value O +
of O +
angiogenesis O +
in O +
operable O +
non O -
- O -
small O +
cell O +
lung O +
cancer O -
. O +

Tumour O +
angiogenesis O +
is O +
an O +
important O +
factor O +
for O +
tumour O +
growth O +
and O +
metastasis O -
. O +

Although O +
some O +
recent O +
reports O +
suggest O +
that O +
microvessel O +
counts O +
in O +
non O -
- O -
small O +
cell O +
lung O +
cancer O +
are O +
related O +
to O +
a O +
poor O +
disease O +
outcome O -
, O +
the O +
results O +
were O +
not O +
conclusive O +
and O +
were O +
not O +
compared O +
with O +
other O +
molecular O +
prognostic O +
markers O -
. O +

In O +
the O +
present O +
study O -
, O +
the O +
vascular O +
grade O +
was O +
assessed O +
in O +
107 O +
( O -
T1,2-N0,1 O -
) O +
operable O +
non O -
- O -
small O +
cell O +
lung O +
carcinomas O -
, O +
using O +
the O +
JC70 O +
monoclonal O +
antibody O +
to O +
CD31 O -
. O +

Three O +
vascular O +
grades O +
were O +
defined O +
with O +
appraisal O +
by O +
eye O +
and O +
by O +
Chalkley O +
counting O -
: O +
high O +
( O -
Chalkley O +
score O +
7 O -
- O -
12 O -
) O -
, O +
medium O +
( O -
5 O -
- O -
6 O -
) O -
, O +
and O +
low O +
( O -
2 O -
- O -
4 O -
) O -
. O +

There O +
was O +
a O +
significant O +
correlation O +
between O +
eye O +
appraisal O +
and O +
Chalkley O +
counting O +
( O -
P O +
less O +
than O +
0.0001 O -
) O -
. O +

Vascular O +
grade O +
was O +
not O +
related O +
to O +
histology O -
, O +
grade O -
, O +
proliferation O +
index O +
( O -
Ki67 O -
) O -
, O +
or O +
EGFR O +
or O +
p53 O +
expression O -
. O +

Tumours O +
from O +
younger O +
patients O +
had O +
a O +
higher O +
grade O +
of O +
angiogenesis O +
( O -
P O +
= O +
0.05 O -
) O -
. O +

Apart O +
from O +
the O +
vascular O +
grade O -
, O +
none O +
of O +
the O +
other O +
factors O +
examined O +
was O +
statistically O +
related O +
to O +
lymph O +
node O +
metastasis O +
( O -
P O +
less O +
than O +
0.0001 O -
) O -
. O +

A O +
univariate O +
analysis O +
of O +
survival O +
showed O +
that O +
vascular O +
grade O +
was O +
the O +
most O +
significant O +
prognostic O +
factor O +
( O -
P O +
= O +
0.0004 O -
) O -
, O +
followed O +
by O +
N O -
- O -
stage O +
( O -
P O +
= O +
0.001 O -
) O -
. O +

In O +
a O +
multivariate O +
analysis O -
, O +
N O -
- O -
stage O +
and O +
vascular O +
grade O +
were O +
not O +
found O +
to O +
be O +
independent O +
prognostic O +
factors O -
, O +
since O +
they O +
were O +
strongly O +
related O +
to O +
each O +
other O -
. O +

Excluding O +
N O -
- O -
stage O -
, O +
vascular O +
grade O +
was O +
the O +
only O +
independent O +
prognostic O +
factor O +
( O -
P O +
= O +
0.007 O -
) O -
. O +

Kaplan O -
- O -
Meier O +
survival O +
curves O +
showed O +
a O +
statistically O +
significant O +
worse O +
prognosis O +
for O +
patients O +
with O +
high O +
vascular O +
grade O -
, O +
but O +
no O +
difference O +
was O +
observed O +
between O +
low O +
and O +
medium O +
vascular O +
grade O -
. O +

These O +
data O +
suggest O +
that O +
angiogenesis O +
in O +
operable O +
non O -
- O -
small O +
cell O +
lung O +
cancer O +
is O +
a O +
major O +
prognostic O +
factor O +
for O +
survival O +
and O -
, O +
among O +
the O +
parameters O +
tested O -
, O +
is O +
the O +
only O +
factor O +
related O +
to O +
cancer O +
cell O +
migration O +
to O +
lymph O +
nodes O -
. O +

The O +
integration O +
of O +
vascular O +
grading O +
in O +
clinical O +
trials O +
on O +
adjuvant O +
chemotherapy O +
and/or O +
radiotherapy O +
could O +
substantially O +
contribute O +
in O +
defining O +
groups O +
of O +
operable O +
patients O +
who O +
might O +
benefit O +
from O +
cytotoxic O +
treatment O -
. O +

Curcumin B-Chemical +
induces O +
apoptosis O +
in O +
immortalized O +
NIH O +
3T3 O +
and O +
malignant O +
cancer O +
cell O +
lines O -
. O +

Curcumin B-Chemical -
, O +
which O +
is O +
a O +
widely O +
used O +
dietary O +
pigment O +
and O +
spice O -
, O +
has O +
been O +
demonstrated O +
to O +
be O +
an O +
effective O +
inhibitor O +
of O +
tumor O +
promotion O +
in O +
mouse O +
skin O +
carcinogenesis O -
. O +

We O +
report O +
that O +
curcumin B-Chemical +
induces O +
cell O +
shrinkage O -
, O +
chromatin O +
condensation O -
, O +
and O +
DNA O +
fragmentation O -
, O +
characteristics O +
of O +
apoptosis O -
, O +
in O +
immortalized O +
mouse O +
embryo O +
fibroblast O +
NIH O +
3T3 O +
erb O +
B2 O +
oncogene O -
- O -
transformed O +
NIH O +
3T3 O -
, O +
mouse O +
sarcoma O +
S180 O -
, O +
human O +
colon O +
cancer O +
cell O +
HT-29 O -
, O +
human O +
kidney O +
cancer O +
cell O +
293 O -
, O +
and O +
human O +
hepatocellular O +
carcinoma O +
Hep O +
G2 O +
cells O -
, O +
but O +
not O +
in O +
primary O +
culture O +
of O +
mouse O +
embryonic O +
fibroblast O +
C3H O +
10T1 O -
/ O -
2 O -
, O +
rat O +
embryonic O +
fibroblast O -
, O +
and O +
human O +
foreskin O +
fibroblast O +
cells O +
in O +
a O +
concentration- O +
and O +
time O -
- O -
dependent O +
manner O -
. O +

Many O +
cellular O +
and O +
biochemical O +
effects O +
of O +
curcumin B-Chemical +
in O +
mouse O +
fibroblast O +
cells O +
have O +
been O +
reported O -
, O +
such O +
as O +
inhibition O +
of O +
protein O +
kinase O +
C O +
( O -
PKC O -
) O +
activity O +
induced O +
by O +
phorbol B-Chemical +
12-myristate I-Chemical +
13-acetate I-Chemical +
treatment O -
, O +
inhibition O +
of O +
tyrosine O +
protein O +
kinase O +
activity O -
, O +
and O +
inhibition O +
of O +
arachidonic B-Chemical +
acid I-Chemical +
( O -
AA B-Chemical -
) O +
metabolism O -
. O +

Treatment O +
of O +
NIH O +
3T3 O +
cells O +
with O +
the O +
PKC O +
inhibitor O +
staurosporine B-Chemical -
, O +
the O +
tyrosine O +
kinase O +
inhibitor O +
herbimycin B-Chemical +
A I-Chemical -
, O +
and O +
the O +
AA B-Chemical +
metabolism O +
inhibitor O +
quinacrine B-Chemical +
induces O +
apoptotic O +
cell O +
death O -
. O +

These O +
results O +
suggest O +
that O -
, O +
in O +
some O +
immortalized O +
and O +
transformed O +
cells O -
, O +
blocking O +
the O +
cellular O +
signal O +
transduction O +
might O +
trigger O +
the O +
induction O +
of O +
apoptosis O -
. O +

Gene O +
transfer O +
of O +
naked O +
DNA O +
encoding O +
for O +
three O +
isoforms O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
stimulates O +
collateral O +
development O +
in O +
vivo O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
is O +
a O +
naturally O +
secreted O +
endothelial O +
cell O -
- O -
specific O +
mitogen O -
. O +

We O +
investigated O +
the O +
hypothesis O +
that O +
naked O +
DNA O +
encoding O +
for O +
VEGF O +
could O +
be O +
used O +
in O +
a O +
strategy O +
of O +
arterial O +
gene O +
therapy O +
to O +
stimulate O +
collateral O +
artery O +
development O -
. O +

Plasmid O +
DNA O +
encoding O +
each O +
of O +
the O +
three O +
principal O +
human O +
VEGF O +
isoforms O +
( O -
phVEGF121 O -
, O +
phVEGF165 O -
, O +
or O +
phVEGF189 O -
) O +
was O +
applied O +
to O +
the O +
hydrogel O +
polymer O +
coating O +
of O +
an O +
angioplasty O +
balloon O +
and O +
delivered O +
percutaneously O +
to O +
one O +
iliac O +
artery O +
of O +
rabbits O +
with O +
operatively O +
induced O +
hindlimb O +
ischemia O -
. O +

Compared O +
with O +
control O +
animals O +
transfected O +
with O +
LacZ O -
, O +
site O -
- O -
specific O +
transfection O +
of O +
phVEGF O +
resulted O +
in O +
augmented O +
collateral O +
vessel O +
development O +
documented O +
by O +
serial O +
angiography O -
, O +
and O +
improvement O +
in O +
calf O +
blood O +
pressure O +
ratio O +
( O -
ischemic O +
to O +
normal O +
limb O -
) O -
, O +
resting O +
and O +
maximum O +
blood O +
flow O -
, O +
and O +
capillary O +
to O +
myocyte O +
ratio O -
. O +

Similar O +
results O +
were O +
obtained O +
with O +
phVEGF121 O -
, O +
phVEGF165 O -
, O +
and O +
phVEGF189 O -
, O +
which O +
suggests O +
that O +
these O +
isoforms O +
are O +
biologically O +
equivalent O +
with O +
respect O +
to O +
in O +
vivo O +
angiogenesis O -
. O +

The O +
fact O +
that O +
viral O +
or O +
other O +
adjunctive O +
vectors O +
were O +
not O +
required O +
further O +
suggests O +
that O +
secreted O +
gene O +
products O +
may O +
have O +
potential O +
therapeutic O +
utility O +
even O +
when O +
the O +
number O +
of O +
successfully O +
transfected O +
cells O +
remains O +
low O -
. O +

Arterial O +
gene O +
transfer O +
of O +
naked O +
DNA O +
encoding O +
for O +
a O +
secreted O +
angiogenic O +
cytokine O -
, O +
thus O -
, O +
represents O +
a O +
potential O +
alternative O +
to O +
recombinant O +
protein O +
administration O +
for O +
stimulating O +
collateral O +
vessel O +
development O -
. O +

Metastasis O -
- O -
associated O +
5T4 O +
antigen O +
disrupts O +
cell O -
- O -
cell O +
contacts O +
and O +
induces O +
cellular O +
motility O +
in O +
epithelial O +
cells O -
. O +

The O +
5T4 O +
antigen O +
is O +
defined O +
by O +
a O +
monoclonal O +
antibody O +
( O -
MAb O -
) O +
specific O +
for O +
human O +
trophoblast O -
. O +

It O +
is O +
also O +
expressed O +
by O +
many O +
types O +
of O +
tumour O +
cell O +
and O +
has O +
been O +
associated O +
with O +
metastasis O +
and O +
poor O +
clinical O +
outcome O +
in O +
a O +
number O +
of O +
cancers O -
. O +

This O +
pattern O +
of O +
expression O +
is O +
consistent O +
with O +
a O +
mechanistic O +
involvement O +
of O +
5T4 O +
molecules O +
in O +
the O +
spread O +
of O +
cancer O +
cells O -
. O +

The O +
5T4 O +
antigen O +
is O +
a O +
transmembrane O +
glycoprotein O +
with O +
a O +
310 O +
amino O +
acid O +
extracellular O +
domain O +
and O +
a O +
44 O +
amino O +
acid O +
cytoplasmic O +
domain O -
. O +

Transfection O +
of O +
full O -
- O -
length O +
5T4 O +
cDNA O +
into O +
epithelial O +
cells O +
alters O +
cell O -
- O -
cell O +
contacts O +
and O +
cellular O +
motility O -
. O +

Thus O -
, O +
in O +
5T4-transfected O +
CL O -
- O -
S1 O +
murine O +
mammary O +
cells O -
, O +
5T4 O +
expression O +
is O +
associated O +
with O +
dendritic O +
morphology O -
, O +
accompanied O +
by O +
abrogation O +
of O +
actin O -
/ O -
cadherin O -
- O -
containing O +
contacts O +
and O +
increased O +
motility O -
. O +

In O +
transfected O +
MDCK O +
canine O +
kidney O +
epithelial O +
cells O -
, O +
5T4 O +
over O -
- O -
expression O +
also O +
results O +
in O +
increased O +
motility O -
, O +
but O +
disruption O +
of O +
cell O -
- O -
cell O +
contacts O -
, O +
either O +
by O +
culturing O +
cells O +
in O +
low O +
calcium B-Chemical +
medium O +
or O +
by O +
addition O +
of O +
HGF O -
/ O -
SF O -
, O +
is O +
needed O -
. O +

The O +
effects O +
of O +
5T4 O +
expression O +
on O +
morphology O +
and O +
motility O +
are O +
separable O +
since O +
cells O +
transfected O +
with O +
a O +
truncated O +
form O +
of O +
5T4 O +
cDNA O +
in O +
which O +
the O +
cytoplasmic O +
domain O +
is O +
deleted O +
reveal O +
that O +
the O +
latter O +
is O +
necessary O +
to O +
abrogate O +
actin O -
/ O -
cadherin O -
- O -
containing O +
contacts O +
but O +
does O +
not O +
influence O +
the O +
effects O +
on O +
motility O -
. O +

Thus O -
, O +
5T4 O +
molecules O +
can O +
deliver O +
signals O +
through O +
both O +
the O +
extracellular O +
and O +
intracellular O +
domains O -
, O +
and O +
the O +
resultant O +
effects O +
are O +
consistent O +
with O +
a O +
role O +
for O +
5T4 O +
molecules O +
in O +
invasion O +
processes O -
. O +

Prevention O +
of O +
hepatic O +
tumor O +
metastases O +
in O +
rats O +
with O +
herpes O +
viral O +
vaccines O +
and O +
gamma O -
- O -
interferon O -
. O +

Previous O +
studies O +
showed O +
that O +
gammaIFN O +
decreases O +
metastatic O +
hepatic O +
tumor O +
growth O +
by O +
stimulating O +
Kupffer O +
cells O +
( O -
KC O -
) O -
. O +

The O +
present O +
studies O +
examine O +
whether O +
lymphocyte O +
stimulation O +
via O +
cells O +
engineered O +
to O +
secrete O +
GM O -
- O -
CSF O +
or O +
IL-2 O +
decreases O +
hepatic O +
tumor O +
growth O -
, O +
and O +
whether O +
stimulation O +
of O +
both O +
macrophages O +
and O +
lymphocytes O +
is O +
more O +
effective O +
than O +
either O +
individually O -
. O +

Rats O +
were O +
immunized O +
with O +
irradiated O +
hepatoma O +
cells O +
transduced O +
by O +
herpes O +
viral O +
amplicon O +
vectors O +
containing O +
the O +
genes O +
for O +
GM O -
- O -
CSF O -
, O +
IL-2 O +
or O +
LacZ. O +
On O +
day O +
18 O -
, O +
half O +
of O +
each O +
group O +
was O +
treated O +
with O +
5 O +
x O +
10 O -
( O -
4 O -
) O +
U O +
gammaIFN O -
, O +
or O +
saline B-Chemical +
intraperitoneally O +
for O +
3 O +
d. O +
On O +
day O +
21 O -
, O +
all O +
rats O +
received O +
5 O +
x O +
10 O -
( O -
5 O -
) O +
hepatoma O +
cells O +
intrasplenically O -
. O +

On O +
day O +
41 O -
, O +
rats O +
were O +
killed O +
and O +
tumor O +
nodules O +
were O +
counted O -
. O +

Separate O +
rats O +
underwent O +
splenocyte O +
and O +
KC O +
harvest O +
for O +
assessment O +
of O +
lymphocyte- O +
and O +
macrophage O -
- O -
mediated O +
tumor O +
cell O +
kill O +
in O +
vitro O -
. O +

GM O -
- O -
CSF O +
or O +
IL-2 O +
vaccines O +
or O +
gammaIFN O +
decreased O +
tumor O +
nodules O +
significantly O +
( O -
GM O -
- O -
CSF O +
13+ O -
/ O -
-4 O -
, O +
IL-2 O +
14+ O -
/ O -
-6 O +
vs. O +
control O +
75+ O -
/ O -
-24 O -
, O +
P O +
< O +
0.001 O -
) O -
. O +

Combination O +
therapy O +
was O +
more O +
effective O -
, O +
and O +
completely O +
eliminated O +
tumor O +
in O +
4 O +
of O +
12 O +
IFN O -
- O -
GM O -
- O -
CSF O +
and O +
8 O +
of O +
11 O +
IFN O -
- O -
IL-2 O +
animals O -
. O +

Additional O +
rats O +
underwent O +
partial O +
hepatectomy O -
, O +
an O +
immunosuppressive O +
procedure O +
known O +
to O +
accelerate O +
the O +
growth O +
of O +
hepatic O +
tumor O -
, O +
following O +
tumor O +
challenge O -
. O +

Therapy O +
was O +
equally O +
effective O +
in O +
this O +
immunosuppressive O +
setting O -
. O +

Vaccination O +
is O +
associated O +
with O +
enhancement O +
of O +
splenocyte O -
- O -
mediated O +
tumoricidal O +
activity O -
, O +
whereas O +
the O +
effect O +
of O +
gammaIFN O +
is O +
mediated O +
by O +
KC O -
. O +

GM O -
- O -
CSF O +
and O +
IL-2 O +
vaccine O +
therapy O +
and O +
pretreatment O +
with O +
gammaIFN O +
represent O +
effective O +
strategies O +
in O +
reducing O +
hepatic O +
tumor O -
. O +

Combination O +
therapy O +
targets O +
both O +
lymphocytes O +
and O +
macrophages O -
, O +
and O +
is O +
more O +
effective O +
in O +
reducing O +
tumor O +
than O +
either O +
therapy O +
alone O -
. O +

Changes O +
in O +
plasminogen O +
activator O +
inhibitor-1 O +
levels O +
in O +
non O -
- O -
small O +
cell O +
lung O +
cancer O -
. O +

Increased O +
urokinase O +
plasminogen O +
activator O +
( O -
uPA O -
) O +
levels O +
are O +
increased O +
in O +
a O +
number O +
of O +
malignancies O +
and O +
have O +
been O +
correlated O +
with O +
decreased O +
disease O -
- O -
free O +
interval O +
and O +
decreased O +
overall O +
survival O -
. O +

We O +
have O -
, O +
therefore O -
, O +
examined O +
components O +
of O +
this O +
plasminogen O +
activating O +
system O +
in O +
patients O +
with O +
Non O -
- O -
Small O +
Cell O +
Lung O +
Cancer O +
( O -
NSCLC O -
) O -
. O +

Levels O +
of O +
uPA O -
, O +
urokinase O -
- O -
plasminogen O +
activator O +
receptor O +
( O -
uPAR O -
) O +
and O +
plasminogen O +
activator O +
inhibitor-1 O +
( O -
PAI-1 O -
) O +
were O +
measured O +
semiquantitatively O +
in O +
paraffin O +
sections O +
of O +
tumours O +
from O +
147 O +
patients O +
with O +
NSCLC O -
. O +

Immunohistochemically O +
stained O +
sections O +
of O +
tumour O +
were O +
allocated O +
a O +
score O +
for O +
stain O +
intensity O +
and O +
results O +
correlated O +
to O -
: O +
survival O -
; O +
tumour O +
stage O -
( O -
T O -
) O -
; O +
nodal O +
stage O -
( O -
N O -
) O -
; O +
stage O +
grouping O +
( O -
I O +
to O +
IIIb O -
) O -
, O +
survival O +
status O +
and O +
sex O -
. O +

Increased O +
levels O +
of O +
PAI-1 O +
were O +
associated O +
with O +
a O +
decreased O +
survival O +
in O +
squamous O +
cell O +
carcinoma O +
( O -
SCC O -
) O +
X2 O +
= O +
5.72 O -
, O +
p O +
= O +
0.017 O +
( O -
n O +
= O +
74 O -
) O -
. O +

There O +
was O +
a O +
significant O +
positive O +
relationship O +
between O +
PAI-1 O +
levels O +
and O +
N O -
- O -
stage O +
( O -
p O +
= O +
< O +
0.05 O -
) O -
, O +
presence O +
of O +
nodal O +
metastases O +
( O -
p O +
= O +
< O +
0.05 O -
) O -
, O +
stage O +
grouping O +
( O -
p O +
= O +
< O +
0.01 O -
) O +
and O +
extent O +
of O +
disease O +
( O -
p O +
= O +
< O +
0.05 O -
) O +
in O +
the O +
total O +
group O +
and O +
the O +
SCC O +
subgroup O -
, O +
but O +
not O +
adenocarcinoma O -
. O +

There O +
was O +
a O +
significant O +
positive O +
relationship O +
between O +
PAI-1 O +
levels O +
and O +
T O -
- O -
stage O +
( O -
p O +
= O +
< O +
0.05 O -
) O +
in O +
the O +
total O +
group O -
, O +
and O +
survival O +
status O +
( O -
p O +
= O +
< O +
0.05 O -
) O +
in O +
the O +
SCC O +
subgroup O +
alone O -
. O +

uPA O +
and O +
uPAR O +
levels O +
were O +
not O +
significantly O +
associated O +
with O +
tumour O +
staging O +
or O +
survival O -
. O +

We O +
conclude O +
that O +
increased O +
PAI-1 O +
antigen O +
levels O +
may O +
be O +
associated O +
with O +
a O +
decreased O +
survival O +
in O +
patients O +
with O +
SCC O -
. O +

Insulin O -
- O -
like O +
growth O +
factor O +
I O +
induces O +
tumor O +
hexokinase O +
RNA O +
expression O +
in O +
cancer O +
cells O -
. O +

Increased O +
glycolysis O +
is O +
a O +
characteristic O +
of O +
cancer O +
cells O -
. O +

Though O +
less O +
efficient O +
in O +
energy O +
production O -
, O +
it O +
ensures O +
continuous O +
supply O +
of O +
energy O +
and O +
phosphometabolites O +
for O +
biosynthesis O +
enabling O +
metastatic O +
and O +
less O +
vascularized O +
cancer O +
cells O +
to O +
proliferate O +
even O +
under O +
hypoxic O +
conditions O -
. O +

Since O +
hexokinase O +
is O +
the O +
first O +
rate O +
limiting O +
enzyme O +
in O +
the O +
glycolytic O +
pathway O -
, O +
elevated O +
levels O +
of O +
Type O +
II O +
like O +
hexokinase O +
in O +
tumors O +
are O +
of O +
great O +
significance O +
in O +
this O +
context O -
. O +

Under O +
normal O +
conditions O +
insulin O +
regulates O +
expression O +
of O +
hexokinase O +
Type O +
II O +
isoenzyme O -
, O +
which O +
is O +
predominantly O +
expressed O +
in O +
muscle O -
. O +

On O +
the O +
other O +
hand O +
cancer O +
cells O +
overexpress O +
insulin O -
- O -
like O +
growth O +
factors O +
and O +
their O +
receptors O +
which O +
mimic O +
many O +
activities O +
of O +
insulin O -
. O +

This O +
prompted O +
us O +
to O +
examine O +
a O +
hypothesis O +
that O +
insulin O -
- O -
like O +
growth O +
factors O +
may O +
be O +
responsible O +
for O +
overexpression O +
of O +
tumor O +
hexokinase O -
. O +

Our O +
experiments O +
demonstrate O +
that O +
insulin O -
- O -
like O +
growth O +
factor O +
I O +
indeed O +
induces O +
hexokinase O +
gene O +
expression O +
in O +
a O +
concentration O +
and O +
time O +
dependent O +
manner O +
in O +
two O +
cancer O +
cell O +
lines O +
we O +
studied O -
. O +

The O +
Wilms O +
tumor O +
suppressor O +
gene O +
WT1 O +
induces O +
G1 O +
arrest O +
and O +
apoptosis O +
in O +
myeloblastic O +
leukemia O +
M1 O +
cells O -
. O +

WT1 O +
was O +
isolated O +
as O +
a O +
tumor O +
suppressor O +
gene O +
of O +
Wilms O +
tumor O -
. O +

However O -
, O +
high O +
expression O +
of O +
WT1 O +
correlates O +
with O +
poor O +
prognosis O +
in O +
acute O +
leukemia O -
. O +

In O +
addition O +
suppression O +
of O +
WT1 O +
expression O +
by O +
WT1 O +
anti O -
- O -
sense O +
oligonucleotide O +
inhibits O +
proliferation O +
of O +
leukemia O +
cells O -
, O +
suggesting O +
that O +
WT1 O +
is O +
important O +
for O +
their O +
proliferation O -
. O +

To O +
further O +
elucidate O +
the O +
biological O +
significance O +
of O +
WT1 O +
in O +
leukemic O +
cell O +
growth O -
, O +
we O +
overexpressed O +
exogenous O +
WT1 O +
in O +
murine O +
M1 O +
myeloblastic O +
leukemia O +
cells O +
using O +
the O +
isopropyl B-Chemical -
- I-Chemical -
beta I-Chemical -
- I-Chemical -
D I-Chemical -
- I-Chemical -
thiogalactoside I-Chemical +
( O -
IPTG B-Chemical -
) O -
-controlled O +
expression O +
system O -
. O +

We O +
found O +
that O +
induction O +
of O +
one O +
splicing O +
variant O +
of O +
WT1 O +
[ O -
WT1 O -
- O -
17AA O -
( O -
+ O -
) O -
-KTS O -
( O -
- O -
) O -
] O +
in O +
M1 O +
cells O +
induces O +
cell O +
cycle O +
arrest O +
and O +
apoptotic O +
cell O +
death O -
. O +

These O +
results O +
suggest O +
that O +
the O +
role O +
of O +
WT1 O +
is O +
different O +
depending O +
on O +
the O +
type O +
of O +
leukemia O +
cell O +
in O +
which O +
it O +
is O +
expressed O -
. O +

CD56 O -
+ O +
putative O +
natural O +
killer O +
cell O +
lymphomas O -
: O +
production O +
of O +
cytolytic O +
effectors O +
and O +
related O +
proteins O +
mediating O +
tumor O +
cell O +
apoptosis O -
? O +

Apoptosis O +
is O +
a O +
regulated O +
form O +
of O +
cell O +
death O +
that O +
may O +
be O +
triggered O +
by O +
natural O +
killer O +
( O -
NK O -
) O +
or O +
cytotoxic O +
T O +
cells O -
, O +
which O +
effect O +
target O +
cell O +
lysis O +
by O +
cytolytic O +
effector O +
and O +
related O +
proteins O +
through O +
complex O +
intracellular O +
signals O -
. O +

This O +
study O +
was O +
aimed O +
to O +
investigate O +
whether O +
there O +
is O +
selective O +
expression O +
of O +
these O +
cytolytic O +
markers O +
in O +
the O +
putative O +
NK O -
- O -
cell O +
lymphomas O +
and O +
whether O +
there O +
is O +
correlation O +
with O +
zonal O +
tumor O +
cell O +
death O +
in O +
these O +
tumors O -
. O +

Expression O +
of O +
the O +
cytolytic O +
effectors O +
perforin O -
, O +
granzyme O +
B9 O -
, O +
and O +
the O +
granule O +
membrane O +
protein O +
TIA1 O +
were O +
examined O +
in O +
24 O +
putative O +
NK O -
- O -
cell O +
lymphomas O -
, O +
18 O +
postthymic O +
T O -
- O -
cell O +
lymphomas O +
( O -
one O +
case O +
CD8 O -
+ O +
CD56 O -
+ O +
and O +
three O +
anaplastic O +
large O +
cell O +
lymphomas O +
( O -
ALCL O -
) O -
, O +
three O +
T O -
- O -
lymphoblastic O +
lymphomas O -
, O +
and O +
20 O +
B O -
- O -
cell O +
lymphomas O -
. O +

Nineteen O +
( O -
79 O -
% O -
) O +
putative O +
NK O -
- O -
cell O +
lymphomas O +
expressed O +
perforin O -
, O +
and O +
all O +
24 O +
cases O +
expressed O +
granzyme O +
B9 O +
and O +
TIA1 O -
. O +

The O +
only O +
CD8 O -
+ O +
CD56 O -
+ O +
postthymic O +
T O -
- O -
cell O +
lymphoma O +
also O +
expressed O +
all O +
three O +
cytolytic O +
markers O -
, O +
two O +
CD8- O +
ALCL O +
expressed O +
TIA1 O -
; O +
other O +
postthymic O +
T O -
- O -
cell O -
, O +
T O -
- O -
lymphoblastic O -
, O +
and O +
B O -
- O -
cell O +
lymphomas O +
were O +
consistently O +
negative O -
. O +

There O +
was O +
strong O +
correlation O +
between O +
percentage O +
perforin O -
- O -
positive O +
cells O +
and O +
zonal O +
tumor O +
cell O +
death O -
. O +

Angioinvasion O -
, O +
in O +
contrast O -
, O +
was O +
present O +
only O +
in O +
a O +
proportion O +
( O -
37 O -
% O -
) O +
of O +
these O +
lymphomas O +
despite O +
the O +
frequent O +
presence O +
of O +
zonal O +
tumor O +
cell O +
death O +
( O -
71 O -
% O -
) O -
. O +

We O +
propose O +
that O +
cytolytic O +
effector O +
and O +
related O +
proteins O +
produced O +
by O +
putative O +
NK O +
and O +
some O +
CD8 O -
+ O +
CD56 O -
+ O +
postthymic O +
T O -
- O -
cell O +
lymphomas O -
, O +
probably O +
in O +
conjunction O +
with O +
other O +
mechanisms O -
, O +
may O +
effect O +
massive O +
tumor O +
cell O +
apoptosis O -
. O +

The O +
frequent O +
expression O +
of O +
cytolytic O +
effector O +
markers O +
in O +
the O +
CD2 O -
+ O +
surface O +
CD3- O +
CD56 O -
+ O +
putative O +
NK O -
- O -
cell O +
lymphomas O +
lends O +
further O +
support O +
to O +
their O +
probable O +
NK O +
cell O +
origin O -
. O +

Calretinin O -
. O +

A O +
selective O +
marker O +
of O +
normal O +
and O +
neoplastic O +
mesothelial O +
cells O +
in O +
serous O +
effusions O -
. O +

OBJECTIVE O -
: O +
To O +
document O +
that O +
a O +
polyclonal O +
antiserum O +
to O +
calretinin O -
, O +
a O +
29-kd O +
calcium B-Chemical -
- O -
binding O +
protein O -
, O +
consistently O +
decorates O +
normal O +
and O +
tumor O +
mesothelial O +
cells O +
in O +
cytologic O +
preparations O -
. O +

STUDY O +
DESIGN O -
: O +
Thirty O -
- O -
three O +
archival O +
cytologic O +
specimens O +
from O +
eight O +
patients O +
with O +
histologically O +
confirmed O +
malignant O +
mesothelioma O +
and O +
13 O +
from O +
patients O +
with O +
metastatic O +
serous O +
effusions O +
were O +
destained O +
and O +
then O +
immunostained O +
with O +
anticalretinin O +
antiserum O -
. O +

For O +
investigation O +
of O +
cell O +
suspensions O -
, O +
four O +
pleural O +
fluids O +
were O +
incubated O +
with O +
anticalretinin O +
antiserum O -
. O +

After O +
cytocentrifugation O +
the O +
specimens O +
were O +
stained O +
in O +
accordance O +
with O +
the O +
alkaline O +
phosphatase O +
anti O -
- O -
alkaline O +
phosphatase O +
( O -
APAAP O -
) O +
method O -
. O +

For O +
electron O +
microscopic O +
examination O +
the O +
cell O +
suspensions O +
were O +
then O +
incubated O +
with O +
gold B-Chemical -
- O -
labeled O +
antirabbit O +
antibody O -
. O +

RESULTS O -
: O +
The O +
diagnostic O +
sensitivity O +
of O +
this O +
new O +
immunocytochemical O +
approach O +
reached O +
100 O -
% O +
for O +
the O +
eight O +
malignant O +
mesotheliomas O +
investigated O -
. O +

Only O +
3 O +
of O +
the O +
13 O +
adenocarcinomas O +
metastatic O +
to O +
the O +
serous O +
membranes O +
included O +
in O +
this O +
study O +
were O +
weakly O +
reactive O -
, O +
accounting O +
for O +
81 O -
% O +
specificity O -
. O +

Binding O +
of O +
anticalretinin O +
antiserum O +
to O +
living O +
mesothelial O +
cells O +
was O +
consistently O +
documented O +
in O +
all O +
four O +
cases O +
investigated O -
. O +

CONCLUSION O -
: O +
Calretinin O +
is O +
a O +
very O +
useful O +
marker O +
for O +
positive O +
identification O +
of O +
normal O +
and O +
tumor O +
mesothelial O +
cells O +
in O +
serous O +
effusions O -
. O +

Store O -
- O -
operated O +
calcium B-Chemical +
entry O +
promotes O +
shape O +
change O +
in O +
pulmonary O +
endothelial O +
cells O +
expressing O +
Trp1 O -
. O +

Activation O +
of O +
Ca2 B-Chemical -
+ I-Chemical +
entry O +
is O +
known O +
to O +
produce O +
endothelial O +
cell O +
shape O +
change O -
, O +
leading O +
to O +
increased O +
permeability O -
, O +
leukocyte O +
migration O -
, O +
and O +
initiation O +
of O +
angiogenesis O +
in O +
conduit O -
- O -
vessel O +
endothelial O +
cells O -
. O +

The O +
mode O +
of O +
Ca2 B-Chemical -
+ I-Chemical +
entry O +
regulating O +
cell O +
shape O +
is O +
unknown O -
. O +

We O +
hypothesized O +
that O +
activation O +
of O +
store O -
- O -
operated O +
Ca2 B-Chemical -
+ I-Chemical +
channels O +
( O -
SOCs O -
) O +
is O +
sufficient O +
to O +
promote O +
cell O +
shape O +
change O +
necessary O +
for O +
these O +
processes O -
. O +

SOC O +
activation O +
in O +
rat O +
pulmonary O +
arterial O +
endothelial O +
cells O +
increased O +
free O +
cytosolic O +
Ca2 B-Chemical -
+ I-Chemical +
that O +
was O +
dependent O +
on O +
a O +
membrane O +
current O +
having O +
a O +
net O +
inward O +
component O +
of O +
5.45 O +
+ O -
/- O +

0.90 O +
pA O -
/ O -
pF O +
at O +
-80 O +
mV. O +
Changes O +
in O +
endothelial O +
cell O +
shape O +
accompanied O +
SOC O +
activation O +
and O +
were O +
dependent O +
on O +
Ca2 B-Chemical -
+ I-Chemical +
entry O -
- O -
induced O +
reconfiguration O +
of O +
peripheral O +
( O -
cortical O -
) O +
filamentous O +
actin O +
( O -
F O -
- O -
actin O -
) O -
. O +

Because O +
the O +
identity O +
of O +
pulmonary O +
endothelial O +
SOCs O +
is O +
unknown O -
, O +
but O +
mammalian O +
homologues O +
of O +
the O +
Drosophila O +
melanogaster O +
transient O +
receptor O +
potential O +
( O -
trp O -
) O +
gene O +
have O +
been O +
proposed O +
to O +
form O +
Ca2 B-Chemical -
+ I-Chemical +
entry O +
channels O +
in O +
nonexcitable O +
cells O -
, O +
we O +
performed O +
RT O -
- O -
PCR O +
using O +
Trp O +
oligonucleotide O +
primers O +
in O +
both O +
rat O +
and O +
human O +
pulmonary O +
arterial O +
endothelial O +
cells O -
. O +

Both O +
cell O +
types O +
were O +
found O +
to O +
express O +
Trp1 O -
, O +
but O +
neither O +
expressed O +
Trp3 O +
nor O +
Trp6 O -
. O +

Our O +
study O +
indicates O +
that O +
1 O -
) O +
Ca2 B-Chemical -
+ I-Chemical +
entry O +
in O +
pulmonary O +
endothelial O +
cells O +
through O +
SOCs O +
produces O +
cell O +
shape O +
change O +
that O +
is O +
dependent O +
on O +
site O -
- O -
specific O +
rearrangement O +
of O +
the O +
microfilamentous O +
cytoskeleton O +
and O +
2 O -
) O +
Trp1 O +
may O +
be O +
a O +
component O +
of O +
pulmonary O +
endothelial O +
SOCs O -
. O +

Glucose B-Chemical +
and O +
lactate B-Chemical +
metabolism O +
in O +
C6 O +
glioma O +
cells O -
: O +
evidence O +
for O +
the O +
preferential O +
utilization O +
of O +
lactate B-Chemical +
for O +
cell O +
oxidative O +
metabolism O -
. O +

13C B-Chemical +
and O +
1H B-Chemical +
nuclear O +
magnetic O +
resonance O +
spectroscopy O +
( O -
NMR O -
) O +
was O +
used O +
to O +
investigate O +
the O +
metabolism O +
of O +
L B-Chemical -
- I-Chemical -
lactate I-Chemical +
and O +
D B-Chemical -
- I-Chemical -
glucose I-Chemical +
in O +
C6 O +
glioma O +
cells O -
. O +

The O +
13C B-Chemical +
enrichment O +
of O +
cell O +
metabolites O +
was O +
examined O +
after O +
a O +
4-h O +
incubation O +
in O +
media O +
containing O +
5.5 O +
mM O +
glucose B-Chemical +
and O +
11 O +
mM O +
lactate B-Chemical -
, O +
each O +
metabolite O +
being O +
alternatively O +
labelled O +
with O +
either O +
[ B-Chemical -
1 I-Chemical -
- I-Chemical -
13C I-Chemical -
] I-Chemical -
D I-Chemical -
- I-Chemical -
glucose I-Chemical +
or O +
[ B-Chemical -
3 I-Chemical -
- I-Chemical -
13C I-Chemical -
] I-Chemical -
L I-Chemical -
- I-Chemical -
lactate I-Chemical -
. O +

The O +
results O +
indicated O +
that O +
exogenous O +
lactate B-Chemical +
was O +
the O +
major O +
substrate O +
for O +
oxidative O +
metabolism O -
. O +

They O +
were O +
consistent O +
with O +
the O +
concept O +
of O +
the O +
existence O +
of O +
2 O +
pools O +
of O +
both O +
lactate B-Chemical +
and O +
pyruvate B-Chemical -
, O +
of O +
which O +
1 O +
pool O +
was O +
closely O +
connected O +
with O +
exogenous O +
lactate B-Chemical +
and O +
oxidative O +
metabolism O -
, O +
and O +
the O +
other O +
pool O +
was O +
closely O +
related O +
to O +
glycolysis O +
and O +
disconnected O +
from O +
oxidative O +
metabolism O -
. O +

The O +
molecular O +
basis O +
of O +
this O +
behaviour O +
could O +
be O +
related O +
to O +
different O +
locations O +
for O +
the O +
lactate O +
dehydrogenase O +
isoenzymes O -
, O +
as O +
suggested O +
by O +
their O +
immunohistochemical O +
labelling O -
. O +

Tumors O +
of O +
the O +
retinal O +
pigment O +
epithelium O +
metastasize O +
to O +
inguinal O +
lymph O +
nodes O +
and O +
spleen O +
in O +
tyrosinase O -
- O -
related O +
protein O +
1 O -
/ O -
SV40 O +
T O +
antigen O +
transgenic O +
mice O -
. O +

The O +
pigment O +
epithelium O +
of O +
the O +
retina O +
( O -
RPE O -
) O +
is O +
derived O +
from O +
the O +
optic O +
cup O +
and O +
is O +
essential O +
for O +
function O +
and O +
development O +
of O +
the O +
eye O -
. O +

We O +
produced O +
a O +
transgenic O +
mouse O +
line O +
that O +
expresses O +
simian O +
virus O +
( O -
SV40 O -
) O +
transforming O +
sequences O +
under O +
control O +
of O +
the O +
1.4 O +
kb O +
tyrosinase O -
- O -
related O +
protein O +
1 O +
( O -
TRP-1 O -
) O +
promoter O -
, O +
targeting O +
expression O +
of O +
T O +
antigen O +
( O -
Tag O -
) O +
to O +
the O +
RPE O -
. O +

In O +
transgenic O +
embryos O -
, O +
RPE O +
cells O +
proliferated O +
in O +
the O +
anterior O +
part O +
of O +
the O +
eye O +
and O +
near O +
the O +
optic O +
nerve O -
. O +

This O +
resulted O +
in O +
formation O +
of O +
tumors O -
, O +
which O +
were O +
pigmented O +
and O +
of O +
epithelial O +
origin O -
. O +

In O +
3 O +
months O -
- O -
old O +
mice O -
, O +
pigmented O +
cells O +
were O +
detected O +
in O +
spleen O +
and O +
inguinal O +
lymph O +
nodes O -
. O +

In O +
spleen O -
, O +
tyrosinase O -
, O +
TRP-1 O +
and O +
SV40 O +
Tag O +
were O +
expressed O +
and O +
tyrosinase O +
was O +
enzymatically O +
active O -
. O +

Pigmented O +
regions O +
were O +
positive O +
for O +
an O +
epithelial O +
marker O -
, O +
cytokeratin O -
. O +

Cell O +
lines O +
were O +
established O +
from O +
tumor O +
and O +
metastases O +
and O +
kept O +
in O +
culture O +
for O +
more O +
than O +
2 O +
months O -
. O +

These O +
were O +
pigmented O -
, O +
and O +
maintained O +
expression O +
of O +
tyrosinase O -
, O +
TRP-1 O -
, O +
cytokeratin O +
and O +
SV40 O +
Tag O -
. O +

This O +
demonstrates O +
that O +
RPE O +
tumor O +
cells O +
metastasize O +
to O +
lymph O +
node O +
and O +
spleen O -
. O +

In O +
conclusion O -
, O +
the O +
metastasis O +
from O +
TRP-1 O -
/ O -
Tag O +
RPE O +
tumors O +
towards O +
spleen O +
and O +
lymph O +
nodes O +
serves O +
as O +
potential O +
tool O +
to O +
investigate O +
biology O +
and O +
metastasis O +
of O +
tumors O +
derived O +
from O +
the O +
pigment O +
epithelium O -
. O +

Requirement O +
of O +
estrogen O +
receptor O +
expression O +
and O +
function O +
for O +
[ O -
12Val O -
] O +
K O -
- O -
Ras O -
- O -
mediated O +
NIH3T3 O +
cell O +
transformation O -
. O +

We O +
investigated O +
the O +
biological O +
significance O +
of O +
estrogen O +
receptors O +
( O -
ERs O -
) O +
in O +
NIH3T3 O +
cell O +
transformation O +
by O +
the O +
[ O -
12Val O -
] O +
K O -
- O -
Ras O +
mutant O -
. O +

This O +
mutant O +
enhanced O +
the O +
steady O -
- O -
level O +
and O +
transcriptional O +
activity O +
of O +
ER O -
. O +

Coexpression O +
of O +
the O +
progesterone O +
receptor O +
with O +
mutant O +
K O -
- O -
Ras O +
led O +
to O +
suppression O +
of O +
tumorigenicity O +
and O +
inhibition O +
of O +
the O +
activation O +
of O +
ER O -
. O +

The O +
antisense O +
oligomers O +
complementary O +
to O +
the O +
ER O +
suppressed O +
proliferation O +
and O +
transformed O +
phenotypes O +
of O +
K12V O +
cells O -
. O +

These O +
observations O +
support O +
the O +
importance O +
of O +
ER O +
in O +
Ras O -
- O -
mediated O +
cell O +
transformation O -
. O +

Potential O +
roles O +
for O +
focal O +
adhesion O +
kinase O +
in O +
development O -
. O +

Focal O +
adhesion O +
kinase O +
( O -
pp125FAK O +
or O +
FAK O -
) O +
is O +
a O +
protein O +
tyrosine O +
kinase O +
which O +
is O +
associated O +
with O +
intracellular O +
signalling O +
cascades O +
which O +
are O +
initiated O +
when O +
the O +
integrin O +
family O +
of O +
cell O +
adhesion O +
molecules O +
engage O +
extracellular O +
matrix O +
molecules O -
. O +

In O +
cultured O +
cells O -
, O +
this O +
molecule O +
is O +
physically O +
associated O +
with O +
focal O +
adhesions O -
, O +
which O +
are O +
well O -
- O -
defined O +
regions O +
of O +
intimate O +
cell O -
- O -
to O -
- O -
substratum O +
adhesion O -
. O +

In O +
this O +
location O -
, O +
it O +
interacts O +
with O +
other O +
proteins O +
of O +
the O +
focal O +
adhesion O +
to O +
activate O +
intracellular O +
signalling O +
events O +
associated O +
with O +
cell O +
adhesion O -
. O +

The O +
in O +
vitro O +
expression O +
of O +
FAK O +
and O +
its O +
level O +
of O +
phosphorylation O +
appear O +
to O +
be O +
related O +
to O +
several O +
physiological O +
phenomena O -
, O +
including O +
cell O +
spreading O -
, O +
cell O +
differentiation O -
, O +
cell O +
locomotion O +
and O +
cell O +
death O -
. O +

Because O +
these O +
phenomena O +
are O +
all O +
of O +
critical O +
importance O +
during O +
morphogenesis O -
, O +
and O +
because O +
FAK O +
is O +
expressed O +
in O +
embryonic O +
cells O -
, O +
evidence O +
has O +
been O +
accumulating O +
to O +
indicate O +
that O +
FAK O +
may O +
be O +
an O +
important O +
modulator O +
of O +
developmental O +
processes O -
. O +

In O +
this O +
review O -
, O +
this O +
evidence O +
is O +
surveyed O +
together O +
with O +
evidence O +
from O +
analogous O +
situations O -
, O +
such O +
as O +
tumour O +
cell O +
migration O +
and O +
invasiveness O -
. O +

Although O +
evidence O +
suggesting O +
a O +
role O +
for O +
FAK O +
in O +
morphogenesis O +
is O +
accumulating O -
, O +
current O +
uncertainties O +
regarding O +
its O +
cytoplasmic O +
location O +
and O +
its O +
molecular O +
interactions O +
in O +
vivo O +
make O +
it O +
difficult O +
to O +
reach O +
definitive O +
conclusions O +
regarding O +
the O +
significance O +
of O +
its O +
contributions O +
to O +
developmental O +
processes O -
. O +

